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reamble (UPDATED)
t is important that the medical profession play a significant
ole in critically evaluating the use of diagnostic procedures
nd therapies as they are introduced and tested in the
etection, management, or prevention of disease states.
igorous and expert analysis of the available data docu-
enting relative benefits and risks of those procedures and
herapies can produce helpful guidelines that improve the
ffectiveness of care, optimize patient outcomes, and favor-
bly affect the overall cost of care by focusing resources on
he most effective strategies.
The American College of Cardiology Foundation
ACCF) and the American Heart Association (AHA) have
ointly engaged in the production of such guidelines in the
rea of cardiovascular disease since 1980. This effort is
irected by the ACCF/AHA Task Force on Practice Guide-
ines, whose charge is to develop and revise practice guide-
ines for important cardiovascular diseases and procedures.
Experts in the subject under consideration are selected
rom both organizations and charged with examining
ubject-specific data and writing or updating these guide-
ines. The process includes additional representatives from
ther medical practitioner and specialty groups where ap-
ropriate. Writing groups are specifically charged to per-
orm a formal literature review, weigh the strength of
vidence for or against a particular treatment or procedure,
nd include estimates of expected health outcomes where
ata exist. Patient-specific modifiers, comorbidities, and
ssues of patient preference that might influence the choice
f particular tests or therapies are considered, as are fre-
uency of follow-up and cost-effectiveness. When available,
nformation from studies on cost will be considered; how-
ver, review of data on efficacy and clinical outcomes will
onstitute the primary basis for preparing recommendations
n these guidelines.
The ACCF/AHA Task Force on Practice Guidelines
akes every effort to avoid any actual, potential, or per-
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2009 ACCF/AHA Heart Failure Guidelines April 14, 2009:e1–90eived conflicts of interest that might arise as a result of an
utside relationship or personal interest of a member of the
riting committee. Specifically, all members of the writing
ommittee, as well as peer reviewers of the document, are
sked to provide disclosure statements of all such relation-
hips that might be perceived as real or potential conflicts of
nterest. Writing committee members are also strongly
ncouraged to declare a previous relationship with industry
hat may be perceived as relevant to guideline development.
f a writing committee member develops a new relationship
uring his or her tenure, he or she is required to notify the
uideline writing staff in writing. The continued participa-
ion of the writing committee member will be reviewed by
he parent task force, reported orally to all members of the
riting panel at each meeting, and updated and reviewed by
he writing committee as changes occur. Please refer to the
ethodology manual for the ACCF/AHA guideline writ-
ng committees for further description and the relationships
ith industry policy (1). See Appendix 1 for a list of writing
able 1. Applying Classification of Recommendations and Leve
Data available from clinical trials or registries about the usefulness/efficacy in different subpop
ailure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply th
end themselves to clinical trials. Even though randomized trials are not available, there may b
CCF/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use wh
xpress a complete thought, such that a recommendation, even if separated and presented apar
he full intent of the recommendation. It is hoped that this will increase readers’ comprehensioommittee member relationships with industry and Appen- oix 2 for a listing of peer reviewer relationships with
ndustry that are pertinent to this guideline.
The practice guidelines produced are intended to assist
ealthcare providers in clinical decision making by describ-
ng a range of generally acceptable approaches for the
iagnosis, management, or prevention of specific diseases or
onditions. These guidelines attempt to define practices that
eet the needs of most patients in most circumstances.
hese guideline recommendations reflect a consensus of
xpert opinion after a thorough review of the available,
urrent scientific evidence and are intended to improve
atient care. If these guidelines are used as the basis for
egulatory/payer decisions, the ultimate goal is quality of
are and serving the patient’s best interests. The ultimate
udgment regarding care of a particular patient must be
ade by the healthcare provider and patient in light of all of
he circumstances presented by that patient.
The 2005 guidelines were approved for publication by the
overning bodies of the ACCF and the AHA and have been
vidence
, such as gender, age, history of diabetes, history of prior myocardial infarction, history of heart
ecommendation is weak. Many important clinical questions addressed in the guidelines do not
y clear clinical consensus that a particular test or therapy is useful or effective. †In 2003, the
ing recommendations. All guideline recommendations have been written in full sentences that
he rest of the document (including headings above sets of recommendations), would still convey
guidelines and will allow queries at the individual recommendation level.l of E
ulations
at the r
e a ver
en writfficially endorsed by the American College of Chest
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ransplantation, and the Heart Rhythm Society. The sum-
ary article including recommendations was published in
he September 20, 2005, issues of both the Journal of the
merican College of Cardiology and Circulation. The full-text
uideline is posted on the World Wide Web sites of the
CC (www.acc.org) and the AHA (my.americanheart.org).
opies of the full text and the summary article are available
rom both organizations.
The current document is a re-publication of the “ACC/
HA 2005 Guideline Update for the Diagnosis and Man-
gement of Chronic Heart Failure in the Adult” (2), revised
o incorporate updated recommendations and text from a
ocused update performed during 2008 (3). Recommenda-
ions have been updated with new information that has
merged from clinical trials or other ACCF/AHA guideline
r consensus documents. In addition, the writing committee
elt that a new section, the Hospitalized Patient, was
ecessary to address the increasingly recognized problem of
he patient with acute decompensated heart failure, as
pposed to the patient with chronic heart failure. Heart
ailure is now the single most common reason why patients
ver 65 years are admitted to the hospital, and the updated
uidelines review important management principles for this
opulation. For easy reference, this online-only version
enotes sections that have been updated.
Elliott M. Antman, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines, 2003–2005
Sidney C. Smith, Jr, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines, 2006–2008
. Introduction (UPDATED)
eart failure (HF) is a major and growing public health
roblem in the United States. Approximately 5 million
atients in this country have HF, and over 550 000 patients
re diagnosed with HF for the first time each year (4). The
isorder is the primary reason for 12 to 15 million office
isits and 6.5 million hospital days each year (5). From 1990
o 1999, the annual number of hospitalizations has in-
reased from approximately 810 000 to over 1 million for
F as a primary diagnosis and from 2.4 to 3.6 million for
F as a primary or secondary diagnosis (6). In 2001, nearly
3 000 patients died of HF as a primary cause. The number
f HF deaths has increased steadily despite advances in
reatment, in part because of increasing numbers of patients
ith HF due to better treatment and “salvage” of patients
ith acute myocardial infarctions (MIs) earlier in life (4).
Heart failure is primarily a condition of the elderly (7),
nd thus the widely recognized “aging of the population”
lso contributes to the increasing incidence of HF. The
ncidence of HF approaches 10 per 1000 population after
ge 65 (4), and approximately 80% of patients hospitalized
ith HF are more than 65 years old (8). Heart failure is the
ost common Medicare diagnosis-related group (i.e., hos- aital discharge diagnosis), and more Medicare dollars are
pent for the diagnosis and treatment of HF than for any
ther diagnosis (9). The total estimated direct and indirect
osts for HF in 2005 were approximately $27.9 billion (4).
n the United States, approximately $2.9 billion annually is
pent on drugs for the treatment of HF (4).
.1. Evidence Review (UPDATED)
he ACCF and the AHA first published guidelines for the
valuation and management of HF in 1995 and published
evised guidelines in 2001 (10). Since that time, a great deal
f progress has been made in the development of both
harmacological and nonpharmacological approaches to
reatment for this common, costly, disabling, and poten-
ially fatal disorder. The number of available treatments has
ncreased, but this increase has rendered clinical decision
aking far more complex. The timing and sequence of
nitiating treatments and the appropriateness of prescribing
hem in combination are uncertain. The increasing recog-
ition of the existence of clinical HF in patients with a
ormal ejection fraction (EF) (see Section 4.3.2.1) has also
ed to heightened awareness of the limitations of evidence-
ased therapy for this important group of patients. For these
easons, the 2 organizations believed that it was appropriate
o reassess and update these guidelines, fully recognizing
hat the optimal therapy of HF remains a work in progress
nd that future advances will require that the guideline be
pdated again.
The recommendations listed in the 2005 guideline are
vidence based whenever possible. Pertinent medical liter-
ture in the English language was identified through a series
f computerized literature searches (including Medline and
MBASE) and a manual search of selected articles. Refer-
nces selected and published in this document are represen-
ative but not all inclusive. Recommendations relevant to a
lass of drugs specify the use of the drugs shown to be
ffective in clinical trials unless there is reason to believe that
uch drugs have a broad class effect.
In 2005, the committee elected to focus this document on
he prevention of HF and on the diagnosis and management
f chronic HF in the adult patient with normal or low
VEF. Other guidelines are relevant to the HF population,
nd include the ACC/AHA Guidelines for the Manage-
ent of Patients With ST-Elevation Myocardial Infarction
11) and the ACC/AHA 2002 Update of the Guidelines for
he Management of Unstable Angina and Non-ST Eleva-
ion Myocardial Infarction (12). These guidelines have
xcluded HF in children, both because the underlying
auses of HF in children differ from those in adults and
ecause none of the controlled trials of treatments for HF
ave included children. We have not considered the man-
gement of HF due to primary valvular disease (see ACC/
HA Guidelines on the Management of Patients With
alvular Heart Disease [13]) or congenital malformations,nd we have not included recommendations for the treat-
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2009 ACCF/AHA Heart Failure Guidelines April 14, 2009:e1–90ent of specific myocardial disorders (e.g., hemochromato-
is, sarcoidosis, or amyloidosis).
For the 2009 focused update, late-breaking clinical trials
resented at the 2005, 2006, and 2007 annual scientific
eetings of the ACCF, AHA, and European Society of
ardiology, as well as selected other data, from 2005
hrough November 2007, were reviewed by the standing
uideline writing committee along with the parent task
orce to identify those trials and other key data that might
mpact guideline recommendations. On the basis of the
riteria/considerations noted earlier, recent trial data and
ther clinical information were considered important
nough to prompt a focused update of the ACCF/AHA
005 Guideline Update for the Diagnosis and Management
f Chronic Heart Failure in the Adult (2). In addition, the
uidelines writing committee thought that a new section on
he management of the hospitalized patient with HF should
e included in this update. A number of recent HF trials
eviewed for this update, were, in fact, performed on
ospitalized patients, and a number of newer therapies are
nder development for this population. Moreover, there is
ncreasing government and other third-party payer interest
n the prevention of HF hospitalizations, and rehospitaliza-
ions. Quality indicators about the process of discharging
he HF patient have already been developed, and data about
ehospitalizations for HF by hospital have been made
ublic. Thus, the committee thought that a new section
bout this important aspect of HF care should be added to
he update.
When considering the new data for the focused update,
he writing group faced the task of weighing evidence from
tudies enrolling large numbers of subjects outside North
merica. While noting that practice patterns and the rigor
pplied to data collection, as well as the genetic makeup of
ubjects, might influence the observed magnitude of a
reatment’s effect, the writing group believed that the data
ere relevant to formulation of recommendations for the
anagement of HF in North America.
.2. Organization of Committee and Relationships
ith Industry (UPDATED)
he 2005 writing committee was composed of 15 members
ho represented the ACCF and AHA, as well as invited
articipants from the American College of Chest Physi-
ians, the Heart Failure Society of America, the Interna-
ional Society for Heart and Lung Transplantation, the
merican Academy of Family Physicians, and the Ameri-
an College of Physicians. Both the academic and private
ractice sectors were represented.
For the 2009 focused update, all members of the 2005
F writing committee were invited to participate; those
ho agreed (referred to as the 2009 Focused Update
riting Group) were required to disclose all relationships
ith industry relevant to the data under consideration (1) as
ere all peer reviewers of the document (see Appendixes 4nd 5 for a listing of relationships with industry for the 2009 hocused Update Writing Group and peer reviewers, respec-
ively). Each recommendation required a confidential vote
y the writing group members before and after external
eview of the document. Writing group members who had
significant (greater than $10 000) relationship with indus-
ry relevant to a recommendation were required to recuse
hemselves from voting on that recommendation.
.3. Review and Approval (NEW)
he 2005 Guideline document was reviewed by 3 official
eviewers nominated by the ACCF, 3 official reviewers
ominated by the AHA, 1 reviewer nominated by the
merican Academy of Family Physicians, 2 reviewers nom-
nated by the American College of Chest Physicians, 1
eviewer nominated by the American College of Physicians,
reviewers nominated by the Heart Failure Society of
merica, and 1 reviewer nominated by the International
ociety for Heart and Lung Transplantation. In addition, 9
ontent reviewers and the following committees reviewed
he document: ACCF/AHA Committee to Develop Per-
ormance Measures for Heart Failure, ACCF/AHA Com-
ittee to Revise Guidelines for the Management of Patients
ith Acute Myocardial Infarction, ACCF/AHA/ESC
ommittee to Update Guidelines on the Management of
atients with Atrial Fibrillation, ACCF/AHA Committee
o Update Guidelines on Coronary Artery Bypass Graft
urgery, ACCF Committee to Develop Data Standards on
eart Failure, AHA Quality of Care and Outcomes Re-
earch Interdisciplinary Working Group Steering Commit-
ee, and AHA Council on Clinical Cardiology Committee
n Heart Failure and Transplantation.
The 2009 focused update was reviewed by 2 external
eviewers nominated by both the ACCF and AHA, as well
s a reviewer from the ACCF/AHA Task Force on Practice
uidelines, 10 organizational reviewers representing the
merican College of Chest Physicians, the American Col-
ege of Physicians, the American Academy of Family
hysicians, the Heart Failure Society of America, and the
nternational Society for Heart and Lung Transplantation,
nd 14 individual content reviewers. All information about
eviewers’ relationships with industry was collected and
istributed to the writing committee and is published in this
ocument (see Appendix 5 for details).
The 2009 focused update was approved for publication by
he governing bodies of the ACCF and the AHA and
ndorsed by the International Society for Heart and Lung
ransplantation.
.4. Stages of Heart Failure (UPDATED)
he HF writing committee previously developed a new
pproach to the classification of HF (2), one that em-
hasized both the development and progression of the
isease. In doing so, they identified 4 stages involved in
he development of the HF syndrome. The first 2 stages
A and B) are clearly not HF but are an attempt to help
ealthcare providers with the early identification of
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April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure Guidelinesatients who are at risk for developing HF. Stages A and
patients are best defined as those with risk factors that
learly predispose toward the development of HF. For
xample, patients with coronary artery disease, hyperten-
ion, or diabetes mellitus who do not yet demonstrate
mpaired left ventricular (LV) function, hypertrophy, or
eometric chamber distortion would be considered Stage
, whereas patients who are asymptomatic but demon-
trate LV hypertrophy (LVH) and/or impaired LV func-
ion would be designated as Stage B. Stage C then
enotes patients with current or past symptoms of HF
ssociated with underlying structural heart disease (the
ulk of patients with HF), and Stage D designates
atients with truly refractory HF who might be eligible
or specialized, advanced treatment strategies, such as
echanical circulatory support, procedures to facilitate
uid removal, continuous inotropic infusions, or cardiac
ransplantation or other innovative or experimental sur-
ical procedures, or for end-of-life care, such as hospice.
This classification recognizes that there are established
isk factors and structural prerequisites for the develop-
ent of HF and that therapeutic interventions intro-
uced even before the appearance of LV dysfunction or
ymptoms can reduce the population morbidity and
ortality of HF. This classification system is intended to
omplement but in no way to replace the New York
eart Association (NYHA) functional classification,
hich primarily gauges the severity of symptoms in
atients who are in Stage C or Stage D. It has been
ecognized for many years that the NYHA functional
lassification reflects a subjective assessment by a health-
are provider and can change frequently over short
eriods of time. It has also been recognized that the
reatments used may not differ significantly across the
lasses. Therefore, the committee believed that a staging
ystem was needed that would reliably and objectively
dentify patients during the course of their developing
isease and that would be linked to treatments uniquely
ppropriate at each stage of illness. According to this new
taging approach, patients would only be expected to
ither not advance at all or to advance from one stage to
he next, unless progression of the disease was slowed or
topped by treatment, and spontaneous reversal of this
rogression would be considered unusual. For instance,
lthough symptoms (NYHA functional class) might vary
idely over time (in response to therapy or to progression
f disease) in a patient who has already developed the
linical syndrome of HF (Stage C), the patient could
ever return to Stage B (never had HF), and therapies
ecommended for Stage C will be appropriate even if this
atient is in NYHA class I. This new classification
cheme adds a useful dimension to our thinking about
F that is similar to that achieved by staging or risk
ssessment systems for other disorders (e.g., those used in
he approach to cancer). o. Characterization of Heart Failure as a
linical Syndrome
.1. Definition of Heart Failure
eart failure is a complex clinical syndrome that can result
rom any structural or functional cardiac disorder that
mpairs the ability of the ventricle to fill with or eject blood.
he cardinal manifestations of HF are dyspnea and fatigue,
hich may limit exercise tolerance, and fluid retention,
hich may lead to pulmonary congestion and peripheral
dema. Both abnormalities can impair the functional capac-
ty and quality of life of affected individuals, but they do not
ecessarily dominate the clinical picture at the same time.
ome patients have exercise intolerance but little evidence of
uid retention, whereas others complain primarily of edema
nd report few symptoms of dyspnea or fatigue. Because not
ll patients have volume overload at the time of initial or
ubsequent evaluation, the term “heart failure” is preferred
ver the older term “congestive heart failure.”
The clinical syndrome of HF may result from disorders of
he pericardium, myocardium, endocardium, or great ves-
els, but the majority of patients with HF have symptoms
ue to an impairment of LV myocardial function. Heart
ailure may be associated with a wide spectrum of LV
unctional abnormalities, which may range from patients
ith normal LV size and preserved EF to those with severe
ilatation and/or markedly reduced EF. In most patients,
bnormalities of systolic and diastolic dysfunction coexist,
egardless of EF. Patients with normal EF may have a
ifferent natural history and may require different treatment
trategies than patients with reduced EF, although such
ifferences remain controversial (see Section 4.3.2.1).
Coronary artery disease, hypertension, and dilated car-
iomyopathy are the causes of HF in a substantial propor-
ion of patients in the Western world. As many as 30% of
atients with dilated cardiomyopathy may have a genetic
ause (14). Valvular heart disease is still a common cause of
F. In fact, nearly any form of heart disease may ultimately
ead to the HF syndrome.
It should be emphasized that HF is not equivalent to
ardiomyopathy or to LV dysfunction; these latter terms
escribe possible structural or functional reasons for the
evelopment of HF. Instead, HF is defined as a clinical
yndrome that is characterized by specific symptoms (dys-
nea and fatigue) in the medical history and signs (edema,
ales) on the physical examination. There is no single
iagnostic test for HF because it is largely a clinical
iagnosis that is based on a careful history and physical
xamination.
.2. Heart Failure as a Symptomatic Disorder
he approach that is most commonly used to quantify the
egree of functional limitation imposed by HF is one first
eveloped by the NYHA. This system assigns patients to 1
f 4 functional classes, depending on the degree of effort
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2009 ACCF/AHA Heart Failure Guidelines April 14, 2009:e1–90eeded to elicit symptoms: patients may have symptoms of
F at rest (class IV), on less-than-ordinary exertion (class
II), on ordinary exertion (class II), or only at levels of
xertion that would limit normal individuals (class I).
lthough the functional class tends to deteriorate over
eriods of time, most patients with HF do not typically
how an uninterrupted and inexorable worsening of symp-
oms. Instead, the severity of symptoms characteristically
uctuates even in the absence of changes in medications,
nd changes in medications and diet can have either
avorable or adverse effects on functional capacity in the
bsence of measurable changes in ventricular function.
ome patients may demonstrate remarkable recovery, some-
imes associated with improvement in structural and func-
ional abnormalities. Usually, sustained improvement is
ssociated with drug therapy, and that therapy should be
ontinued indefinitely.
The mechanisms responsible for the exercise intolerance
f patients with chronic HF have not been defined clearly.
lthough HF is generally regarded as a hemodynamic
isorder, many studies have indicated that there is a poor
elation between measures of cardiac performance and the
ymptoms produced by the disease. Patients with a very low
F (see Section 4.3.2.1) may be asymptomatic, whereas
atients with preserved LVEF may have severe disability.
he apparent discordance between EF and the degree of
unctional impairment is not well understood but may be
xplained in part by alterations in ventricular distensibility,
alvular regurgitation, pericardial restraint, cardiac rhythm,
onduction abnormalities, and right ventricular function
14). In addition, in ambulatory patients, many noncardiac
actors may contribute substantially to exercise intolerance.
hese factors include but are not limited to changes in
eripheral vascular function, skeletal muscle physiology,
ulmonary dynamics, neurohormonal and reflex autonomic
ctivity, and renal sodium handling. The existence of these
oncardiac factors may explain why the hemodynamic
mprovement produced by therapeutic agents in patients
ith chronic HF may not be immediately or necessarily
ranslated into clinical improvement. Although pharmaco-
ogical interventions may produce rapid changes in hemo-
ynamic variables, signs and symptoms may improve slowly
ver weeks or months or not at all.
.3. Heart Failure as a Progressive Disorder
eft ventricular dysfunction begins with some injury to, or
tress on, the myocardium and is generally a progressive
rocess, even in the absence of a new identifiable insult to
he heart. The principal manifestation of such progression is
change in the geometry and structure of the LV, such that
he chamber dilates and/or hypertrophies and becomes
ore spherical—a process referred to as cardiac remodeling.
his change in chamber size and structure not only in-
reases the hemodynamic stresses on the walls of the failing
eart and depresses its mechanical performance but may
lso increase regurgitant flow through the mitral valve.hese effects, in turn, serve to sustain and exacerbate the
emodeling process. Cardiac remodeling generally precedes
he development of symptoms (occasionally by months or
ven years), continues after the appearance of symptoms,
nd contributes substantially to worsening of symptoms
espite treatment. Progression of coronary artery disease,
iabetes mellitus, hypertension, or the onset of atrial fibril-
ation may also contribute to the progression of HF. The
evelopment of structural abnormalities can have 1 of 3
utcomes: 1) patients die before developing symptoms (in
tage A or B) , 2) patients develop symptoms controlled by
reatment, or 3) patients die of progressive HF. Sudden
eath can interrupt this course at any time.
Although several factors can accelerate the process of LV
emodeling, there is substantial evidence that the activation
f endogenous neurohormonal systems plays an important
ole in cardiac remodeling and thereby in the progression of
F. Patients with HF have elevated circulating or tissue
evels of norepinephrine, angiotensin II, aldosterone, endo-
helin, vasopressin, and cytokines, which can act (alone or in
oncert) to adversely affect the structure and function of the
eart. These neurohormonal factors not only increase the
emodynamic stresses on the ventricle by causing sodium
etention and peripheral vasoconstriction but may also exert
irect toxic effects on cardiac cells and stimulate myocardial
brosis, which can further alter the architecture and impair
he performance of the failing heart. Neurohormonal acti-
ation also has direct deleterious effects on the myocytes and
nterstitium, altering the performance and phenotype of
hese cells.
The development of HF can be appropriately character-
zed by considering 4 stages of the disease, as described in
he Introduction. This staging system recognizes that HF,
ike coronary artery disease, has established risk factors and
tructural prerequisites; that the development of HF has
symptomatic and symptomatic phases; and that specific
reatments targeted at each stage can reduce the morbidity
nd mortality of HF (Figure 1).
. Initial and Serial Clinical Assessment of
atients Presenting With Heart Failure
UPDATED)
he changes in this section are made to clarify the role of
unctional assessment of the HF patient, beyond the NYHA
unctional classification, and to expand on the use of B-type
atriuretic peptide (BNP) and N-terminal pro-B-type natri-
retic peptide (NT-proBNP) testing within the context of the
verall evaluation of the patient (Table 2).
ecommendations for Initial Clinical Assessment of
atients Presenting With Heart Failure
LASS I
. A thorough history and physical examination should be obtained/
performed in patients presenting with HF to identify cardiac and
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April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure Guidelinesnoncardiac disorders or behaviors that might cause or accelerate
the development or progression of HF. (Level of Evidence: C)
. A careful history of current and past use of alcohol, illicit drugs,
current or past standard or “alternative therapies,” and chemo-
therapy drugs should be obtained from patients presenting with
HF. (Level of Evidence: C)
. In patients presenting with HF, initial assessment should be
made of the patient’s ability to perform routine and desired
activities of daily living. (Level of Evidence: C)
. Initial examination of patients presenting with HF should include
assessment of the patient’s volume status, orthostatic blood
pressure changes, measurement of weight and height, and
calculation of body mass index. (Level of Evidence: C)
. Initial laboratory evaluation of patients presenting with HF
should include complete blood count, urinalysis, serum electro-
lytes (including calcium and magnesium), blood urea nitrogen,
serum creatinine, fasting blood glucose (glycohemoglobin), lipid
profile, liver function tests, and thyroid-stimulating hormone. (Level
of Evidence: C)
. Twelve-lead electrocardiogram and chest radiograph (posterior-
anterior and lateral) should be performed initially in all patients
presenting with HF. (Level of Evidence: C)
. Two-dimensional echocardiography with Doppler should be per-
formed during initial evaluation of patients presenting with HF to
assess LVEF, left ventricular size, wall thickness, and valve
function. Radionuclide ventriculography can be performed to
igure 1. Stages in the Development of Heart Failure/Recommend
CEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor
V, left ventricular; LVH, left ventricular hypertrophy; and MI, myocardial infarction.assess LVEF and volumes. (Level of Evidence: C). Coronary arteriography should be performed in patients present-
ing with HF who have angina or significant ischemia unless the
patient is not eligible for revascularization of any kind (15–19).
(Level of Evidence: B)
LASS IIa
. Coronary arteriography is reasonable for patients presenting with
HF who have chest pain that may or may not be of cardiac origin
who have not had evaluation of their coronary anatomy and who
have no contraindications to coronary revascularization. (Level of
Evidence: C)
. Coronary arteriography is reasonable for patients presenting with
HF who have known or suspected coronary artery disease but
who do not have angina unless the patient is not eligible for
revascularization of any kind. (Level of Evidence: C)
. Noninvasive imaging to detect myocardial ischemia and via-
bility is reasonable in patients presenting with HF who have
known coronary artery disease and no angina unless the
patient is not eligible for revascularization of any kind (20). (Level
of Evidence: B)
. Maximal exercise testing with or without measurement of respi-
ratory gas exchange and/or blood oxygen saturation is reason-
able in patients presenting with HF to help determine whether HF
is the cause of exercise limitation when the contribution of HF is
uncertain. (Level of Evidence: C)
. Maximal exercise testing with measurement of respiratory gas
herapy by Stage
r; EF, ejection fraction; FHx CM, family history of cardiomyopathy; HF, heart failure;ed T
blockeexchange is reasonable to identify high-risk patients presenting
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2009 ACCF/AHA Heart Failure Guidelines April 14, 2009:e1–90with HF who are candidates for cardiac transplantation or other
advanced treatments (21–23). (Level of Evidence: B)
. Screening for hemochromatosis, sleep-disturbed breathing, or
human immunodeficiency virus is reasonable in selected patients
who present with HF. (Level of Evidence: C)
. Diagnostic tests for rheumatologic diseases, amyloidosis, or
pheochromocytoma are reasonable in patients presenting with
HF in whom there is a clinical suspicion of these diseases. (Level
of Evidence: C)
. Endomyocardial biopsy can be useful in patients presenting with
HF when a specific diagnosis is suspected that would influence
therapy (24). (Level of Evidence: C)
. Measurement of natriuretic peptides (BNP and NT-proBNP) can
be useful in the evaluation of patients presenting in the urgent
care setting in whom the clinical diagnosis of HF is uncertain.
Measurement of natriuretic peptides (BNP and NT-proBNP) can
be helpful in risk stratification (25–32). (Level of Evidence: A)
LASS IIb
. Noninvasive imaging may be considered to define the likelihood
of coronary artery disease in patients with HF and LV dysfunc-
tion. (Level of Evidence: C)
. Holter monitoring might be considered in patients presenting
with HF who have a history of MI and are being considered for
electrophysiologic study to document VT inducibility. (Level of
Evidence: C)
LASS III
. Endomyocardial biopsy should not be performed in the routine
evaluation of patients with HF (24). (Level of Evidence: C)
. Routine use of signal-averaged electrocardiography is not recom-
mended for the evaluation of patients presenting with HF. (Level
of Evidence: C)
. Routine measurement of circulating levels of neurohormones
(e.g., norepinephrine or endothelin) is not recommended for
patients presenting with HF. (Level of Evidence: C)
ecommendations for Serial Clinical Assessment of
atients Presenting With Heart Failure
LASS I
. Assessment should be made at each visit of the ability of a
patient with HF to perform routine and desired activities of daily
living. (Level of Evidence: C)
. Assessment should be made at each visit of the volume status
and weight of a patient with HF. (Level of Evidence: C)
. Careful history of current use of alcohol, tobacco, illicit drugs,
“alternative therapies,” and chemotherapy drugs, as well as diet
and sodium intake, should be obtained at each visit of a patient
with HF. (Level of Evidence: C)
LASS IIa
. Repeat measurement of EF and the severity of structural remod-
eling can be useful to provide information in patients with HF who
have had a change in clinical status or who have experienced or
recovered from a clinical event or received treatment that might
have had a significant effect on cardiac function. (Level of
Evidence: C)
LASS IIb
. The value of serial measurements of BNP to guide therapy for
patients with HF is not well established. (Level of Evidence: C) f.1. Initial Evaluation of Patients
.1.1. Identification of Patients (UPDATED)
n general, patients with LV dysfunction or HF present to
he healthcare provider in 1 of 3 ways:
. With a syndrome of decreased exercise tolerance.
Most patients with HF seek medical attention with
complaints of a reduction in their effort tolerance due to
dyspnea and/or fatigue. These symptoms, which may
occur at rest or during exercise, may be attributed
inappropriately by the patient and/or healthcare provider
to aging, other physiological abnormalities (e.g., decon-
ditioning), or other medical disorders (e.g., pulmonary
disease). Therefore, in a patient whose exercise capacity
is limited by dyspnea or fatigue, the healthcare provider
must determine whether the principal cause is HF or
another abnormality. Elucidation of the precise reason
for exercise intolerance can be difficult because several
disorders may coexist in the same patient. A clear
distinction can sometimes be made only by measure-
ments of gas exchange or blood oxygen saturation or by
invasive hemodynamic measurements during graded lev-
els of exercise (see ACC/AHA 2002 Guideline Update
for Exercise Testing [33]).
. With a syndrome of fluid retention. Patients may
present with complaints of leg or abdominal swelling as
their primary (or only) symptom. In these patients, the
impairment of exercise tolerance may occur so gradually
that it may not be noted unless the patient is questioned
carefully and specifically about a change in activities of
daily living.
. With no symptoms or symptoms of another cardiac
or noncardiac disorder. During their evaluation for a
disorder other than HF (e.g., abnormal heart sounds or
abnormal electrocardiogram or chest x-ray, hyperten-
sion or hypotension, diabetes mellitus, an acute myo-
cardial infarction (MI), an arrhythmia, or a pulmonary
or systemic thromboembolic event), patients may be
found to have evidence of cardiac enlargement or
dysfunction.
A variety of approaches have been used to quantify the
egree of functional limitation imposed by HF. The most
idely used scale is the NYHA functional classification
34), but this system is subject to considerable interobserver
ariability and is insensitive to important changes in exercise
apacity. These limitations may be overcome by formal tests
f exercise tolerance. Measurement of the distance that a
atient can walk in 6 minutes may have prognostic signif-
cance and may help to assess the level of functional
mpairment in the very sick, but serial changes in walking
istance may not parallel changes in clinical status. Maximal
xercise testing, with measurement of peak oxygen uptake,
as been used to identify appropriate candidates for cardiac
ransplantation, to determine disability, and to assist in the
ormulation of an exercise prescription, but its role in the
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April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure Guidelineseneral management of patients with HF has not been
efined.
.1.2. Identification of a Structural and Functional
bnormality (UPDATED)
complete history and physical examination are the first
teps in evaluating the structural abnormality or cause
esponsible for the development of HF. Direct inquiry may
eveal prior or current evidence of MI, valvular disease, or
ongenital heart disease, whereas examination of the heart
ay suggest the presence of cardiac enlargement, murmurs,
r a third heart sound. Although the history and physical
xamination may provide important clues about the nature
f the underlying cardiac abnormality, identification of the
tructural abnormality leading to HF generally requires
nvasive or noninvasive imaging of the cardiac chambers or
reat vessels.
The single most useful diagnostic test in the evaluation of
atients with HF is the comprehensive 2-dimensional
chocardiogram coupled with Doppler flow studies to de-
ermine whether abnormalities of myocardium, heart valves,
r pericardium are present and which chambers are in-
olved. Three fundamental questions must be addressed: 1)
s the LV ejection fraction (EF) preserved or reduced? 2) Is
he structure of the LV normal or abnormal? 3) Are there
ther structural abnormalities such as valvular, pericardial,
r right ventricular abnormalities that could account for the
linical presentation? This information should be quantified
ith a numerical estimate of EF, measurement of ventric-
lar dimensions and/or volumes, measurement of wall
hickness, and evaluation of chamber geometry and regional
all motion.
Right ventricular size and systolic performance should be
ssessed. Atrial size should also be determined semiquanti-
atively and left atrial dimensions and/or volumes measured.
ll valves should be evaluated for anatomic and flow
bnormalities to exclude the presence of primary valve
isease. Secondary changes in valve function, particularly
he severity of mitral and tricuspid valve insufficiency,
hould be determined.
Noninvasive hemodynamic data acquired at the time of
chocardiography are an important additional correlate for
atients with preserved or reduced EF. Combined quanti-
cation of the mitral valve inflow pattern, pulmonary venous
nflow pattern, and mitral annular velocity provides data
bout characteristics of LV filling and left atrial pressure.
valuation of the tricuspid valve regurgitant gradient cou-
led with measurement of inferior vena caval dimension and
ts response during respiration provides an estimate of
ystolic pulmonary artery pressure and central venous pres-
ure. Stroke volume may be determined with combined
imension measurement and pulsed Doppler in the LV
utflow tract (35). However, abnormalities can be present in
ny of these parameters in the absence of HF. No single
arameter necessarily correlates specifically with HF; dowever, a totally normal filling pattern argues against
linical HF.
A comprehensive echocardiographic evaluation is impor-
ant, because it is common for patients to have more than 1
ardiac abnormality that contributes to the development of
F. Furthermore, the study may serve as a baseline for
omparison, because measurement of EF and the severity of
tructural remodeling can provide useful information in
atients who have had a change in clinical status or who
ave experienced or recovered from a clinical event or
eceived treatment that might have had a significant effect
n cardiac function.
Other tests may be used to provide information regarding
he nature and severity of the cardiac abnormality. Radio-
uclide ventriculography can provide highly accurate mea-
urements of LV function and right ventricular EF, but it is
nable to directly assess valvular abnormalities or cardiac
ypertrophy. Magnetic resonance imaging or computed
omography may be useful in evaluating chamber size and
entricular mass, detecting right ventricular dysplasia, or
ecognizing the presence of pericardial disease, as well as in
ssessing cardiac function and wall motion (36).
Magnetic resonance imaging may also be used to identify
yocardial viability and scar tissue (37). Chest radiography
an be used to estimate the degree of cardiac enlargement
nd pulmonary congestion or to detect the presence of
ulmonary disease. A 12-lead electrocardiogram may dem-
nstrate evidence of prior MI, LV hypertrophy, cardiac
onduction abnormality (e.g., left bundle-branch block), or
cardiac arrhythmia. However, because of their low sensi-
ivity and specificity, neither the chest x-ray nor the elec-
rocardiogram should form the primary basis for determin-
ng the specific cardiac abnormality responsible for the
evelopment of HF.
.1.3. Evaluation of the Cause of Heart Failure
dentification of the condition responsible for the cardiac
tructural and/or functional abnormalities may be impor-
ant, because some conditions that lead to LV dysfunction
re potentially treatable and/or reversible. Efforts to identify
cause frequently allow the detection of coexistent condi-
ions that may contribute to or exacerbate the severity of
ymptoms. However, it may not be possible to discern the
ause of HF in many patients presenting with this syn-
rome, and in others, the underlying condition may not be
menable to treatment. Hence, clinicians should focus their
fforts on diagnoses that have implications for therapy.
.1.3.1. HISTORY AND PHYSICAL EXAMINATION
valuation of potential causative factors begins with a
horough history and careful physical examination (see
able 2). Healthcare providers should inquire about a
istory of hypertension; diabetes mellitus; dyslipidemia;
obacco use; coronary, valvular, or peripheral vascular dis-
ase; rheumatic fever; heart murmur or congenital heart
isease; personal or family history of myopathy; mediastinal
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2009 ACCF/AHA Heart Failure Guidelines April 14, 2009:e1–90rradiation; sleep-disturbed breathing; and exposure to car-
iotoxic agents, including ephedra, and antineoplastic
gents such as anthracyclines, trastuzumab (Herceptin, an
ntibody for the treatment of breast cancer), or high-dose
yclophosphamide. Heart failure may occur years after
xposure to anthracyclines or mediastinal irradiation. Pa-
ients should be questioned carefully about illicit drug use,
urrent and past alcohol consumption, symptoms suggestive
f sleep-disturbed breathing, and exposure to sexually trans-
itted diseases. The history and physical evaluation should
nclude specific consideration of noncardiac diseases such as
ollagen vascular disease, bacterial or parasitic infection,
besity, thyroid excess or deficiency, amyloidosis, and pheo-
hromocytoma. The physical examination should document
pecific signs of right or left HF, with particular attention to
he presence of elevated jugular venous pressure and a third
eart sound, because these have been shown to have
rognostic significance (38).
A detailed family history should be obtained not only to
etermine whether there is a familial predisposition to
therosclerotic disease but also to identify relatives with
ardiomyopathy, sudden unexplained death, conduction
ystem disease, and skeletal myopathies. Recent studies
uggest that as many as 30% of cases of idiopathic dilated
ardiomyopathy may be familial, and polymorphisms in
enes encoding cardiac proteins may provide important prog-
ostic information (39). However, the cost-effectiveness of
amily screening has not been established, and determina-
ion of the genotype of patients with familial cardiomyop-
thies or investigation of genetic polymorphisms is not
outinely performed. Instead, an electrocardiogram and
chocardiogram should be considered in first-degree rela-
ives of patients with a dilated cardiomyopathy, and families
able 2. Evaluation of the Cause of Heart Failure—The History
istory to include inquiry re:
Hypertension
Diabetes
Dyslipidemia
Valvular heart disease
Coronary or peripheral vascular
disease
Myopathy
Rheumatic fever
Mediastinal irradiation
History or symptoms of sleep-
disordered breathing
Exposure to cardiotoxic agents
Current and past alcohol
consumption
Smoking
Collagen vascular disease
Exposure to sexually
transmitted diseases
Thyroid disorder
Pheochromocytoma
Obesity
Family history to include inquiry re:
Predisposition to atherosclerotic
disease (history of MIs, strokes,
PAD)
Sudden cardiac death
Myopathy
Conduction system disease (need
for pacemaker)
Tachyarrhythmia
Cardiomyopathy (unexplained HF)
Skeletal myopathy
F indicates heart failure; MI, myocardial infarction; and PAD, peripheral arterial disease.ith multiple cases of dilated cardiomyopathy should be aeferred to a center with expertise in genetic analysis and
ounseling.
.1.3.2. LABORATORY TESTING (UPDATED)
aboratory testing may reveal the presence of disorders or
onditions that can lead to or exacerbate HF. The initial
valuation of patients with HF should include a complete
lood count, urinalysis, serum electrolytes (including cal-
ium and magnesium), glycohemoglobin, and blood lipids,
s well as tests of both renal and hepatic function, a chest
adiograph, and a 12-lead electrocardiogram. Thyroid func-
ion tests (especially thyroid-stimulating hormone) should
e measured, because both hyperthyroidism and hypothy-
oidism can be a primary or contributory cause of HF. A
asting transferrin saturation is useful to screen for hemo-
hromatosis; several mutated alleles for this disorder are
ommon in individuals of Northern European descent, and
ffected patients may show improvement in LV function
fter treatment with phlebotomy and chelating agents.
agnetic resonance imaging of the heart or liver may be
eeded to confirm the presence of iron overload. Screening
or human immunodeficiency virus (HIV) is reasonable and
hould be considered for all high-risk patients. However,
ther clinical signs of HIV infection typically precede any
F symptoms in those patients who develop HIV cardio-
yopathy. Serum titers of antibodies developed in response
o infectious organisms are occasionally measured in pa-
ients with a recent onset of HF (especially in those with a
ecent viral syndrome), but the yield of such testing is low,
nd the therapeutic implications of a positive result are
ncertain (see a recent review of the role of endomyocardial
iopsy (24), and Section 3.1.3.4, Evaluation of the Possi-
ility of Myocardial Disease. Assays for connective tissue
iseases and for pheochromocytoma should be performed if
hese diagnoses are suspected, and serum titers of Chagas
isease antibodies should be checked in patients with
onischemic cardiomyopathy who have traveled in or im-
igrated from an endemic region.
Several recent assays have been developed for natriuretic
eptides (BNP and NT-proBNP). Several of the natriuretic
eptides are synthesized by and released from the heart.
levated plasma BNP levels have been associated with
educed LVEF (40), LV hypertrophy, elevated LV filling
ressures, and acute MI and ischemia, although they can
ccur in other settings, such as pulmonary embolism and
hronic obstructive pulmonary disease.
Natriuretic peptides are sensitive to other biological
actors, such as age, sex, weight, and renal function (41).
levated levels lend support to a diagnosis of abnormal
entricular function or hemodynamics causing symptomatic
F (42). Trials with these diagnostic markers suggest use in
he urgent-care setting, where they have been used in
ombination with clinical evaluation to differentiate dyspnea
ue to HF from dyspnea of other causes (15), and suggest
hat its use may reduce both the time to hospital discharge
nd the cost of treatment (43). BNP levels tend to be less
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April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure Guidelineslevated in HF with preserved EF than in HF with low EF
nd are lower in obese patients (44,45). Levels of natriuretic
eptides may be elevated meaningfully in women and in
eople over 60 years of age who do not have HF, and thus
hese levels should be interpreted cautiously in such indi-
iduals when distinguishing between cardiac and noncardiac
auses of dyspnea. Elevated natriuretic peptide levels may
end weight to a suspected diagnosis of HF or trigger
onsideration of HF when the diagnosis is unknown but
hould not be used in isolation to confirm or exclude the
resence of HF (43,46).
.1.3.3. EVALUATION OF THE POSSIBILITY OF CORONARY ARTERY DISEASE
oronary artery disease is believed to be the underlying
ause in approximately two thirds of patients with HF and
ow EF and also contributes to the progression of HF
hrough mechanisms that include endothelial dysfunction,
schemia, and infarction. Recent cohort studies suggest that
here is less often a history of prior MI in patients with HF
nd preserved EF, although coronary artery disease is often
vident on angiography or at autopsy (47–49). Therefore, it
ay be useful to define the presence, anatomic characteris-
ics, and functional significance of coronary artery disease in
elected patients who present with this syndrome.
ATIENTS WITH CORONARY ARTERY DISEASE AND ANGINA.
oronary artery bypass grafting has been shown to improve
ymptoms and survival in patients with modestly reduced
F (variably defined in clinical trials) and angina, although
atients with HF or markedly reduced EFs were not
ncluded in these studies (15). An ongoing National Insti-
utes of Health–funded trial is evaluating the utility of
urgical revascularization in such patients. Because revascu-
arization is recommended in individuals with significant
schemic chest pain regardless of the degree of ischemia or
iability, there would appear to be little role for noninvasive
ardiac testing in such patients. Clinicians should proceed
irectly to coronary angiography in patients who have
ngina and impaired ventricular function (16).
ATIENTS WITH CORONARY ARTERY DISEASE AND NO ANGINA.
ontrolled trials have not addressed the issue of whether
oronary revascularization can improve clinical outcomes in
atients with HF who do not have angina. Nevertheless, the
CC/AHA 2004 Guideline Update for Coronary Artery
ypass Graft Surgery (16) recommends revascularization in
atients with a significant left main stenosis and in patients
ho have large areas of noninfarcted but hypoperfused and
ypocontractile myocardium on noninvasive testing.
Observational studies have shown that revascularization
an favorably affect LV function in some patients with
mpaired yet viable myocardium, but it is not clear how such
atients should be identified because the sensitivity and
pecificity of an abnormal imaging test have not been
alidated in patients with HF (50). Additional studies are
eeded to determine whether the possibility of myocardial tschemia or viability should be evaluated routinely to assess
he contribution of coronary artery disease in patients with
F and reduced LVEF who do not have angina (see the
CC/AHA/ASE 2003 Guideline Update for the Clinical
pplication of Echocardiography [51] and the ACC/AHA/
SNC Guidelines for Clinical Use of Cardiac Radionuclide
maging [52]).
ATIENTS IN WHOM THE POSSIBILITY OF CORONARY ARTERY
ISEASE HAS NOT BEEN EVALUATED. Up to one third of
atients with nonischemic cardiomyopathy complain of
hest pain, which may resemble angina or may be atypical in
ature. Because coronary revascularization would play a role
n the management of these patients if their chest pain were
elated to the presence of coronary artery disease, coronary
ngiography is generally recommended in these circum-
tances to define the presence or absence of large-vessel
oronary obstructions. Although many healthcare providers
erform noninvasive testing before coronary angiography in
hese patients, inhomogeneous nuclear images and abnor-
al wall-motion patterns are common in patients with a
onischemic cardiomyopathy. Hence, in most situations,
linicians should proceed directly to coronary angiography
n patients who have HF and chest pain.
How should healthcare providers evaluate patients with
F due to LV dysfunction who do not have chest pain and
ho do not have a history of coronary artery disease? The
se of coronary angiography appears reasonable in young
atients to exclude the presence of congenital coronary
nomalies. In older patients, however, efforts to detect the
resence of coronary artery disease may not be worthwhile,
ecause revascularization has not been shown to improve
linical outcomes in patients without angina (16). Never-
heless, the observation that revascularization might have a
avorable effect on LV function has led some experts to
uggest that coronary artery disease should be excluded
henever possible, especially in patients with diabetes mel-
itus or other states associated with silent myocardial isch-
mia. Only coronary arteriography can reliably demonstrate
r exclude the presence of obstructed coronary vessels,
ecause perfusion deficits and segmental wall-motion ab-
ormalities suggestive of coronary artery disease are com-
only present in patients with a nonischemic cardiomyop-
thy on noninvasive imaging.
In patients in whom coronary artery disease has been
xcluded previously as the cause of LV dysfunction,
epeated invasive or noninvasive assessment for ischemia
s generally not indicated unless there is a change in
linical status that suggests the interim development of
schemic disease.
.1.3.4. EVALUATION OF THE POSSIBILITY OF MYOCARDIAL DISEASE
ne half of patients with HF and low EF have normal or
ear-normal coronary arteries on coronary angiography, and
yocardial disorders are responsible for the development of
ardiomyopathy in most such individuals (17). Most pa-
ients with a cardiomyopathy have no identifiable causative
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2009 ACCF/AHA Heart Failure Guidelines April 14, 2009:e1–90actor (i.e., idiopathic dilated cardiomyopathy), but in some
atients, the cardiomyopathy is related to a systemic disor-
er (e.g., hypertension, diabetes mellitus, hyperthyroidism,
emochromatosis, or hypocalcemia), exposure to a cardio-
oxic agent (alcohol, cocaine, methamphetamine, anthracy-
line, or trastuzumab), or the presence of myocardial in-
ammation or infiltration.
Although some of these conditions may be detected by
ndomyocardial biopsy, the overall usefulness of endomyo-
ardial biopsy in the evaluation of patients with a cardio-
yopathy of unknown cause is not clear (53). Most patients
ith a nonischemic cardiomyopathy show nonspecific
hanges on biopsy (including hypertrophy, cell loss, and
brosis), and it has not been established conclusively how
iopsy findings (even when positive) affect patient manage-
ent (54). For example, an endomyocardial biopsy might
etect inflammatory cell infiltrates attributed to viral myo-
arditis in some patients with acute or even chronic HF.
evertheless, many patients with biopsy-proven myocarditis
mprove with supportive care only, without specific antiviral
r anti-inflammatory treatment; the prognosis of these
atients has not been influenced clearly by immunosuppres-
ion (55). Similarly, an endomyocardial biopsy can be used
o make a diagnosis of sarcoidosis and amyloidosis, but
hanges characteristic of these disorders are often missed on
istological evaluation, and there is no conclusive evidence
hat treatment can favorably affect the course of these
iseases.
Examples of cases in which a biopsy might be helpful
sually occur in a setting in which the cause of the
ardiomyopathy is already suspected because of other
upportive data. Tissue obtained by biopsy can be used to
ake the diagnosis of hemochromatosis, endocardial
broelastosis, and Loeffler’s syndrome in patients in
hom these disorders are suspected on clinical grounds.
iopsy tissue may also be used to assess the risk of
ontinued anthracycline therapy in patients with cancer,
specially when combined with imaging of ventricular
unction (56,57). Biopsies can confirm the presence of
ardiac disorders that often might weigh against eligibil-
ty for heart transplantation (e.g., amyloidosis). Finally,
he biopsy can be used to identify patients with giant-cell
yocarditis, who generally progress rapidly to death and
re unresponsive to treatment and who thus may be
onsidered for mechanical circulatory support or imme-
iate heart transplantation (58).
However, endomyocardial biopsy is not indicated in the
outine evaluation of cardiomyopathy. Although the risk of
serious complication is less than 1% in centers experienced
n this technique, biopsies should be performed only when
here is a strong reason to believe that the results will have
meaningful effect on subsequent therapeutic decisions or
rognosis and only by operators experienced in its
erformance. i.2. Ongoing Evaluation of Patients
nce the nature and cause of the structural abnormalities
eading to the development of HF have been defined,
ealthcare providers should focus on the clinical assessment
f patients, both during the initial presentation and during
ubsequent visits. This clinical assessment should identify
ymptoms and their functional consequences and should
valuate the short- and long-term risks of disease progres-
ion and death whenever appropriate. This ongoing review
f the patient’s clinical status is critical to the appropriate
election and monitoring of treatments.
.2.1. Assessment of Functional Capacity
uring the initial and subsequent visits, healthcare provid-
rs should inquire about the type, severity, and duration of
ymptoms that occur during activities of daily living and
hat may impair the patient’s functional capacity. Questions
egarding the ability to perform specific tasks may provide
reater insight than general inquiries about what symptoms
he patient is experiencing, because many patients curtail
heir activities to limit discomfort. Patients with modest
imitations of activity should be asked about their partici-
ation in sports or their ability to perform strenuous
xercise, whereas patients with substantial limitations of
ctivity should be asked about their ability to get dressed
ithout stopping, take a shower or bath, climb stairs, or
erform specific routine household chores. A useful ap-
roach is to ask patients to describe activities that they
ould like to do but can no longer perform, because changes
n the ability to perform specific tasks are generally related
o important changes in clinical status or course. Ideally,
hese inquiries should be coupled with direct observations of
he patient during a walk around the clinic or up the stairs.
A variety of approaches have been used to quantify the
egree of functional limitation imposed by HF. The most
idely used scale is the NYHA functional classification
34), but this system is subject to considerable interobserver
ariability and is insensitive to important changes in exercise
apacity. These limitations may be overcome by formal tests
f exercise tolerance. Measurement of the distance that a
atient can walk in 6 minutes may have prognostic signif-
cance and may help to assess the level of functional
mpairment in the very sick, but serial changes in walking
istance may not parallel changes in clinical status. Maximal
xercise testing, with measurement of peak oxygen uptake,
as been used to identify appropriate candidates for cardiac
ransplantation, to determine disability, and to assist in the
ormulation of an exercise prescription, but its role in the
eneral management of patients with HF has not been
efined.
.2.2. Assessment of Volume Status
t is critically important for healthcare providers to evaluate
he fluid or volume status of patients with HF during the
nitial visit and each follow-up examination. This assess-
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April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure Guidelinesent plays a pivotal role in determining the need for
iuretic therapy and in detecting sodium excesses or defi-
iencies that may limit efficacy and decrease the tolerability
f drugs used to treat HF. The physical examination is the
rimary step in evaluating the presence and severity of fluid
etention in patients with HF. At each visit, healthcare
roviders should record the patient’s body weight and
itting and standing blood pressures and determine the
egree of jugular venous distension and its response to
bdominal pressure, the presence and severity of organ
ongestion (pulmonary rales and hepatomegaly), and the
agnitude of peripheral edema in the legs, abdomen,
resacral area, and scrotum, as well as ascites in the
bdomen.
The most reliable sign of volume overload is jugular
enous distention (59–61). Right-sided filling pressures are
levated in the basal state or with abdominal compression
hepatojugular reflux) in many patients with chronically
levated elevated left-sided filling pressures (62). Most
atients with peripheral edema should also be considered to
ave volume overload, but the possibility of noncardiac
auses for edema may limit the utility of this sign in some
atients. In contrast, most patients with chronic HF do not
ave rales. This is true even in patients with end-stage
isease who have markedly elevated left-sided filling pres-
ures. The presence of rales generally reflects the rapidity of
nset of HF rather than the degree of volume overload.
ndeed, many patients with chronic HF have elevated
ntravascular volume in the absence of peripheral edema or
ales. Studies using 131I-tagged albumin have demonstrated
lasma volume expansion in more than 50% of patients in
hom clinical volume overload was not recognized (63).
hort-term changes in fluid status are best assessed by
easuring changes in body weight; however, changes in
ody weight may be less reliable during long periods of
ollow-up, because many patients may gain nonfluid weight
nd others may lose skeletal muscle mass and body fat as HF
rogresses due to the development of cardiac cachexia.
The majority of patients with clinical evidence of volume
verload do not exhibit hypoperfusion, even though cardiac
erformance may be severely depressed. Clinical signs of
ypoperfusion become most apparent when cardiac output
eclines markedly or abruptly. Clues that suggest the
resence of such a marked reduction in cardiac output
nclude narrow pulse pressure, cool extremities, altered
entation, Cheyne-Stokes respiration, resting tachycardia,
nd a disproportionate elevation of blood urea nitrogen
elative to serum creatinine. Renal dysfunction in HF is
oorly understood and appears to be mediated by interac-
ions between the heart and kidney beyond those primarily
ue to depressed cardiac output (41).
.2.3. Laboratory Assessment (UPDATED)
erum electrolytes and renal function should be monitored
outinely in patients with HF. Of particular importance is
he serial measurement of serum potassium concentration, gecause hypokalemia is a common adverse effect of treat-
ent with diuretics and may cause fatal arrhythmias and
ncrease the risk of digitalis toxicity, whereas hyperkalemia
ay complicate therapy with angiotensin-converting en-
yme (ACE) inhibitors, angiotensin II receptor blockers
ARBs), and aldosterone antagonists. Worsening renal
unction may require adjustment of the doses of diuretics,
enin-angiotensin-aldosterone system antagonists, digoxin,
nd noncardiac medications. Development of hyponatremia
r anemia may be a sign of disease progression and is
ssociated with impaired survival.
Serum BNP levels have been shown to parallel the clinical
everity of HF as assessed by NYHA functional class in
road populations. Levels are higher in hospitalized patients
nd tend to decrease during aggressive therapy for decom-
ensation (see Section 3.1.3.2, Laboratory Testing) (42).
ndeed, there is an increasing body of evidence demonstrat-
ng the power of the addition of BNP (or NT-proBNP)
evels in the assessment of prognosis in a variety of cardio-
ascular disorders. However, it cannot be assumed that
NP levels can be used effectively as targets for adjustment
f therapy in individual patients. Many patients taking
ptimal doses of medications continue to show markedly
levated levels of BNP, and some patients demonstrate
NP levels within the normal range despite advanced HF.
he use of BNP measurements to guide the titration of drug
oses has not been shown conclusively to improve outcomes
ore effectively than achievement of the target doses of
rugs shown in clinical trials to prolong life (64). Ongoing
rials will help to determine the role of serial BNP (or other
atriuretic peptides) measurements in both diagnosis and
anagement of HF.
Serial chest radiographs are not recommended in the
anagement of chronic HF. Although the cardiothoracic
atio is commonly believed to reflect the cardiac dilatation
hat is characteristic of HF, enlargement of the cardiac
ilhouette primarily reflects changes in right ventricular
olume rather than LV function, because the right ventricle
orms most of the border of dilated hearts on radiographs.
imilarly, changes in the radiographic assessment of pulmo-
ary vascular congestion are too insensitive to detect any but
he most extreme changes in fluid status (65).
Repeat assessment of EF may be most useful when the
atient has demonstrated a major change in clinical status.
oth improvement and deterioration may have important
mplications for future care, although the recommended
edical regimen should be continued in most cases. Im-
rovement may reflect recovery from a previous condition,
uch as viral myocarditis or hypothyroidism, or may occur
fter titration of recommended therapies for chronic HF.
hus, it is appropriate to obtain a repeat EF after some
eriod of optimal medical therapy, typically 4 to 6 months,
o decide about the implantation of an implantable
ardioverter-defibrillator (ICD). Deterioration may reflect
radual disease progression or a new event, such as recurrent
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rbitrary intervals is not recommended.
There has been no established role for periodic invasive or
oninvasive hemodynamic measurements in the manage-
ent of HF. Most drugs used for the treatment of HF are
rescribed on the basis of their ability to improve symptoms
r survival rather than their effect on hemodynamic vari-
bles. Moreover, the initial and target doses of these drugs
re selected on the basis of experience in controlled trials
nd are not based on the changes they may produce in
ardiac output or pulmonary wedge pressure. Nevertheless,
nvasive hemodynamic measurements may assist in the
etermination of volume status and in distinguishing HF
rom other disorders that may cause circulatory instability,
uch as pulmonary diseases and sepsis. Measurements of
ardiac output and pulmonary wedge pressure through a
ulmonary artery catheter have also been used in patients
ith refractory HF to assess pulmonary vascular resistance,
determinant of eligibility for heart transplantation. Car-
iac output can also be measured by noninvasive methods.
.2.4. Assessment of Prognosis (UPDATED)
lthough both healthcare providers and patients may be
nterested in defining the prognosis of an individual patient
ith HF, the likelihood of survival can be determined
eliably only in populations and not in individuals. How-
ver, some attempt at prognostication in HF may provide
etter information for patients and their families to help
hem appropriately plan for their futures. It also identifies
atients in whom cardiac transplantation or mechanical
evice therapy should be considered.
Multivariate analysis of clinical variables has helped to
dentify the most significant predictors of survival, and
rognostic models have been developed and validated (66).
ecreasing LVEF, worsening NYHA functional status,
egree of hyponatremia, decreasing peak exercise oxygen
ptake, decreasing hematocrit, widened QRS on 12-lead
lectrocardiogram, chronic hypotension, resting tachycar-
ia, renal insufficiency, intolerance to conventional therapy,
nd refractory volume overload are all generally recognized
ey prognostic parameters, although the actual prognostic
odels incorporating them are not widely used in clinical
ractice (66,67). Although elevated circulating levels of
eurohormonal factors have also been associated with high
ortality rates, the routine assessment of neurohormones
uch as norepinephrine or endothelin is neither feasible nor
elpful in clinical management. Likewise, elevated BNP (or
T-proBNP) levels predict higher risk of HF and other
vents after MI, whereas marked elevation in BNP levels
uring hospitalization for HF may predict rehospitalization
nd death. Nonetheless, the BNP measurement has not
een clearly shown to supplement careful clinical assessment
or management.
Because treatment of HF has improved over the past 10
ears, the older prognostic models need to be revalidated
68), and newer prognostic models may have to be devel-ped. Outcomes have been improved for most high-risk
atients, which has resulted in a shift in the selection
rocess for patients referred for heart transplantation (68).
outine use of ambulatory electrocardiographic monitoring,
-wave alternans analysis, heart rate variability measure-
ent, and signal-averaged electrocardiography have not
een shown to provide incremental value in assessing overall
rognosis, although ambulatory electrocardiographic mon-
toring can be useful in decision making regarding place-
ent of ICDs (69).
. Therapy
.1. Patients at High Risk for Developing
eart Failure (Stage A)
ecommendations
LASS I
. In patients at high risk for developing HF, systolic and diastolic
hypertension should be controlled in accordance with contempo-
rary guidelines. (Level of Evidence: A)
. In patients at high risk for developing HF, lipid disorders should
be treated in accordance with contemporary guidelines. (Level of
Evidence: A)
. For patients with diabetes mellitus (who are all at high risk for
developing HF), blood sugar should be controlled in accordance
with contemporary guidelines. (Level of Evidence: C)
. Patients at high risk for developing HF should be counseled to
avoid behaviors that may increase the risk of HF (e.g., smoking,
excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
. Ventricular rate should be controlled or sinus rhythm restored in
patients with supraventricular tachyarrhythmias who are at high
risk for developing HF. (Level of Evidence: B)
. Thyroid disorders should be treated in accordance with contem-
porary guidelines in patients at high risk for developing HF. (Level
of Evidence: C)
. Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
. In patients at high risk for developing HF who have known
atherosclerotic vascular disease, healthcare providers should
follow current guidelines for secondary prevention. (Level of
Evidence: C)
. Healthcare providers should perform a noninvasive evaluation of
LV function (i.e., LVEF) in patients with a strong family history of
cardiomyopathy or in those receiving cardiotoxic interventions.
(Level of Evidence: C)
LASS IIa
. Angiotensin converting enzyme inhibitors can be useful to pre-
vent HF in patients at high risk for developing HF who have a
history of atherosclerotic vascular disease, diabetes mellitus, or
hypertension with associated cardiovascular risk factors. (Level
of Evidence: A)
. Angiotensin II receptor blockers can be useful to prevent HF in
patients at high risk for developing HF who have a history of
atherosclerotic vascular disease, diabetes mellitus, or hyperten-
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April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure Guidelinession with associated cardiovascular risk factors. (Level of Evi-
dence: C)
LASS III
. Routine use of nutritional supplements solely to prevent the
development of structural heart disease should not be recom-
mended for patients at high risk for developing HF. (Level of
Evidence: C)
Table 3 describes cardiovascular medications useful for
reatment of various stages of HF. Many conditions or
able 3. Cardiovascular Medications Useful for Treatment of
arious Stages* of Heart Failure
Drug Stage A Stage B Stage C
CE Inhibitors
Benazepril H — —
Captopril H, DN Post MI HF
Enalapril H, DN HF HF
Fosinopril H — HF
Lisinopril H, DN Post MI HF
Moexipril H — —
Perindopril H, CV Risk — —
Quinapril H — HF
Ramipril H, CV Risk Post MI Post MI
Trandolapril H Post MI Post MI
ngiotensin Receptor Blockers
Candesartan H — HF
Eprosartan H — —
Irbesartan H, DN — —
Losartan H, DN CV Risk —
Olmesartan H — —
Telmisartan H — —
Valsartan H, DN Post MI Post MI, HF
ldosterone Blockers
Eplerenone H Post MI Post MI
Spironolactone H — HF
eta Blockers
Acebutolol H — —
Atenolol H Post MI —
Betaxolol H — —
Bisoprolol H — HF
Carteolol H — —
Carvedilol H Post MI HF, Post MI
Labetalol H — —
Metoprolol succinate H — HF
Metoprolol tartrate H Post MI —
Nadolol H — —
Penbutolol H — —
Pindolol H — —
Propranolol H Post MI —
Timolol H Post MI —
igoxin — — HF
See Figure 1 for explanation of stages of heart failure.
Asymptomatic CV Risk indicates reduction in future cardiovascular events; DN, diabetic
ephropathy; H, hypertension; HF, heart failure; LVSD, asymptomatic left ventricular systolic
ysfunction; and Post MI, reduction in heart failure or other cardiac events following myocardial
nfarction.ehaviors that are associated with an increased risk of ctructural heart disease can be identified before patients
how any evidence of structural abnormalities. Because early
odification of many of these factors can reduce the risk of
F, the recommendation of appropriate medical interven-
ions to patients with these risk factors provides the earliest
pportunity to reduce the impact of HF on public and
ndividual health.
.1.1. Control of Risk
.1.1.1. TREATMENT OF HYPERTENSION
levated levels of diastolic and especially systolic blood
ressure are major risk factors for the development of HF
70,71), and long-term treatment of both systolic and
iastolic hypertension has been shown to reduce the risk of
F (72–74). A number of large, controlled studies have
uite uniformly demonstrated that optimal blood pressure
ontrol decreases the risk of new HF by approximately 50%
75). Because approximately one fourth of the American
opulation is hypertensive, and the lifetime risk of develop-
ng hypertension in the United States exceeds 75% (76),
trategies to control hypertension are certainly a vital part of
ny effort to prevent HF. The subsequent structural abnor-
alities that occur in patients with hypertension, including
VH or MI (e.g., Stage B HF), portend an even higher
umber of adverse cardiovascular outcomes. Left ventricular
ypertrophy is an independent cardiovascular risk factor
hat is as potent as age or systolic blood pressure in
redicting MI, stroke, sudden death, or HF (77). In the
ramingham Heart Study, hypertension accounted for 39%
f HF cases in men and 59% in women (70). In addition,
he benefits of treating hypertension in patients who have
ad a prior MI (Stage B) are even more dramatic, with an
1% reduction in the incidence of HF (73).
Healthcare providers should lower both systolic and
iastolic blood pressure in accordance with the recommen-
ations provided in published guidelines, including the most
ecently published report of the Joint National Committee
n Prevention, Detection, Evaluation, and Treatment of
igh Blood Pressure (78); target levels of blood pressure are
ower in patients with associated major cardiovascular risk
actors, especially those with diabetes mellitus (79,80).
hen an antihypertensive regimen is devised, optimal
ontrol of blood pressure should remain the primary goal,
ith the choice of drugs determined by the concomitant
edical problems (e.g., coronary artery disease, diabetes, or
enal disease). Diuretic-based antihypertensive therapy has
epeatedly been shown to prevent HF in a wide range of
arget populations (81). ACE inhibitors (ACEIs) and beta-
lockers are also effective in the prevention of HF (78),
hereas calcium antagonists and alpha-blockers are less
ffective in preventing HF syndrome (82). However, ACEIs
nd beta blockers, as single therapies, are not superior to
ther antihypertensive drug classes in the reduction of all
ardiovascular outcomes.
Nevertheless, among patients with diabetes or other
ardiovascular complications (83,84), ACEIs have been
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2009 ACCF/AHA Heart Failure Guidelines April 14, 2009:e1–90ost notable with respect to a reduction in the onset of HF
nd new-onset diabetes. Likewise, compared with placebo,
he ARBs losartan (85) and irbesartan (86) significantly
educed the incidence of HF in patients with type 2 diabetes
ellitus and nephropathy. Ultimately, an appropriate anti-
ypertensive regimen frequently consists of several drugs
sed in combination. Although prevention of HF is the focus
f these guidelines, overall cardiovascular preventative strate-
ies have also been the subject of published guidelines (87).
.1.1.2. TREATMENT OF DIABETES
besity and insulin resistance are important risk factors for
he development of HF (88,89). The presence of clinical
iabetes mellitus markedly increases the likelihood of HF in
atients without structural heart disease (90) and adversely
ffects the outcomes of patients with established HF
91,92). In a study of patients with type 2 diabetes mellitus
ore than 50 years of age who had urinary albumin greater
han 20 mg per liter, 4% of patients developed HF over the
tudy period, of whom 36% died (93). The occurrence of
F represents a major and adverse prognostic turn in a
iabetic patient’s life. There is a differential gender effect
ssociated with this risk; diabetes mellitus only modestly
ncreases the risk of HF for men, but it increases the relative
isk of HF more than 3-fold among women (70). Health-
are providers should make every effort to control hypergly-
emia, although such control has not yet been shown to
educe the subsequent risk of HF. In addition, ACEIs or
RBs can prevent the development of end-organ disease
nd the occurrence of clinical events in diabetic patients,
ven in those who do not have hypertension (83,94).
ong-term treatment with several ACEIs or ARBs has
een shown to decrease the risk of renal disease in diabetic
atients (95,96), and prolonged therapy with the ACEI
amipril has been shown to lower the likelihood of cardio-
ascular death, MI, and HF (83). Likewise, the use of ARBs
n patients with diabetes mellitus and hypertension or LVH
as been shown to reduce the incidence of first hospitaliza-
ion for HF, in addition to having other beneficial effects on
enal function (85,86,97).
.1.1.3. MANAGEMENT OF THE METABOLIC SYNDROME
he clustering of cardiovascular risk factors in individual
atients, termed the metabolic syndrome or syndrome X,
ncludes any 3 of the following criteria: abdominal adiposity,
ypertriglyceridemia, low high-density lipoprotein, hyper-
ension, and fasting hyperglycemia. It is estimated that the
revalence of the metabolic syndrome in the United States
xceeds 20% of individuals who are at least 20 years of age
nd 40% of the population over 40 years of age (98). The
ajor adverse consequence of the metabolic syndrome is
ardiovascular disease in general and may include an in-
reased incidence of new HF (99). As noted previously, the
ppropriate treatment of hypertension, diabetes mellitus,
nd dyslipidemia (100) as they occur in isolation can
ignificantly reduce the development of HF. A number of
rials are currently in progress to determine the most tffective intervention for patients with the metabolic
yndrome.
.1.1.4. MANAGEMENT OF ATHEROSCLEROTIC DISEASE
atients with known atherosclerotic disease (e.g., of the
oronary, cerebral, or peripheral blood vessels) are likely to
evelop HF, and healthcare providers should seek to control
ascular risk factors in such patients according to recom-
ended guidelines (87). In one large-scale trial, long-term
reatment with an ACEI decreased the risk of the primary
ndpoint of cardiovascular death, MI, and stroke in patients
ith established vascular disease who were without evidence
f HF or reduced LVEF at the time of randomization but
he incidence of new HF was not a primary or secondary
ndpoint, although it was improved (83). Among patients
ith established coronary artery disease and no HF, another
CEI significantly reduced incidence of death, MI, or
ardiac arrest, but again the incidence of new HF was
either a primary nor a secondary endpoint (84). A more
ecent large trial of ACEI versus placebo failed to show a
eduction in the primary composite endpoint, although a
ost hoc analysis did show some reduction in HF hospital-
zation (101). The committee, in reviewing the accruing
ata, decided to change the level of recommendation for the
se of ACEI for Stage A patients from Class I in the 2001
ocument to Class IIa in this document. Treatment of
yperlipidemia (in accordance with published guidelines)
as been shown to reduce the likelihood of death and of HF
n patients with a history of MI (100,102–104).
.1.1.5. CONTROL OF CONDITIONS THAT MAY CAUSE CARDIAC INJURY
any therapeutic and recreational agents can exert impor-
ant cardiotoxic effects, and patients should be strongly
dvised about the hazards of smoking, as well as the use of
lcohol, cocaine, amphetamines, and other illicit drugs.
everal epidemiological studies have revealed no correlation
etween the amount of alcohol ingested and the subsequent
evelopment of HF; nevertheless, the writing committee
trongly believed that any patient with a history of alcohol
buse or with current substantial routine alcohol consump-
ion and new-onset HF without other obvious cause should
e counseled to become abstinent. Many HF programs limit
lcoholic beverage consumption to no more than 1 alcoholic
everage serving daily for all patients with LV dysfunction,
egardless of cause (105,106). Several interventions used in
he treatment of cancer can injure the heart and lead to the
evelopment of HF, even in patients with no other cardio-
ascular risk factors. Such treatments include ionizing radi-
tion that involves the mediastinum (107) and chemother-
peutic agents such as anthracyclines, immunotherapy such
s trastuzumab, or high-dose cyclophosphamide (108–110).
atients who take trastuzumab in combination with anthra-
yclines are at particular risk of HF. Heart failure may occur
ears after initial exposure to anthracyclines or mediastinal
adiotherapy. Use of ephedra, formerly a common ingredi-
nt in over-the-counter weight loss preparations, may con-
ribute to the development of HF as well (111).
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here is no direct evidence that control of dietary sodium or
articipation in regular exercise can prevent the develop-
ent of HF; however, in patients with hypertension or
ther vascular disease, these efforts may have other health
enefits and may enhance a general sense of well-being.
here is also no evidence that routine use of nutritional
upplements can prevent dysfunction of or injury to the heart.
.1.2. Early Detection of Structural Abnormalities
symptomatic patients with ventricular dilatation and re-
uced LVEF carry substantially higher risk for subsequent
orbidity and mortality than the general population. It
ould be desirable to construct cost-effective strategies to
dentify such patients in the interest of reducing their
ubsequent risk.
Limited information is available to support the cost-
ffectiveness of broad population screening. Brain natri-
retic peptide levels represent a potential tool for this
urpose (112). An analysis of the implications of elevated
NP has suggested that the screening of asymptomatic
eople over the age of 60 years with this blood test could
ield cost-effective improvement in clinical outcomes across
he population (113). Certain patients are appropriate tar-
ets for more aggressive screening on the basis of charac-
eristics that denote an increase in the risk for structural
eart disease. Healthcare professionals should perform
chocardiographic evaluation in selected patients without
pparent structural heart disease who are at very high risk of
cardiomyopathy (e.g., those with a strong family history of
ardiomyopathy or those receiving cardiotoxic interven-
ions) (114,115). Routine periodic assessment of LV func-
ion in other patients is not recommended.
.2. Patients With Cardiac Structural Abnormalities
r Remodeling Who Have Not Developed Heart
ailure Symptoms (Stage B)
ecommendations
LASS I
. All Class I recommendations for Stage A should apply to patients
with cardiac structural abnormalities who have not developed
HF. (Levels of Evidence: A, B, and C as appropriate)
. Beta blockers and ACEIs should be used in all patients with a
recent or remote history of MI regardless of EF or presence of HF
(see Table 3). (Level of Evidence: A)
. Beta blockers are indicated in all patients without a history of MI
who have a reduced LVEF with no HF symptoms (see Table 3 and
text). (Level of Evidence: C)
. Angiotensin converting enzyme inhibitors should be used in
patients with a reduced EF and no symptoms of HF, even if they
have not experienced MI. (Level of Evidence: A)
. An ARB should be administered to post-MI patients without HF
who are intolerant of ACEIs and have a low LVEF. (Level of
Evidence: B)
. Patients who have not developed HF symptoms should be treated
according to contemporary guidelines after an acute MI. (Level
of Evidence: C) w. Coronary revascularization should be recommended in appropri-
ate patients without symptoms of HF in accordance with con-
temporary guidelines (see ACC/AHA/ACP-ASIM Guidelines for
the Management of Patients With Chronic Stable Angina [712]).
(Level of Evidence: A)
. Valve replacement or repair should be recommended for patients
with hemodynamically significant valvular stenosis or regurgita-
tion and no symptoms of HF in accordance with contemporary
guidelines. (Level of Evidence: B)
LASS IIa
. Angiotensin converting enzyme inhibitors or ARBs can be bene-
ficial in patients with hypertension and LVH and no symptoms of
HF. (Level of Evidence: B)
. Angiotensin II receptor blockers can be beneficial in patients
with low EF and no symptoms of HF who are intolerant of ACEIs.
(Level of Evidence: C)
. Placement of an ICD is reasonable in patients with ischemic
cardiomyopathy who are at least 40 days post-MI, have an LVEF
of 30% or less, are NYHA functional class I on chronic optimal
medical therapy, and have reasonable expectation of survival
with a good functional status for more than 1 year. (Level of
Evidence: B)
LASS IIb
. Placement of an ICD might be considered in patients without HF
who have nonischemic cardiomyopathy and an LVEF less than or
equal to 30% who are in NYHA functional class I with chronic
optimal medical therapy and have a reasonable expectation of
survival with good functional status for more than 1 year. (Level
of Evidence: C)
LASS III
. Digoxin should not be used in patients with low EF, sinus rhythm,
and no history of HF symptoms, because in this population, the
risk of harm is not balanced by any known benefit. (Level of
Evidence: C)
. Use of nutritional supplements to treat structural heart disease
or to prevent the development of symptoms of HF is not recom-
mended. (Level of Evidence: C)
. Calcium channel blockers with negative inotropic effects may be
harmful in asymptomatic patients with low LVEF and no symp-
toms of HF after MI (see text in Stage C). (Level of Evidence: C)
Patients without HF symptoms but who have had an MI
r who have evidence of LV remodeling are at considerable
isk of developing HF (116,117). In such patients, the
ncidence of HF can be decreased by reducing the risk of
dditional injury and by retarding the evolution and pro-
ression of LV remodeling. Initial appropriate measures
nclude those listed as Class I recommendations for patients
n Stage A (also see Section 5).
As is the case with patients who have no structural heart
isease, there is no evidence that the use of nutritional
upplements can prevent the development of HF in patients
ith a recent or remote MI with or without LV remodeling.
he aldosterone antagonist eplerenone has been shown to
educe morbidity and mortality in a population of patients
ith low EF and HF after MI that has already been treated
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2009 ACCF/AHA Heart Failure Guidelines April 14, 2009:e1–90ith ACEIs and beta blockers (118,119). Other preventive
easures have been addressed in related guidelines (120).
.2.1. Prevention of Cardiovascular Events
.2.1.1. PATIENTS WITH AN ACUTE MYOCARDIAL INFARCTION
n patients who are experiencing an acute MI, the infusion
f a fibrinolytic agent or the use of percutaneous coronary
ntervention can decrease the risk of developing HF (121),
nd these interventions can reduce the risk of death,
specially in patients with a prior myocardial injury
122,123). Patients with an acute infarction also benefit
rom the administration of both a beta blocker and either an
CEI or ARB, which can decrease the risk of reinfarction
r death when initiated within days after the ischemic event,
specially in patients whose course is complicated by HF
124 –130). Combined neurohormonal blockade (beta
locker and ACEI or ARB) produces additive benefits (131).
or recommendations on the treatment of patients with MI,
ee the ACC/AHA Guidelines for the Management of Pa-
ients With ST-Elevation Myocardial Infarction (11).
.2.1.2. PATIENTS WITH A HISTORY OF MI BUT NORMAL LEFT VENTRICULAR
JECTION FRACTION
oth hypertension and hyperlipidemia should be treated
igorously in patients with a history of MI, because the
enefits of treating these coronary risk factors are particu-
arly marked in patients with a prior ischemic event (72,73).
atients with a recent MI should also receive treatment with
CEIs and beta blockers (124,125,128,129,131), which
ave been shown to reduce the risk of death when initiated
ays or weeks after an ischemic cardiac event. Evidence
rom 2 large-scale studies indicates that prolonged therapy
ith an ACEI can also reduce the risk of a major cardio-
ascular event, even when treatment is initiated months or
ears after MI (83,84).
.2.1.3. PATIENTS WITH HYPERTENSION AND LEFT VENTRICULAR HYPERTROPHY
ee Section 4.1.1.1.
.2.1.4. PATIENTS WITH CHRONIC REDUCTION OF LEFT VENTRICULAR EJECTION
RACTION BUT NO SYMPTOMS
ong-term treatment with an ACEI has been shown to
elay the onset of HF symptoms and decrease the risk of
eath and hospitalization for HF in asymptomatic patients
ith reduced LVEF, whether due to a remote ischemic
njury or to a nonischemic cardiomyopathy (117,132).
lthough a recent trial investigated patients with low EF
nd HF at the time of MI, there are no studies that
pecifically address use of ARBs in asymptomatic patients
ith reduced LVEF. Given results of studies in symptom-
tic patients with low EF, ARBs may be an appropriate
lternative, particularly in patients who cannot tolerate an
CEI. Furthermore, although controlled clinical trials are
acking, the use of beta blockers in patients with a low EF
nd no symptoms (especially those with coronary artery
isease) is also recommended (127,131). In such cases, the same beta blockers should be used that were employed in
he large HF trials.
The use of ICD therapy in patients with chronic reduc-
ion of LVEF but no symptoms has been evaluated in one
arge trial including only patients with ischemic cardiomy-
pathy. The trials assessing ICD for primary prophylaxis in
onischemic cardiomyopathy have not included functional
lass I patients and the efficacy of ICDs in this population
s a whole is unknown (133). The trial involving patients
ith ischemic cardiomyopathy included a subset of asymp-
omatic patients post-MI with LVEF 30% or less, and there
as demonstrated benefit of ICD placement (MADIT-II)
n that subset. The findings potentially apply to large
umbers of patients, and the number needed to treat to have
enefit would be great. The writing committee struggled
ith this issue since guidelines are meant to summarize
urrent science and not take into account economic issues or
he societal impact of making a recommendation. However,
he committee recognizes that economic impact and societal
ssues will clearly modulate how these recommendations are
mplemented.
In contrast, there are no data to recommend the use of
igoxin in patients with asymptomatic reduction of LVEF,
xcept in those with atrial fibrillation. Because the only
eason to treat such patients is to prevent the progression of
F, and because digoxin has a minimal effect on disease
rogression in symptomatic patients (134), it is unlikely that
he drug would be beneficial in those with no symptoms.
ikewise, there are no data to recommend the routine use of
alcium channel blockers in patients with asymptomatic
eduction of LVEF, but they have not been shown to have
dverse effects and may be helpful for concomitant condi-
ions such as hypertension. However, the use of calcium
hannel blockers with negative inotropic effects is not
ecommended in asymptomatic patients with EF less than
0% after MI (135).
Healthcare providers should pay particular attention to
atients whose cardiomyopathy is associated with a rapid
rrhythmia of supraventricular origin (e.g., atrial flutter or
trial fibrillation). Although healthcare providers frequently
onsider such tachycardias to be the result of an impairment
f ventricular function, these rhythm disorders may lead to
r exacerbate the development of a cardiomyopathy
136,137). Therefore, in patients with a reduced LVEF,
very effort should be made to control the ventricular
esponse to these tachyarrhythmias or to restore sinus
hythm (see Section 5, Treatment of Special Populations).
.2.1.5. PATIENTS WITH SEVERE VALVULAR DISEASE BUT NO SYMPTOMS
alve replacement or repair surgery should be considered for
atients with severe aortic or mitral valve stenosis or
egurgitation, even when ventricular function is impaired
138–141). Long-term treatment with a systemic vasodila-
or drug may be considered for those with severe aortic
egurgitation who are deemed to be poor candidates for
urgery. Several studies (142,143) have suggested that pro-
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April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure Guidelinesonged therapy with hydralazine and nifedipine in patients
ith severe aortic regurgitation and preserved LV function
ight act to minimize structural changes in the ventricle and
hereby possibly delay the need for surgical intervention;
owever, these drugs are often poorly tolerated in this setting,
nd no trial has shown that these vasodilators can reduce the
isk of HF or death (see ACC/AHA Guidelines for the
anagement of Patients With Valvular Heart Disease [138]).
here are no long-term studies of vasodilator therapy in
atients with severe asymptomatic mitral regurgitation.
.2.2. Early Detection of Heart Failure
s noted, the symptoms and signs of HF are often difficult
o identify because they are frequently confused with other
isorders or are attributed to aging, obesity, or lack of
onditioning. Limitations of exercise tolerance can occur so
radually that patients may adapt their lifestyles (consciously
r subconsciously) to minimize symptoms and thus fail to
eport them to healthcare providers. Hence, patients at risk
hould be advised to inform their healthcare providers about
imitations of exercise tolerance or unexplained fatigue, and
ealthcare providers should intensify their vigilance for the
igns and symptoms of HF in such individuals.
.3. Patients With Current or Prior Symptoms of HF
Stage C)
.3.1. Patients With Reduced Left Ventricular
jection Fraction (UPDATED)
hanges in this section focused on 3 areas: recommendations
bout electrical device therapy (e.g., cardiac resynchronization
herapy [CRT] and ICDs), the use of a fixed dose combination
able 4. Oral Diuretics Recommended for Use in the Treatmen
Drug Initial Daily Dose(s)
oop Diuretics
Bumetanide 0.5 to 1.0 mg once or twice
Furosemide 20 to 40 mg once or twice
Torsemide 10 to 20 mg once
hiazide Diuretics
Chlorothiazide 250 to 500 mg once or twic
Chlorthalidone 12.5 to 25 mg once
Hydrochlorothiazide 25 mg once or twice
Indapamide 2.5 mg once
Metolazone 2.5 mg once
otassium-Sparing Diuretics*
Amiloride 5 mg once
Spironolactone 12.5 to 25 mg once
Triamterene 50 to 75 mg twice
equential Nephron Blockade
Metolazone 2.5 to 10 mg once plus loop diu
Hydrochlorothiazide 25 to 100 mg once or twice plus loo
Chlorothiazide (IV) 500 to 1000 mg once plus loop d
Eplerenone, although also a diuretic, is primarily used in chronic heart failure as a suppresso
onitoring.
IV indicates intravenous; and mg, milligrams.f hydralazine and isosorbide dinitrate in self-identified Africanmericans, and the management of atrial fibrillation in pa-
ients with HF. The previous version of the guidelines had a
umber of possibly confusing recommendations about selection of
atients for ICD implantation. The writing group has tried to
implify the recommendations, and keep them concordant with
he most recent guidelines covering the same issue (69,144).
pdated trial information has led to the change in the
ecommendations about the use of hydralazine/isosorbide
initrate and about the management of atrial fibrillation
Table 3).
ecommendations
LASS I
1. Measures listed as Class I recommendations for patients in
stages A and B are also appropriate for patients in Stage C.
(Levels of Evidence: A, B, and C as appropriate)
2. Diuretics and salt restriction are indicated in patients with
current or prior symptoms of HF and reduced LVEF who have
evidence of fluid retention (see Table 4). (Level of Evidence: C)
3. Angiotensin-converting enzyme inhibitors are recommended for
all patients with current or prior symptoms of HF and reduced
LVEF, unless contraindicated (see Table 3) (145–157). (Level
of Evidence: A)
4. Use of 1 of the 3 beta blockers proven to reduce mortality (i.e.,
bisoprolol, carvedilol, and sustained release metoprolol succi-
nate) is recommended for all stable patients with current or
prior symptoms of HF and reduced LVEF, unless contraindicated
(see Table 3) (158–176). (Level of Evidence: A)
5. Angiotensin II receptor blockers (see Table 3) are recom-
mended in patients with current or prior symptoms of HF and
reduced LVEF who are ACEI-intolerant (see text for information
regarding patients with angioedema) (130,177–186). (Level of
hronic Heart Failure
Maximum Total Daily Dose Duration of Action
10 mg 4 to 6 hours
600 mg 6 to 8 hours
200 mg 12 to 16 hours
1000 mg 6 to 12 hours
100 mg 24 to 72 hours
200 mg 6 to 12 hours
5 mg 36 hours
20 mg 12 to 24 hours
20 mg 24 hours
50 mg† 2 to 3 days
200 mg 7 to 9 hours
etic
c
e rennin-angiotensin-aldosterone system. †Higher doses may occasionally be used with closet of C
e
retic
p diur
iureti
r of thEvidence: A)
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with current or prior symptoms of HF and reduced LVEF should
be avoided or withdrawn whenever possible (e.g., nonsteroidal
anti-inflammatory drugs, most antiarrhythmic drugs, and most
calcium channel blocking drugs; see text) (187–193). (Level of
Evidence: B)
7. Exercise training is beneficial as an adjunctive approach to
improve clinical status in ambulatory patients with current or
prior symptoms of HF and reduced LVEF (193a–193d). (Level of
Evidence: B)
8. An implantable cardioverter-defibrillator is recommended as
secondary prevention to prolong survival in patients with cur-
rent or prior symptoms of HF and reduced LVEF who have a
history of cardiac arrest, ventricular fibrillation, or hemodynam-
ically destabilizing ventricular tachycardia (194–196). (Level of
Evidence: A)
9. Implantable cardioverter-defibrillator therapy is recommended
for primary prevention of sudden cardiac death to reduce total
mortality in patients with non-ischemic dilated cardiomyopathy
or ischemic heart disease at least 40 days post-MI, a LVEF less
than or equal to 35%, and NYHA functional class II or III
symptoms while receiving chronic optimal medical therapy, and
who have reasonable expectation of survival with a good
functional status for more than 1 year (144,196–202). (Level of
Evidence: A)
0. Patients with LVEF of less than or equal to 35%, sinus rhythm,
and NYHA functional class III ambulatory class IV symptoms
despite recommended optimal medical therapy and who have
cardiac dyssynchrony, which is currently defined as a QRS
duration greater than or equal to 0.12 seconds, should receive
cardiac resynchronization therapy, with or without an ICD,
unless contraindicated (203–218). (Level of Evidence: A)
1. Addition of an aldosterone antagonist is recommended in
selected patients with moderately severe to severe symptoms
of HF and reduced LVEF who can be carefully monitored for
preserved renal function and normal potassium concentration.
Creatinine should be 2.5 mg per dL or less in men or 2.0 mg per
dL or less in women and potassium should be less than 5.0 mEq
per liter. Under circumstances where monitoring for hyperkale-
mia or renal dysfunction is not anticipated to be feasible, the
risks may outweigh the benefits of aldosterone antagonists
(219–221). (Level of Evidence: B)
2. The combination of hydralazine and nitrates is recommended to
improve outcomes for patients self-described as African-
Americans, with moderate-severe symptoms on optimal therapy
with ACEIs, beta blockers, and diuretics (222,223). (Level of
Evidence: B)
LASS IIa
. It is reasonable to treat patients with atrial fibrillation and HF
with a strategy to maintain sinus rhythm or with a strategy to
control ventricular rate alone (224–228). (Level of Evidence: A)
. Maximal exercise testing with or without measurement of respi-
ratory gas exchange is reasonable to facilitate prescription of an
appropriate exercise program for patients presenting with HF.
(Level of Evidence: C)
. Angiotensin II receptor blockers are reasonable to use as alter-
natives to ACEIs as first-line therapy for patients with mild to tmoderate HF and reduced LVEF, especially for patients already
taking ARBs for other indications (130,177–185). (Level of
Evidence: A)
. Digitalis can be beneficial in patients with current or prior
symptoms of HF and reduced LVEF to decrease hospitalizations
for HF (134,229–235). (Level of Evidence: B)
. The addition of a combination of hydralazine and a nitrate is
reasonable for patients with reduced LVEF who are already
taking an ACEI and beta blocker for symptomatic HF and who
have persistent symptoms (222,236). (Level of Evidence: B)
. For patients who have LVEF less than or equal to 35%, a QRS
duration of greater than or equal to 0.12 seconds, and atrial
fibrillation (AF), CRT with or without an ICD is reasonable for the
treatment of NYHA functional class III or ambulatory class IV
heart failure symptoms on optimal recommended medical ther-
apy (2, 237). (Level of Evidence: B)
. For patients with LVEF of less than or equal to 35% with NYHA
functional class III or ambulatory class IV symptoms who are
receiving optimal recommended medical therapy and who have
frequent dependence on ventricular pacing, CRT is reasonable
(2). (Level of Evidence: C)
LASS IIb
. A combination of hydralazine and a nitrate might be reasonable in
patients with current or prior symptoms of HF and reduced LVEF
who cannot be given an ACEI or ARB because of drug intoler-
ance, hypotension, or renal insufficiency (222,238,239). (Level
of Evidence: C)
. The addition of an ARB may be considered in persistently
symptomatic patients with reduced LVEF who are already being
treated with conventional therapy (130,177–185). (Level of
Evidence: B)
LASS III
. Routine combined use of an ACEI, ARB, and aldosterone antag-
onist is not recommended for patients with current or prior
symptoms of HF and reduced LVEF. (Level of Evidence: C)
. Calcium channel blocking drugs are not indicated as routine
treatment for HF in patients with current or prior symptoms of HF
and reduced LVEF (135,240–242). (Level of Evidence: A)
. Long-term use of an infusion of a positive inotropic drug may be
harmful and is not recommended for patients with current or prior
symptoms of HF and reduced LVEF, except as palliation for
patients with end-stage disease who cannot be stabilized with
standard medical treatment (see recommendations for Stage D).
(Level of Evidence: C)
. Use of nutritional supplements as treatment for HF is not
indicated in patients with current or prior symptoms of HF and
reduced LVEF. (Level of Evidence: C)
. Hormonal therapies other than to replete deficiencies are not
recommended and may be harmful to patients with current or
prior symptoms of HF and reduced LVEF. (Level of Evidence: C)
.3.1.1. GENERAL MEASURES (UPDATED)
easures listed as Class I recommendations for patients in
tage A or B are also appropriate for patients with current or
rior symptoms of HF (also see Section 5, Treatment of
pecial Populations). In addition, moderate sodium restric-
ion, along with daily measurement of weight, is indicated
o permit effective use of lower and safer doses of diuretic
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April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure Guidelinesrugs, even if overt sodium retention can be controlled by
he use of diuretics. Immunization with influenza and
neumococcal vaccines may reduce the risk of a respiratory
nfection. Although most patients should not participate in
eavy labor or exhaustive sports, physical activity should be
ncouraged (except during periods of acute exacerbation of
he signs and symptoms of HF, or in patients with suspected
yocarditis), because restriction of activity promotes phys-
cal deconditioning, which may adversely affect clinical
tatus and contribute to the exercise intolerance of patients
ith HF (243–246).
Three classes of drugs can exacerbate the syndrome of HF
nd should be avoided in most patients:
) Antiarrhythmic agents (247) can exert important car-
diodepressant and proarrhythmic effects. Of available
agents, only amiodarone and dofetilide (248) have been
shown not to adversely affect survival.
) Calcium channel blockers can lead to worsening HF and
have been associated with an increased risk of cardiovas-
cular events (249). Of available calcium channel block-
ers, only the vasoselective ones have been shown not to
adversely affect survival (240,250).
) Nonsteroidal anti-inflammatory drugs can cause sodium
retention and peripheral vasoconstriction and can atten-
uate the efficacy and enhance the toxicity of diuretics and
ACEIs (187–190). A discussion of the use of aspirin as
a unique agent is found later in this section (see Section
4.3.1.2.2.1, Angiotensin Converting Enzyme Inhibitors
in the Management of Heart Failure).
Patients with HF should be monitored carefully for
hanges in serum potassium, and every effort should be
ade to prevent the occurrence of either hypokalemia or
yperkalemia, both of which may adversely affect cardiac
xcitability and conduction and may lead to sudden death
251). Activation of both the sympathetic nervous system
nd renin-angiotensin system can lead to hypokalemia
252,253), and most drugs used for the treatment of HF can
lter serum potassium (254). Even modest decreases in
erum potassium can increase the risks of using digitalis and
ntiarrhythmic drugs (251,255), and even modest increases
n serum potassium may prevent the use of treatments
nown to prolong life (256). Hence, many experts believe
hat serum potassium concentrations should be targeted in
he 4.0 to 5.0 mEq per liter range. In some patients,
orrection of potassium deficits may require supplementa-
ion of magnesium and potassium (257). In others (partic-
larly those taking ACEIs alone or in combination with
ldosterone antagonists), the routine prescription of potas-
ium salts may be unnecessary and potentially deleterious.
Of the general measures that should be used in patients
ith HF, possibly the most effective yet least used is close
bservation and follow-up. Nonadherence with diet and
edications can rapidly and profoundly affect the clinical
tatus of patients, and increases in body weight and minor
hanges in symptoms commonly precede by several days the accurrence of major clinical episodes that require emergency
are or hospitalization. Patient education and close super-
ision, which includes surveillance by the patient and his or
er family, can reduce the likelihood of nonadherence and
ead to the detection of changes in body weight or clinical
tatus early enough to allow the patient or a healthcare
rovider an opportunity to institute treatments that can
revent clinical deterioration. Supervision need not be
erformed by a physician and may ideally be accomplished
y a nurse or physician’s assistant with special training in the
are of patients with HF. Such an approach has been
eported to have significant clinical benefits (258–261).
Recommendations Concerning Aldosterone Antagonists. The
ddition of low-dose aldosterone antagonists is recom-
ended in carefully selected patients with moderately severe
r severe HF symptoms and recent decompensation or with
V dysfunction early after MI. These recommendations are
ased on the strong data demonstrating reduced death and
ehospitalization in 2 clinical trial populations (118,256).
he entry criteria for these trials describe a broader popu-
ation than was actually enrolled, such that the favorable
fficacy/toxicity ratio may not be as applicable to patients at
he margins of trial eligibility. For both of these major trials,
atients were excluded for a serum creatinine level in excess
f 2.5 mg per dL, but few patients were actually enrolled
ith serum creatinine levels over 1.5 mg per dL. In the trial
f patients after MI, there was a significant interaction
etween serum creatinine and benefit of eplerenone. The
verage serum creatinine of enrolled patients was 1.1 mg per
L, above which there was no demonstrable benefit for
urvival.
To minimize the risk of life-threatening hyperkalemia in
atients with low LVEF and symptoms of HF, patients
hould have initial serum creatinine less than 2.0 to 2.5 mg
er dL without recent worsening and serum potassium less
han 5.0 mEq per dL without a history of severe hyperka-
emia. In view of the consistency of evidence for patients
ith low LVEF early after MI and patients with recent
ecompensation and severe symptoms, it may be reasonable
o consider addition of aldosterone antagonists to loop
iuretics for some patients with mild to moderate symptoms
f HF; however, the writing committee strongly believes
hat there are insufficient data or experience to provide a
pecific or strong recommendation. Because the safety and
fficacy of aldosterone antagonist therapy have not been
hown in the absence of loop diuretic therapy, it is not
urrently recommended that such therapy be given without
ther concomitant diuretic therapy in chronic HF. Al-
hough 17% of patients in the CHARM (Candesartan in
eart Failure: Assessment of Reduction in Mortality and
orbidity) add-on trial (186) were receiving spironolac-
one, the safety of the combination of ACEIs, ARBs, and
ldosterone antagonists has not been explored adequately,
nd this combination cannot be recommended.
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ost patients with HF should be routinely managed with a
ombination of 3 types of drugs: a diuretic, an ACEI or an
RB, and a beta blocker (262). The value of these drugs has
een established by the results of numerous large-scale
linical trials, and the evidence supporting a central role for
heir use is compelling and persuasive. Patients with evi-
ence of fluid retention should take a diuretic until a
uvolemic state is achieved, and diuretic therapy should be
ontinued to prevent the recurrence of fluid retention. Even
f the patient has responded favorably to the diuretic,
reatment with both an ACEI and a beta blocker should be
nitiated and maintained in patients who can tolerate them
ecause they have been shown to favorably influence the
ong-term prognosis of HF. Therapy with digoxin as a
ourth agent may be initiated at any time to reduce symp-
oms, prevent hospitalization, control rhythm, and enhance
xercise tolerance.
.3.1.2.1. DIURETICS. Diuretics interfere with the sodium reten-
ion of HF by inhibiting the reabsorption of sodium or
hloride at specific sites in the renal tubules. Bumetanide,
urosemide, and torsemide act at the loop of Henle (thus,
hey are called loop diuretics), whereas thiazides, metola-
one, and potassium-sparing agents (e.g., spironolactone)
ct in the distal portion of the tubule (263,264). These 2
lasses of diuretics differ in their pharmacological actions.
he loop diuretics increase sodium excretion up to 20% to
5% of the filtered load of sodium, enhance free water
learance, and maintain their efficacy unless renal function is
everely impaired. In contrast, the thiazide diuretics increase
he fractional excretion of sodium to only 5% to 10% of the
ltered load, tend to decrease free water clearance, and lose
heir effectiveness in patients with impaired renal function
creatinine clearance less than 40 mL per min). Conse-
uently, the loop diuretics have emerged as the preferred
iuretic agents for use in most patients with HF; however,
hiazide diuretics may be preferred in hypertensive HF
atients with mild fluid retention because they confer more
ersistent antihypertensive effects.
ffect of Diuretics in the Management of HF. Controlled trials
ave demonstrated the ability of diuretic drugs to increase
rinary sodium excretion and decrease physical signs of fluid
etention in patients with HF (265,266). In these short-
erm studies, diuretic therapy has led to a reduction in
ugular venous pressures, pulmonary congestion, peripheral
dema, and body weight, all of which were observed within
ays of initiation of therapy. In intermediate-term studies,
iuretics have been shown to improve cardiac function,
ymptoms, and exercise tolerance in patients with HF
267–269). There have been no long-term studies of di-
retic therapy in HF, and thus, their effects on morbidity
nd mortality are not known.
When using diuretics in patients with HF, healthcare
roviders should keep several points in mind: d) Diuretics produce symptomatic benefits more rapidly
than any other drug for HF. They can relieve pulmonary
and peripheral edema within hours or days, whereas the
clinical effects of digitalis, ACEIs, or beta blockers may
require weeks or months to become apparent (270,271).
) Diuretics are the only drugs used for the treatment of
HF that can adequately control the fluid retention of
HF. Although both digitalis and low doses of ACEIs
can enhance urinary sodium excretion (121,123), few
patients with HF and a history of fluid retention can
maintain sodium balance without the use of diuretic
drugs. Attempts to substitute ACEIs for diuretics can
lead to pulmonary and peripheral congestion (269).
) Diuretics should not be used alone in the treatment of
Stage C HF. Even when diuretics are successful in
controlling symptoms and fluid retention, diuretics alone
are unable to maintain the clinical stability of patients
with HF for long periods of time (269). The risk of clinical
decompensation can be reduced, however, when diuretics
are combined with an ACEI and a beta blocker (229).
) Appropriate use of diuretics is a key element in the
success of other drugs used for the treatment of HF.
The use of inappropriately low doses of diuretics will
result in fluid retention, which can diminish the re-
sponse to ACEIs and increase the risk of treatment with
beta blockers (272).
Conversely, the use of inappropriately high doses of
iuretics will lead to volume contraction, which can increase
he risk of hypotension with ACEIs and vasodilators (272,
73) and the risk of renal insufficiency with ACEIs and
RBs (274). Optimal use of diuretics is the cornerstone of
ny successful approach to the treatment of HF.
RACTICAL USE OF DIURETIC THERAPY. Selection of patients.
iuretics should be prescribed to all patients who have
vidence of, and to most patients with a prior history of,
uid retention. Diuretics should generally be combined with
n ACEI and a beta blocker. Few patients with HF will be
ble to maintain dry weight without the use of diuretics.
RACTICAL USE OF DIURETIC THERAPY. Initiation and
aintenance. The most commonly used loop diuretic for the
reatment of HF is furosemide, but some patients respond
avorably to other agents in this category (such as torsemide)
ecause of superior absorption and longer duration of action
275,276). In outpatients with HF, therapy is commonly
nitiated with low doses of a diuretic, and the dose is
ncreased until urine output increases and weight decreases,
enerally by 0.5 to 1.0 kg daily. Further increases in the dose
r frequency (i.e., twice-daily dosing) of diuretic adminis-
ration may be required to maintain an active diuresis and
ustain the loss of weight. The ultimate goal of diuretic
reatment is to eliminate clinical evidence of fluid retention,
uch as jugular venous pressure elevation and peripheral
dema. Diuretics are generally combined with moderate
ietary sodium restriction.
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April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure GuidelinesIf electrolyte imbalances are seen, these should be treated
ggressively and the diuresis continued. If hypotension or
zotemia is observed before the goals of treatment are
chieved, the physician may elect to slow the rapidity of
iuresis, but diuresis should nevertheless be maintained
ntil fluid retention is eliminated, even if this strategy
esults in mild or moderate decreases in blood pressure or
enal function, as long as the patient remains asymptomatic.
xcessive concern about hypotension and azotemia can lead
o the underutilization of diuretics and a state of refractory
dema. Persistent volume overload not only contributes to
he persistence of symptoms but may also limit the efficacy
nd compromise the safety of other drugs used for the
reatment of HF (277).
Once fluid retention has resolved, treatment with the
iuretic should be maintained to prevent the recurrence of
olume overload. Patients are commonly prescribed a fixed
ose of diuretic, but the dose of these drugs frequently may
eed adjustment. In many cases, this adjustment can be
ccomplished by having patients record their weight each
ay and making changes in their diuretic dosage if the
eight increases or decreases beyond a specified range.
The response to a diuretic is dependent on the concen-
ration of the drug and the time course of its entry into the
rine (148,149). Patients with mild HF respond favorably to
ow doses because they absorb diuretics rapidly from the
owel and deliver these drugs rapidly to the renal tubules.
owever, as HF advances, the absorption of the drug may
e delayed by bowel edema or intestinal hypoperfusion, and
he delivery of the drug and the response to a given
ntratubular concentration may be impaired by a decline in
enal perfusion and function (278–280). Consequently, the
linical progression of HF is characterized by the need for
ncreasing doses of diuretics.
Patients may become unresponsive to high doses of
iuretic drugs if they consume large amounts of dietary
odium, are taking agents that can block the effects of
iuretics (e.g., nonsteroidal anti-inflammatory drugs, in-
luding cyclo-oxygenase-2 inhibitors) (188,189,281), or
ave a significant impairment of renal function or perfusion
275). Diuretic resistance can generally be overcome by the
ntravenous administration of diuretics (including the use of
ontinuous infusions) (282), the use of 2 or more diuretics in
ombination (e.g., furosemide and metolazone) (283–286),
r the use of diuretics together with drugs that increase renal
lood flow (e.g., positive inotropic agents) (286).
RACTICAL USE OF DIURETIC THERAPY. Risks of treatment.
he principal adverse effects of diuretics include electrolyte
nd fluid depletion, as well as hypotension and azotemia.
iuretics may also cause rashes and hearing difficulties, but
hese are generally idiosyncratic or are seen with the use of
ery large doses, respectively.
Diuretics can cause the depletion of important cations
potassium and magnesium), which can predispose patients
o serious cardiac arrhythmias, particularly in the presence of sigitalis therapy (287). The risk of electrolyte depletion is
arkedly enhanced when 2 diuretics are used in combina-
ion. The loss of electrolytes is related to enhanced delivery
f sodium to distal sites in the renal tubules and the
xchange of sodium for other cations, a process that is
otentiated by activation of the renin-angiotensin-
ldosterone system (264). Potassium deficits can be cor-
ected by the short-term use of potassium supplements or, if
evere, by the addition of magnesium supplements (288).
oncomitant administration of ACEIs alone or in combi-
ation with potassium-retaining agents (such as spironolac-
one) can prevent electrolyte depletion in most patients with
F who are taking a loop diuretic. When these drugs are
rescribed, long-term oral potassium supplementation fre-
uently is not needed and may be deleterious.
Excessive use of diuretics can decrease blood pressure and
mpair renal function and exercise tolerance (272–274,289),
ut hypotension and azotemia may also occur as a result of
orsening HF, which may be exacerbated by attempts to
educe the dose of diuretics. If there are no signs of fluid
etention, hypotension and azotemia are likely to be related
o volume depletion and may resolve after a reduction in
iuretic dose. The signs of fluid retention, hypotension and
zotemia, are likely to reflect worsening HF and a decline in
ffective peripheral perfusion. This is an ominous clinical
cenario and necessitates considering the measures discussed
nder Stage D HF. Tables 4 and 5 illustrate oral and
ntravenous diuretics recommended for use in the treatment
f chronic HF.
.3.1.2.2. INHIBITORS OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM-
Inhibition of the renin-angiotensin-aldosterone system
an take place at multiple sites: at the level of the enzyme
hat converts angiotensin I to angiotensin II (ACEIs), at the
ngiotensin receptor (ARBs), or at the receptor for aldoste-
one, which is under control of both the renin angiotensin
able 5. Intravenous Diuretic Medications Useful for the
reatment of Severe Heart Failure
Drug Initial Dose Maximum Single Dose
oop Diuretics
Bumetanide 1.0 mg 4 to 8 mg
Furosemide 40 mg 160 to 200 mg
Torsemide 10 mg 100 to 200 mg
hiazide Diuretics
Chlorothiazide 500 mg 1000 mg
equential Nephron Blockade
Chlorothiazide 500 to 1000 mg (IV) once or twice plus
loop diuretics once; multiple doses per day
Metozalone (as Zaroxolyn
or Diulo)
2.5 to 5 mg PO once or twice daily
with loop diuretic
V Infusions
Bumetanide 1-mg IV load then 0.5 to 2 mg per hour infusion
Furosemide 40-mg IV load then 10 to 40mg per hour infusion
Torsemide 20-mg IV load then 5 to 20mg per hour infusion
V indicates intravenous; kg, kilograms; mg, milligrams; and PO, by mouth.ystem and other systemic and local influences (aldosterone
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2009 ACCF/AHA Heart Failure Guidelines April 14, 2009:e1–90ntagonists). Angiotensin converting enzyme inhibitors are
he best-studied class of agents in HF, with multiple
echanisms of benefit for both HF, coronary disease, and
ther atherosclerotic vascular disease, as well as diabetic
ephropathy. During chronic therapy with ACEIs, the
enin-angiotensin system demonstrates partial “escape”
rom inhibition with “normalization” of angiotensin levels,
n part owing to alternative local pathways for production of
ngiotensin. This leaves the potential for benefit from
dditional therapy with ARBs and with the aldosterone
ntagonists.
.3.1.2.2.1. Angiotensin Converting Enzyme Inhibitors in the
anagement of Heart Failure. It is not clear whether the
ffects of ACEIs can be explained solely by the suppression
f angiotensin II production, because ACE inhibition not
nly interferes with the renin-angiotensin system but also
nhances the action of kinins and augments kinin-mediated
rostaglandin production (290–292). In experimental mod-
ls of HF, ACEIs modify cardiac remodeling more favor-
bly than ARBs (293–296), and this advantage of ACEIs is
bolished by the coadministration of a kinin receptor
locker (293,295). Angiotensin converting enzyme inhibi-
ors have been evaluated in more than 7000 patients with
F who participated in more than 30 placebo-controlled
linical trials (146). All of these trials enrolled patients with
educed LVEF (EF less than 35% to 40%) who were treated
ith diuretics, with or without digitalis. These trials re-
ruited many types of patients, including women and the
lderly, as well as patients with a wide range of causes and
everity of LV dysfunction. However, patients with pre-
erved systolic function, low blood pressure (less than 90
m Hg systolic), or impaired renal function (serum creat-
nine greater than 2.5 mg per mL) were not recruited or
epresented a small proportion of patients who participated
n these studies.
Analysis of this collective experience indicates that
CEIs can alleviate symptoms, improve clinical status, and
nhance the overall sense of well-being of patients with HF
145,147–157). In addition, ACEIs can reduce the risk of
eath and the combined risk of death or hospitalization
155–157). These benefits of ACE inhibition were seen in
atients with mild, moderate, or severe symptoms and in
atients with or without coronary artery disease.
RACTICAL USE OF ACEIS. Selection of patients. Angiotensin
onverting enzyme inhibitors should be prescribed to all
atients with HF due to LV systolic dysfunction with
educed LVEF unless they have a contraindication to their
se or have been shown to be unable to tolerate treatment
ith these drugs. Because of their favorable effects on
urvival, treatment with an ACEI should not be delayed
ntil the patient is found to be resistant to treatment with
ther drugs.
In general, ACEIs are used together with a beta blocker.
ngiotensin converting enzyme inhibitors should not be
rescribed without diuretics in patients with a current or iecent history of fluid retention, because diuretics are
eeded to maintain sodium balance and prevent the devel-
pment of peripheral and pulmonary edema (269). Angio-
ensin converting enzyme inhibitors are often preferred over
RBs or direct-acting vasodilators (156,297) because of the
reater experience and weight of evidence in support of their
ffectiveness.
Patients should not be given an ACEI if they have
xperienced life-threatening adverse reactions (angioedema
r anuric renal failure) during previous exposure to the drug
r if they are pregnant. They should take an ACEI with
aution if they have very low systemic blood pressures
systolic blood pressure less than 80 mm Hg), markedly
ncreased serum levels of creatinine (greater than 3 mg per
L), bilateral renal artery stenosis, or elevated levels of
erum potassium (greater than 5.5 mEq per liter). Finally,
reatment with an ACEI should not be initiated in hypo-
ensive patients who are at immediate risk of cardiogenic
hock. Such patients should first receive other forms of
reatment for their HF and then be re-evaluated for ACE
nhibition once stability has been achieved.
RACTICAL USE OF ACEIS. Initiation and maintenance. Al-
hough most of the evidence that supports an effect of
CEIs on the survival of patients with HF is derived from
xperience with enalapril, the available data suggest that
here are no differences among available ACEIs in their
ffects on symptoms or survival (146). Although some have
uggested that drugs in this class may differ in their ability
o inhibit tissue ACE, no trial has shown that tissue ACE
nhibiting agents are superior to other ACEIs in any clinical
spect of HF. Nevertheless, in selecting among ACEIs, it is
ecommended that preference be given to ACEIs that have
een shown to reduce morbidity and mortality in clinical
rials in HF or post-MI populations (captopril, enalapril,
isinopril, perindopril, ramipril, and trandolapril), because
hese studies have clearly defined a dose that is effective in
odifying the natural history of the disease. Such informa-
ion is generally lacking for ACEIs that have not been
hown to be effective in large-scale studies.
Treatment with an ACEI should be initiated at low doses
see Table 5), followed by gradual increments in dose if
ower doses have been well tolerated. Renal function and
erum potassium should be assessed within 1 to 2 weeks of
nitiation of therapy and periodically thereafter, especially in
atients with preexisting hypotension, hyponatremia, dia-
etes mellitus, or azotemia or in those taking potassium
upplements. Because fluid retention can blunt the thera-
eutic effects and fluid depletion can potentiate the adverse
ffects of ACE (274,277), healthcare providers should
nsure that patients are being given appropriate doses of
iuretics before and during treatment with these drugs.
ost patients (85% to 90%) with HF can tolerate short-
nd long-term therapy with these drugs (155–157).
What dose of an ACEI should physicians try to achieven patients with HF? In controlled clinical trials that were
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April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure Guidelinesesigned to evaluate survival, the dose of the ACEI was not
etermined by a patient’s therapeutic response but was
ncreased until a target dose was reached (193–195). How-
ver, these drugs are commonly prescribed in clinical prac-
ice at much lower doses that are similar to those recom-
ended for initiation rather than maintenance of therapy.
hich approach should be followed? In the controlled
linical trials of ACEIs, low or intermediate doses were
ommonly prescribed if higher doses could not be tolerated.
n controlled trials with newer agents for HF, intermediate
oses rather than high doses of ACEIs were generally used
s background therapy. Higher doses of an ACEI were
etter than low doses in reducing the risk of hospitalization,
ut they showed similar effects on symptoms and mortality
298,299). Clinicians should attempt to use doses that have
een shown to reduce the risk of cardiovascular events in
linical trials. If these target doses of an ACEI cannot be
sed or are poorly tolerated, intermediate doses should be
sed with the expectation that there are likely to be only
mall differences in efficacy between low and high doses.
ore importantly, clinicians should not delay the institu-
ion of beta blockers in patients because of a failure to reach
arget ACEI doses. Once the drug has been titrated to the
ppropriate dose, patients can generally be maintained on
ong-term therapy with an ACEI with little difficulty.
lthough symptoms may improve in some patients within
he first 48 hours of therapy with an ACEI, the clinical
esponses to these drugs are generally delayed and may
equire several weeks, months, or more to become apparent
145,270). Even if symptoms do not improve, long-term
reatment with an ACEI should be maintained to reduce
he risk of death or hospitalization. Abrupt withdrawal of
reatment with an ACEI can lead to clinical deterioration
nd should be avoided (300) in the absence of life-
hreatening complications (e.g., angioedema).
Every effort should be made to minimize the occurrence
f sodium retention or depletion during long-term treat-
ent with an ACEI, because changes in salt and water
alance can exaggerate or attenuate the cardiovascular and
enal effects of treatment (274,277). Fluid retention can
inimize the symptomatic benefits of ACE inhibition,
hereas fluid loss increases the risk of hypotension and
zotemia. The use of an ACEI can also minimize or
liminate the need for long-term potassium supplementa-
ion. Nonsteroidal anti-inflammatory drugs can block the
avorable effects and enhance the adverse effects of ACEIs
n patients with HF and should be avoided (190,252).
Clinical experience in patients who are hemodynamically
r clinically unstable suggests that the hypotensive effects of
CE inhibition may attenuate the natriuretic response to
iuretics and antagonize the pressor response to intravenous
asoconstrictors (301,302). As a result, in such patients
particularly those who are responding poorly to diuretic
rugs), it may be prudent to interrupt treatment with the
CEI temporarily until the clinical status of the patienttabilizes. iRetrospective analyses of large-scale clinical trials have
uggested that aspirin might interfere with the benefits of
CE inhibition in patients with HF by inhibiting kinin-
ediated prostaglandin synthesis. In short-term hemody-
amic and maximal-exercise studies, aspirin can attenuate
he hemodynamic actions of ACEIs in patients with HF
303,304), an effect not seen with nonaspirin antiplatelet
gents (e.g., clopidogrel) (305).
In several multicenter trials, concomitant use of aspirin
as associated with a diminution of the effect of ACEIs on
urvival and on cardiovascular morbidity (306,307). A re-
ent comprehensive systematic overview of 22 060 patients
rom 6 long-term randomized trials of ACEIs reevaluated
he issue of the potential detrimental effect of combining
spirin with ACEI therapy. When all of these trials were
onsidered together, the effects of ACEIs were significantly
eneficial in patients with and without aspirin therapy. The
omposite risk reduction was 20% for patients taking aspirin
nd 29% for those not taking aspirin, a difference that did
ot reach statistical significance (308). A second retrospec-
ive review subsequently also reported no adverse effect of
oncomitant aspirin use with ACEIs on long-term survival
309). Given these retrospective results, many physicians
elieve the data justify prescribing aspirin and ACEIs
ogether when there is an indication for use of aspirin.
owever, these large overviews are subject to varying
nterpretation. Other physicians would consider not com-
ining aspirin with an ACEI because there are no data to
ndicate that it can reduce the risk of ischemic events in
atients with HF (310,311), or they might consider the use
f an alternative antiplatelet agent such as clopidogrel,
hich does not interact with ACEIs and which may have
uperior effects in preventing ischemic events (312). How-
ver, clopidogrel does not have an indication for the primary
revention of ischemic events. There may be an important
nteraction between aspirin and ACEIs, but there is con-
roversy regarding this point, and it requires further study.
RACTICAL USE OF ACEIS. Risks of treatment. Most of the
dverse reactions of ACEIs can be attributed to the 2
rincipal pharmacological actions of these drugs: those
elated to angiotensin suppression and those related to kinin
otentiation. Other types of side effects may also occur (e.g.,
ash and taste disturbances).
dverse effects related to angiotensin suppression.
. HYPOTENSION
he most common adverse effects of ACE inhibition in
atients with HF are hypotension and dizziness. Blood
ressure declines without symptoms in nearly every patient
reated with an ACEI, so hypotension is generally a concern
nly if it is accompanied by postural symptoms, worsening
enal function, blurred vision, or syncope. Hypotension is
een most frequently during the first few days of initiation of
ncrements in therapy, particularly in patients with hypovo-
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2009 ACCF/AHA Heart Failure Guidelines April 14, 2009:e1–90emia, a recent marked diuresis, or severe hyponatremia (serum
odium concentration less than 130 mmol per liter) (313).
Should symptomatic hypotension occur with the first
oses, it may not recur with repeated administration of the
ame doses of the drug. However, it is prudent under such
ircumstances to reduce the activation of and dependence
n the renin-angiotensin system by reducing the dose of
iuretics, liberalizing salt intake, or both, provided the
atient does not have significant fluid retention. The doses
f other hypotensive agents (especially vasodilators) can be
educed or staggered so their peak effect does not coincide
ith that of the ACEI. Most patients who experience early
ymptomatic hypotension remain excellent candidates for
ongterm ACE inhibition if appropriate measures are taken
o minimize recurrent hypotensive reactions.
. WORSENING RENAL FUNCTION
n states characterized by reduced renal perfusion (such as
F), glomerular filtration is critically dependent on
ngiotensin-mediated efferent arteriolar vasoconstriction
314), and ACE inhibition may cause functional renal
nsufficiency (274). Because the decline in glomerular filtra-
ion is related to the withdrawal of the actions of angioten-
in II, the risk of azotemia is highest in patients who are
ost dependent on the renin-angiotensin system for sup-
ort of renal homeostasis (i.e., class IV hyponatremic
atients) (315). A significant increase in serum creatinine
e.g., greater than 0.3 mg per dL) with the use of ACEIs is
bserved in 15% to 30% of patients with severe HF (316),
ut in only 5% to 15% of patients with mild to moderate
ymptoms (317). The risks are substantially greater if
atients have bilateral renal artery stenosis or are taking
onsteroidal anti-inflammatory drugs (189,252,318). Renal
unction usually improves after a reduction in the dose of
oncomitantly administered diuretics, and thus, these pa-
ients can generally be managed without the need to
ithdraw treatment with the ACEI (274). However, if the
ose of diuretic cannot be reduced because the patient has
uid retention, the physician and patient may need to
olerate mild to moderate degrees of azotemia to maintain
herapy with the ACEI.
. POTASSIUM RETENTION
yperkalemia can occur during ACE inhibition in patients
ith HF and may be sufficiently severe to cause cardiac
onduction disturbances. In general, hyperkalemia is seen in
atients whose renal function deteriorates or who are taking
ral potassium supplements or potassium-sparing diuretics,
r aldosterone antagonists, especially if they have diabetes
ellitus (319).
dverse effects related to kinin potentiation.
. COUGH
ough related to the use of ACEIs is the most common
eason for the withdrawal of long-term treatment with these trugs (320); the frequency of cough is approximately 5% to
0% in white patients of European descent and rises to
early 50% in Chinese patients (321). It is characteristically
onproductive, is accompanied by a persistent and annoying
tickle” in the back of the throat, usually appears within the
rst months of therapy, disappears within 1 to 2 weeks of
iscontinuing treatment, and recurs within days of rechal-
enge. Other causes of cough, especially pulmonary conges-
ion, should always be considered, and the ACEI should be
mplicated only after these have been excluded. Demonstra-
ion that the cough disappears after drug withdrawal and
ecurs after rechallenge with another ACEI strongly sug-
ests that ACE inhibition is the cause of the cough. In a
umber of studies of ACEI cough, it was found that this
ymptom did not recur with rechallenge and probably was a
oincidental finding. Because of the long-term benefits of
CEIs, physicians should encourage patients to continue
aking these drugs if the cough is not severe. Only if the
ough proves to be persistent and troublesome should the
hysician consider withdrawal of the ACEI and the use of
lternative medications (e.g., an ARB).
. ANGIOEDEMA
ngioedema occurs in fewer than 1% of patents taking an
CEI but is more frequent in blacks. Because its occurrence
ay be life-threatening, the clinical suspicion of this reac-
ion justifies subsequent avoidance of all ACEIs for the
ifetime of the patient (320). Angiotensin converting en-
yme inhibitors should not be initiated in any patient with
history of angioedema. Although ARBs may be consid-
red as alternative therapy for patients who have developed
ngioedema while taking an ACEI, there are a number of
atients who have also developed angioedema with ARBs
nd extreme caution is advised when substituting an ARB in
patient who has had angioedema associated with ACEI
se (177,322–324).
.3.1.2.2.2. Angiotensin Receptor Blockers. Agents that block
hese receptors were developed on the rationale that 1)
ngiotensin II production continues in the presence of ACE
nhibition, driven through alternative enzyme pathways, and
) interference with the renin-angiotensin system without
nhibition of kininase would produce all of the benefits of
CEIs while minimizing the risk of their adverse reactions
325). However, it is now known that some of the benefits
ay be related to the accumulation of kinins (326) rather
han to the suppression of angiotensin II formation, whereas
ome of the side effects of ACEIs in HF are related to the
uppression of angiotensin II formation (293–295). Table 6
ists the inhibitors of the renin-angiotensin-aldosterone
ystem and beta blockers that are commonly used for the
reatment of patients with HF with low ejection fraction.
Several ARBs (e.g., candesartan, eprosartan, irbesartan,
osartan, telmisartan, olmesartan, and valsartan) are avail-
ble for clinical use. Experience with these drugs in con-
rolled clinical trials of patients with HF is considerably less
han that with ACEIs. Nevertheless, in several placebo-
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emodynamic, neurohormonal, and clinical effects consis-
ent with those expected after interference with the renin
ngiotensin system (178–183). In patients with evidence of
V dysfunction early after MI, a recent trial demonstrated
hat ARBs had a benefit that was not inferior to that of
CEIs without an advantage in terms of tolerability (130).
owever, the addition of an ARB to an ACEI did not
mprove outcomes and resulted in more side effects.
For patients unable to tolerate ACEIs because of cough
r angioedema, the ARBs valsartan and candesartan
177,184) have demonstrated benefit by reducing hospital-
zations and mortality. The combination of an ACEI and
RBs may produce more reduction of LV size than either
gent alone (185). The addition of ARBs to chronic ACEI
herapy caused a modest decrease in hospitalization in 2
tudies, with a trend to decreased total mortality in one and
o impact on mortality in another (184,185,327).
Recommendations Concerning Angiotensin Receptor Blockers.
ngiotensin converting enzyme inhibitors remain the first
hoice for inhibition of the renin-angiotensin system in
hronic HF, but ARBs can now be considered a reasonable
lternative. Candesartan improved outcomes in patients
ith preserved LVEF who were intolerant of ACEIs in the
andesartan in Heart Failure Assessment of Reduction in
able 6. Inhibitors of the Renin-Angiotensin-Aldosterone
ystem and Beta Blockers Commonly Used for the Treatment
f Patients With HF With Low Ejection Fraction
Drug
Initial Daily
Dose(s)
Maximum
Doses(s)
CE Inhibitors
Captopril 6.25 mg 3 times 50 mg 3 times
Enalapril 2.5 mg twice 10 to 20 mg twice
Fosinopril 5 to 10 mg once 40 mg once
Lisinopril 2.5 to 5 mg once 20 to 40 mg once
Perindopril 2 mg once 8 to 16 mg once
Quinapril 5 mg twice 20 mg twice
Ramipril 1.25 to 2.5 mg once 10 mg once
Trandolapril 1 mg once 4 mg once
ngiotensin Receptor Blockers
Candesartan 4 to 8 mg once 32 mg once
Losartan 25 to 50 mg once 50 to 100 mg once
Valsartan 20 to 40 mg twice 160 mg twice
ldosterone Antagonists
Spironolactone 12.5 to 25 mg once 25mg once or twice
Eplerenone 25 mg once 50 mg once
eta Blockers
Bisoprolol 1.25 mg once 10 mg once
Carvedilol 3.125 mg twice 25 mg twice
50 mg twice for
patients 85 kg
Metoprolol succinate
extended release
(metoprolol CR/XL)
12.5 to 25 mg once 200 mg once
CE indicates angiotensin converting enzyme; kg, kilograms, and mg, milligrams.ortality and Morbidity (CHARM) Alternative trial (177). fngiotensin receptor blockers are as likely to produce
ypotension, worsening renal function, and hyperkalemia as
CEIs. Although angioedema is much less frequent with
RBs, there are cases of patients who developed angio-
dema to both ACEIs and later to ARBs (177). There is
ittle information available about the addition of ARBs to
herapy with both ACEIs and aldosterone antagonists, but
isks of renal dysfunction and hyperkalemia would be
urther increased. Until further information is available, the
outine combined use of all 3 inhibitors of the renin-
ngiotensin system cannot be recommended.
RACTICAL USE OF ARBS. Initiation and maintenance. When
sed, angiotensin receptor antagonists should be initiated
ith the starting doses shown in Table 6. Many of the
onsiderations with ARB are similar to those with initiation
f an ACEI, as discussed above. Blood pressure (including
ostural blood pressure changes), renal function, and potas-
ium should be reassessed within 1 to 2 weeks after
nitiation and followed closely after changes in dose. Pa-
ients with systolic blood pressure below 80 mm Hg, low
erum sodium, diabetes mellitus, and impaired renal func-
ion merit particular surveillance during therapy with inhib-
tors of the renin angiotensin-aldosterone system. Titration
s generally achieved by doubling doses. For stable patients,
t is reasonable to add therapy with beta-blocking agents
efore full target doses of either ACEIs or ARBs are
eached.
The risks of treatment with ARBs are those attributed to
uppression of angiotensin stimulation, as discussed above
or ACEIs. These risks of hypotension, renal dysfunction,
nd hyperkalemia are greater when combined with another
nhibitor of this axis, such as ACEIs or aldosterone
ntagonists.
.3.1.2.2.3. Aldosterone Antagonists. Although short-term
herapy with both ACEIs and ARBs can lower circulating
evels of aldosterone, such suppression may not be sustained
uring long-term treatment (328). The lack of long-term
uppression may be important, because experimental data
uggest that aldosterone exerts adverse effects on the struc-
ure and function of the heart, independently of and in
ddition to the deleterious effects produced by angiotensin
I (329–335).
Spironolactone is the most widely used aldosterone an-
agonist. In a large-scale, long-term trial (256), low doses of
pironolactone (starting at 12.5 mg daily) were added to
CEI therapy for patients with NYHA functional class IV
F symptoms or class III symptoms and recent hospital-
zation. The risk of death was reduced from 46% to 35%
30% relative risk reduction) over 2 years, with a 35%
eduction in HF hospitalization and an improvement in
unctional class. Initial creatinine levels were below 2.0 mg
er dL in the dose-ranging pilot trial and below 2.5 mg per
L in the main trial. Potassium replacements were stopped
t trial entry, and serum potassium and renal function were
ollowed very closely.
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nist eplerenone in patients with LVEF less than or equal to
0% and clinical evidence of HF or diabetes mellitus within
4 days of MI. Mortality was decreased from 13.6% to
1.8% at 1 year. Hyperkalemia occurred in 5.5% of patients
reated with eplerenone compared with 3.9% of those given
lacebo overall and in up to 10.1% versus 4.6% of patients
ith estimated creatinine clearance less than 50 mL per
inute (118).
RACTICAL USE OF ALDOSTERONE ANTAGONISTS. Selection
f patients. Decisions regarding the selection of patients for
ldosterone antagonists reflect the balance between poten-
ial benefit to decrease death and hospitalization from HF
nd potential risks of life-threatening hyperkalemia. Despite
his, patients who meet recommended criteria from formal
rials may need to be excluded in practice for a recent history
f renal dysfunction characterized by higher creatinine,
arkedly elevated blood urea nitrogen, or hyperkalemia,
articularly in the presence of insulin-requiring diabetes
ellitus. Serum creatinine levels often underestimate renal
ysfunction, particularly in the elderly, in whom estimated
reatinine clearance less than 50 mL per minute should
rigger a reduction of the initial dose of spironolactone to
2.5 mg daily or of eplerenone to 25 mg daily, and
ldosterone antagonists should not be given when clearance
s less than 30 mL per minute (Table 7). Patients chronically
equiring high doses of diuretics without potassium replace-
ent should be evaluated closely, because potassium han-
able 7. Guidelines for Minimizing the Risk of Hyperkalemia
n Patients Treated With Aldosterone Antagonists
. Impaired renal function is a risk factor for hyperkalemia during treatment
with aldosterone antagonists. The risk of hyperkalemia increases
progressively when serum creatinine exceeds 1.6 mg/dL.* In elderly
patients or others with low muscle mass in whom serum creatinine does not
accurately reflect glomerular filtration rate, determination that glomerular
filtration rate or creatinine clearance exceeds 30 ml per minute is
recommended.
. Aldosterone antagonists should not be administered to patients with
baseline serum potassium in excess of 5.0 mEq per liter.
. An initial dose of spironolactone of 12.5 mg or eplerenone 25 mg is
recommended, following which the dose may be increased to
spironolactone 25 mg or eplerenone 50 mg if appropriate.
. The risk of hyperkalemia is increased with concomitant use of higher doses
of ACEIs (captopril greater than or equal to 75 mg daily; enalapril or
lisinopril greater than or equal to 10 mg daily.
. Non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors
should be avoided.
. Potassium supplements should be discontinued or reduced.
. Close monitoring of serum potassium is required; potassium levels and
renal function should be checked in 3 days and at 1 week after initiating
therapy and at least monthly for the first 3 months.
. Diarrhea or other causes of dehydration should be addressed emergently.
Although the entry criteria for the trials of aldosterone antagonists included creatinine greater
han 2.5 mg per dL, the majority of patients had creatinine much lower; in 1 trial (335a) 95% of
atients had creatinine less than or equal to 1.7 mg per dL.
ACEI indicates angiotensin converting enzyme inhibitor.ling may be impaired. lRACTICAL USE OF ALDOSTERONE ANTAGONISTS. Risks of
ldosterone Antagonists. The major risk of aldosterone an-
agonists is hyperkalemia due to inhibition of potassium
xcretion. Renal dysfunction may be aggravated, which
urther impairs potassium excretion. The positive results of
recent trial led to wider use of spironolactone in HF
egimens. The subsequent incidence of hyperkalemia was
eported to be as high as 24% in one series (219), in which
alf of the subjects with hyperkalemia had potassium levels
n excess of 6 mEq per liter. Similar results were reported
rom Norway (221). Although this far exceeded the 2%
ncidence in the large trial, it is comparable to the 13%
bserved in the preceding pilot trial with a 25-mg dose and
0% with a 50-mg dose.
The potential impact on the overall HF population is
uggested by a population-based analysis in Ontario, Can-
da, of more than 30 000 patients taking ACEIs after a
ospitalization for HF. After publication of these trial
esults in 1999, prescriptions for spironolactone in this
eographic area more than tripled, the rate of hospitaliza-
ion for hyperkalemia increased from 2.4 to 11 patients per
housand, and the associated mortality increased from 0.3 to
per thousand (220). These observations lead to a strong
ecommendation for caution in the selection and monitor-
ng of patients to be given aldosterone antagonists, because
he observations make it clear that clinical trial populations
re highly selected, and there is a great increase in evidence
f toxicity when the trial results are applied to the general
opulation.
Although aldosterone antagonists usually have a relatively
eak diuretic effect, some patients may experience marked
otentiation of other diuretic therapy after the addition of
ldosterone antagonists. Fluid depletion can occur, which
urther increases the risk of renal dysfunction and hyperka-
emia. During chronic therapy after initial stabilization,
yperkalemia may occur in the setting of other conditions
hat cause volume depletion, such as gastroenteritis. Gy-
ecomastia or other antiandrogen effects that can occur
uring therapy with spironolactone are not generally seen
ith the newer aldosterone antagonist eplerenone (118).
RACTICAL USE OF ALDOSTERONE ANTAGONISTS. Initiation
nd Monitoring. Spironolactone should be initiated at a dose
f 12.5 to 25 mg daily, or occasionally on alternate days.
plerenone was used after MI in one study (118) at doses of
5 mg per day, increasing to 50 mg daily. Potassium
upplementation is generally stopped after the initiation of
ldosterone antagonists, and patients should be counseled to
void high potassium–containing foods. However, patients
ho have required large amounts of potassium supplemen-
ation may need to continue receiving supplementation,
lbeit at a lower dose, particularly when previous episodes of
ypokalemia have been associated with ventricular arrhyth-
ias. On the other hand, potassium supplementation re-
uired during vigorous therapy of fluid overload is often no
onger necessary once the goal is to maintain even fluid
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April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure Guidelinesalance. Patients should be cautioned to avoid the addition
f nonsteroidal anti-inflammatory agents and cyclo-
xygenase- 2 inhibitors, which can lead to worsening renal
unction and hyperkalemia. Potassium levels and renal
unction should be rechecked within 3 days and again at 1
eek after initiation of an aldosterone antagonist. Subse-
uent monitoring should be dictated by the general clinical
tability of renal function and fluid status but should occur
t least monthly for the first 3 months and every 3 months
hereafter. The addition or an increase in dosage of ACEIs
r ARBs should trigger a new cycle of monitoring. In view
f the potential risk for hyperkalemia, the writing commit-
ee recommends that the routine triple combination of
CEIs, ARBs, and an aldosterone antagonist be avoided.
The development of potassium levels in excess of 5.5
Eq per liter should generally trigger discontinuation or
ose reduction of the aldosterone antagonist unless patients
ave been receiving potassium supplementation, which
hould then be stopped. The development of worsening
enal function should lead to careful evaluation of the entire
edical regimen and consideration for stopping the aldo-
terone antagonist. Patients should be instructed specifically
o stop the aldosterone antagonist during an episode of
iarrhea or while loop diuretic therapy is interrupted.
.3.1.2.3. BETA-ADRENERGIC RECEPTOR BLOCKERS. Beta blockers act
rincipally to inhibit the adverse effects of the sympathetic
ervous system in patients with HF, and these effects far
utweigh their well-known negative inotropic effects.
hereas cardiac adrenergic drive initially supports the
erformance of the failing heart, long-term activation of the
ympathetic nervous system exerts deleterious effects that
an be antagonized by the use of beta blockers. Sympathetic
ctivation can increase ventricular volumes and pressure by
ausing peripheral vasoconstriction (336) and by impairing
odium excretion by the kidneys (337). Norepinephrine can
lso induce cardiac hypertrophy but restrict the ability of the
oronary arteries to supply blood to the thickened ventric-
lar wall, leading to myocardial ischemia (316,338,339).
ctivation of the sympathetic nervous system can also
rovoke arrhythmias by increasing the automaticity of
ardiac cells, increasing triggered activity in the heart, and
romoting the development of hypokalemia (253,340–342).
orepinephrine can also increase heart rate and potentiate
he activity and actions of other neurohormonal systems.
inally, by stimulating growth and oxidative stress in
erminally differentiated cells, norepinephrine can trigger
rogrammed cell death or apoptosis (343). These deleterious
ffects are mediated through actions on alpha-1–, beta-1–, and
eta-2–adrenergic receptors (253,316,336–343).
Three beta blockers have been shown to be effective in
educing the risk of death in patients with chronic HF:
isoprolol (158) and sustained-release metoprolol (succi-
ate) (159), which selectively block beta-1–receptors, and
arvedilol (165,166), which blocks alpha-1–, beta-1–, and
eta-2–receptors. Positive findings with these 3 agents,
owever, should not be considered indicative of a beta- nlocker class effect, as shown by the lack of effectiveness of
ucindolol and the lesser effectiveness of short-acting meto-
rolol in clinical trials (160,161,344). Patients who have
tage C HF should be treated with 1 of these 3 beta-
lockers. The relative efficacy among these 3 agents is not
nown, but available evidence does suggest that beta-
lockers can differ in their effects on survival (160). In one
rial (161), carvedilol (target dose 25 mg twice daily) was
ompared with immediate-release metoprolol tartrate (tar-
et dose 50 mg twice daily). In that trial, carvedilol was
ssociated with a significantly reduced mortality compared
ith metoprolol tartrate. Although both the dose and the
ormulation of metoprolol (metoprolol tartrate) used in the
bove-referenced trial are commonly prescribed by physi-
ians for the treatment of HF, they were neither the dose
or the formulation used in the controlled trial (159) that
howed that sustained-release metoprolol (metoprolol suc-
inate) reduces the risk of death (162). There have been no
rials to explore whether the survival benefits of carvedilol
re greater than those of sustained-released metoprolol
hen both are used at the target doses.
ffect of Beta Blockers in the Management of HF. Beta
lockers have now been evaluated in more than 20 000
atients with HF who participated in more than 20 pub-
ished placebo-controlled clinical trials (89,93,158,162–
64,166,167,345). All trials enrolled patients with reduced
VEF (EF less than 35% to 45%) who had already been
reated with diuretics and an ACEI, with or without
igitalis. These trials recruited many types of patients,
ncluding women and the elderly, as well as patients with a
ide range of causes and severity of LV dysfunction, but
atients with preserved systolic function, low heart rates
less than 65 beats per min), or low systolic blood pressure
less than 85 mm Hg) and those who were hospitalized or
ho had class IV HF were not recruited or represented a
mall proportion of the patients who participated in these
ublished studies. An exception was one trial with carvedilol
hat enrolled clinically stable patients with NYHA func-
ional class III and IV symptoms who were free of edema.
hat trial also demonstrated a reduction in mortality similar
o the trials of patients with less advanced disease (345).
This collective experience indicates that long-term treat-
ent with beta blockers can lessen the symptoms of HF,
mprove the clinical status of patients, and enhance the
atient’s overall sense of well-being (168–175). In addition,
ike ACEIs, beta blockers can reduce the risk of death and
he combined risk of death or hospitalization (158,162,164,
76,346). These benefits of beta blockers were seen in
atients with or without coronary artery disease and in
atients with or without diabetes mellitus, as well as in
omen and black patients. The favorable effects of beta
lockers were also observed in patients already taking
CEIs, which suggests that combined blockade of the 2
eurohormonal systems can produce additive effects.
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eta blockers should be prescribed to all patients with stable
F due to reduced LVEF unless they have a contraindica-
ion to their use or have been shown to be unable to tolerate
reatment with these drugs. Because of the favorable effects
f beta blockers on survival and disease progression, treat-
ent with a beta blocker should be initiated as soon as LV
ysfunction is diagnosed. Even when symptoms are mild or
ave responded to other therapies, beta-blocker therapy is
mportant and should not be delayed until symptoms return
r disease progression is documented during treatment with
ther drugs. Therefore, even if patients do not benefit
ymptomatically because they have little disability, they
hould receive treatment with a beta-blocker to reduce the
isk of disease progression, future clinical deterioration, and
udden death (158,162,164,175,176).
Patients need not be taking high doses of ACEIs before
eing considered for treatment with a beta blocker, because
ost patients enrolled in the beta-blocker trials were not
aking high doses of ACEIs. Furthermore, in patients
aking a low dose of an ACEI, the addition of a beta-
locker produces a greater improvement in symptoms and
eduction in the risk of death than an increase in the dose of
he ACEI, even to the target doses used in clinical trials
298,347). In patients with current or recent history of fluid
etention, beta blockers should not be prescribed without
iuretics, because diuretics are needed to maintain sodium
nd fluid balance and prevent the exacerbation of fluid
etention that can accompany the initiation of beta-blocker
herapy (348–350).
Which patients are sufficiently stable to be considered for
reatment with a beta blocker? Regardless of the severity of
ymptoms, patients should not be hospitalized in an inten-
ive care unit, should have no or minimal evidence of fluid
verload or volume depletion, and should not have required
ecent treatment with an intravenous positive inotropic
gent. Those excluded from treatment for these reasons
hould first receive intensified treatment with other drugs
or HF (e.g., diuretics) and then be re-evaluated for beta-
lockade after clinical stability has been achieved. Beta-
lockers may be considered in patients who have reactive
irway disease or asymptomatic bradycardia but should be
sed with great caution or not at all in patients with
ersistent symptoms of either condition.
RACTICAL USE OF BETA BLOCKERS. Initiation and mainte-
ance. Treatment with a beta blocker should be initiated at
ery low doses (see Table 6), followed by gradual increments
n dose if lower doses have been well tolerated. Patients
hould be monitored closely for changes in vital signs and
ymptoms during this uptitration period. In addition, be-
ause initiation of therapy with a beta-blocker can cause
uid alpha retention (348–350), physicians should ask
atients to weigh themselves daily and to manage any
ncrease in weight by immediately increasing the dose of
oncomitantly administered diuretics until weight is re- atored to pretreatment levels. Planned increments in the
ose of a beta blocker should be delayed until any side effects
bserved with lower doses have disappeared. Using such a
autious approach, most patients (approximately 85%) en-
olled in clinical trials with beta blockers were able to
olerate short- and long-term treatment with these drugs
nd achieve the maximum planned trial dose (158,162,
64,165). Recent data show that beta blockers can be safely
tarted before discharge even in patients hospitalized for
F, provided they do not require intravenous therapy for
F (351).
What dose of a beta blocker should physicians try to
chieve in patients with HF? As with ACEIs, the dose of
eta blockers in controlled clinical trials was not determined
y a patient’s therapeutic response but was increased until
he patient received a prespecified target dose. Low doses
ere prescribed only if the target doses were not tolerated,
nd thus, most trials did not evaluate whether low doses
ould be effective. Therefore, physicians, especially cardi-
logists and primary care physicians, should make every
ffort to achieve the target doses of the beta blockers shown
o be effective in major clinical trials.
Once the target dose has been achieved, patients can
enerally continue long-term therapy with a beta blocker
ith little difficulty. Patients should be advised that clinical
esponses to the drug are generally delayed and may require
to 3 months to become apparent (273). Even if symptoms
o not improve, long-term treatment should be maintained
o reduce the risk of major clinical events. Abrupt with-
rawal of treatment with a beta blocker can lead to clinical
eterioration and should be avoided (352).
How should clinical deterioration be managed in patients
ho have been taking a beta blocker for long periods of time
more than 3 months)? Because long-term treatment with a
eta blocker reduces the risk of worsening HF, discontinu-
tion of long-term treatment with these drugs after an
pisode of worsening HF will not diminish and may in fact
ncrease the subsequent risk of clinical decompensation.
onsequently, if patients develop fluid retention, with or
ithout mild symptoms, it is reasonable to continue the beta
locker while the dose of diuretic is increased (353).
owever, if the deterioration in clinical status is character-
zed by hypoperfusion or requires the use of intravenous
ositive inotropic drugs, it may be prudent to halt or
ignificantly reduce treatment with beta blockers tempo-
arily until the status of the patient stabilizes. In such
atients, positive inotropic agents whose effects are medi-
ted independently of the beta receptor (e.g., a phosphodi-
sterase inhibitor such as milrinone) may be preferred. Once
tabilized, the beta blocker should be reintroduced to reduce
he subsequent risk of clinical deterioration.
RACTICAL USE OF BETA BLOCKERS. Risks of treatment. Ini-
iation of treatment with a beta blocker has produced 4 types
f adverse reactions that require attention and management,
s discussed below.
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nitiation of therapy with a beta blocker can cause fluid
etention (348–350), which is usually asymptomatic and is
etected primarily by an increase in body weight but which
ay become sufficiently marked to cause worsening symp-
oms of HF (354). Patients with fluid retention before
reatment are at greatest risk of fluid retention during
reatment, and thus, physicians should ensure that patients
re not volume overloaded before a beta blocker is initiated.
Furthermore, physicians should monitor patients closely
or increases in weight and for worsening signs and symp-
oms of HF and should augment the dose of diuretic if
eight increases whether or not other signs or symptoms of
orsening HF are present. The occurrence of fluid retention
r worsening HF is not generally a reason for the permanent
ithdrawal of treatment. Such patients generally respond
avorably to intensification of conventional therapy, and
nce treated, such patients remain excellent candidates for
ong-term treatment with a beta blocker.
. FATIGUE
reatment with a beta blocker can be accompanied by
eelings of general fatigue or weakness. In many cases, the
ense of lassitude resolves spontaneously within several
eeks without treatment, but in some patients, it may be
evere enough to limit increments in dose or require the
ithdrawal of treatment. Complaints of fatigue can gener-
lly be managed by a reduction in the dose of the beta
locker (or the accompanying diuretic), but treatment
hould be discontinued if the syndrome of weakness is
ccompanied by evidence of peripheral hypoperfusion.
einitiation at a later time or with a different effective beta
locker may be successful.
. BRADYCARDIA AND HEART BLOCK
he slowing of heart rate and cardiac conduction produced
y beta blockers is generally asymptomatic and thus gener-
lly requires no treatment; however, if the bradycardia is
ccompanied by dizziness or lightheadedness or if second-
r third-degree heart block occurs, physicians should de-
rease the dose of the beta blocker. Physicians should also
onsider the possibility of drug interactions, because other
rugs can cause bradycardia or heart block and may be
iscontinued. The role of pacemaker therapy with or with-
ut cardiac resynchronization therapy (CRT) to permit the
se of beta-blocker therapy is entirely unknown.
. HYPOTENSION
eta blockers, especially those that also block alpha-1–
eceptors, can produce hypotension, which is usually asymp-
omatic but may produce dizziness, lightheadedness, or
lurred vision (164). For beta blockers that also block alpha
eceptors, such as carvedilol, these vasodilatory side effects
re generally seen within 24 to 48 hours of the first dose or
he first increments in dose and usually subside with sepeated dosing without any change in dose. Physicians may
inimize the risk of hypotension by administering the beta
locker and ACEI at different times during the day. If this
s ineffective, the occurrence of hypotension may require a
emporary reduction in the dose of the ACEI. Hypotensive
ymptoms may also resolve after a decrease in the dose of
iuretics in patients who are volume depleted, but in the
bsence of such depletion, relaxation of diuretic therapy
ay increase the risk or consequences of fluid retention
348–350). If hypotension is accompanied by other clinical
vidence of hypoperfusion, beta-blocker therapy should
e decreased or discontinued pending further patient
valuation.
.3.1.2.4. DIGITALIS. The digitalis glycosides exert their effects
n patients with HF by virtue of their ability to inhibit
odium-potassium (Na-K) adenosine triphosphatase
ATPase) (355). Inhibition of this enzyme in cardiac cells
esults in an increase in the contractile state of the heart, and
or many decades, the benefits of digitalis in HF were
scribed exclusively to this positive inotropic action. How-
ver, recent evidence suggests that the benefits of digitalis
ay be related in part to enzyme inhibition in noncardiac
issues. Inhibition of Na-K ATPase in vagal afferent
bers acts to sensitize cardiac baroreceptors, which in turn
educes sympathetic outflow from the central nervous sys-
em (356,357). In addition, by inhibiting Na-K ATPase
n the kidney, digitalis reduces the renal tubular reabsorp-
ion of sodium (358); the resulting increase in the delivery of
odium to the distal tubules leads to the suppression of renin
ecretion from the kidneys (359). These observations have
ed to the hypothesis that digitalis acts in HF primarily by
ttenuating the activation of neurohormonal systems and
ot as a positive inotropic drug (360). Although a variety of
igitalis glycosides have been used in the treatment of HF
or the last 200 years, the most commonly used preparation
n the United States is digoxin.
FFECT OF DIGITALIS IN THE TREATMENT OF HF. Several
lacebo-controlled trials have shown that treatment with
igoxin for 1 to 3 months can improve symptoms, quality of
ife, and exercise tolerance in patients with mild to moderate
F (229–235). These benefits have been seen regardless of
he underlying rhythm (normal sinus rhythm or atrial
brillation), cause of HF (ischemic or nonischemic cardio-
yopathy), or concomitant therapy (with or without
CEIs). In a long-term trial that enrolled patients who
rimarily had Class II or III symptoms, treatment with
igoxin for 2 to 5 years had no effect on mortality but
odestly reduced the combined risk of death and hospital-
zation (134).
RACTICAL USE OF DIGITALIS IN HF. Selection of patients.
hysicians may consider adding digoxin in patients with
ersistent symptoms of HF during therapy with diuretics,
n ACEI (or ARB), and a beta blocker (361,362). Digoxin
ay also be added to the initial regimen in patients withevere symptoms who have not yet responded symptomat-
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lockers. Alternatively, treatment with digoxin may be
elayed until the patient’s response to ACEIs and beta
lockers has been defined and be used only in patients who
emain symptomatic despite therapy with the neurohor-
onal antagonists. Yet another strategy is to initiate aldo-
terone antagonists in this type of symptomatic patient and
elay the addition of digoxin except in patients who do not
espond or who cannot tolerate aldosterone antagonists. If a
atient is taking digoxin but not an ACEI or a beta blocker,
reatment with digoxin should not be withdrawn, but
ppropriate therapy with the neurohormonal antagonists
hould be instituted. Digoxin is prescribed routinely in
atients with HF and chronic atrial fibrillation, but beta
lockers are usually more effective when added to digoxin in
ontrolling the ventricular response, particularly during
xercise (363–366). Because beta blockers improve survival
nd may be effective in controlling rate alone, digoxin
hould be considered as an adjunctive agent for rate control.
Digoxin is not indicated as primary therapy for the
tabilization of patients with an acute exacerbation of HF
ymptoms, including fluid retention or hypotension. Such
atients should first receive appropriate treatment for HF
usually with intravenous medications); therapy with
igoxin may be initiated after stabilization as part of an
ffort to establish a long-term treatment strategy.
Patients should not be given digoxin if they have signif-
cant sinus or atrioventricular block, unless the block has
een addressed with a permanent pacemaker. The drug
hould be used cautiously in patients taking other drugs that
an depress sinus or atrioventricular nodal function or affect
igoxin levels (e.g., amiodarone or a beta blocker), even
hough such patients usually tolerate digoxin without
ifficulty.
RACTICAL USE OF DIGITALIS IN HF. Initiation and mainte-
ance. Although a variety of glycosides have been utilized,
igoxin is the most commonly used, and it is the only
lycoside that has been evaluated in placebo-controlled
rials. There is little reason to prescribe other cardiac
lycosides for the management of HF.
Therapy with digoxin is commonly initiated and main-
ained at a dose of 0.125 to 0.25 mg daily. Low doses (0.125
g daily or every other day) should be used initially if the
atient is more than 70 years old, has impaired renal
unction, or has a low lean body mass (367). Higher doses
e.g., digoxin 0.375 to 0.50 mg daily) are rarely used or
eeded in the management of patients with HF. There is no
eason to use loading doses of digoxin to initiate therapy in
atients with HF.
Doses of digoxin that achieve a concentration of drug in
lasma in the range of 0.5 to 1.0 ng per mL are suggested,
iven the limited evidence currently available. There has
een no prospective, randomized evaluation of the relative
fficacy or safety of different plasma concentrations of
igoxin. Retrospective analysis of 2 studies of digoxin rithdrawal found that the prevention of worsening HF by
igoxin at lower concentrations in plasma (0.5 to 0.9 ng per
L) was as great as that achieved at higher concentrations
368). In a retrospective analysis of the Digitalis Investiga-
ion Group trial, risk-adjusted mortality increased as the
lasma concentrations exceeded 1.0 ng per mL (369).
owever, the likelihood that reduced clearance of digoxin
y renal and hepatic P-glycoprotein transporters reflects HF
everity provides an alternate explanation of the relationship
f higher plasma levels with mortality, and the most
onservative interpretation is that levels of digoxin greater
han 1.0 ng per mL were not associated with a superior
utcome.
RACTICAL USE OF DIGITALIS IN HF. Risks of treatment.
hen administered with attention to dose and to factors
hat alter its disposition, digoxin is well tolerated by most
atients with HF (370). The principal adverse reactions
ccur primarily when digoxin is administered in large doses,
ut large doses may not be needed to produce clinical
enefits (371–373). The major side effects include cardiac
rrhythmias (e.g., ectopic and re-entrant cardiac rhythms
nd heart block), gastrointestinal symptoms (e.g., anorexia,
ausea, and vomiting), and neurological complaints (e.g.,
isual disturbances, disorientation, and confusion). Overt
igitalis toxicity is commonly associated with serum digoxin
evels greater than 2 ng per mL. However, toxicity may
ccur with lower digoxin levels, especially if hypokalemia,
ypomagnesemia, or hypothyroidism coexists (374,375).
he concomitant use of clarithromycin, erythromycin, ami-
darone, itraconazole, cyclosporine, verapamil, or quinidine
an increase serum digoxin concentrations and may increase
he likelihood of digitalis toxicity (219,376,377). The dose
f digoxin should be reduced if treatment with these drugs
s initiated. Spironolactone does not inhibit the disposition
f digoxin (378); cross-reactivity of some digoxin antibodies
ith spironolactone confounded earlier attempts to assess
he effect of spironolactone on digoxin clearance. In addi-
ion, a low lean body mass and impaired renal function can
lso elevate serum digoxin levels, which may explain the
ncreased risk of digitalis toxicity in elderly patients. Of
ote, one analysis suggested that women may not benefit
rom digoxin therapy and may be at increased risk for death
ith such therapy (379).
In addition to these established side effects, there is
oncern that levels of digoxin that previously had been
onsidered to be in the therapeutic range (up to 2 ng per
L) may exert deleterious cardiovascular effects in the long
erm, even though such levels appear to be well tolerated in
he short-term. In one major long-term trial, serum digoxin
oncentrations in the therapeutic range were associated with
n increased frequency of hospitalizations for cardiovascular
vents other than HF and an increased risk of death due to
rrhythmias or MI (134). These effects neutralized any
enefit on survival that might otherwise have been seen as a
esult of the favorable effect of the drug on HF. These
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April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure Guidelinesbservations have raised the possibility that digoxin doses
nd serum digoxin concentrations that are generally consid-
red by physicians to be safe may adversely affect the heart
380). Digoxin should be used with caution or not used at all
n post-MI patients, particularly if they have ongoing
schemia (381).
The writing committee has re-evaluated the evidence
ertinent to the value of digitalis therapy in patients with
F. Although no new data or trials using digitalis have
merged since publication of the 2001 guidelines, the
riting committee believes that in terms of safety and
fficacy, digitalis does not compare favorably with such
gents as the aldosterone blockers, to which the writing
ommittee has assigned a Class IIa level of recommenda-
ion. If digitalis were a new drug with clinical trials showing
very narrow risk/benefit ratio (especially for potential use
n the aging population) and no mortality benefit, it would
learly not be considered for a Class I recommendation. The
riting committee, therefore, decided to change the level of
ecommendation for digitalis glycosides from Class I to
lass IIa in the current document.
.3.1.2.5. VENTRICULAR ARRHYTHMIAS AND PREVENTION OF SUDDEN DEATH
UPDATED). Patients with LV dilation and reduced LVEF
requently manifest ventricular tachyarrhythmias, both non-
ustained ventricular tachycardia (VT) and sustained VT.
he cardiac mortality of patients with all types of ventricular
achyarrhythmias is high. The high mortality results from
rogressive HF, as well as from sudden death. Sudden death
s often equated with a primary arrhythmic event, but
ultiple causes of sudden death have been documented and
nclude ischemic events such as acute MI (382), electrolyte
isturbances, pulmonary or systemic emboli, or other vas-
ular events. Although ventricular tachyarrhythmias are the
ost common rhythms associated with unexpected sudden
eath, bradycardia and other pulseless supraventricular
hythms are common in patients with advanced HF (383).
Sudden death can be decreased meaningfully by the
herapies that decrease disease progression, as discussed
lsewhere in these guidelines. For instance, clinical trials
ith beta blockers have shown a reduction in sudden death,
s well as in all-cause mortality, in both postinfarction
atients and patients with HF regardless of cause
124,125,158,162,164). Aldosterone antagonists decrease
udden death and overall mortality in HF early after MI and
n advanced HF (118). Sudden unexpected death can be
ecreased further by the use of implanted devices that
erminate sustained arrhythmias (144,205). Even when
pecific antiarrhythmic therapy is necessary to diminish
ecurrent ventricular tachyarrhythmias and device firings,
he frequency and tolerance of arrhythmias may be im-
roved with appropriate therapy for HF. In some cases,
efinitive therapy of myocardial ischemia or other reversible
actors may prevent recurrence of tachyarrhythmia, partic-
larly polymorphic VT, ventricular fibrillation, and nonsus-
ained VT. Nonetheless, implantable defibrillators should
e recommended in all patients who have had a life- 3hreatening tachyarrhythmia and have an otherwise good
rognosis.
The absolute frequency of sudden death is highest in
atients with severe symptoms, or Stage D HF. Many
atients with end-stage symptoms experience “sudden
eath” that is nonetheless expected. Prevention of sudden
eath in this population could potentially shift the mode of
eath from sudden to that of progressive HF without
ecreasing total mortality, as competing risks of death
merge. On the other hand, prevention of sudden death in
ild HF may allow many years of meaningful survival. This
akes it imperative for physicians to not only assess an
ndividual patient’s risk for sudden death but also assess
verall prognosis and functional capacity before consider-
tion of device implantation.
econdary Prevention of Sudden Death. Patients with previous
ardiac arrest or documented sustained ventricular arrhyth-
ias have a high risk of recurrent events. Implantation of an
CD has been shown to reduce mortality in cardiac arrest
urvivors. An ICD is indicated for secondary prevention of
eath from ventricular tachyarrhythmias in patients with
therwise good clinical function and prognosis, for whom
rolongation of survival is a goal. Patients with chronic HF
nd a low EF who experience syncope of unclear origin have
high rate of subsequent sudden death and should also be
onsidered for placement of an ICD (198). However, when
entricular tachyarrhythmias occur in a patient with a
rogressive and irreversible downward spiral of clinical HF
ecompensation, placement of an ICD is not indicated to
revent recurrence of sudden death, because death is likely
mminent regardless of mode. An exception may exist for
he small minority of patients for whom definitive therapy
uch as cardiac transplantation is planned.
rimary Prevention of Sudden Death. Patients with low EF
ithout prior history of cardiac arrest, spontaneous VT, or
nducible VT (positive programmed electrical stimulation
tudy) have a risk of sudden death that is lower than for
hose who have experienced previous events, but it remains
ignificant. Within this group, it has not yet been possible to
dentify those patients at highest risk, especially in the
bsence of prior MI. Approximately 50% to 70% of patients
ith low EF and symptomatic HF have episodes of non-
ustained VT on routine ambulatory electrocardiographic
onitoring; however, it is not clear whether the occurrence
f complex ventricular arrhythmias in these patients with
F contributes to the high frequency of sudden death or,
lternatively, simply reflects the underlying disease process
384–386). Antiarrhythmic drugs to suppress premature
entricular depolarizations and nonsustained ventricular ar-
hythmias have not improved survival (191,192), although
onsustained VT may play a role in triggering ventricular
achyarrhythmias. Furthermore, most antiarrhythmic drugs
ave negative inotropic effects and can increase the risk of
erious arrhythmia; these adverse cardiovascular effects are
articularly pronounced in patients with low EF (193,247,
87). This risk is especially high with the use of Class IA
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ainide and propafenone), and some Class III agents (d-
otalol) (191,192,388,389), which have increased mortality
n post-MI trials (390).
Amiodarone is a Class III antiarrhythmic agent but
iffers from other drugs in this Class in having a sympa-
holytic effect on the heart (391). Amiodarone has been
ssociated with overall neutral effects on survival when
dministered to patients with low EF and HF (196,392–
94). Amiodarone therapy may also act through mecha-
isms other than antiarrhythmic effects, because amioda-
one has been shown in some trials to increase LVEF and
ecrease the incidence of worsening HF (393,394). Side
ffects of amiodarone have included thyroid abnormalities,
ulmonary toxicity, hepatotoxicity, neuropathy, insomnia,
nd numerous other reactions. Therefore, amiodarone
hould not be considered as part of the routine treatment of
atients with HF, with or without frequent premature
entricular depolarizations or asymptomatic nonsustained
T; however, it remains the agent most likely to be safe and
ffective when antiarrhythmic therapy is necessary to pre-
ent recurrent atrial fibrillation or symptomatic ventricular
rrhythmias. Other pharmacological antiarrhythmic thera-
ies, apart from beta blockers, are rarely indicated in HF but
ay occasionally be used to suppress recurrent ICD shocks
hen amiodarone has been ineffective or discontinued
wing to toxicity.
The role of ICDs in the primary prevention of sudden
eath in patients without prior history of symptomatic
rrhythmias has been explored recently in a number of trials.
f sustained ventricular tachyarrhythmias can be induced in
he electrophysiology laboratory in patients with previous
I or chronic ischemic heart disease, the risk of sudden
eath in these patients is in the range of 5% to 6% per year
nd can be improved by ICD implantation (199).
The role of ICD implantation for the primary prevention
f sudden death in patients with HF and low EF and no
istory of spontaneous or inducible VT has been addressed
y several large trials that used only readily available clinical
ata as entry criteria (196,200,201). The first of these
emonstrated that ICDs, compared with standard medical
herapy, decreased the occurrence of total mortality for
atients with EF of 30% or less after remote MI (200).
bsolute mortality was decreased in the ICD arm by 5.6%,
relative decrease of 31% over 20 months. In a second trial,
survival benefit was not demonstrated with devices im-
lanted within 6 to 40 days after an acute MI in patients
ho at that time had an EF less than 35% and abnormal
eart rate variability. Although sudden deaths were de-
reased, there was an increase in other events, and ICD
mplantation did not confer any survival benefit in this
etting (201). A third trial examining the benefit of ICD
mplantation for patients with EF less than 35% and
YHA functional class II to III symptoms of HF included
oth ischemic and nonischemic causes of HF; absolute
ortality was decreased by 7.2% over a 5-year period in the drm that received a simple “shock-box” ICD with backup
acing at a rate of 40 bpm. This represented a relative
ortality decrease of 23%, which was a survival increase of
1% (196). There was no improvement in survival during
he first year, with a 1.8% absolute survival benefit per year
veraged over the next 4 years. The DEFINITE (Defibril-
ators in Non-Ischemic Cardiomyopathy Treatment Eval-
ation) trial compared medical therapy alone with medical
herapy plus an ICD in patients with nonischemic cardio-
yopathy, NYHA functional class I to III HF, and an
VEF less than 36% (395). The ICD was associated with a
eduction in all-cause mortality that did not reach statistical
ignificance but was consistent in terms of magnitude of
ffect (30%) with the findings of the MADIT II (Multi-
enter Automatic Defibrillator Implantation II) (200) and
he SCD-HeFT (Sudden Cardiac Death in Heart Failure:
rial of prophylactic amiodarone versus implantable defi-
rillator therapy) (196).
There is an intrinsic variability in measurement of EF
articularly shortly after recovery from an acute coronary
yndrome event. Moreover, as reviewed earlier, the pivotal
rimary prevention trials used a variable inclusion EF,
anging below 30% or 36%. Given the totality of the data
emonstrating the efficacy of an ICD in reducing overall
ortality in a population with dilated cardiomyopathy of
ither ischemic or nonischemic origins, the current recom-
endation is to include all such patients with an LVEF of
ess than or equal to 35%.
ICDs are highly effective in preventing death due to
entricular tachyarrhythmias; however, frequent shocks
rom an ICD can lead to a reduced quality of life, whether
riggered appropriately by life-threatening rhythms or inap-
ropriately by sinus or other supraventricular tachycardia.
or symptoms from recurrent discharges triggered by ven-
ricular arrhythmias or atrial fibrillation, antiarrhythmic
herapy, most often amiodarone, may be added. For recur-
ent ICD discharges from VT despite antiarrhythmic ther-
py, catheter ablation may be effective (396).
It is important to recognize that ICDs have the potential
o aggravate HF and have been associated with an increase
n HF hospitalizations (200,202). This may result from
ight ventricular pacing that produces dyssynchronous car-
iac contraction; however, the occurrence of excess nonsud-
en events with ICDs placed early after MI suggests that
ther factors may also limit the overall benefit from ICDs.
areful attention to the details of ICD implantation,
rogramming, and pacing function is important for all
atients with low EF who are treated with an ICD. The
CC/AHA/HRS 2008 Guidelines for Device-Based Ther-
py of Cardiac Rhythm Abnormalities (144) provides fur-
her discussion of the potential problem of worsening HF
nd LV function in all patients with right ventricular pacing.
The decision regarding the balance of potential risks and
enefits of ICD implantation for an individual patient thus
emains a complex one. A decrease in incidence of sudden
eath does not necessarily translate into decreased total
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prolongation of survival with meaningful quality of life.
his concept is particularly important in patients with
imited prognosis owing to advanced HF or other serious
omorbidities, because there was no survival benefit ob-
erved from ICD implantation until after the first year in 2
f the major trials (196,200). Furthermore, the average age
f patients with HF and low EF is over 70 years, a
opulation not well represented in any of the ICD trials.
omorbidities common in the elderly population, such as
rior stroke, chronic pulmonary disease, and crippling
rthritic conditions, as well as nursing home residence,
hould be factored into discussions regarding ICD. Atrial
brillation, a common trigger for inappropriate shocks, is
ore prevalent in the elderly population. The gap between
ommunity and trial populations is particularly important
or a device therapy that may prolong survival but has no
ositive impact on function or quality of life. Some patients
ay suffer a diminished quality of life because of device-
ite complications, such as bleeding, hematoma, or infec-
ions, or after ICD discharges, particularly those that are
nappropriate.
Consideration of ICD implantation is thus recom-
ended in patients with EF less than or equal to 35% and
ild to moderate symptoms of HF and in whom survival
ith good functional capacity is otherwise anticipated to
xtend beyond 1 year. Because medical therapy may sub-
tantially improve EF, consideration of ICD implants
hould follow documentation of sustained reduction of EF
espite a course of beta blockers and ACEIs or ARBs;
owever, ICDs are not warranted in patients with refractory
ymptoms of HF (Stage D) or in patients with concomitant
iseases that would shorten their life expectancy indepen-
ent of HF. Before implantation, patients should be fully
nformed of their cardiac prognosis, including the risk of
oth sudden and nonsudden mortality; the efficacy, safety,
nd risks of an ICD; and the morbidity associated with an
CD shock. Patients and families should clearly understand
hat the ICD does not improve clinical function or delay
F progression. Most important, the possible reasons and
rocess for potential future deactivation of defibrillator
eatures should be discussed long before functional capacity
r outlook for survival is severely reduced.
.3.1.3. INTERVENTIONS TO BE CONSIDERED FOR USE IN SELECTED PATIENTS
ontrolled clinical trials have shown some interventions to
e useful in limited cohorts of patients with HF. Several of
hese interventions are undergoing active investigation in
arge-scale trials to determine whether their role in the
anagement of HF might be justifiably expanded, and
thers have already been validated as useful in specific cohorts.
.3.1.3.1. ISOSORBIDE DINITRATE. Isosorbide dinitrate was one of
he first vasodilator agents reported to be useful for chronic
herapy of HF. Nitrate therapy may decrease symptoms of
yspnea at night and during exercise and may improve
xercise tolerance in patients who have persistent limitations bespite optimization of other therapies (397). Most experi-
nce relates to the oral dinitrate and more recently the
ononitrate preparations, with little information available
bout topical nitrate therapy in this population. Recent
vidence suggests that nitrates can inhibit abnormal myo-
ardial and vascular growth (398,399) and may thereby
ttenuate the process of ventricular remodeling (400) and
mprove symptoms.
The only common side effects of nitrate therapy are
eadaches and hypotension. In clinical use, nitrates are
requently prescribed to patients with persistent congestive
ymptoms. Although the only large trial of nitrates in HF
239) used a combination of nitrates and hydralazine,
itrates predominantly are potent venodilators that also
ave effects on arterial tone when used alone, particularly
hen systemic vascular resistance is severely elevated. Be-
ause they act through cyclic guanosine monophosphate,
here is a theoretical reason that they may be titrated up to
acilitate weaning of intravenous infusions that act through
he same pathway.
There is extensive literature regarding the development of
itrate tolerance. This appears to be minimized by prescrip-
ion of a “nitrate-free interval” of at least 10 hours and by
ombination with ACEIs or hydralazine.
.3.1.3.2. HYDRALAZINE. Hydralazine is an arterial vasodilator
ith relatively little effect on venous tone and cardiac filling
ressures. The rationale for its combined use with nitrates
as to achieve both venous and arterial vasodilation
401,402). In addition to its direct vascular actions, hydral-
zine in theory may interfere with the biochemical and
olecular mechanisms responsible for the progression of
F (403,404) and the development of nitrate tolerance
405–408). There are limited data regarding the use of
ydralazine alone in HF.
.3.1.3.3. HYDRALAZINE AND ISOSORBIDE DINITRATE (UPDATED).
n a large-scale trial that compared the vasodilator combi-
ation with placebo, the use of hydralazine and isosorbide
initrate reduced mortality but not hospitalizations in pa-
ients with HF treated with digoxin and diuretics but not an
CEI or beta blocker (238,239). However, in another
arge-scale trial that compared the vasodilator combination
ith an ACEI, the ACEI produced more favorable effects
n survival (156), a benefit not evident in the subgroup of
atients with class III to IV HF. In both trials, the use of
ydralazine and isosorbide dinitrate produced frequent ad-
erse reactions (primarily headache and gastrointestinal
omplaints), and many patients could not continue treat-
ent at target doses.
Of note, a post hoc retrospective analysis of both vaso-
ilator trials demonstrated particular efficacy of isosorbide
initrate and hydralazine in the African American cohort
222). A confirmatory trial has been done. In that trial,
hich was limited to the patients self-described as African
merican, the addition of hydralazine and isosorbide dini-
rate to standard therapy with an ACEI and/or a beta
locker was shown to be of significant benefit (223). The
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ioavailability. Accordingly, this combination is recom-
ended for African Americans who remain symptomatic
espite optimal medical therapy. Whether this benefit is
vident in other patients with HF remains to be investi-
ated. The combination of hydralazine and isosorbide
initrate should not be used for the treatment of HF in
atients who have no prior use of an ACEI and should not
e substituted for ACEI in patients who are tolerating
CEIs without difficulty.
Despite the lack of data with the vasodilator combination
n patients who are intolerant of ACEIs, the combined use
f hydralazine and isosorbide dinitrate may be considered as
therapeutic option in such patients. However, compliance
ith this combination has generally been poor because of
he large number of tablets required and the high incidence
f adverse reactions (156,238). For patients with more
evere HF symptoms and ACEI intolerance, the combina-
ion of hydralazine and nitrates is used frequently, particu-
arly when ACEI therapy is limited by hypotension or renal
nsufficiency. There are, however, no trials addressing the
se of isosorbide dinitrate and hydralazine specifically in the
opulation of patients who have persistent symptoms and
ntolerance to inhibitors of the renin-angiotensin system.
.3 .1.3.4. CARDIAC RESYNCHRONIZATION THERAPY (UPDATED).
pproximately one-third of patients with low EF and class
II to IV symptoms of HF manifest a QRS duration greater
han 0.12 seconds (409–411). This electrocardiographic
epresentation of abnormal cardiac conduction has been
sed to identify patients with dyssynchronous ventricular
ontraction. While imperfect, no other consensus definition
f cardiac dyssynchrony exists as yet, although several
chocardiographic measures appear promising. The me-
hanical consequences of dyssynchrony include suboptimal
entricular filling, a reduction in LV dP/dt (rate of rise of
entricular contractile force or pressure), prolonged duration
and therefore greater severity) of mitral regurgitation, and
aradoxical septal wall motion (412–414). Ventricular dys-
ynchrony has also been associated with increased mortality
n HF patients (206–208). Dyssynchronous contraction can
e addressed by electrically activating the right and left
entricles in a synchronized manner with a biventricular
acemaker device. This approach to HF therapy, commonly
alled cardiac resynchronization therapy (CRT), may en-
ance ventricular contraction and reduce the degree of
econdary mitral regurgitation (209–211). In addition, the
hort-term use of CRT has been associated with improve-
ents in cardiac function and hemodynamics without an
ccompanying increase in oxygen use (212), as well as adaptive
hanges in the biochemistry of the failing heart (210).
To date, more than 4000 HF patients with ventricular
yssynchrony have been evaluated in randomized controlled
rials of optimal medical therapy alone versus optimal
edical therapy plus CRT with or without an ICD. CRT,
hen added to optimal medical therapy in persistentlyymptomatic patients, has resulted in significant improve- pents in quality of life, functional class, exercise capacity (by
eak oxygen uptake) and exercise distance during a
-minute walk test, and EF in patients randomized to CRT
213) or to the combination of CRT and ICD (205,214,215).
n a meta-analysis of several CRT trials, HF hospitaliza-
ions were reduced by 32% and all-cause mortality by 25%
215). The effect on mortality in this meta-analysis became
pparent after approximately 3 months of therapy (215). In
study, subjects were randomized to optimal pharmacolog-
cal therapy alone, optimal medical therapy plus CRT alone,
r optimal medical therapy plus the combination of CRT
nd an ICD. Compared with optimal medical therapy
lone, both device arms significantly decreased the com-
ined risk of all-cause hospitalization and all-cause mortal-
ty by approximately 20%, whereas the combination of a
RT and an ICD decreased all-cause mortality significantly
y 36% (216). More recently, in a randomized controlled
rial comparing optimal medical therapy alone with optimal
edical therapy plus CRT alone (without a defibrillator),
RT significantly reduced the combined risk of death of
ny cause or unplanned hospital admission for a major
ardiovascular event (analyzed as time to first event) by 37%
204). In that trial, all-cause mortality was significantly
educed by 36% and HF hospitalizations by 52% with the
ddition of CRT.
Thus, there is strong evidence to support the use of CRT
o improve symptoms, exercise capacity, quality of life,
VEF, and survival and to decrease hospitalizations in
atients with persistently symptomatic HF undergoing
ptimal medical therapy who have cardiac dyssynchrony (as
videnced by a prolonged QRS duration). The use of an
CD in combination with CRT should be based on the
ndications for ICD therapy.
With few exceptions, resynchronization trials have en-
olled patients in normal sinus rhythm. Although the entry
riteria specified QRS duration only longer than 0.12
econds, the average QRS duration in the large trials was
onger than 0.15 seconds, with less information demonstrat-
ng benefit in patients with lesser prolongation of QRS.
wo small studies, one randomized (217) and the other
bservational (218), evaluated the potential benefit of CRT
n HF patients with ventricular dyssynchrony and atrial
brillation. Although both studies demonstrated the benefit
f CRT in these patients, the total number of patients
xamined (fewer than 100) precludes a recommendation for
RT in otherwise eligible patients with atrial fibrillation.
o date, only a small number of patients with “pure” right
undle-branch block have been enrolled in CRT trials.
imilarly, the prolonged QRS duration associated with right
entricular pacing has also been associated with ventricular
yssynchrony that may be improved by CRT, but no
ublished studies have addressed this situation as yet.
ecommendations regarding CRT for patients with LVEF
f less than or equal to 35%, NYHA functional class III, and
mbulatory class IV symptoms or dependence on ventricular
acing have been updated to be consistent with the ACC/
A
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ardiac Rhythm Abnormalities (144).
Ten studies have reported on CRT peri-implant morbid-
ty and mortality. There were 13 deaths in 3113 patients
0.4%). From a pooled assessment of 3475 patients in 17
tudies, the success rate of implantation was approximately
0% (215). Device-related problems during the first 6
onths after implantation reported in 13 studies included
ead malfunction or dislodgement in 8.5%, pacemaker
roblems in 6.7%, and infection in 1.4% of cases. These
orbidity and mortality data are derived from trials that
sed expert centers. Results in individual clinical centers
ay vary considerably and are subject to a significant
earning curve for each center; however, as implantation
echniques evolve and equipment improves, complication
ates may also decline (215).
.3.1.3.5. EXERCISE TRAINING. In the past, patients with HF were
dvised to avoid physical exertion in the hope that bed rest
ight minimize symptoms (415) and in the belief that
hysical activity might accelerate the progression of LV
ysfunction (416–418); however, it is now understood that
reduction in physical activity (produced by the symptoms
f HF or prescribed by physicians treating HF) leads to a
tate of physical deconditioning that contributes to the
ymptoms and exercise intolerance of patients with chronic
F (243,246). Limitations of activity not only may impair
xercise capacity but also may produce adverse psychological
ffects and impair peripheral vasodilatory responses
245,419). These findings have led to the hypothesis that
xercise training might improve the clinical status of pa-
ients with chronic HF (243,420).
Several controlled trials have shown that exercise training
an lessen symptoms, increase exercise capacity, and im-
rove the quality of life of patients with chronic HF
421–430). The improvement was comparable to that
chieved with pharmacological interventions (420), was in
ddition to the benefits of ACEIs and beta blockers
422,423), and was associated with an enhancement of
ndothelium-dependent peripheral vasodilation and skeletal
uscle metabolism (422,431). In these studies, physical
onditioning was generally accomplished in the context of a
ormal program, which required patients to gradually achieve
orkloads of 40% to 70% of maximal effort for 20 to 45
inutes 3 to 5 times per week for periods of 8 to 12 weeks (429).
The long-term effects of exercise training have not been
ompletely defined. In short-term studies, exercise training
as been accompanied by a reduction in the activation of
eurohormonal systems and attenuation of the process of
entricular remodeling (424,432,433). In the experimental
etting, exercise appears to attenuate the rate of progression
f HF (434,435). These observations suggest that exercise
raining might have a favorable effect on the natural history
f HF. Only 1 study has evaluated the long-term effect of
hysical conditioning in patients with HF (430), and in that
rial, exercise training was associated with a reduction in the
isk of hospitalization and death. Little work has been conducted to identify patients most likely to respond favor-
bly to training and to define optimal exercise protocols.
ecommendations Concerning Exercise Training. Exercise
raining should be considered for all stable outpatients with
hronic HF who are able to participate in the protocols
eeded to produce physical conditioning. Exercise training
hould be used in conjunction with drug therapy.
.3.1.4. DRUGS AND INTERVENTIONS UNDER ACTIVE INVESTIGATION
everal drugs and other interventions are undergoing active
valuation in long-term, large-scale trials because they
howed promise in pilot studies that involved small numbers
f patients. Until the results of definitive trials are available,
one of these interventions can be recommended for use in
atients with HF. Several drugs that showed promise in
ilot studies and were included in this section in the 2001
uidelines failed to live up to their promise in long-term,
arge-scale trials and are no longer included as “promising”
n this update. Several remain under or have begun active
nvestigation. Investigational drug therapies currently in
hase III evaluation for the treatment of chronic HF include
asopressin receptor antagonists, intermittent nesiritide in-
usions, and oral phosphodiesterase III inhibitors. In addi-
ion, newer devices and technologies, such as implantable
emodynamic monitors and internal cardiac support de-
ices, external counterpulsation, treatment for sleep-
isordered breathing, myocardial growth factors and stem
ell transplantation, and devices to achieve intravascular
olume reduction, as well as novel surgical approaches,
ncluding surgical ventricular restoration, are under active
nvestigation. Several of these are discussed below.
.3.1.4.1. TECHNIQUES FOR RESPIRATORY SUPPORT. Patients with HF
requently exhibit abnormal respiratory patterns, including
heyne-Stokes breathing and sleep-disordered breathing
436). In the Sleep Heart Health Study, the presence of
leep-disturbed breathing was associated with a 2.38 relative
isk of HF independent of other known risk factors (437).
his risk of HF exceeded that for all other cardiovascular
isease syndromes evaluated, including hypertension,
troke, and coronary artery disease. The use of nocturnal
xygen and devices that provide continuous positive airway
ressure has been reported to produce symptomatic im-
rovement (438,439). Although there is no direct evidence
hat treatment of sleep-disturbed breathing prevents inci-
ent HF, treatment of established LV dysfunction with
ontinuous positive airway pressure breathing has been
hown to improve LV structure and function in patients
ith either obstructive or central sleep apnea disturbed-
reathing syndrome (440). Additional studies are in
rogress to evaluate the efficacy of these interventions. It is
oped that such studies will provide information about the
fficacy and safety of this approach and help identify
atients most likely to benefit from treatment.
.3.1.4.2. EXTERNAL COUNTERPULSATION. The technique of external
ounterpulsation involves the use of a device with inflatable
uffs that surround the lower limbs and inflate and deflate in
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igned to reduce loading conditions in systole while increas-
ng coronary perfusion pressures in diastole (441). External
ounterpulsation has been shown to reduce the frequency
nd severity of anginal attacks in patients with symptomatic
oronary artery disease (442). A possible mechanism of
ction for this observed clinical effect may be an improve-
ent in endothelial function of the coronary vascular bed
443,444). Early trials of this therapy in patients with HF
nd low EF have been encouraging, and a randomized trial
as been completed recently (445,446). Until more data are
vailable, routine use of this therapy cannot be recom-
ended for the management of patients with symptomatic
educed LVEF.
.3.1.4.3. VASOPRESSIN RECEPTOR ANTAGONISTS. Arginine vasopres-
in is a peptide hormone with significant cardiovascular and
enal effects. These effects are mediated through at least 2
eceptor subtypes: the V1A receptor, which is found on
ascular smooth muscle cells and in the myocardium, and
he V2 receptors, which are found in the kidney. Vasopres-
in levels are often elevated in patients with HF and LV
ysfunction, and they appear to be associated with adverse
utcomes in the setting of low EF after MI (447).
Early studies with 2 different vasopressin receptor antag-
nists have shown favorable changes in hemodynamics and
rine output without a significant change in blood pressure
r heart rate. The drugs appear to reduce body weight and
dema, and they normalized serum sodium in patients with
yponatremia, but the duration and significance of these
linical effects are not clear (448,449). Currently, longer-
erm clinical trials are under way to determine the role, if
ny, of these vasopressin antagonists in patients with
hronic HF (450,451).
.3.1.4.4. IMPLANTABLE HEMODYNAMIC MONITORS. Several implant-
ble systems are in development for the chronic, remote,
utpatient monitoring of ventricular filling pressures and
ther hemodynamic and clinical variables in HF patients.
ne such system has completed phase I and II study and is
urrently being evaluated in a phase III randomized out-
omes trial. The hypothesis underlying this approach sug-
ests that changes in therapy to optimize LV filling pressure
ay improve outcomes in HF patients (452,453).
.3.1.4.5. CARDIAC SUPPORT DEVICES. There is developing experi-
nce with surgical devices that are designed to alter physical
tresses on the LV; theoretically, the devices may improve
erformance or attenuate further ventricular dilatation. One
uch device now being evaluated clinically is a cardiac
rapping device made from a bidirectional woven polyester
hat allows for shortening but resists circumferential expan-
ion beyond the limits of the wrap (454). Clinical trials in
urope (455) and the United States are currently under way
o evaluate the safety and efficacy of this device in patients.
ther ventricular constraint or support devices are also
nder investigation in Europe and the United States.
.3.1.4.6. SURGICAL APPROACHES UNDER INVESTIGATION. A number of
urgical approaches have emerged as potentially beneficial in satients with ischemic HF. The goals of such procedures
enerally include revascularization, reduction in “geometric”
r functional mitral regurgitation, and restoration of a more
ormal LV geometry and function. In this context, the
o-called surgical ventricular restoration procedure is one of
he most extensively studied and applied techniques for
eshaping or excluding anteroapical and septal regions of
synergy (456–458). The surgical ventricular restoration
rocedure, although extensively applied to the treatment of
V asynergy, is now being studied prospectively in a
andomized trial comparing standard medical therapy versus
urgical therapy (coronary artery bypass grafting) alone
ersus surgical ventricular restoration plus coronary artery
ypass grafting in patients with ischemic HF. The National
eart, Lung, and Blood Institute’s multicenter, interna-
ional, randomized STICH (Surgical Treatment for Isch-
mic Heart Failure) trial began enrolling patients with
oronary artery disease and HF in the spring of 2002. The
oal of this study is to determine whether a benefit over
edical therapy can be found for coronary revascularization
nd whether this benefit can be enhanced by ventricular
estoration surgery.
.3.1.4.7. NESIRITIDE. Natriuretic peptides are novel compounds
hat promote diuresis and natriuresis, have vasodilatory
roperties, lead to an indirect increase in cardiac output, and
uppress neurohormonal activation; they have been ap-
roved for use in the management of acute HF (459–461).
n this setting, nesiritide has been shown to improve
ymptoms of acute HF, but the effect on morbidity and
ortality has not been clear from available clinical trials
462,463).
They are currently under investigation as adjunctive
herapy, administered on an intermittent outpatient basis,
or advanced chronic HF. Unless a definitive study does
emonstrate safety and efficacy, intermittent or continuous
utpatient infusion of nesiritide and other natriuretic pep-
ides is not recommended.
.3.1.5. DRUGS AND INTERVENTIONS OF UNPROVED VALUE AND NOT
ECOMMENDED
.3.1.5.1. NUTRITIONAL SUPPLEMENTS AND HORMONAL THERAPIES. Pa-
ients with HF, particularly those treated with diuretics,
ay become deficient in vitamins and micronutrients. Sev-
ral nutritional supplements (e.g., coenzyme Q10, carnitine,
aurine, and antioxidants) and hormonal therapies (e.g.,
rowth hormone or thyroid hormone) have been proposed
or the treatment of HF (464–469). Aside from replenish-
ent of documented deficiencies, randomized trials have
ailed to demonstrate benefit for routine vitamin, nutri-
ional, or hormonal supplementation (470).
In most data or other literature regarding nutraceuticals,
here are issues, including outcomes analyses, adverse ef-
ects, and drug-nutraceutical interactions, that remain un-
esolved. No clinical trials have demonstrated improved
urvival in users of nutritional or hormonal therapy. Some
tudies have suggested a possible effect for coenzyme Q10 in
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ients with HF, but these benefits have not been seen
niformly (471–474). Because of possible adverse effects
nd drug interactions of nutritional supplements and their
idespread use, physicians caring for patients with HF
hould routinely inquire about their use. Until more data are
vailable, nutritional supplements or hormonal therapies are
ot recommended for the treatment of HF. The ACCF
linical Expert Consensus Document on Integrating Com-
lementary Medicine Into Cardiovascular Medicine (475)
ill provide more details regarding cardiovascular issues
ith alternative and complementary medicine.
Most patients with HF due to reduced LVEF respond
avorably to pharmacological and nonpharmacological treat-
ents and enjoy a good quality of life and enhanced
urvival; however, some patients do not improve or experi-
nce rapid recurrence of symptoms despite optimal medical
herapy. Such patients characteristically have symptoms at
est or on minimal exertion, including profound fatigue;
annot perform most activities of daily living; frequently
ave evidence of cardiac cachexia; and typically require
epeated and/or prolonged hospitalizations for intensive
anagement. These individuals represent the most ad-
anced stage of HF and should be considered for specialized
reatment strategies, such as mechanical circulatory support,
ontinuous intravenous positive inotropic therapy, referral
or cardiac transplantation, or hospice care.
Before a patient is considered to have refractory HF,
hysicians should confirm the accuracy of the diagnosis,
dentify any contributing conditions, and ensure that all
onventional medical strategies have been optimally em-
loyed. Measures listed as Class I recommendations for
atients in stages A, B, and C are also appropriate for
atients in end-stage HF (also see Section 5). When no
urther therapies are appropriate, careful discussion of the
rognosis and options for end-of life care should be initiated
see Section 7).
.3.1.5.2. INTERMITTENT INTRAVENOUS POSITIVE INOTROPIC THERAPY (UPDA-
ED). Although positive inotropic agents can improve cardiac
erformance during short- and long-term therapy
476,477), long-term oral therapy with these drugs has not
mproved symptoms or clinical status (233,478–488) and
as been associated with a significant increase in mortality,
specially in patients with advanced HF (486,489–494).
espite these data, some physicians have proposed that the
egularly scheduled intermittent use of intravenous positive
notropic drugs (e.g., dobutamine or milrinone) in a super-
ised outpatient setting might be associated with some
linical benefits (59–61).
However, there has been little experience with intermit-
ent home infusions of positive inotropic agents in con-
rolled clinical trials. Nearly all of the available data are
erived from open-label and uncontrolled studies or from
rials that have compared one inotropic agent with another,
ithout a placebo group (59–61,495). Most trials have beenmall and short in duration and thus have not been able to srovide reliable information about the effect of treatment on
he risk of serious cardiac events. Much, if not all, of the
enefit seen in these uncontrolled reports may have been
elated to the increased surveillance of the patient’s status
nd intensification of concomitant therapy and not to the
se of positive inotropic agents. Only 1 placebo-controlled
rial of intermittent intravenous positive inotropic therapy
as been published (496), and its findings are consistent
ith the results of long-term studies with continuous oral
ositive inotropic therapy in HF (e.g., with milrinone),
hich showed little efficacy and were terminated early
ecause of an increased risk of death.
Given the lack of evidence to support their efficacy and
oncerns about their toxicity, intermittent infusions of
ositive inotropic agents (whether at home, in an outpatient
linic, or in a short-stay unit) should not be used in the
ong-term treatment of HF, even in its advanced stages.
he use of continuous infusions of positive inotropic agents
s palliative therapy in patients with end-stage disease
Stage D) is discussed later in this document (226,227).
.3.2. Patients With Heart Failure and Normal
eft Ventricular Ejection Fraction
ecommendations
LASS I
. Physicians should control systolic and diastolic hypertension in
patients with HF and normal LVEF, in accordance with published
guidelines. (Level of Evidence: A)
. Physicians should control ventricular rate in patients with HF and
normal LVEF and atrial fibrillation. (Level of Evidence: C)
. Physicians should use diuretics to control pulmonary congestion
and peripheral edema in patients with HF and normal LVEF.
(Level of Evidence: C)
LASS IIa
. Coronary revascularization is reasonable in patients with HF and
normal LVEF and coronary artery disease in whom symptomatic
or demonstrable myocardial ischemia is judged to be having an
adverse effect on cardiac function. (Level of Evidence: C)
LASS IIb
. Restoration and maintenance of sinus rhythm in patients with
atrial fibrillation and HF and normal LVEF might be useful to
improve symptoms. (Level of Evidence: C)
. The use of beta-adrenergic blocking agents, ACEIs, ARBs, or
calcium antagonists in patients with HF and normal LVEF and
controlled hypertension might be effective to minimize symp-
toms of HF. (Level of Evidence: C)
. The usefulness of digitalis to minimize symptoms of HF in
patients with HF and normal LVEF is not well established. (Level
of Evidence: C)
Table 8 summarizes the recommendations for treatment
f patients with HF and normal LVEF.
.3.2.1. IDENTIFICATION OF PATIENTS
or many years, the syndrome of HF was considered to be
ynonymous with diminished contractility of the LV, or
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2009 ACCF/AHA Heart Failure Guidelines April 14, 2009:e1–90educed LVEF. Over the past few years, however, there has
een a growing appreciation that a large number of patients
ith HF have a relatively normal EF, or preserved EF. The
athophysiology of this type of HF has been reviewed in
epth (497), and a large, randomized study that enrolled
atients with HF and normal EF has been completed (327).
urrently, a number of investigators are seeking to clarify
he epidemiology, clinical characteristics, and prognosis of
atients with HF and a normal LVEF (498).
Depending on the criteria used to delineate HF and the
ccepted threshold for defining preserved LVEF, it is
stimated that as many as 20% to 60% of patients with HF
ave a relatively (or near) normal LVEF and, in the absence
f valvular disease, are believed to have reduced ventricular
ompliance as a major contributor to the clinical syndrome
499–503). Some investigators have found that in a signif-
cant number of patients, a tendency to fluid retention and
educed vascular compliance, rather than myocardial stiff-
ess, represent the principal abnormalities (504). Regard-
ess, abnormal renal sodium handling and arterial stiffness,
n addition to myocardial stiffness, are likely to play impor-
ant pathophysiologic roles in many patients. Diastole is
hat period in the cardiac cycle during which the myocar-
ium loses its ability to generate force and shorten and
eturns to an unstressed length and force, and diastolic
ysfunction occurs when these events are prolonged, slowed,
r are incomplete (497). It should also be recognized that
iastolic function is abnormal in patients with HF and
able 8. Recommendations for Treatment of Patients With
eart Failure and Normal Left Ventricular Ejection Fraction
Recommendation Class
Level of
Evidence
hysicians should control systolic and diastolic
hypertension, in accordance with published
guidelines.
I A
hysicians should control ventricular rate in
patients with atrial fibrillation.
I C
hysicians should use diuretics to control
pulmonary congestion and peripheral
edema.
I C
hysicians might recommend coronary
revascularization in patients with coronary
artery disease in whom symptomatic or
demonstrable myocardial ischemia is judged
to be having an adverse effect on cardiac
function.
IIa C
estoration and maintenance of sinus rhythm
in patients with atrial fibrillation might be
useful to improve symptoms.
IIb C
he use of beta-adrenergic blocking agents,
angiotensin converting enzyme inhibitors,
angiotensin receptor blockers, or calcium
antagonists in patients with controlled
hypertension might be effective to minimize
symptoms of heart failure.
IIb C
he use of digitalis to minimize symptoms of
heart failure might be considered.
IIb Ceduced LVEF, as well as those with preserved LVEF. oeveral recognized myocardial disorders are associated with
F and a normal LVEF, including restrictive cardiomyop-
thy, obstructive and nonobstructive hypertrophic cardio-
yopathy, and infiltrative cardiomyopathies. The vast ma-
ority of patients with HF and relatively preserved LVEF
ave a history of hypertension, and many, if not most, of
hese patients have evidence of LVH on echocardiography.
owever, some patients who present with HF and relatively
reserved LVEF have no identifiable myocardial pathology.
ecause these patients usually present with symptoms typ-
cal of HF, they should be classified as Stage C. Indeed,
ost patients will have some detectable structural abnor-
ality of the heart, including LVH, atrial dilation, mitral
nnular calcification, aortic sclerosis, or myocardial scar.
Heart failure associated with relatively preserved LVEF is
ost prevalent among elderly women, most of whom have
ypertension, diabetes mellitus, or both and often coronary
rtery disease or atrial fibrillation as well (500). This
bservation may be related to the fact that aging has a
reater impact on ventricular filling characteristics than on
F (505). Aging is associated with decreases in the elastic
roperties of the heart and great vessels, which leads to an
ncrease in systolic blood pressure and an increase in
yocardial stiffness. The rate of ventricular filling decreases
n part because of structural changes in the heart (due to
brosis) and because of a decline in relaxation and compli-
nce. These deleterious effects on diastolic function are
xacerbated by a decrease in beta-adrenergic receptor den-
ity and a decline in peripheral vasodilator capacity, both of
hich are characteristic of elderly patients. In addition,
lderly patients commonly have associated disorders (e.g.,
oronary artery disease, diabetes mellitus, aortic stenosis,
trial fibrillation, or obesity), which can adversely affect the
iastolic properties of the heart or decrease the time
vailable for ventricular filling. There may also be sex-
pecific responses to hypertension and diabetes mellitus that
ake women more susceptible than men to the cumulative
ffects of aging on diastolic function (506).
A number of recent investigations have focused on the
ifferences between HF with preserved EF and that with
ow LVEF (48,49,498). Myocardial infarction or other
vidence of atherosclerotic disease appears to be less com-
on in HF with normal LVEF, but hypertension is at least
s common in this subgroup. The morbidity and mortality
ssociated with HF and a relatively preserved LVEF may be
early as profound as that with low LVEF; frequent and
epeated hospitalizations characterize the patient with HF
nd a normal LVEF (507,508). Most, but not all, series of
atients with HF and relatively preserved LVEF have
hown better survival than is seen in patients with HF and
educed LVEF; however, these comparisons are difficult to
nterpret, because it is difficult to be certain that such series
o not contain at least some patients in whom the diagnosis
f HF is erroneous.
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here have been several proposed criteria by which clini-
ians and investigators may define HF with a relatively
reserved LVEF (509–512). In general, a definitive diag-
osis can be made when the rate of ventricular relaxation is
lowed; this physiological abnormality is characteristically
ssociated with the finding of an elevated LV filling pressure
n a patient with normal LV volumes and contractility. In
ractice, the diagnosis is generally based on the finding of
ypical symptoms and signs of HF in a patient who is shown
o have a normal LVEF and no valvular abnormalities
aortic stenosis or mitral regurgitation, for example) on
chocardiography. Every effort should be made to exclude
ther possible explanations or disorders that may present in
similar manner (503,513) (Table 9).
Noninvasive methods (especially those that rely on
oppler echocardiography) have been developed to assist in
he diagnosis of HF with normal LVEF, but these tests
ave significant limitations, because cardiac filling patterns
re readily altered by nonspecific and transient changes in
oading conditions in the heart and by aging, changes in
eart rate, or the presence of mitral regurgitation (514–
20). The analysis of BNP levels in association with
chocardiographic filling patterns can improve diagnostic
ccuracy. For example, a normal BNP level along with
ompletely normal diastolic end-filling parameters makes
F much less likely; however, HF does remain a strictly
linical diagnosis (521).
.3.2.3. PRINCIPLES OF TREATMENT
n contrast to the treatment of HF due to reduced LVEF,
ew clinical trials are available to guide the management of
atients with HF and relatively preserved LVEF. Although
ontrolled studies have been performed with digitalis,
CEIs, ARBs, beta blockers, and calcium channel blockers
n patients with HF who had a relatively preserved LVEF,
able 9. Differential Diagnosis in a Patient With Heart Failure
nd Normal Left Ventricular Ejection Fraction
ncorrect diagnosis of HF
naccurate measurement of LVEF
rimary valvular disease
estrictive (infiltrative) cardiomyopathies
Amyloidosis, sarcoidosis, hemochromatosis
ericardial constriction
pisodic or reversible LV systolic dysfunction
evere hypertension, myocardial ischemia
F associated with high metabolic demand (high output states)
Anemia, thyrotoxicosis, arteriovenous fistulae
hronic pulmonary disease with right HF
ulmonary hypertension associated with pulmonary vascular disorders
trial myxoma
iastolic dysfunction of uncertain origin
besity
F indicates heart failure; LV, left ventricular; and LVEF, left ventricular ejection fraction.or the most part, these trials have been small or have broduced inconclusive results (134,241,522–524). Never-
heless, many patients with HF and normal LVEF are
reated with these drugs because of the presence of comor-
id conditions (i.e., atrial fibrillation, hypertension, diabetes
ellitus, and coronary artery disease). A large, randomized
rial recently completed included patients with HF and
ormal LVEF, which demonstrates that studies in such
atients can be accomplished (327). In that trial, the
ddition of candesartan to the treatment regimen for pa-
ients with symptomatic HF and relatively preserved LVEF
ignificantly reduced morbidity but did not reach the pri-
ary endpoint.
In the absence of other controlled clinical trials, the
anagement of these patients is based on the control of
hysiological factors (blood pressure, heart rate, blood
olume, and myocardial ischemia) that are known to exert
mportant effects on ventricular relaxation (503). Likewise,
iseases that are known to cause HF with normal LVEF
hould be treated, such as coronary artery disease, hyper-
ension, or aortic stenosis. Clinically, it seems reasonable to
arget symptom reduction, principally by reducing cardiac
lling pressures at rest and during exertion (497). Recom-
endations regarding the use of anticoagulation and anti-
rrhythmic agents apply to all patients with HF, irrespective
f LVEF.
OTENTIAL TREATMENT STRATEGIES. Hypertension exerts
deleterious effect on ventricular function by causing both
tructural and functional changes in the heart. Increases in
ystolic blood pressure have been shown to slow myocardial
elaxation (525), and the resulting hypertrophy may ad-
ersely affect passive chamber stiffness. Physicians should
ake every effort to control both systolic and diastolic
ypertension with effective antihypertensive therapy in ac-
ordance with published guidelines (78). Consideration
hould at least be given to achieving target levels of blood
ressure lower than those recommended for patients with
ncomplicated hypertension (e.g., less than 130 mm Hg
ystolic and less than 80 mm Hg diastolic) (78,524,526).
ecause myocardial ischemia can impair ventricular relax-
tion, coronary revascularization should be considered in
atients with coronary artery disease in whom symptomatic
r demonstrable myocardial ischemia is believed to be
xerting a deleterious effect on cardiac function (for more
nformation, see the ACC/AHA 2004 Guideline Update
or Coronary Artery Bypass Graft Surgery [16]).
Because tachycardia can shorten the time available for
entricular filling and coronary perfusion, drugs that slow
he heart rate or the ventricular response to atrial arrhyth-
ias (e.g., beta blockers, digoxin, and some calcium channel
lockers) can provide symptomatic relief in patients with
F and normal LVEF. Similarly, patients with HF and
reserved LVEF may be particularly sensitive to loss of
trial kick, which supports a potential benefit for restoration
f sinus rhythm in patients with atrial fibrillation. The
enefits of restoring sinus rhythm in these individuals are
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2009 ACCF/AHA Heart Failure Guidelines April 14, 2009:e1–90ess clear, and the large trials of rhythm versus rate control
n atrial fibrillation published recently have excluded pa-
ients with HF. Moreover, the presence of systolic or
iastolic dysfunction may diminish the efficacy and enhance
he toxicity of drugs used to achieve and maintain sinus
hythm.
Circulating blood volume is a major determinant of
entricular filling pressure, and the use of diuretics may
mprove breathlessness in patients with HF and normal
VEF as well as those with reduced LVEF. Other possible
gents used to reduce diastolic filling pressures are nitrates
r agents that block neurohumoral activation. Hypotension
ay be a significant problem in this population, especially in
he very elderly, because they can be quite sensitive to
reload reduction.
.4. Patients With Refractory End-Stage Heart
ailure (Stage D) (UPDATED)
he role of intermittent infusions as effective treatment for
dvanced HF has been further clarified by an additional
ulticenter trial (Table 4).
ecommendations
LASS I
. Meticulous identification and control of fluid retention is recom-
mended in patients with refractory end-stage HF (279,282,527–
532). (Level of Evidence: B)
. Referral for cardiac transplantation in potentially eligible pa-
tients is recommended for patients with refractory end-stage HF
(533). (Level of Evidence: B)
. Referral of patients with refractory end-stage HF to a HF program
with expertise in the management of refractory HF is useful
(534–537). (Level of Evidence: A)
. Options for end-of-life care should be discussed with the patient
and family when severe symptoms in patients with refractory
end-stage HF persist despite application of all recommended
therapies. (Level of Evidence: C)
. Patients with refractory end-stage HF and implantable defibrilla-
tors should receive information about the option to inactivate the
defibrillator. (Level of Evidence: C)
LASS IIa
. Consideration of an LV assist device as permanent or “destina-
tion” therapy is reasonable in highly selected patients with
refractory end-stage HF and an estimated 1-year mortality over
50% with medical therapy (538,539). (Level of Evidence: B)
LASS IIb
. Pulmonary artery catheter placement may be reasonable to
guide therapy in patients with refractory end-stage HF and
persistently severe symptoms (533,540). (Level of Evidence: C)
. The effectiveness of mitral valve repair or replacement is not well
established for severe secondary mitral regurgitation in refrac-
tory end-stage HF (141 541,542). (Level of Evidence: C)
. Continuous intravenous infusion of a positive inotropic agent
may be considered for palliation of symptoms in patients with
refractory end-stage HF (543,544). (Level of Evidence: C) iLASS III
. Partial left ventriculectomy is not recommended in patients with
nonischemic cardiomyopathy and refractory end-stage HF. (Level
of Evidence: C)
. Routine intermittent infusions of vasoactive and positive inotro-
pic agents are not recommended for patients with refractory
end-stage HF (545,546). (Level of Evidence: A)
Most patients with HF due to reduced LVEF respond
avorably to pharmacological and nonpharmacological treat-
ents and enjoy a good quality of life and enhanced
urvival; however, some patients do not improve or experi-
nce rapid recurrence of symptoms despite optimal medical
herapy. Such patients characteristically have symptoms at
est or on minimal exertion, including profound fatigue;
annot perform most activities of daily living; frequently
ave evidence of cardiac cachexia; and typically require
epeated and/or prolonged hospitalizations for intensive
anagement. These individuals represent the most ad-
anced stage of HF and should be considered for specialized
reatment strategies, such as mechanical circulatory support,
ontinuous intravenous positive inotropic therapy, referral
or cardiac transplantation, or hospice care.
Before a patient is considered to have refractory HF,
hysicians should confirm the accuracy of the diagnosis,
dentify any contributing conditions, and ensure that all
onventional medical strategies have been optimally em-
loyed. Measures listed as Class I recommendations for
atients in stages A, B, and C are also appropriate for
atients in end-stage HF (see also Section 5). When no
urther therapies are appropriate, careful discussion of the
rognosis and options for end-of-life care should be initi-
ted (see Section 7).
.4.1. Management of Fluid Status
any patients with advanced HF have symptoms that are
elated to the retention of salt and water and thus will
espond favorably to interventions designed to restore so-
ium balance. Hence, a critical step in the successful
anagement of end-stage HF is the recognition and me-
iculous control of fluid retention.
In most patients with chronic HF, volume overload can
e treated adequately with low doses of a loop diuretic
ombined with moderate dietary sodium restriction; how-
ver, as HF advances, the accompanying decline in renal
erfusion can limit the ability of the kidneys to respond to
iuretic therapy (263,275). In such patients, the control of
uid retention may require progressive increments in the
ose of a loop diuretic and frequently the addition of a
econd diuretic that has a complementary mode of action
e.g., metolazone) (283,285). If the patient continues to
xhibit evidence of volume overload despite these measures,
ospitalization is generally required for further adjustment
f therapy (282,527), possibly including intravenous dopa-
ine or dobutamine. This strategy can elicit a markedncrease in urine volume, but such a diuresis is frequently
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re also being treated with an ACEI. Provided that renal
unction stabilizes, small or moderate elevations of blood
rea nitrogen and serum creatinine should not lead to efforts
o minimize the intensity of therapy; however, if the degree
f renal dysfunction is severe or if the edema becomes
esistant to treatment, ultrafiltration or hemofiltration may
e needed to achieve adequate control of fluid retention
547,548). The use of such mechanical methods of fluid
emoval can produce meaningful clinical bene fits in patients
ith diuretic-resistant HF and may restore responsiveness
o conventional doses of loop diuretics.
In general, patients should not be discharged from the
ospital until a stable and effective diuretic regimen is
stablished, and ideally, not until euvolemia is achieved.
atients who are sent home before these goals are reached
re at high risk of recurrence of fluid retention and early
eadmission (549), because unresolved edema may itself
ttenuate the response to diuretics (278–280). Once euvol-
mia is achieved, the patient’s dry weight can be defined and
sed as a continuing target for the adjustment of diuretic
oses. Many patients are able to modify their own diuretic
egimen in response to changes in weight that exceed a
redefined range. The restriction of dietary sodium (to 2 g
aily or less) can greatly assist in the maintenance of volume
alance.
Patients with persistent or recurrent fluid retention de-
pite sodium restriction and high-dose diuretic use may
enefit from review of fluid intake and restriction to 2 liters
aily. The ongoing control of fluid retention may be
nhanced by enrollment in an HF program, which can
rovide the close surveillance and education needed for the
arly recognition and treatment of volume overload (258–261).
.4.2. Utilization of Neurohormonal Inhibitors
ontrolled trials suggest that patients with advanced HF
espond favorably to treatment with both ACEIs and beta
lockers in a manner similar to those with mild to moderate
isease (155,158,162–165,297,298,300 –302,305,310 –
21,336 –343,550). However, because neurohormonal
echanisms play an important role in the support of
irculatory homeostasis as HF progresses, neurohormonal
ntagonism may be less well tolerated by patients with
evere symptoms than by patients with mild symptoms.
atients who are at the end stage of their disease are at
articular risk of developing hypotension and renal insuffi-
iency after the administration of an ACEI and of experi-
ncing worsening HF after treatment with a beta blocker.
s a result, patients with refractory HF may tolerate only
mall doses of these neurohormonal antagonists or may not
olerate them at all.
Consequently, physicians should exercise great care when
onsidering the use of both ACEIs and beta blockers in
atients with refractory HF. Treatment with either type of
rug should not be initiated in patients who have systolic
lood pressures less than 80 mm Hg or who have signs of seripheral hypoperfusion. In addition, patients should not
e started on a beta blocker if they have significant fluid
etention or if they recently required treatment with an
ntravenous positive inotropic agent. Treatment with an
CEI or beta blocker should be initiated in very low doses,
nd patients should be monitored closely for signs or
ymptoms of intolerance. If low doses are tolerated, further
osage increments may be considered but may not be
olerated. However, clinical trials with lisinopril and carve-
ilol suggest that even low doses of these drugs may provide
mportant benefits (174,551).
Alternative pharmacological treatments may be consid-
red for patients who cannot tolerate ACEIs or beta-
lockers. A combination of nitrates and hydralazine has
een reported to have favorable effects on survival in patients
ith mild to moderate symptoms who were not taking an
CEI or a beta blocker (238), but the utility of this
asodilator combination in patients with end-stage disease
ho are being given these neurohormonal antagonists
emains unknown. In addition, many patients experience
eadaches or gastrointestinal distress with these direct-
cting vasodilators, which can prevent patients from under-
oing long-term treatment. Spironolactone has been re-
orted to prolong life and reduce the risk of hospitalization
or HF in patients with advanced disease (256); however,
he evidence supporting the use of the drug has been derived
n patients who have preserved renal function, and the drug
an produce dangerous hyperkalemia in patients with im-
aired renal function. Finally, although ARBs (325) are
requently considered as alternatives to ACEIs because of
he low incidence of cough and angioedema with these
edications, it is not clear that ARBs are as effective as
CEIs, and they are as likely as ACEIs to produce
ypotension or renal insufficiency (297,552).
.4.3. Intravenous Peripheral Vasodilators and
ositive Inotropic Agents (UPDATED)
atients with refractory HF are hospitalized frequently for
linical deterioration, and during such admissions, they
ommonly receive infusions of both positive inotropic
gents (dobutamine, dopamine, or milrinone) and vasodi-
ator drugs (nitroglycerin, nitroprusside, or nesiritide) in an
ffort to improve cardiac performance, facilitate diuresis,
nd promote clinical stability. Some physicians have advo-
ated the placement of pulmonary artery catheters in pa-
ients with refractory HF, with the goal of obtaining
emodynamic measurements that might be used to guide
he selection and titration of therapeutic agents (540).
owever, the logic of this approach has been questioned,
ecause many useful drugs for HF produce benefits by
echanisms that cannot be evaluated by measuring their
hort-term hemodynamic effects (352,553). Regardless of
hether invasive hemodynamic monitoring is used, once the
linical status of the patient has stabilized, every effort
hould be made to devise an oral regimen that can maintain
ymptomatic improvement and reduce the subsequent risk
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2009 ACCF/AHA Heart Failure Guidelines April 14, 2009:e1–90f deterioration. Assessment of the adequacy and tolerabil-
ty of orally based strategies may necessitate observation in
he hospital for at least 48 hours after the infusions are
iscontinued (554).
Patients who cannot be weaned from intravenous to oral
herapy despite repeated attempts may require placement of
n indwelling intravenous catheter to allow for the contin-
ous infusion of dobutamine or milrinone or, as has been
sed more recently, nesiritide. Such a strategy is commonly
sed in patients who are awaiting cardiac transplantation,
ut it may also be used in the outpatient setting in patients
ho otherwise cannot be discharged from the hospital. The
ecision to continue intravenous infusions at home should
ot be made until all alternative attempts to achieve stability
ave failed repeatedly, because such an approach can present
major burden to the family and health services and may
ltimately increase the risk of death. However, continuous
ntravenous support may provide palliation of symptoms as
art of an overall plan to allow the patient to die with
omfort at home (543,544). The use of continuous intrave-
ous support to allow hospital discharge should be distin-
uished from the intermittent administration of infusions of
uch agents to patients who have been successfully weaned
rom inotropic support (536). Intermittent outpatient infu-
ions of either vasoactive drugs such as nesiritide or positive
notropic drugs have not shown to improve symptoms or
urvival in patients with advanced HF (536,545,546).
.4.4. Mechanical and Surgical Strategies
ardiac transplantation is currently the only established
urgical approach to the treatment of refractory HF, but it
s available to fewer than 2500 patients in the United States
ach year (555,556). Current indications for cardiac trans-
lantation focus on the identification of patients with severe
unctional impairment or dependence on intravenous ino-
ropic agents (Table 10). Less common indications for
ardiac transplantation include recurrent life-threatening
entricular arrhythmias or angina that is refractory to all
urrently available treatments (557).
Alternative surgical and mechanical approaches for the
reatment of end-stage HF are under development. Clinical
mprovement has been reported after mitral valve repair or
eplacement in patients who have a clinically important degree
f mitral regurgitation that is secondary to LV dilatation (141).
owever, no controlled studies have evaluated the effects of
his procedure on ventricular function, clinical status, or sur-
ival. One recent single-center report of a nonrandomized
eries of patients considered appropriate candidates for mitral
alve repair did not demonstrate a survival advantage (541).
Although both cardiomyoplasty and left ventriculectomy
Batista procedure) at one time generated considerable
xcitement as potential surgical approaches to the treatment
f refractory HF (558,559), these procedures failed to result
n clinical improvement and were associated with a high risk
f death (560). A variant of the aneurysmectomy procedure
s now being developed for the management of patients with oschemic cardiomyopathy (458), but its role in the manage-
ent of HF remains to be defined. None of the current
urgical reconstruction techniques offer “rescue therapy” to
atients with critical hemodynamic compromise.
The use of mechanical circulatory assist devices in end-
tage HF is an area of intense investigation. Extracorporeal
evices can be used for short-term circulatory support in
atients who are expected to recover from a major cardiac
nsult (e.g., myocardial ischemia, postcardiotomy shock, or
ulminant myocarditis). Left ventricular assist devices pro-
ide similar degrees of hemodynamic support; many are
mplantable and thus allow for long-term support, patient
mbulation, and hospital discharge (561). Most clinical
xperience with these devices has been derived from their
se in patients being “bridged” to transplant. The comple-
ion of the Randomized Evaluation of Mechanical Assis-
ance for the Treatment of Congestive Heart Failure (RE-
ATCH) trial investigated the use of these devices as
ermanent or “destination” therapy in selected non–
ransplant-eligible patients.
This trial enrolled 129 patients, for whom 2-year survival
as 23% in the 68 patients treated with the device and 8%
n the 61 patients who received medical therapy (562).
evice-related adverse events were numerous and included
leeding, infection, thromboembolic events, and device
ailure. This trial established the efficacy of device therapy
or end-stage HF. Improvements in newer generations of
evices will hopefully permit even further prolongation of
urvival. Presently, destination device therapy is anticipated
o benefit those patients predicted to have a 1-year survival
f less than 50%. One such group could be the population
able 10. Indications for Cardiac Transplantation
bsolute Indications in Appropriate Patients
or hemodynamic compromise due to HF
● Refractory cardiogenic shock
● Documented dependence on IV inotropic support to maintain adequate
organ perfusion
● Peak VO2 less than 10 mL per kg per minute with achievement of
anaerobic metabolism
evere symptoms of ischemia that consistently limit routine activity and are
not amenable to coronary artery bypass surgery or percutaneous coronary
intervention
ecurrent symptomatic ventricular arrhythmias refractory to all therapeutic
modalities
elative Indications
Peak VO2 11 to 14 mL per kg per minute (or 55% predicted) and major
limitation of the patient’s daily activities
Recurrent unstable ischemia not amenable to other intervention
Recurrent instability of fluid balance/renal function not due to patient
noncompliance with medical regimen
nsufficient Indications
Low left ventricular ejection fraction
History of functional class III or IV symptoms of HF
Peak VO2 greater than 15 mL per kg per minute (and greater than 55%
predicted) without other indications
F indicates heart failure; IV, intravenous; and VO2, oxygen consumption per unit time.f non–transplant-eligible patients requiring continuous
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ested that prolonged mechanical decompression of the failing
eart may occasionally be followed by sufficient recovery of
yocardial function to allow explantation of the device (563).
mprovements in ventricular mechanics, myocardial energetics,
istology, and cell signaling have been reported with LV assist
evice support. However, the frequency and duration of
yocardial recovery have been variable (564), and sufficient
ecovery to permit device explantation is rare except in a few
atients with acute onset of HF and the absence of coronary
rtery disease. Coupling of device therapy with cell transplan-
ation and a variety of angiogenesis or myocardial growth
actors are approaches planned for future investigation.
Many patients with HF are members of subpopulations
ho are likely to exhibit unique responses that accelerate the
evelopment or progression of HF or complicate the man-
gement of HF.
.5. The Hospitalized Patient (NEW)
ecommendations
LASS I
1. The diagnosis of HF is primarily based on signs and symptoms
derived from a thorough history and physical examination. Clini-
cians should determine the following:
a. adequacy of systemic perfusion;
b. volume status;
c. the contribution of precipitating factors and/or comorbidities;
d. if the heart failure is new onset or an exacerbation of chronic
disease; and
e. whether it is associated with preserved ejection fraction.
Chest radiographs, electrocardiogram, and echocardiography are
key tests in this assessment. (Level of Evidence: C)
2. Concentrations of B-type natriuretic peptide (BNP) or N-terminal
pro-B-type natriuretic peptide (NT-proBNP) should be measured in
patients being evaluated for dyspnea in which the contribution of
HF is not known. Final diagnosis requires interpreting these
results in the context of all available clinical data and ought not to
be considered a stand-alone test (565,566). (Level of Evidence: A)
3. Acute coronary syndrome precipitating HF hospitalization should
be promptly identified by electrocardiogram and cardiac troponin
testing, and treated as appropriate to the overall condition and
prognosis of the patient. (Level of Evidence: C)
4. It is recommended that the following common potential precipi-
tating factors for acute HF be identified as recognition of these
comorbidities is critical to guide therapy:
a. acute coronary syndromes/coronary ischemia;
b. severe hypertension;
c. atrial and ventricular arrhythmias;
d. infections;
e. pulmonary emboli;
f. renal failure; and
g. medical or dietary noncompliance. (Level of Evidence: C)
5. Oxygen therapy should be administered to relieve symptoms
related to hypoxemia. (Level of Evidence: C)
6. Whether the diagnosis of HF is new or chronic, patients who
present with rapid decompensation and hypoperfusion associ-
ated with decreasing urine output and other manifestations ofshock are critically ill and rapid intervention should be used to
improve systemic perfusion. (Level of Evidence: C)
7. Patients admitted with HF and with evidence of significant fluid
overload should be treated with intravenous loop diuretics. Ther-
apy should begin in the emergency department or outpatient
clinic without delay, as early intervention may be associated with
better outcomes for patients hospitalized with decompensated HF
(32,567,568). (Level of Evidence: B) If patients are already receiv-
ing loop diuretic therapy, the initial intravenous dose should equal
or exceed their chronic oral daily dose. Urine output and signs and
symptoms of congestion should be serially assessed, and diuretic
dose should be titrated accordingly to relieve symptoms and to
reduce extracellular fluid volume excess. (Level of Evidence: C)
8. Effect of HF treatment should be monitored with careful measure-
ment of fluid intake and output; vital signs; body weight, deter-
mined at the same time each day; clinical signs (supine and
standing) and symptoms of systemic perfusion and congestion.
Daily serum electrolytes, urea nitrogen, and creatinine concentra-
tions should be measured during the use of IV diuretics or active
titration of HF medications. (Level of Evidence: C)
9. When diuresis is inadequate to relieve congestion, as evidenced
by clinical evaluation, the diuretic regimen should be intensified
using either:
a. higher doses of loop diuretics;
b. addition of a second diuretic (such as metolazone, spironolac-
tone, or intravenous chlorothiazide); or
c. continuous infusion of a loop diuretic. (Level of Evidence: C)
10. In patients with clinical evidence of hypotension associated with
hypoperfusion and obvious evidence of elevated cardiac filling
pressures (e.g., elevated jugular venous pressure; elevated pulmo-
nary artery wedge pressure), intravenous inotropic or vasopressor
drugs should be administered to maintain systemic perfusion and
preserve end-organ performance while more definitive therapy is
considered. (Level of Evidence: C)
11. Invasive hemodynamic monitoring should be performed to guide
therapy in patients who are in respiratory distress or with clinical
evidence of impaired perfusion in whom the adequacy or excess
of intracardiac filling pressures cannot be determined from clini-
cal assessment. (Level of Evidence: C)
12. Medications should be reconciled in every patient and adjusted as
appropriate on admission to and discharge from the hospital.
(Level of Evidence: C)
13. In patients with reduced ejection fraction experiencing a symp-
tomatic exacerbation of HF requiring hospitalization during
chronic maintenance treatment with oral therapies known to
improve outcomes, particularly ACEIs or ARBs and beta-blocker
therapy, it is recommended that these therapies be continued in
most patients in the absence of hemodynamic instability or
contraindications. (Level of Evidence: C)
14. In patients hospitalized with HF with reduced ejection fraction not
treated with oral therapies known to improve outcomes, particu-
larly ACEIs or ARBs and beta-blocker therapy, initiation of these
therapies is recommended in stable patients prior to hospital
discharge (569,570). (Level of Evidence: B)
15. Initiation of beta-blocker therapy is recommended after optimiza-
tion of volume status and successful discontinuation of intrave-
nous diuretics, vasodilators, and inotropic agents. Beta-blocker
therapy should be initiated at a low dose and only in stable
patients. Particular caution should be used when initiating beta
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hospital course (569,570). (Level of Evidence: B)
16. In all patients hospitalized with HF, both with preserved (see
Section 4.3.2, Patients With Heart Failure and Normal Left Ven-
tricular Ejection Fraction) and low EF, transition should be made
from intravenous to oral diuretic therapy with careful attention to
oral diuretic dosing and monitoring of electrolytes. With all med-
ication changes, the patient should be monitored for supine and
upright hypotension, and worsening renal function and HF signs/
symptoms. (Level of Evidence: C)
17. Comprehensive written discharge instructions for all patients with
a hospitalization for HF and their caregivers is strongly recom-
mended, with special emphasis on the following 6 aspects of
care: diet; discharge medications, with a special focus on adher-
ence, persistence, and uptitration to recommended doses of
ACEI/ARB and beta-blocker medication; activity level; follow-up
appointments; daily weight monitoring; and what to do if HF
symptoms worsen. (Level of Evidence: C)
18. Postdischarge systems of care, if available, should be used to
facilitate the transition to effective outpatient care for patients
hospitalized with HF (215,571–577). (Level of Evidence: B)
LASS IIa
1. When patients present with acute HF and known or suspected
acute myocardial ischemia due to occlusive coronary disease,
especially when there are signs and symptoms of inadequate
systemic perfusion, urgent cardiac catheterization and revascular-
ization is reasonable where it is likely to prolong meaningful
survival. (Level of Evidence: C)
2. In patients with evidence of severely symptomatic fluid overload in
the absence of systemic hypotension, vasodilators such as intrave-
nous nitroglycerin, nitroprusside or nesiritide can be beneficial
when added to diuretics and/or in those who do not respond to
diuretics alone. (Level of Evidence: C)
3. Invasive hemodynamic monitoring can be useful for carefully se-
lected patients with acute HF who have persistent symptoms
despite empiric adjustment of standard therapies, and
a. whose fluid status, perfusion, or systemic or pulmonary vascu-
lar resistances are uncertain;
b. whose systolic pressure remains low, or is associated with
symptoms, despite initial therapy;
c. whose renal function is worsening with therapy;
d. who require parenteral vasoactive agents; or
e. who may need consideration for advanced device therapy or
transplantation. (Level of Evidence: C)
4. Ultrafiltration is reasonable for patients with refractory congestion
not responding to medical therapy (578). (Level of Evidence: B)
LASS IIb
. Intravenous inotropic drugs such as dopamine, dobutamine or
milrinone might be reasonable for those patients presenting with
documented severe systolic dysfunction, low blood pressure and
evidence of low cardiac output, with or without congestion, to
maintain systemic perfusion and preserve end-organ performance.
(Level of Evidence: C)
LASS III
. Use of parenteral inotropes in normotensive patients with acute
decompensated HF without evidence of decreased organ perfusion
is not recommended (579). (Level of Evidence: B). Routine use of invasive hemodynamic monitoring in normotensive
patients with acute decompensated HF and congestion with symp-
tomatic response to diuretics and vasodilators is not recommended
(580). (Level of Evidence: B)
A patient may develop acute or progressive symptoms of
F and require hospitalization. In general, there are 3
linical profiles that describe the hospitalized patient with
F: 1) the patient with volume overload, manifested by
ulmonary and/or systemic congestion, frequently precipi-
ated by an acute increase in chronic hypertension; 2) the
atient with profound depression of cardiac output mani-
ested by hypotension, renal insufficiency, and/or a shock
yndrome, and 3) the patient with signs and symptoms of
oth fluid overload and shock. Irrespective of the presenting
linical picture, there have been a confusing variety of terms
n the literature used to describe these patients, including
cute HF syndrome, acute decompensated HF, or cardio-
enic shock. However different these 3 groups of patients
ay be in outcome, they can all be characterized as having
change in HF signs and symptoms resulting in a need for
rgent therapy. Patients with HF and preserved LVEF (see
ection 4.3.2, Patients With Heart Failure and Normal Left
entricular Ejection Fraction) are just as likely to be
dmitted to hospital as those with HF and low LVEF (581).
dmission with HF is often triggered by a concomitant
ardiovascular event such as a symptomatic tachyarrhyth-
ia, unstable coronary syndrome, or a cerebrovascular
vent; often the admission is related to medical or dietary
oncompliance. The threshold for admission may also be
owered when HF exacerbation is accompanied with a
oncardiac condition such as pneumonia or newly diag-
osed anemia. Indeed, it is important to note that concur-
ent conditions and comorbidities such as coronary artery
isease, hypertension, valvular heart disease, arrhythmias, renal
ysfunction, diabetes, thromboembolism, and anemia are often
resent, more so than has usually been described in clinical
rials, and may precipitate or contribute to the pathophysiology
f the syndrome. Unfortunately, the precipitating event leading
o hospitalization is not always readily apparent.
ommon Factors That Precipitate Hospitalization for
eart Failure
• Noncompliance with medical regimen, sodium and/or
fluid restriction
• Acute myocardial ischemia
• Uncorrected high blood pressure
• Atrial fibrillation and other arrhythmias
• Recent addition of negative inotropic drugs (e.g.,
verapamil, nifedipine, diltiazem, beta blockers)
• Pulmonary embolus
• Nonsteroidal anti-inflammatory drugs
• Excessive alcohol or illicit drug use
• Endocrine abnormalities (e.g., diabetes mellitus, hy-
perthyroidism, hypothyroidism)
• Concurrent infections (e.g., pneumonia, viral illnesses)
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he overall costs of caring for patients with HF and may be
ssociated with a staggering degree of morbidity and mor-
ality, particularly in the elderly population. It is evident that
he prognosis after an index hospitalization for HF is
minous, with a 50% rate of readmission at 6 months and a
5% to 35% incidence of death at 12 months (582–586).
ndeed, many HF trials now incorporate the need for
ospitalization as an important endpoint with which to
valuate a new therapy; government agencies and insurance
ompanies are increasingly interested in understanding the
requency of repeat HF hospitalizations. Thus, it is impor-
ant to outline what should occur in the hospital for the HF
atient requiring therapy. The scope of these recommenda-
ions are based on evidence from the few available random-
zed trials evaluating management strategies in the acute
ecompensated HF patient (461,578–580,587), analyses of
arge registries, and consensus opinion. Additional and
ore comprehensive information on this subject may be
ound in the guidelines from the Heart Failure Society
f America and the European Society of Cardiology
588,589,589a).
.5.1. Diagnostic Strategies
he diagnosis of HF in the hospitalized patient should be
ased primarily on signs and symptoms, as discussed in
ection 3.1., Initial Evaluation of Patients. Clinicians need
o determine as accurately and as quickly as possible 1) the
olume status of the patient, 2) the adequacy of circulatory
upport or perfusion, and 3) the role or presence of
recipitating factors and/or comorbidities. In the patient
ith previously established HF, efforts should likewise be
irected toward understanding what has caused the appar-
nt acute worsening of clinical symptoms. Many of the steps
n this investigation are identical to those used in the initial
valuation of HF (see Sections 3.1.3, Evaluation of the
ause of Heart Failure and 3.2, Ongoing Evaluation of
atients). When the diagnosis of HF is uncertain, determi-
ation of plasma BNP or NT-proBNP concentration
hould be considered in patients being evaluated for dyspnea
ho have signs and symptoms compatible with HF. The
atriuretic peptide concentration should not be interpreted
n isolation but in the context of all available clinical data
earing on the diagnosis of HF.
An important cause of worsening HF, and for new-onset
F, is an acute MI. Because many patients admitted with
cute HF have coronary artery disease, troponins are typi-
ally evaluated at admission for acute exacerbation. Actual
riteria for an acute coronary event that may indicate the
eed for further intervention may be present in up to 20% of
atients (590,591). However, many other patients may have
ow levels of detectable troponins not meeting criteria for an
cute ischemic event but typical of chronic HF with an acute
xacerbation (592). Registry data have suggested that the
se of coronary angiography is low for patients hospitalized
ith decompensated HF and opportunities to diagnose omportant coronary artery disease may be missed. Symptoms
f HF or cardiogenic shock associated with an ischemic
vent are covered in other guidelines (10,593) and are
eyond the scope of this update. For the patient with newly
iscovered HF, clinicians should be aware of the important
ole of coronary artery disease in causing HF and should be
ertain that coronary structure and function are well delin-
ated (see Section 3.1.2, Identification of a Structural and
unctional Abnormality) while simultaneously beginning
reatment. Coronary visualization may be an important part
f the evaluation of patients hospitalized with HF.
Often, patients with chronic HF are admitted with acute
ecompensation from a number of possible precipitating
auses. Clinicians should carefully review the patient’s
aintenance HF medications and decide whether adjust-
ents should be made as a result of the hospitalization. The
arge majority of patients with HF admitted to the hospital,
specially those with concomitant hypertension, should have
heir oral therapy continued, or even uptitrated, during
ospitalization. It is important to note that it has been
hown that continuation of beta blockers for most patients
s well tolerated and results in better outcomes (569,570).
ithholding of or reduction in beta-blocker therapy should
e considered only in patients hospitalized after recent
nitiation or increase in beta-blocker therapy or with marked
olume overload. Patients admitted with worsening
zotemia should be considered for a reduction in or tempo-
ary discontinuation of their ACEIs, ARBs, and/or aldo-
terone antagonists until renal function improves. Patients
ith marked volume overload will require intravenous
iuretic therapy with uptitration of diuretic dose and/or
ddition of synergistic diuretic agents. It should be noted
hat uptitration of ACEIs or beta blockers during decom-
ensation may reduce the efficacy of the acute interventions
o relieve congestion. Although it is important to ensure
hat evidence-based medications are instituted prior to the
atient leaving the hospital, it is equally as critical to reassess
edications on admission and to adjust their administration
n light of the worsening HF.
.5.2. Treatment in the Hospital
.5.2.1. DIURETICS: THE PATIENT WITH VOLUME OVERLOAD
atients admitted with evidence of significant fluid overload
hould initially be treated with loop diuretics, usually given
ntravenously. Therapy for this compelling presentation of
F should begin in the emergency department and should
e initiated without delay. Early intervention has been
ssociated with better outcomes for patients hospitalized
ith decompensated HF (594,595). After admission to the
ospital, patients should be carefully monitored in accor-
ance with the severity of their symptoms and the results of
nitial findings on the physical examination and laboratory
ssessment. Careful and frequent serial evaluation of the
atient is important primarily to assess volume status (see
ection 3.2.2, Assessment of Volume Status) and adequacy
f circulatory support. Laboratory parameters are likewise
n
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aboratory Testing, and 3.2.3, Laboratory Assessment).
onitoring of daily weight, supine and standing vital signs,
uid input, and output is a necessary part of daily manage-
ent; assessment of daily electrolytes and renal function
hould be done while intravenous diuretics or active HF
edication titration is being undertaken.
Intravenous loop diuretics have the potential to reduce
lomerular filtration rate (GFR), further worsen neurohu-
oral activation, and produce electrolyte disturbances.
hus, although the use of diuretics may result in the
ffective relief of symptoms, their impact on mortality has
ot been well studied. Diuretics should be administered at
oses sufficient to produce a rate of diuresis that will
ptimize volume status and relieve signs and symptoms of
ongestion without inducing an excessively rapid reduction
n intravascular volume, which could result in hypotension,
enal dysfunction, or both (see Sections 4.3.1.2.1, Diuretics,
nd 4.4.1, Management of Fluid Status). Because loop
iuretics have a relatively short half-life, sodium reabsorp-
ion in the tubules will occur once the tubular concentration
f the diuretics declines. Therefore, strictly limiting sodium
ntake and dosing the diuretic multiple times per day will
nhance effectiveness of the diuresis (275–279,596–598).
ome patients may present with congestion and moderate to
evere renal dysfunction. The response to diuretics may be
ignificantly blunted, requiring higher initial doses. In many
ases, reduction of fluid overload may improve not only
ongestion but also renal dysfunction, particularly if signif-
cant venous congestion is reduced (599).
Clinical experience suggests it is difficult to determine
hether congestion has been adequately treated in many
atients, and registry data have confirmed that patients are
requently discharged after a net weight loss of only a few
ounds. Although patients may rapidly improve symptom-
tically, they may remain hemodynamically compromised.
nfortunately, the routine use of serial natriuretic peptide
easurement (BNP or NT-proBNP) or even a Swan-Ganz
atheter to monitor hemodynamics has not been shown to
e helpful in improving the outcomes of the hospitalized
atient with HF. Nevertheless, careful evaluation of all
hysical findings, laboratory parameters, weight change, and
et fluid change should be considered before discharge
lanning is commenced.
When a patient with congestion fails to respond to initial
oses of intravenous diuretics, several options may be
onsidered. Efforts should be taken to make certain that,
ndeed, congestion persists and that another hemodynamic
rofile or perhaps another disease process is not evident.
his is particularly important for the patient with progres-
ive renal insufficiency. If there is substantial doubt about
he fluid status of the patient, HF experts suggest that it is
n appropriate time for a formal hemodynamic assessment
f ventricular filling pressures and cardiac output, typically
one with a right heart catheterization. If volume overloads confirmed, the dose of the loop diuretic should be initially oncreased to ensure that adequate drug levels reach the
idney. If this is inadequate, a second type of diuretic,
ypically a thiazide (metolazone or intravenous chlorothia-
ide) or spironolactone, can be added to improve diuretic
esponsiveness. As a third strategy, continuous infusion of
he loop diuretic may be considered. By continuous delivery
f the diuretic to the nephron, rebound resorption occurring
uring the time blood levels of diuretic are low is avoided
nd ototoxicity risk may actually be reduced (see Sections
.3.1.2.1, Diuretics, and 4.4.1, Management of Fluid Sta-
us) (279,280,282–286,598,600,601). If all diuretic strate-
ies are unsuccessful, ultrafiltration or another renal replace-
ent strategy may be reasonable. Ultrafiltration moves
ater and small- to medium-weight solutes across a semi-
ermeable membrane to reduce volume overload. Because
he electrolyte concentration is similar to plasma, relatively
ore sodium can be removed than by diuretics (529,578,
02–604). Consultation with a kidney specialist may be
ppropriate before opting for any mechanical strategy to
ffect diuresis.
.5.2.2. VASODILATORS
here are a number of clinical scenarios whereby the
ddition of vasodilators to the HF regimen of the hospital-
zed patient might be appropriate. For patients with ade-
uate blood pressure and ongoing congestion not sufficiently
esponsive to diuretics and standard oral therapy (e.g.,
aintenance of prior HF medications, if applicable), intra-
enous vasodilators such as nitroprusside, nitroglycerin, or
esiritide may be added to the treatment regimen. Regard-
ess of the agent used, the clinician should make certain that
ntravascular volume is, in fact, expanded and that the
atient’s blood pressure can tolerate the addition of the
asodilating drug.
Intravenous nitroglycerin, primarily through venodilation
ffects, lowers preload and may help to more rapidly reduce
ulmonary congestion. Patients with HF and hypertension,
oronary ischemia, or significant mitral regurgitation are
ften cited as ideal candidates for the use of intravenous
itroglycerin. However, tachyphylaxis to nitroglycerin may
evelop rather quickly and up to 20% of those with HF may
evelop resistance to even high doses (605–607). Sodium
itroprusside is a balanced preload-reducing venodilator and
fterload-reducing arteriodilator that also dilates the pulmo-
ary vasculature. Data demonstrating efficacy are limited,
nd invasive hemodynamic blood pressure monitoring is
ypically required. Nitroprusside has the potential for pro-
ucing marked hypotension and is usually used in the
ntensive care setting as well; longer infusions of the drug
ave been associated with thiocyanate toxicity, particularly
n the setting of renal insufficiency. Nitroprusside is poten-
ially of value in severely congested patients with hyperten-
ion or severe mitral valve regurgitation complicating LV
ysfunction. Nesiritide (human BNP) reduces LV filling
ressure but has variable effects on cardiac output, urinary
utput, and sodium excretion. The severity of dyspnea is
r
n
n
l
u
t
s
(
t
o
h
H
d
s
o
H
i
m
H
4
P
s
c
n
n
p
s
I
r
v
a
p
a
o
s
s
h
a
c
c
s
n
i
s
b
i
p
n
p
(
i
T
p
w
c
t
c
w
c
n
h
p
w
w
P
b
l
d
c
m
c
i
c
p
r
c
t
t
t
s
s
r
r
p
4
O
f
t
a
E
h
b
r
u
u
c
a
i
R
P
E
i
i
A
a
s
e51JACC Vol. 53, No. 15, 2009 Hunt et al.
April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure Guidelineseduced more rapidly compared to diuretics alone. Because
esiritide has a longer effective half-life than nitroglycerin or
itroprusside, side effects such as hypotension may persist
onger. Conservative dosing of the drug (i.e., no bolus) and
se of only the recommended doses may reduce complica-
ions. Adverse renal consequences with nesiritide have been
uggested; careful monitoring of renal function is mandatory
459,461–463,608–610). The effects of nesiritide on mor-
ality remain uncertain and active clinical investigation is
ngoing.
The role of intravenous vasodilators for the patient
ospitalized with HF can not be generalized. The goals of
F therapy with vasodilators, in the absence of more
efinitive data, include a more rapid resolution of congestive
ymptoms; relief of anginal symptoms while awaiting cor-
nary intervention; control of hypertension complicating
F; and, in conjunction with ongoing hemodynamic mon-
toring while the intravenous drug is administered, improve-
ent of hemodynamic abnormalities prior to instituting oral
F medications.
.5.2.3. INOTROPES
atients presenting with either predominantly low output
yndrome (e.g., symptomatic hypotension) or combined
ongestion and low output may be considered for intrave-
ous inotropes such as dopamine, dobutamine, and milri-
one. These agents may help relieve symptoms due to poor
erfusion and preserve end-organ function in patients with
evere systolic dysfunction and dilated cardiomyopathy.
notropic agents are of greatest value in patients with
elative hypotension and intolerance or no response to
asodilators and diuretics. Clinicians should be cautioned
gain that the use of these drugs portends a very poor
rognosis for their patients; a thorough hemodynamic
ssessment must be undertaken to ensure that the low
utput syndrome is responsible for the presenting clinical
igns and symptoms. Likewise, clinicians should not use a
pecific blood pressure value that might or might not mean
ypotension, to dictate the use of inotropic agents. Rather,
depressed blood pressure associated with signs of poor
ardiac output or hypoperfusion (e.g., cold clammy skin,
ool extremities, decreased urine output, altered mentation)
hould prompt a consideration for more aggressive intrave-
ous therapy. Dobutamine requires the beta-receptor for its
notropic effects, while milrinone does not. This may be a
ignificant consideration for patients already maintained on
eta-blocking drugs. Furthermore, milrinone has vasodilat-
ng properties for both the systemic circulation and the
ulmonary circulation. Despite these considerations, there is
o evidence of benefit for routine use of inotropic support in
atients presenting with acute HF due to congestion only
579,611–613). Indeed, data from several studies suggest an
ncrease in adverse outcomes when inotropes are used.
hus, inotropes should be confined to carefully selected
atients with low blood pressure and reduced cardiac output
ho can have blood pressure and heart rhythm monitored olosely (see Section 4.4.3, Intravenous Peripheral Vasodila-
ors and Positive Inotropic Agents).
Routine invasive hemodynamic monitoring is not indi-
ated for most patients hospitalized with symptoms of
orsening HF. Recent evaluations of the use of right heart
atheterization to improve outcomes have been essentially
eutral with regard to overall benefit (580,614). However,
emodynamic monitoring should be strongly considered in
atients whose volume and filling pressures are uncertain or
ho are refractory to initial therapy, particularly in those
hose filling pressures and cardiac output are unclear.
atients with clinically significant hypotension (systolic
lood pressure typically less than 90 mm Hg or symptomatic
ow systolic blood pressure) and/or worsening renal function
uring initial therapy might also benefit. Patients being
onsidered for cardiac transplantation or placement of a
echanical circulatory support device are also candidates for
omplete right heart catheterization, a necessary part of the
nitial evaluation (see Section 4.4.4, Mechanical and Surgi-
al Strategies). Invasive hemodynamic monitoring should be
erformed in patients with 1) presumed cardiogenic shock
equiring escalating pressor therapy and consideration of me-
hanical support; 2) severe clinical decompensation in which
herapy is limited by uncertainty regarding relative contribu-
ions of elevated filling pressures, hypoperfusion, and vascular
one; 3) apparent dependence on intravenous inotropic infu-
ions after initial clinical improvement; or 4) persistent severe
ymptoms despite adjustment of recommended therapies. This
einforces the concept that right heart catheterization is best
eserved for those situations where a specific clinical or thera-
eutic question needs to be addressed.
.5.2.4. OTHER CONSIDERATIONS
ther treatment or diagnostic strategies may be necessary
or individual patients after stabilization, particularly related
o the underlying cause of the acute event. Considerations
re similar to those previously discussed in Section 3.1.3,
valuation of the Cause of Heart Failure. The patient
ospitalized with HF is at increased risk for thromboem-
olic complications and deep venous thrombosis and should
eceive prophylactic anticoagulation with either intravenous
nfractionated heparin or subcutaneous preparations of
nfractionated or low-molecular-weight heparin, unless
ontraindicated (615).
As the hospitalized patient becomes more clinically stable
nd volume status normalizes, oral HF therapy should be
nitiated or reintroduced (see Sections 4.3.1, Patients With
educed Left Ventricular Ejection Fraction, and 4.3.2,
atients With Heart Failure and Normal Left Ventricular
jection Fraction). Particular caution should be used when
nitiating beta blockers in patients who have required
notropes during their hospital course or when initiating
CEIs in those patients who have experienced marked
zotemia. During additional hospital days, the patient
hould be fully transitioned off all intravenous therapy, and
ral therapy should be adjusted and maximized. The clinical
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atient and family. The treating clinicians should also
eassess overall prognosis once current functional status and
recipitating causes of the hospitalization have been deter-
ined. The appropriateness of discussion about advanced
herapy or end-of-life preferences should also be considered
see Sections 3.2.4, Assessment of Prognosis, and 7, End-
f-Life Considerations). On discharge, the patient, the
amily, and the patient’s primary physician should be aware
nd supportive of the follow-up plans.
.5.3. The Hospital Discharge
o ensure safe, high-quality, and efficient care for patients
ollowing hospitalization for HF, the consistent use of
linical practice guidelines developed by the ACCF, the
HA, and the Heart Failure Society of America should be
romoted during and after the hospital stay. One critical
erformance measure for care coordination and transition is
hat of written discharge instructions or educational mate-
ial given to patient and/or caregiver at discharge to home or
uring the hospital stay addressing all of the following:
ctivity level, diet, discharge medications, follow-up ap-
ointment, weight monitoring, and what to do if symptoms
orsen (616). Education of HF patients and their families is
ritical and often complex. Failure of these patients to
nderstand how best to comply with physician’s and other
ealthcare providers’ instructions is often a cause of HF
xacerbation leading to subsequent hospital readmission.
Large registries of hospitalized HF patients suggest that
any patients are discharged before optimal volume status
s achieved, or sent home without the benefit of life-saving
herapies such as ACE/ARB and beta-blocker medications.
mong hospitals providing care for patients with HF, there
s significant individual variability in conformity to quality-
f-care indicators and clinical outcomes and a substantial
ap in overall performance (617). Patients are discharged
ithout adequate control of their blood pressure or the
entricular response to atrial fibrillation. Often, the treating
linician fails to appreciate the severity of the HF process or
elays diagnostic testing until the patient is seen as an
utpatient. These problems, and others, may account for the
igh rate of HF rehospitalizations seen in the United States.
It is, therefore, incumbent on healthcare professionals to
e certain that patients and their families have an under-
tanding of the causes of HF, prognosis, therapy, dietary
estrictions, activity, importance of compliance, and signs
nd symptoms of recurrent HF. Thorough discharge plan-
ing that includes a special emphasis on ensuring compli-
nce with an evidence-based medication regimen (571) is
ssociated with improved patient outcomes (572,618,619).
Several studies have examined the effect of providing
ore intensive delivery of discharge instructions coupled
ightly with subsequent well-coordinated follow-up care for
atients hospitalized with HF, many with positive results
215,573–575). Comprehensive discharge planning plus
ostdischarge support for older patients with HF can significantly reduce readmission rates and may improve
ealth outcomes such as survival and quality of life without
ncreasing costs. A meta-analysis (576) of 18 studies repre-
enting data from 8 countries randomized 3304 older
npatients with HF to comprehensive discharge planning
lus postdischarge support or usual care. During a mean
bservation period of 8 months, fewer intervention patients
ere readmitted compared with controls. Analysis of studies
eporting secondary outcomes found a trend toward lower
ll-cause mortality, length of stay, hospital costs, and
mprovement in quality-of-life scores for patients assigned
o an intervention compared with usual care. One other
mportant study (577) focusing on hospital discharge for
atients with HF demonstrated that the addition of a
-hour, nurse educator–delivered teaching session at the
ime of hospital discharge using standardized instructions
esulted in improved clinical outcomes, increased self-care
easure adherence, and reduced cost of care. Patients
eceiving the education intervention had a lower risk of
ehospitalization or death and lower costs of care.
The importance of patient safety for all patients hospi-
alized with HF cannot be overemphasized. Meaningful
vidence has facilitated a much better understanding of the
ystems changes necessary to achieve safer care. This in-
ludes the adoption by all U.S. hospitals of a standardized
et of 30 “Safe Practices” endorsed by the National Quality
orum (620), which overlap in many ways with the National
atient Safety Goals espoused by The Joint Commission
621). Improved communication between physicians and
urses, medication reconciliation, transitions between care
ettings, and consistent documentation are examples of
atient safety standards that should be ensured for patients
ischarged from the hospital with HF. Care information,
specially changes in orders and new diagnostic informa-
ion, must be transmitted in a timely and clearly under-
tandable form to all of the patient’s current healthcare
roviders who need that information to provide follow-up care.
Hospitalization is in and of itself an independent risk
actor for shortened survival in patients with chronic HF.
ence, appropriate levels of symptomatic relief, support,
nd palliative care for patients with chronic HF should be
ddressed as an ongoing key component of their plan of
are, especially when hospitalized with acute decompensa-
ion (622). Fortunately, most US hospitals today have direct
ccess to palliative care services (623). Good evidence exists
or the critical importance of delivering comprehensive
upportive care to these patients, including the assessment
nd treatment of dyspnea and physiological issues including
nxiety and depression (624,625,625a,625b).
. Treatment of Special Populations
UPDATED)
he recommendations for hydralazine/isosorbide dinitrate in a
pecific population have been clarified in this section and in a
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April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure Guidelinesrevious section (223,236), based on a recent multicenter trial
Table 6).
ecommendations
LASS I
. The combination of a fixed dose of isosorbide dinitrate and
hydralazine to a standard medical regimen for HF, including
ACEIs and beta blockers, is recommended in order to improve
outcomes for patients self-described as African Americans, with
NYHA functional class III or IV HF. Others may benefit similarly,
but this has not yet been tested (223,236). (Level of Evidence: A)
. Groups of patients including (a) high-risk ethnic minority groups
(e.g., blacks), (b) groups underrepresented in clinical trials, and
(c) any groups believed to be underserved should, in the absence
of specific evidence to direct otherwise, have clinical screening
and therapy in a manner identical to that applied to the broader
population (626,627). (Level of Evidence: B)
. It is recommended that evidence-based therapy for HF be used in
the elderly patient, with individualized consideration of the
elderly patient’s altered ability to metabolize or tolerate standard
medications. (Level of Evidence: C)
.1. Women and Men
any physicians regard HF primarily as a disease of men,
ecause coronary risk factors are common in men and
rimarily men are enrolled in clinical trials of treatments for
F; however, the majority of patients with HF in the
eneral population are women (particularly elderly women),
ho frequently have HF associated with a normal LVEF
48). Even HF due to reduced LVEF may be different in
omen than in men. Yet, most large, multicenter trials have
ot included sufficient numbers of women to allow conclu-
ions about the efficacy and safety of their treatment. Several
tudies have documented a lower use of ACEIs in women
ith HF than in men (628), and another study reported that
omen are given fewer cardiovascular medications after an
I than men (564,629,630). These findings may explain
hy women have been noted to rate their quality of
npatient care lower than men and why they have less
mprovement in physical health status after an episode of
F (564). Some analyses have suggested that women with
F, particularly with asymptomatic reduced LVEF, may
ot show survival benefits from ACE inhibition (631,632).
omen may also have a different safety profile than men, as
videnced by their higher risk of ACEI-induced cough
633). The conflicting data regarding the efficacy of digoxin
n women suggests that if it is prescribed, particular atten-
ion should be paid to dosing and renal function (379).
urrently, great efforts are being made (and mandated) to
nclude a higher proportion of women in government-
ponsored trials.
Because HF is frequently accompanied by erectile dys-
unction, men may express interest in the use of a phospho-
iesterase type 5 inhibitor (e.g., sildenafil) as a means of
nhancing sexual performance. Few patients with HF were
nrolled in controlled trials with sildenafil, and thus, the
fficacy and safety of this drug in patients with HF are not dnown. Nevertheless, recent studies suggest that sildenafil
ay produce hemodynamic benefits in patients with coro-
ary artery disease and may act to improve some of the
eripheral vascular abnormalities that characterize patients
ith HF (634). Although patients with HF appear to
olerate short-term administration of the drug without
ifficulty, sildenafil should not be given to patients taking
itrates, who may experience profound hypotension due to
ts ability to potentiate the systemic vasodilator effects of
rugs that increase intracellular levels of cyclic guanosine
onophosphate (635).
.2. Ethnic Considerations
ace is an imprecise concept that has largely become a social
nd political construct, with more limited biological signif-
cance (636). The concept of racial “minorities” may be
elevant to large populations, especially those in clinical
rials, but is clearly not a concept applicable in many
emographic areas and clinical practices. However, it is
seful to review epidemiological and clinical trial evidence
o raise awareness of potential areas of concern and guide
ocioeconomic and clinical remedies. This has become
specially pertinent in the evaluation of HF as it affects
lacks, although much more information is also needed
bout the effects of current and new therapies in the
ispanic population. Heart failure is a major public health
roblem in blacks. Heart failure is more common in the
lack population, affecting approximately 3% of all black
dults. This reflects a 50% higher incidence of HF in the
lack population than is seen in the general population.
Black patients develop symptoms of HF at an earlier
verage age than nonblacks, possibly because black patients
re more likely to have hypertension and diabetes mellitus
han nonblacks and because they more frequently exhibit
odium retention, ventricular hypertrophy, and vascular
njury. Once the diagnosis is made, HF progresses more
apidly in black than in white patients, as evidenced by a
igher risk of initial and recurrent hospitalizations (637–
39). This risk cannot be explained by the presence of
picardial coronary artery disease or documented MI, both
f which are less common in black than in nonblack patients
ith HF. The data are not clear as to whether a definitive
ncrease in mortality risk exists (637–639).
The literature is mixed on whether blacks with HF more
requently receive suboptimal inpatient care for their HF
640,641). However, deficiencies in cardiovascular risk fac-
or evaluation and disease detection and treatment as well as
n access to quality outpatient care may contribute to the
ncreased incidence and morbidity of blacks with HF
642–644).
Blacks and other racial minorities with HF are underrep-
esented in most clinical trials of HF, which compromises
he extrapolation of results from major clinical trials to
thnic subgroup populations. To date, there are no data to
uggest that any significant treatment variance from stan-
ard care for HF should be acceptable in any particular
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higher than average risk of cough during treatment with
n ACEI. Retrospective analysis of subgroup data has
uggested that, as in the treatment of hypertension, black
atients with HF may experience less efficacy than non-
lacks from the use of ACEIs (222). A recent analysis of a
arge ACEI HF trial that used a matched-cohort design
onfirmed that black patients had a greater number of
ospitalizations for HF than matched white patients (645).
owever, rates of death in that trial were similar between
lack and nonblack patients with HF (645). Interestingly,
he results of 2 trials evaluating the effects of different beta
lockers in black patients have been discordant: bucindolol
aused a nonsignificant increase in the risk of a serious
linical event in black patients, but it reduced deaths and
ospitalizations in nonblack patients (646). Thus, bucindo-
ol may represent a decidedly different beta blocker than
hose already approved for the treatment of HF. Conversely,
he benefit of carvedilol in a separate series of trials was
pparent and of a similar magnitude in both black and
onblack patients with HF (647). There may be race-based
ifferences in the outcome of cardiac transplantation as well
648). Further study is needed to clarify these issues.
The emerging field of genomic medicine has begun to
uggest that important variances in the expression of certain
igh-risk, single-nucleotide polymorphisms may be evident
long racial lines and may provide a physiological basis for
ifferences in the natural history of HF and differences in
rug responsiveness (649–652). Data from these early
nvestigations are not yet definitive; racial groupings are
ecessarily heterogenous, and data will need to be inter-
reted cautiously.
A prospective, double-blind randomized trial conducted
pecifically in blacks with NYHA class III/IV HF has been
ompleted (223). The patient population was characterized
y a much higher likelihood of a nonischemic cause of HF
nd of a history of hypertension and obesity. In this trial, the
djunctive use of a proprietary formulation of isosorbide
initrate and hydralazine along with a standard HF regimen
esulted in a 43% decrease in total mortality, which led to
remature termination of the trial. Additionally, time to
rst hospitalization and quality of life were both improved.
he mechanism of benefit of this regimen may be related to
n improvement in nitric oxide bioavailability, but this
egimen had a small (but significant) effect on blood
ressure lowering. The effect of this combination of isosor-
ide dinitrate and hydralazine in other patients with HF
ho are undergoing standard therapy is not known because
he population studied was limited to blacks, but there is no
eason to believe that this benefit is limited to blacks (223).
.3. Elderly Patients
eart failure is particularly common in elderly patients. The
revalence of HF rises from 2% to 3% at age 65 to more
han 80% in persons over 80 years of age (653), and HF is
he most common reason for hospitalization in elderlyatients (654–657). The high prevalence of HF in the
lderly may be associated with age-related changes in
entricular function (particularly diastolic function) and to
he cumulative effects of hypertension and other chronic risk
actors (658–662). In addition, risk factors for HF (e.g.,
ypertension, diabetes mellitus, and hyperlipidemia) are
enerally not treated aggressively in the elderly, yet elderly
atients commonly take medications that can exacerbate the
yndrome of HF (e.g., nonsteroidal anti-inflammatory
rugs) (187).
Heart failure in elderly patients is inadequately recog-
ized and treated (662). Both patients and physicians
requently attribute the symptoms of HF to aging, and
oninvasive cardiac imaging commonly fails to reveal im-
aired systolic function because HF with a preserved LVEF
s frequently found in the elderly. In addition, some reports
uggest that elderly patients may have diminished responses
o diuretics, ACEIs, and positive inotropic agents (663–
65) compared with younger patients and may experience a
igher risk of adverse effects attributable to treatment
630,666–670). Uncertainties regarding the relation of risk
o benefit are exacerbated by the fact that very old individ-
als are poorly represented in large-scale clinical trials
esigned to evaluate the efficacy and safety of new treat-
ents for HF.
Some multidisciplinary HF programs have been success-
ul in decreasing the rate of readmission and associated
orbidity in elderly patients (258,671). Managed care
rganizations continue to struggle to find improved ways to
mplement these pathways (672,673).
. Patients With Heart Failure Who Have
oncomitant Disorders (UPDATED)
ecommendations
LASS I
. All other recommendations should apply to patients with con-
comitant disorders unless there are specific exceptions. (Level
of Evidence: C)
. Physicians should control systolic and diastolic hypertension and
diabetes mellitus in patients with HF in accordance with recom-
mended guidelines. (Level of Evidence: C)
. Physicians should use nitrates and beta blockers for the treat-
ment of angina in patients with HF. (Level of Evidence: B)
. Physicians should recommend coronary revascularization ac-
cording to recommended guidelines in patients who have both HF
and angina. (Level of Evidence: A)
. Physicians should prescribe anticoagulants in patients with HF
who have paroxysmal or persistent atrial fibrillation or a previous
thromboembolic event. (Level of Evidence: A)
. Physicians should control the ventricular response rate in pa-
tients with HF and atrial fibrillation with a beta blocker (or
amiodarone, if the beta blocker is contraindicated or not toler-
ated). (Level of Evidence: A)
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April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure Guidelines. Patients with coronary artery disease and HF should be treated in
accordance with recommended guidelines for chronic stable
angina. (Level of Evidence: C)
. Physicians should prescribe antiplatelet agents for prevention of
MI and death in patients with HF who have underlying coronary
artery disease. (Level of Evidence: B)
LASS IIa
. It is reasonable to prescribe digitalis to control the ventricular
response rate in patients with HF and atrial fibrillation. (Level of
Evidence: A)
. It is reasonable to prescribe amiodarone to decrease recurrence
of atrial arrhythmias and to decrease recurrence of ICD discharge
for ventricular arrhythmias. (Level of Evidence: C)
LASS IIb
. The usefulness of current strategies to restore and maintain
sinus rhythm in patients with HF and atrial fibrillation is not well
established. (Level of Evidence: C)
. The usefulness of anticoagulation is not well established in
patients with HF who do not have atrial fibrillation or a previous
thromboembolic event. (Level of Evidence: B)
. The benefit of enhancing erythropoiesis in patients with HF and
anemia is not established. (Level of Evidence: C)
LASS III
. Class I or III antiarrhythmic drugs are not recommended in
patients with HF for the prevention of ventricular arrhythmias.
(Level of Evidence: A)
. The use of antiarrhythmic medication is not indicated as primary
treatment for asymptomatic ventricular arrhythmias or to im-
prove survival in patients with HF. (Level of Evidence: A)
Patients with reduced LVEF frequently have associated
ardiovascular and noncardiovascular disorders, the course
r treatment of which may exacerbate the syndrome of HF.
n many patients, appropriate management of these con-
omitant illnesses may produce symptomatic and prognostic
enefits that may be as important as the treatment of the
F condition itself.
.1. Cardiovascular Disorders
.1.1. Hypertension, Hyperlipidemia, and
iabetes Mellitus
pproximately two thirds of patients with HF have a past or
urrent history of hypertension, and approximately one
hird have diabetes mellitus (674). Both disorders can
ontribute to the development of systolic or diastolic dys-
unction (675,676), either directly or by contributing (to-
ether with hyperlipidemia) to the development of coronary
rtery disease (677,678). Long-term treatment of both
ypertension and hyperlipidemia decreases the risk of de-
eloping HF (72,73,679,680). In a large-scale trial, the
dministration of a lipid-lowering agent to patients with
ypercholesterolemia and a history of MI reduced all-cause
ortality and the risk of developing HF (679). In 2
arge-scale multicenter studies, the treatment of hyperten-
ion reduced both the risk of death and the risk of HF; this
as true regardless of whether the elevation of blood sressure was primarily systolic or diastolic (72,73,680). The
enefits of lowering blood pressure may be particularly
arked in patients with diabetes mellitus (80,82,681).
Heart failure may complicate the management of both
ypertension and diabetes mellitus. Some antihypertensive
gents should be avoided in patients with HF because of
heir ability to depress cardiac function or to lead to salt and
ater retention. In addition, HF itself is associated with
esistance to the actions of insulin (682,683), and the
esulting hyperinsulinemia may promote both cardiac and
ascular hypertrophy (684–686) and thus may hasten the
rogression of HF. These mechanisms may compound the
eleterious effects of accelerated atherosclerosis and altered
nergy metabolism on cardiac function and may help to
xplain why diabetic patients with HF have a worse prog-
osis than their nondiabetic counterparts (92).
Thiazolidinediones have been associated with increased
eripheral edema and symptomatic HF in patients with
nderlying risk factors or known cardiovascular disease. The
isk of developing edema with thiazolidinediones is dose
elated and is higher in diabetic patients who are taking
oncomitant insulin therapy. However, the incidence of
hiazolidinedione-related fluid retention is low in patients
ith NYHA functional class I to II symptoms, in whom
hese drugs can be administered safely with careful moni-
oring for fluid retention. Initiation of these drugs is not
ecommended in patients with NYHA functional class III
o IV symptoms of HF. Clinical experience has shown that
ne side effect of newer oral agents of the thiazolidinedione
lass is weight gain, which is due in part to fluid retention.
his effect may have the potential to precipitate or exacer-
ate HF in patients with reduced cardiac reserve. Thiazo-
idinediones probably should be used with caution in such
atients (687,688).
ecommendations Concerning Management. Little is known
bout the benefits of treating hypertension, hypercholester-
lemia, or diabetes mellitus in patients with established
educed LVEF and symptoms of HF. The lack of such data
s noteworthy, both because the progression of HF is
requently associated with decreases in blood pressure (due
o deterioration of cardiac performance) and decreases in
erum lipids (due to development of cardiac cachexia) (679)
nd because the benefits of drugs used to lower blood
ressure or blood lipids may be seen only during prolonged
eriods of treatment (i.e., those that exceed the expected life
pan of many patients with HF) (72,73,679,680). Never-
heless, it is prudent to manage hypertension, hypercholes-
erolemia, and diabetes mellitus in patients with HF as if the
atients did not have HF. This may be particularly true in
atients with HF and preserved LVEF, whose symptoms
ay respond particularly well to treatments that lower blood
ressure (689,690). Renal artery stenosis should be consid-
red in patients with hypertension and HF, because renal
rtery stenting can treat both conditions.
Drugs that can both control blood pressure and treat HF
hould be preferred in patients with both conditions; this
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ontrast, physicians should avoid the use of most calcium
hannel blockers, because of their cardiodepressant effects,
r potent direct-acting vasodilators such as minoxidil, be-
ause of their sodium-retaining effects.
The drugs routinely used in the management of HF in
ondiabetic patients should be administered to those with
iabetes mellitus. Angiotensin converting enzyme inhibitors
nd beta blockers prevent the progression of HF in diabetic
nd nondiabetic patients (157,162,691). Physicians should
ot avoid the use of beta blockers in diabetic patients despite
ears that these drugs may mask symptoms of hypoglycemia
roduced by antidiabetic therapy or may exacerbate glucose
ntolerance or insulin resistance.
.1.2. Coronary Artery Disease
pproximately two thirds of patients with HF have under-
ying coronary artery disease, which may limit exercise
olerance by causing angina pectoris or may lead to further
yocardial injury by causing an MI. Therefore, physicians
hould manage both the symptomatic and prognostic con-
equences of the patient’s underlying coronary artery disease
n accordance with contemporary guidelines.
ecommendations Concerning Management of Patients With
ngina Pectoris. In general, patients who have both angina
ectoris and HF should be given drugs that relieve angina
long with drugs that are appropriate in the management of
F (692). Both nitrates and beta blockers can improve
nginal symptoms and may produce hemodynamic and
linical benefits in patients with reduced LVEF, and thus,
hey are preferred if these conditions coexist (158,162,164,
93,694). Yet, the combination of the 2 drugs may produce
ittle improvement in anginal pain unless fluid retention is
dequately controlled with diuretics. It is therefore notewor-
hy that the decrease in ventricular volume and pressures
roduced by diuretics may exert independent antianginal
ffects (695).
Some have suggested that the systemic and coronary
asodilator actions of calcium channel blockers might im-
rove cardiac performance and relieve myocardial ischemia,
ut these theoretical advantages have not been translated
nto clinical benefits in controlled clinical trials in HF
696–698). These drugs have not improved symptoms of
F or enhanced exercise tolerance (695–699), and short-
nd long-term treatment with these drugs (even the use of
ustained-release or vasoselective preparations) has in-
reased the risk of worsening HF and death in patients with
V dysfunction (135,700–708). Therefore, most calcium
hannel blockers should be avoided in patients with HF,
ven when used for the treatment of angina or hypertension.
f available agents, only amlodipine has been shown not to
dversely affect survival, although experience with the drug
xists largely in patients who are not taking beta blockers (242).
In patients with both HF and angina pectoris, strong
onsideration should be given to the use of coronary
evascularization. Coronary revascularization can relieve tymptoms of myocardial ischemia (709,710), and coronary
rtery bypass surgery has been shown to lessen angina and
educe the risk of death in patients who have multivessel
isease, reduced LVEF, and stable angina (711) (see the
CC/AHA/ACPASIM Guidelines for the Management
f Patients With Chronic Stable Angina [712] or the
CC/AHA 2004 Guideline Update for Coronary Artery
ypass Graft Surgery [16]).
ecommendations Concerning Management of Patients With-
ut Angina. In patients with a prior MI but without HF or
ngina, 4 types of interventions have been used to reduce the
isk of reinfarction and death: neurohormonal antagonists
uch as ACEIs and beta blockers (83,123,124,129); drugs to
ddress dyslipidemia, such as statins; antiplatelet drugs such
s aspirin and clopidogrel (310,312); and coronary revascu-
arization (709). In patients who have had an MI and who
ave HF but not angina, the use of ACEIs and beta
lockers can also decrease the risk of reinfarction and death
126–128,713,714), but it is less clear whether such patients
enefit from the use of aspirin or revascularization.
Aspirin has been shown to reduce the risk of major
schemic events in patients without HF. The role of aspirin
n patients with HF has not been established (709), and
oncerns have been raised that it may attenuate the hemo-
ynamic and survival benefits of ACEIs (303,306,307). For
hese reasons, the role of aspirin in preventing ischemic
vents in patients with chronic HF is controversial (see
ection 4.3.1.2.2.1). Alternative antiplatelet agents (e.g.,
lopidogrel) may not interact adversely with ACEIs (305)
nd may have superior effects in preventing clinical events
312), but their ability to favorably affect outcomes in HF
as not been demonstrated (see Section 4.3.1.2.2.1).
Surgical revascularization has been recommended for a
ertain subset of patients in other guidelines (715). Some
hysicians recommend the use of coronary revascularization
n patients with HF and coronary artery disease who do not
ave symptoms of angina. Advocates of this approach have
uggested that surgical reperfusion can improve cardiac
unction and relieve symptoms of HF in patients with
yocardium that appears on imaging to be viable but not
ontracting normally (716–718) and may also reduce the
isk of a fatal coronary occlusion in patients with established
ultivessel disease (717). Despite these theoretical possibil-
ties, however, coronary revascularization has not been
hown to improve cardiac function or symptoms or to
revent reinfarction or death in patients with HF and no
ngina (15,719).
.1.3. Supraventricular Arrhythmias (UPDATED)
here have been additional trials investigating the appro-
riate management of atrial fibrillation in patients with HF.
he text has been modified to reflect the lessons learned
rom these trials (see Section 4.3.1, Patients With Reduced
eft Ventricular Ejection Fraction). There is also an ACC/
HA/ESC guideline on the management of atrial fibrilla-ion (720).
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y supraventricular tachyarrhythmias, which may occur
hen the myocardial disease process affects the atria or
hen the atria are distended as a result of pressure or volume
verload of the right or left ventricles. The most common
reatable atrial arrhythmia is atrial fibrillation, which affects
0% to 30% of patients with chronic HF and is associated
ith a reduction in exercise capacity and a worse long-term
rognosis (721–723).
Supraventricular tachyarrhythmias may exert adverse ef-
ects via 4 different mechanisms: 1) the loss of atrial
nhancement of ventricular filling may compromise cardiac
utput; 2) the rapid heart rate may increase demand and
ecrease coronary perfusion (by shortening ventricular fill-
ng time); 3) the rapidity of ventricular response may
iminish both cardiac contraction (by aggravating abnor-
alities of the force-frequency relation) (724,725) and
ardiac relaxation (726,727); and 4) the stasis of blood in the
brillating atria may predispose patients to pulmonary or
ystemic emboli. In most patients with an ischemic or
onischemic dilated cardiomyopathy, the rapidity of ven-
ricular response is more important than the loss of atrial
upport, because restoration of sinus rhythm does not result
n predictable clinical benefits (728). Rapid supraventricular
rrhythmias may actually cause a cardiomyopathy (even in
atients without an underlying contractile abnormality) or
ay exacerbate a cardiomyopathy caused by another disor-
er (136,137). Hence, the control of ventricular rate and the
revention of thromboembolic events are essential elements
f treatment of HF in patients with an underlying supraven-
ricular arrhythmia (729,730). Specific care and initially low
oses should be used when beta blockers are instituted to
ontrol heart rate in patients with clinical evidence of HF
ecompensation. The agent previously used in clinical
ractice to slow the ventricular response in patients with HF
nd atrial fibrillation is digoxin, but the cardiac glycoside
lows atrioventricular conduction more effectively at rest
han during exercise (365,731). Hence, digitalis does not
lock the excessive exercise-induced tachycardia that may
imit the functional capacity of patients with HF (363–
65,731). Beta blockers are more effective than digoxin
uring exercise (363,365) and are preferred because of their
avorable effects on the natural history of HF (158,162,164).
he combination of digoxin and beta blockers may be more
ffective than beta blockers alone for rate control. Although
oth verapamil and diltiazem can also suppress the ventric-
lar response during exercise, they can depress myocardial
unction and increase the risk of worsening HF, especially in
atients with HF and low EF, in whom these drugs should
e avoided (703,705). If beta blockers are ineffective or
ontraindicated in patients with atrial fibrillation and HF,
miodarone may be a useful alternative (732). Atrioventric-
lar nodal ablation may be needed if tachycardia persists
espite pharmacological therapy (387). Catheter ablation
or pulmonary vein isolation has been most effective in
atients without structural heart disease; the benefit for patients with established HF is not known (733–735).
egardless of the intervention used, every effort should be
ade to reduce the ventricular response to less than 80 to 90
pm at rest and less than 110 to 130 bpm during moderate
xercise. Anticoagulation should be maintained in all pa-
ients with HF and a history of atrial fibrillation, regardless
f whether sinus rhythm is achieved, because of the high
ate of silent recurrence of atrial fibrillation with its atten-
ant embolic risk, unless a contraindication exists (730).
Should patients with HF and atrial fibrillation be con-
erted to and maintained in sinus rhythm? The efficacy and
afety of restoring and maintaining sinus rhythm in patients
ith atrial fibrillation were evaluated in a total of 5032
atients in 4 separate trials (736). Both strategies for the
anagement of atrial fibrillation, either to restore and
aintain sinus rhythm by electrical or pharmacologic con-
ersion, or to control ventricular rate in atrial fibrillation,
ave been shown to have equivalent outcomes. These results
ere confirmed in 2007 with the conclusion of a large trial
f patients with both atrial fibrillation and HF (226,227,
30). Most patients revert to atrial fibrillation within a short
ime unless they are treated with a Class I or III antiar-
hythmic drug (721). However, patients with HF are not
ikely to respond favorably to Class I drugs and may be
articularly predisposed to their cardiodepressant and proar-
hythmic effects (193,247), which can increase the risk of
eath (191,192,388). Class III antiarrhythmic agents (e.g.,
otalol, dofetilide, and amiodarone) can maintain sinus
hythm in some patients, but treatment with these drugs is
ssociated with an increased risk of organ toxicity (amioda-
one) (737,738) and proarrhythmia (dofetilide) (248). Most
atients who had thromboembolic events, regardless of the
trategy used, were in atrial fibrillation at the time of the
vent and either were not undergoing anticoagulation ther-
py or were undergoing therapy at subtherapeutic levels.
hus, it is reasonable to treat HF patients with atrial
brillation with a strategy of either scrupulous rate control
r an attempt at rhythm control.
.1.4. Prevention of Thromboembolic Events
atients with chronic HF are at increased risk of thrombo-
mbolic events due to stasis of blood in dilated hypokinetic
ardiac chambers and in peripheral blood vessels (739,740)
nd perhaps due to increased activity of procoagulant factors
741). However, in large-scale studies, the risk of thrombo-
mbolism in clinically stable patients has been low (1% to
% per year), even in those with very depressed EFs and
chocardiographic evidence of intracardiac thrombi (742–
46). These rates are sufficiently low to limit the detectable
enefit of anticoagulation in these patients.
In several retrospective analyses, the risk of thromboem-
olic events was not lower in patients with HF taking
arfarin than in patients not treated with antithrombotic
rugs (742,744,745). The use of warfarin was associated
ith a reduction in major cardiovascular events and death in
atients with HF in one retrospective analysis but not in
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utcome of patients with HF and low EF assigned to
spirin, warfarin, or clopidogrel was completed recently.
Unfortunately, low enrollment in the trial precluded
efinitive conclusions about efficacy, but no therapy ap-
eared to be superior. Another trial is currently under way
omparing aspirin with warfarin in patients with reduced
VEF and may provide more definitive data upon which to
ase recommendations.
ecommendations Concerning Management. In the absence of
efinitive trials, it is not clear how anticoagulants should be
rescribed in patients with HF. Despite the lack of support-
ve data, some physicians prescribe anticoagulants to all
atients with markedly depressed EFs and dilated hearts
739). Others would advocate the use of warfarin in patients
ho are known to harbor a cardiac thrombus (740), even
hough many thrombi detected by echocardiography do not
mbolize and many embolic events are probably related to
hrombi that are not visualized (293,750). Anticoagulation
ith warfarin is most justified in patients with HF who have
xperienced a previous embolic event or who have paroxys-
al or persistent atrial fibrillation (730). Anticoagulation
hould also be considered in patients with underlying
isorders that may be associated with an increased throm-
oembolic risk (e.g., amyloidosis or LV noncompaction)
nd in patients with familial dilated cardiomyopathy and a
istory of thromboembolism in first-degree relatives.
.2. Noncardiovascular Disorders
.2.1. Patients With Renal Insufficiency
atients with HF frequently have impaired renal function as
result of poor renal perfusion, intrinsic renal disease, or
rugs used to treat HF. Patients with renal hypoperfusion or
ntrinsic renal disease show an impaired response to diuret-
cs and ACEIs (275,751) and are at increased risk of adverse
ffects during treatment with digitalis (370). Renal function
ay worsen during treatment with diuretics or ACEIs
274,527), although the changes produced by these drugs
re frequently short-lived, generally asymptomatic, and
eversible. Persistent or progressive renal functional impair-
ent often reflects deterioration of the underlying renal
isease process and is associated with a poor prognosis
41,752). The symptoms of HF in patients with end-stage
enal disease may be exacerbated by an increase in loading
onditions produced both by anemia (753) and by fistulas
mplanted to permit dialysis. In addition, toxic metabolites
nd abnormalities of phosphate, thyroid, and parathyroid
etabolism associated with chronic renal insufficiency can
epress myocardial function.
Despite the potential for these adverse interactions, most
atients with HF tolerate mild to moderate degrees of
unctional renal impairment without difficulty. In these
ndividuals, changes in blood urea nitrogen and serum
reatinine are generally clinically insignificant and can usu-
lly be managed without the withdrawal of drugs needed to plow the progression of HF. However, if the serum creati-
ine increases to more than 3 mg per dL, the presence of
enal insufficiency can severely limit the efficacy and enhance
he toxicity of established treatments (275,370,751). In
atients with a serum creatinine greater than 5 mg per dL,
emofiltration or dialysis may be needed to control fluid
etention, minimize the risk of uremia, and allow the patient
o respond to and tolerate the drugs routinely used for the
anagement of HF (548,754).
.2.2. Patients With Pulmonary Disease
ecause dyspnea is the key symptom in both HF and
ulmonary disease, it is important to distinguish the 2
iseases and to quantify the relative contribution of cardiac
nd pulmonary components to the disability of the patient
hen these disorders coexist. Exercise testing with simul-
aneous gas exchange or blood gas measurements may be
elpful in this regard, particularly when used in conjunction
ith right heart catheterization (755).
Some drugs used to treat HF can produce or exacerbate
ulmonary symptoms. Angiotensin converting enzyme in-
ibitors can cause a persistent nonproductive cough that can
e confused with a respiratory infection, and conversely,
CEIs may be inappropriately stopped in patients with
ulmonary causes of cough. Therefore, physicians should
eek a pulmonary cause in all patients with HF who
omplain of cough, whether or not they are taking an
CEI. The cough should be attributed to the ACEI only if
espiratory disorders have been excluded and the cough
isappears after cessation of ACEI therapy and recurs after
einstitution of treatment. Because the ACEI-related cough
oes not represent any serious pathology, many patients can
e encouraged to tolerate it in view of the important
eneficial effects of ACEIs.
Beta blockers can aggravate bronchospastic symptoms in
atients with asthma; however, many patients with asymp-
omatic or mild reactive airways disease tolerate beta-
lockers well. Also, most patients with chronic obstructive
ulmonary disease do not have a bronchospastic component
o their illness and remain reasonable candidates for beta-
lockade (756). Of note, both metoprolol tartrate and
isoprolol may lose their beta-1 selectivity when prescribed
n doses that have been associated with an improvement in
urvival in patients with HF.
.2.3. Patients With Cancer
atients with cancer are particularly predisposed to the
evelopment of HF as a result of the cardiotoxic effects of
any cancer chemotherapeutic agents, especially the an-
hracyclines (757), high-dose cyclophosphamide (758–762),
nd trastuzumab (763). Trastuzumab is a monoclonal anti-
ody recently approved for therapy of metastatic breast
ancer (764) that has a significant potential to cause HF,
specially when combined with anthracyclines. Mediastinal
adiation can also cause acute and chronic injury to the
ericardium, myocardium, cardiac valves, and coronary ar-
t
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oxic chemotherapy (765).
Patients undergoing potentially cardiotoxic treatments
or cancer should be monitored closely for the development
f cardiac dysfunction. Heart failure may appear many years
fter anthracycline exposure, particularly in association with
nother stress, such as tachycardia. Although noninvasive
ssessments of LV function and endomyocardial biopsy
ave been advocated by some investigators (766), many
ases escape early detection despite close surveillance.
Dexrazoxane may confer some cardioprotection in pa-
ients undergoing anthracycline-based chemotherapy and
ay allow for higher doses of the chemotherapy to be given
767,768). Heart failure due to chemotherapeutic agents is
anaged similarly to HF due to other causes, although it is
ot clear whether patients with cancer respond similarly to
atients with other causes of HF. Nevertheless, because
ost patients with anthracycline-induced cardiomyopathy
ave striking degrees of tachycardia, many experts believe
hat beta blockers play a particularly important role in the
anagement of these patients. Although once thought to
rogress inexorably, HF related to chemotherapy often
mproves in response to therapy, even when it appears late
fter exposure.
.2.4. Patients With Thyroid Disease
atients with both hyperthyroidism and hypothyroidism are
rone to develop HF. Special vigilance is required for
atients who are taking amiodarone, who may develop
ither hyperthyroidism or hypothyroidism. New atrial fibril-
ation or exacerbation of ventricular arrhythmias should
rigger reevaluation of thyroid status.
.2.5. Patients With Hepatitis C and Human
mmunodeficiency Virus
epatitis C viral infection can be a cause of cardiomyopathy
nd myocarditis. It appears that the virus can cause both
ilated cardiomyopathy and hypertrophic cardiomyopathy
514,515). The relatively high prevalence of this virus in
apanese populations compared with those in North Amer-
ca and Europe suggests that there may be a genetic
redisposition to this type of viral myocarditis (516,769). A
mall study showed that hepatitis C virus myocarditis might
espond favorably to immunosuppressive therapy with pred-
isone and azathioprine (770,771). Preliminary data also
uggest that this type of myocarditis might respond well to
nterferon therapy (515), although there is concern that
nterferon can also depress myocardial function.
Human immunodeficiency virus has been recognized as a
robable occasional cause of dilated cardiomyopathy. The
resence of reduced LVEF in patients with HIV infection
ppears to correlate with decreased survival (772). Reduced
VEF is often seen in association with a significantly
educed CD4 count, although progression of cardiomyop-
thy does not appear to be related to falling CD4 levels
773). Drug therapy for HIV with zidovudine has also beenmplicated as a cause of cardiomyopathy, possibly through
ts effect on cardiac myocyte mitochondrial function (774).
eart failure in patients with HIV infection may also be
aused or exacerbated by pericardial effusion or pulmonary
ypertension. Interferon-alpha therapy for HIV-related Ka-
osi’s sarcoma has also been associated with reversible
eduction in LVEF. Because of the occurrence of complex
pportunistic infections, autoimmune responses to the viral
nfection, and drug cardiotoxicity, it is difficult to determine
ow therapies influence the development and control of
ardiomyopathy with HIV (775).
.2.6. Patients With Anemia
nemia is seldom the cause of HF in the absence of
nderlying cardiac disease. To be the sole cause of high-
utput HF, anemia must be severe (e.g., hemoglobin levels
ess than 5 g per deciliter). On the other hand, patients with
F frequently have anemia for a variety of reasons. The
everity of anemia may contribute to the increasing severity
f HF. Several studies have demonstrated worse outcomes
n patients with HF and anemia (776,777). It is unclear
hether anemia is the cause of decreased survival or a result
f more severe disease.
Several small studies have suggested benefit from use of
rythropoietin and iron for treatment of mild anemia in HF
778–780). There is concern, however, that thromboem-
olic events may be increased. This therapy is undergoing
urther investigation.
. End-of-Life Considerations
ecommendations
LASS I
. Ongoing patient and family education regarding prognosis for
functional capacity and survival is recommended for patients
with HF at the end of life. (Level of Evidence: C)
. Patient and family education about options for formulating and
implementing advance directives and the role of palliative and
hospice care services with reevaluation for changing clinical
status is recommended for patients with HF at the end of life.
(Level of Evidence: C)
. Discussion is recommended regarding the option of inactivating
ICDs for patients with HF at the end of life. (Level of Evidence: C)
. It is important to ensure continuity of medical care between
inpatient and outpatient settings for patients with HF at the end
of life. (Level of Evidence: C)
. Components of hospice care that are appropriate to the relief of
suffering, including opiates, are recommended and do not pre-
clude the options for use of inotropes and intravenous diuretics
for symptom palliation for patients with HF at the end of life.
(Level of Evidence: C)
. All professionals working with HF patients should examine
current end-of-life processes and work toward improvement in
approaches to palliation and end-of-life care. (Level of Evidence: C)
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. Aggressive procedures performed within the final days of life
(including intubation and implantation of a cardioverter-
defibrillator in patients with NYHA functional class IV symptoms
who are not anticipated to experience clinical improvement from
available treatments) are not appropriate. (Level of Evidence: C)
Although issues surrounding end-of-life care deserve
ttention for all chronic terminal diseases, several general
rinciples merit particular discussion in the context of
hronic HF. Education of both patient and family regarding
he expected or anticipated course of illness, final treatment
ptions, and planning should be undertaken before the
atient becomes too ill to participate in decisions. Discus-
ions regarding treatment preferences, living wills, and
dvance directives should encompass a variety of likely
ontingencies that include responses to a potentially revers-
ble exacerbation of HF, a cardiac arrest, a sudden cata-
trophic event such as a severe cerebrovascular accident, and
orsening of major coexisting noncardiac conditions. In
eviewing these issues with families, short-term intervention
n anticipation of rapid recovery should be distinguished
rom prolonged life support without reasonable expectation
f a return to good functional capacity.
Most patients hospitalized with severe HF indicate a
reference that resuscitation be performed in the event of a
ardiopulmonary arrest. In the largest study of patients
ospitalized with HF, only 23% stated they did not wish
esuscitation, and 40% of these patients subsequently
hanged their minds after the hospitalization (781). These
requencies are higher than those seen in other chronic
iseases (782), perhaps because patients with HF are more
ikely to experience extended periods of stability with good
uality of life after hospitalization for intensive care. Hos-
itals in the United States are required by the Patient
elf-Determination Act (783) to seek and record informa-
ion regarding advance directives at the time of admission.
et, when these have not been addressed in advance, forced
ontemplation of resuscitation options at the time of ad-
ission for worsening HF may heighten patient and family
nxiety without revealing true preferences (784). The ma-
ority of patients with HF who had not discussed resusci-
ation during hospitalization indicated that they had not
esired such an interaction (781). Furthermore, in one
tudy, the impact of resuscitation preferences on in-hospital
utcome was minimal even for patients with HF in inten-
ive care, of whom only 4% experienced unexpected cardiac
rrests compared with more than 25% of patients in inten-
ive care units who had other chronic illnesses (785).
When the limitations imposed by HF alone or in com-
ination with other severe conditions become intolerable,
owever, resuscitation may no longer be desired by the
atient. At this time, it is important to understand which
spects of further care the patient wishes to forego. In some
ases, the patient may want full supportive care while
onscious, other than actual resuscitation; in other circum- ctances, hospitalization may no longer be desired for any
ntervention. Any decision to forego resuscitation should
ead to possible deactivation of the life-saving function of an
mplanted defibrillation device; the poor functional status of
ny patient should also influence the decision regarding
mplantation of such a device in the first place (786). To
bserve both the intent and the directives of the patient and
amily, it is highly desirable that outpatient, inpatient, and
risis management be supervised by the same team to
iminish the hazards of fragmented care during this period.
he patient should be encouraged to choose in advance a
erson to assume legal authority (i.e., designated power of
ttorney or healthcare proxy) for healthcare matters when
he patient cannot be involved in decisions. That individual
hould serve as the contact point for the team. Rapid
ommunications with this team will reduce the conflicts and
ncertainties that may arise when patients are first seen in
n emergent setting by physicians not normally involved in
heir care. The standing-care plans for each patient need to
e quickly accessible to all personnel likely to be involved in
he patient’s care. Professionals caring for patients with
dvanced HF should have realistic expectations for survival
nd communicate those accurately to patients and families.
lso, the professionals should provide realistic recommen-
ations for procedures being done within the final days of
ife that do not add to the hope of recovery or improvement
n life quality. Finally, greater attention and research need to
e devoted to the provision of comfort measures in the final
ays of life, including relief of pain and dyspnea. Hospice
ervices have only recently been extended to patients dying
f HF. Originally developed for patients with end-stage
ancer, the focus of hospice care has now been expanded to
nclude the relief of symptoms other than pain (787). This
s appropriate because the suffering of patients with HF is
haracteristically linked to symptoms of breathlessness, and
hus, compassionate care may require the frequent admin-
stration of intravenous diuretics and, in some cases, the
ontinuous infusion of positive inotropic agents rather than
nly the use of potent analgesics. However, many patients
ying of HF do describe pain during the final days
622,788). Physicians caring for these patients should be-
ome familiar with the prescription of anxiolytics, sleeping
edications, and narcotics to ease distress during the last days.
Traditionally, the utilization of hospice care has required
prediction by a physician of death within 6 months, but
his operational policy may be difficult to apply, because
ealthcare providers are generally unable to accurately pre-
ict the end of life in patients with HF. In a large US study
n the experience of patients hospitalized in intensive care
nits with terminal stages of disease, the majority of patients
ho were identified by broad criteria for hospice care
urvived the next 6 months despite a prediction to the
ontrary (789). This discrepancy between predicted and
ctual survival may be particularly great for patients with
F, which more often than other chronic illnesses isharacterized by periods of good quality of life despite the
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udden death despite a recent remission of symptoms.
urrent guidelines and policies (790) are being revised to
llow patients with HF to benefit from the type of care that
an be provided through hospice services.
Ultimately, the decisions regarding when end of life is
earing reflect a complex interaction between objective
nformation and subjective information, emotions, and pa-
ient and family readiness. Ideally, these decisions would be
ade in conjunction with the individual or team most
xperienced in caring for advanced HF or in collaboration
nd/or consultation with such an expert. In reality, however,
his does not occur often. The writing committee recom-
ends that all those involved with HF care make it a
riority to improve recognition of end-stage disease and
rovide care to patients and families approaching this stage.
s we become more familiar with the steps in progression to
ndstage HF in this era, the current abrupt transition from
ggressive intervention to comfort and bereavement care
ill be softened by a gradual and progressive emphasis on
alliation until it dominates the final days of care (788).
. Implementation of Practice Guidelines
ecommendations
LASS I
. Academic detailing or educational outreach visits are useful to
facilitate the implementation of practice guidelines. (Level of
Evidence: A)
. Multidisciplinary disease-management programs for patients at
high risk for hospital admission or clinical deterioration are
recommended to facilitate the implementation of practice guide-
lines, to attack different barriers to behavioral change, and to
reduce the risk of subsequent hospitalization for HF. (Level of
Evidence: A)
LASS IIa
. Chart audit and feedback of results can be effective to facilitate
implementation of practice guidelines. (Level of Evidence: A)
. The use of reminder systems can be effective to facilitate
implementation of practice guidelines. (Level of Evidence: A)
. The use of performance measures based on practice guidelines
may be useful to improve quality of care. (Level of Evidence: B)
. Statements by and support of local opinion leaders can be helpful
to facilitate implementation of practice guidelines. (Level of
Evidence: A)
LASS IIb
. Multidisciplinary disease-management programs for patients at
low risk for hospital admission or clinical deterioration may be
considered to facilitate implementation of practice guidelines.
(Level of Evidence: B)
LASS III
. Dissemination of guidelines without more intensive behavioral
change efforts is not useful to facilitate implementation of
practice guidelines. (Level of Evidence: A) p. Basic provider education alone is not useful to facilitate imple-
mentation of practice guidelines. (Level of Evidence: A)
Despite the publication of evidence-based guidelines
262,791), the current care of patients with HF remains
uboptimal. Numerous studies document underutilization
f key processes of care, such as use of ACEIs in patients
ith decreased systolic function and the measurement of
VEF (630,792,793). The overall quality of inpatient care
or HF as judged by both explicit and implicit standards is
ariable, with lower quality associated with higher readmis-
ion rates and mortality (549,794,795). Many HF admis-
ions may be prevented with good outpatient care (796).
he literature on implementing practice guidelines for
atients with HF can be divided into 3 areas: isolated
rovider interventions, disease management systems, and
se of performance measures.
.1. Isolated Provider Interventions
controlled trial has shown that the simple dissemination
f an HF guideline followed by written and verbal remind-
rs about recommended actions was unable to change the
reatment of HF in the intensive care unit (797). Indeed, an
xtensive literature has documented how difficult it is to
roduce appropriate changes in physician behavior (798–
00). Basic physician education and passive dissemination
f guidelines alone are generally insufficient to sustain
uality improvement. Chart audit and feedback of results,
eminder systems to consider use of specific medicines or
ests, and the use of local opinion leaders have had variable
esults. Multifactorial interventions that simultaneously at-
ack different barriers to change tend to be more successful
han isolated efforts. For example, academic detailing,
hich involves intensive educational outreach visits that
ncorporate communication and behavioral change tech-
iques, has been effective and is commonly used by phar-
aceutical companies (801). Thus, dissemination of a
ractice guideline must be accompanied by more intensive
ducational and behavioral interventions to maximize the
hances of improving physician practice patterns.
.2. Disease-Management Systems
he disease-management approach views HF as a chronic
llness that spans the home as well as outpatient and
npatient settings. Most patients have multiple medical,
ocial, and behavioral challenges, and effective care requires
multidisciplinary systems approach that addresses these
arious difficulties. Heart failure disease-management pro-
rams vary in their content, but in general, they include
ntensive patient education, encouragement of patients to be
ore aggressive participants in their care, close monitoring
f patients through telephone follow-up or home nursing,
areful review of medications to improve adherence to
vidence-based guidelines, and multidisciplinary care with
urse case management directed by a physician. High-risk
atients have usually been chosen for such programs.
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ave shown that disease-management programs can reduce
he frequency of hospitalization and can improve quality of
ife and functional status (261,802). Patients at high risk for
linical deterioration or hospitalization are likely to benefit
rom disease-management programs and represent those for
hom such interventions are most likely to be cost-effective
803). The largest successful randomized controlled trial of
isease management targeted elderly patients who had been
ospitalized for HF, had a prior history of HF, had 4 or
ore hospitalizations within 5 years, or had an HF exacer-
ation caused by an acute MI or uncontrolled hypertension
258). Patients randomized to the disease-management
rogram had significantly fewer hospitalizations and a
educed cost of care compared with patients in the control
roup. However, it is not clear which elements of disease-
anagement programs are crucial for success. In addition, it
s not known whether such interventions are feasible in
ettings with limited resources and personnel and among
iverse patient populations.
.3. Performance Measures
erformance measures are standards of care for a particular
llness or condition that are designed to assess and subse-
uently improve the quality of medical care. Performance
easures are chosen on the basis of the knowledge or
ssumption that the particular item is linked to improved
atient outcomes. In the field of HF, such measures might
nclude documentation of the level of LV function, medi-
ations used, or patient education measures. These measures
an be used either internally within an organization or
ublicly to compare the performance of providers, hospitals,
nd healthcare organizations. In theory, performance mea-
ures could improve care by encouraging providers to
ompete on the basis of quality as opposed to cost, empow-
ring consumers to make informed choices in the market-
lace, providing incentives to providers to concentrate on
ertain diseases or processes of care, and supplying infor-
ation to aid with internal quality improvement. The
vidence is mixed, but some studies indicate that perfor-
ance measures can improve health outcomes (804).
The ACCF and AHA are collaborating with a variety of
rganizations to develop and implement performance mea-
ures. ACCF/AHA practice guidelines are useful starting
oints for performance measures, but several considerations
pply: 1) ACCF/AHA practice guidelines are designed for
mproving the care of individual patients. Performance
easures are generally used for improving the care of
opulations of patients. Although significant overlap exists
n these goals, performance measures need to take into
ccount additional factors, such as ease of data collection,
implicity of standards, calculation of sufficient numbers of
atients for whom the measure would apply, and provision
f flexibility for clinically diverse situations. 2) In general,
ost performance measures should be chosen from Class Ind Class III practice guideline recommendations; however, Given the additional factors involved in improving the care
f populations of patients, Class IIa recommendations may
e suitable in selected situations. 3) Opportunities should be
iven for clinicians to describe why a particular performance
easures may not be appropriate for an individual patient.
.4. Roles of Generalist Physicians and
ardiologists
nsufficient evidence exists to allow for recommendations
bout the most appropriate roles for generalist physicians
nd cardiologists in the care of patients with HF. Several
tudies indicate that primary care physicians as a group have
ess knowledge about HF and adhere to guidelines less
losely than cardiologists (805–807). Some studies have
oted better patient outcomes in patients cared for by
ardiologists than in those cared for by generalist physicians
808,809), whereas another study reported that cardiologists
eliver more costly care that is accompanied by a trend
oward improved survival (810). Despite these observations,
rimary care physicians with knowledge and experience in
F should be able to care for most patients with uncom-
licated HF. By contrast, patients who remain symptomatic
espite basic medical therapy may benefit from care directed
y consulting physicians who have special expertise and
raining in the care of patients with HF.
Do generalist physicians and cardiologists provide similar
evels of care for the noncardiac comorbid conditions
requently present in patients with HF? What is the optimal
ime for referral to a specialist? What is the most effective
ystem of comanagement of patients by generalists and
ardiologists? What is the most cost-effective entry point
nto a disease-management program? Regardless of the
ltimate answers to these questions, all physicians and other
ealthcare providers must advocate and follow care practices
hat have been shown to improve patient outcomes. If a
hysician is not comfortable following a specific recommen-
ation (e.g., the use of beta blockers), then the physician
hould refer the patient to someone with expertise in HF. A
ollaborative model in which generalist and specialist phy-
icians work together to optimize the care of patients with
F is likely to be most fruitful.
taff
merican College of Cardiology Foundation
ohn C. Lewin, MD, Chief Executive Officer
harlene May, Senior Director, Science and Clinical Policy
isa Bradfield, Associate Director, Clinical Policy and
uidelines
ark D. Stewart, MPH, Associate Director, Evidence-
ased Medicine
ue Keller, BSN, MPH, Senior Specialist, Evidence-Based
edicine
llison McDougall, Senior Specialist, Practice Guidelines
rin A. Barrett, Senior Specialist, Clinical Policy and
uidelines
A
N
G
P
R
e63JACC Vol. 53, No. 15, 2009 Hunt et al.
April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure Guidelinesmerican Heart Association
ancy Brown, Chief Executive Officer
ayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice
resident, Office of Science Operations
EFERENCES
1. ACC/AHA Task Force on Practice Guidelines. Manual for ACC/
AHA Guideline Writing Committees: Methodologies and Policies
from the ACC/AHA Task Force on Practice Guidelines. 2006. Avail-
able at: http://www.acc.org/qualityandscience/clinical/manual/pdfs/
methodology.pdf and http://circ.ahajournals.org/manual/. Accessed Jan-
uary 30, 2008.
2. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005
Guideline Update for the Diagnosis and Management of Chronic
Heart Failure in the Adult: a report of the American College of
Cardiology/American Heart Association Task Force on Practice
Guidelines (Writing Committee to Update the 2001 Guidelines for
the Evaluation and Management of Heart Failure). J Am Coll
Cardiol. 2005;46:e1–82.
3. 2009 Focused Update: ACCF/AHA guidelines for the diagnosis and
management of heart failure in adults: a report of the American
College of Cardiology Foundation/American Heart Association Task
Force on Practice Guidelines. J Am Coll Cardiol. 2009;53:1343–82.
4. American Heart Association. Heart Disease and Stroke Statistics–
2005 Update. Dallas, TX: American Heart Association; 2005.
5. O’Connell JB, Bristow MR. Economic impact of heart failure in the
United States: time for a different approach. J Heart Lung Trans-
plant. 1994;13 Suppl:S107–12.
6. Koelling TM, Chen RS, Lubwama RN, et al. The expanding
national burden of heart failure in the United States: the influence of
heart failure in women. Am Heart J. 2004;147:74–8.
7. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J.
1991;121:951–7.
8. Masoudi FA, Havranek EP, Krumholz HM. The burden of chronic
congestive heart failure in older persons: magnitude and implications
for policy and research. Heart Fail Rev. 2002;7:9–16.
9. Massie BM, Shah NB. Evolving trends in the epidemiologic factors
of heart failure: rationale for preventive strategies and comprehensive
disease management. Am Heart J. 1997;133:703–12.
10. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for
the evaluation and management of chronic heart failure in the adult:
executive summary. A report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines
(Committee to Revise the 1995 Guidelines for the Evaluation and
Management of Heart Failure). J Am Coll Cardiol. 2001;38:
2101–13.
11. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guide-
lines for the management of patients with ST-elevation myocardial
infarction; A report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines
(Committee to Revise the 1999 Guidelines for the Management of
patients with acute myocardial infarction). J Am Coll Cardiol.
2004;44:e1–211.
12. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002
guideline update for the management of patients with unstable
angina and non-ST-segment elevation myocardial infarction—
summary article: a report of the American College of Cardiology/
American Heart Association task force on practice guidelines (Com-
mittee on the Management of Patients With Unstable Angina). J Am
Coll Cardiol. 2002;40:1366–74.
13. Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006
guidelines for the management of patients with valvular heart disease:
a report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Writing Committee
to Revise the 1998 Guidelines for the Management of Patients With
Valvular Heart Disease). J Am Coll Cardiol. 2006;48:e1–148.
14. Francis GS, Pierpont GL. Pathophysiology of congestive heart
failure secondary to congestive and ischemic cardiomyopathy. In:
Shaver JA, editor. Cardiomyopathies: Clinical presentation, differ-
ential diagnosis, and management. Philadelphia: F.A. Davis, 1988:
57–74.15. Alderman EL, Fisher LD, Litwin P, et al. Results of coronary artery
surgery in patients with poor left ventricular function (CASS).
Circulation. 1983;68:785–95.
16. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline
update for coronary artery bypass graft surgery: a report of the
American College of Cardiology/American Heart Association Task
Force on Practice Guidelines (Committee to Update the 1999
Guidelines for Coronary Artery Bypass Graft Surgery). Circulation.
2004;110:e340–7.
17. Fox KF, Cowie MR, Wood DA, et al. Coronary artery disease as the
cause of incident heart failure in the population. Eur Heart J.
2001;22:228–36.
18. Arques S, Ambrosi P, Gelisse R, et al. Prevalence of angiographic
coronary artery disease in patients hospitalized for acute diastolic
heart failure without clinical and electrocardiographic evidence of
myocardial ischemia on admission. Am J Cardiol. 2004;94:133–5.
19. Kurtz CE, Gerber Y, Weston SA, et al. Use of ejection fraction tests
and coronary angiography in patients with heart failure. Mayo Clin
Proc. 2006;81:906–13.
20. Elhendy A, Schinkel AF, van Domburg RT, et al. Incidence and
predictors of heart failure during long-term follow-up after stress
Tc-99m sestamibi tomography in patients with suspected coronary
artery disease. J Nucl Cardiol. 2004;11:527–33.
21. Chomsky DB, Lang CC, Rayos GH, et al. Hemodynamic exercise
testing. A valuable tool in the selection of cardiac transplantation
candidates. Circulation. 1996;94:3176–83.
22. Gullestad L, Myers J, Ross H, et al. Serial exercise testing and
prognosis in selected patients considered for cardiac transplantation.
Am Heart J. 1998;135:221–9.
23. Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart
transplantation: International Society for Heart and Lung Transplan-
tation guidelines for the care of cardiac transplant candidates—2006.
J Heart Lung Transplant. 2006;25:1024–42.
24. Cooper LT, Baughman KL, Feldman AM, et al. The role of
endomyocardial biopsy in the management of cardiovascular disease:
a scientific statement from the American Heart Association, the
American College of Cardiology, and the European Society of
Cardiology. Circulation. 2007;116:2216–33.
25. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic
peptide in cardiovascular disease. Lancet. 2003;362:316–22.
26. Siebert U, Januzzi JL Jr., Beinfeld MT, et al. Cost-effectiveness of
using N-terminal pro-brain natriuretic peptide to guide the diagnos-
tic assessment and management of dyspneic patients in the emer-
gency department. Am J Cardiol. 2006;98:800–5.
27. Gackowski A, Isnard R, Golmard JL, et al. Comparison of echocar-
diography and plasma B-type natriuretic peptide for monitoring the
response to treatment in acute heart failure. Eur Heart J. 2004;25:
1788–96.
28. Bayes-Genis A, Santalo-Bel M, Zapico-Muniz E, et al. N-terminal
probrain natriuretic peptide (NT-proBNP) in the emergency diag-
nosis and in-hospital monitoring of patients with dyspnoea and
ventricular dysfunction. Eur J Heart Fail. 2004;6:301–8.
29. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type
natriuretic peptide in the diagnosis of congestive heart failure in an
urgent-care setting. J Am Coll Cardiol. 2001;37:379–85.
30. Worster A, Balion CM, Hill SA, et al. Diagnostic accuracy of BNP
and NT-proBNP in patients presenting to acute care settings with
dyspnea: a systematic review. Clin Biochem. 2008;41:250–9.
31. O’Donoghue M, Kenney P, Oestreicher E, et al. Usefulness of
aminoterminal pro-brain natriuretic peptide testing for the diagnostic
and prognostic evaluation of dyspneic patients with diabetes mellitus
seen in the emergency department (from the PRIDE Study). Am J
Cardiol. 2007;100:1336–40.
32. Silvers SM, Howell JM, Kosowsky JM, et al. Clinical policy: Critical
issues in the evaluation and management of adult patients presenting
to the emergency department with acute heart failure syndromes.
Ann Emerg Med. 2007;49:627–69.
33. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline
update for exercise testing: summary article. A report of the American
College of Cardiology/American Heart Association Task Force on
Practice Guidelines (Committee to Update the 1997 Exercise Test-
ing Guidelines). J Am Coll Cardiol. 2002;40:1531–40.
e64 Hunt et al. JACC Vol. 53, No. 15, 2009
2009 ACCF/AHA Heart Failure Guidelines April 14, 2009:e1–9034. The Criteria Committee of the New York Heart Association.
Diseases of the heart and blood vessels: nomenclature and criteria for
diagnosis. 6th edition. Boston: Little, Brown, 1964.
35. Vitarelli A, Tiukinhoy S, Di LS, et al. The role of echocardiography
in the diagnosis and management of heart failure. Heart Fail Rev.
2003;8:181–9.
36. Ritchie JL, Bateman TM, Bonow RO, et al. Guidelines for clinical
use of cardiac radionuclide imaging. Report of the American College
of Cardiology/American Heart Association Task Force on Assess-
ment of Diagnostic and Therapeutic Cardiovascular Procedures
(Committee on Radionuclide Imaging), developed in collaboration
with the American Society of Nuclear Cardiology. J Am Coll
Cardiol. 1995;25:521–47.
37. Bello D, Shah DJ, Farah GM, et al. Gadolinium cardiovascular
magnetic resonance predicts reversible myocardial dysfunction and
remodeling in patients with heart failure undergoing beta-blocker
therapy. Circulation. 2003;108:1945–53.
38. Drazner MH, Rame JE, Stevenson LW, et al. Prognostic importance
of elevated jugular venous pressure and a third heart sound in patients
with heart failure. N Engl J Med. 2001;345:574–81.
39. Mestroni L. Genomic medicine and atrial fibrillation. J Am Coll
Cardiol. 2003;41:2193–6.
40. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of
heart failure guided by plasma aminoterminal brain natriuretic
peptide (N-BNP) concentrations. Lancet. 2000;355:1126–30.
41. Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal
dysfunction during intensive therapy for advanced chronic heart
failure. Am Heart J. 1999;138:285–90.
42. Maisel A. B-type natriuretic peptide levels: a potential novel “white
count” for congestive heart failure. J Card Fail. 2001;7:183–93.
43. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic
peptide in the evaluation and management of acute dyspnea. N Engl
J Med. 2004;350:647–54.
44. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma
natriuretic peptide levels. Circulation. 2004;109:594–600.
45. Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed
B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol.
2004;43:1590–5.
46. Wright SP, Doughty RN, Pearl A, et al. Plasma amino-terminal
pro-brain natriuretic peptide and accuracy of heart-failure diagnosis
in primary care: a randomized, controlled trial. J Am Coll Cardiol.
2003;42:1793–800.
47. Gheorghiade M, Bonow RO. Chronic heart failure in the United
States: a manifestation of coronary artery disease. Circulation. 1998;
97:282–9.
48. Masoudi FA, Havranek EP, Smith G, et al. Gender, age, and heart
failure with preserved left ventricular systolic function. J Am Coll
Cardiol. 2003;41:217–23.
49. Smith GL, Masoudi FA, Vaccarino V, et al. Outcomes in heart
failure patients with preserved ejection fraction: mortality, readmis-
sion, and functional decline. J Am Coll Cardiol. 2003;41:1510–8.
50. Allman KC, Shaw LJ, Hachamovitch R, et al. Myocardial viability
testing and impact of revascularization on prognosis in patients with
coronary artery disease and left ventricular dysfunction: a meta-
analysis. J Am Coll Cardiol. 2002;39:1151–8.
51. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/
ASE 2003 Guideline Update for the Clinical Application of Echo-
cardiography: summary article. A report of the American College of
Cardiology/American Heart Association Task Force on Practice
Guidelines (ACC/AHA/ASE Committee to Update the 1997
Guidelines for the Clinical Application of Echocardiography). J Am
Soc Echocardiogr. 2003;16:1091–110.
52. Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guide-
lines for the clinical use of cardiac radionuclide imaging—executive
summary: a report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines (ACC/AHA/
ASNC Committee to Revise the 1995 Guidelines for the Clinical
Use of Cardiac Radionuclide Imaging). J Am Coll Cardiol. 2003;42:
1318–33.
53. Lie JT. Myocarditis and endomyocardial biopsy in unexplained heart
failure: a diagnosis in search of a disease. Ann Intern Med. 1988;
109:525–8.54. Chow LC, Dittrich HC, Shabetai R. Endomyocardial biopsy in
patients with unexplained congestive heart failure. Ann Intern Med.
1988;109:535–9.
55. Mason JW, O’Connell JB, Herskowitz A, et al., for the Myocarditis
Treatment Trial Investigators. A clinical trial of immunosuppressive
therapy for myocarditis. N Engl J Med. 1995;333:269–75.
56. Mason JW, Bristow MR, Billingham ME, et al. Invasive and
noninvasive methods of assessing adriamycin cardiotoxic effects in
man: superiority of histopathologic assessment using endomyocardial
biopsy. Cancer Treat Rep. 1978;62:857–64.
57. Alexander J, Dainiak N, Berger HJ, et al. Serial assessment of
doxorubicin cardiotoxicity with quantitative radionuclide angiocar-
diography. N Engl J Med. 1979;300:278–83.
58. Cooper LT Jr., Berry GJ, Shabetai R. Idiopathic giant-cell myocar-
ditis—natural history and treatment. Multicenter Giant Cell Myo-
carditis Study Group Investigators. N Engl J Med. 1997;336:
1860–6.
59. Cesario D, Clark J, Maisel A. Beneficial effects of intermittent home
administration of the inotrope/vasodilator milrinone in patients with
end-stage congestive heart failure: a preliminary study. Am Heart J.
1998;135:121–9.
60. Leier CV, Binkley PF. Parenteral inotropic support for advanced
congestive heart failure. Prog Cardiovasc Dis. 1998;41:207–24.
61. Marius-Nunez AL, Heaney L, Fernandez RN, et al. Intermittent
inotropic therapy in an outpatient setting: a cost-effective therapeutic
modality in patients with refractory heart failure. Am Heart J.
1996;132:805–8.
62. Drazner MH, Hamilton MA, Fonarow G, et al. Relationship
between right and left-sided filling pressures in 1000 patients with
advanced heart failure. J Heart Lung Transplant. 1999;18:1126–32.
63. Androne AS, Katz SD, Lund L, et al. Hemodilution is common in
patients with advanced heart failure. Circulation. 2003;107:226–9.
64. Tang WH, Girod JP, Lee MJ, et al. Plasma B-type natriuretic
peptide levels in ambulatory patients with established chronic symp-
tomatic systolic heart failure. Circulation. 2003;108:2964–6.
65. Mahdyoon H, Klein R, Eyler W, et al. Radiographic pulmonary
congestion in end-stage congestive heart failure. Am J Cardiol.
1989;63:625–7.
66. Aaronson KD, Schwartz JS, Chen TM, et al. Development and
prospective validation of a clinical index to predict survival in
ambulatory patients referred for cardiac transplant evaluation. Circu-
lation. 1997;95:2660–7.
67. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart
Failure Model: prediction of survival in heart failure. Circulation.
2006;113:1424–33.
68. Butler J, Khadim G, Paul KM, et al. Selection of patients for heart
transplantation in the current era of heart failure therapy. J Am Coll
Cardiol. 2004;43:787–93.
69. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006
guidelines for management of patients with ventricular arrhythmias
and the prevention of sudden cardiac death: a report of the American
College of Cardiology/American Heart Association Task Force and
the European Society of Cardiology Committee for Practice Guide-
lines (Writing Committee to Develop Guidelines for Management of
Patients With Ventricular Arrhythmias and the Prevention of Sud-
den Cardiac Death). J Am Coll Cardiol. 2006;48:e247–346.
70. Levy D, Larson MG, Vasan RS, et al. The progression from
hypertension to congestive heart failure. JAMA. 1996;275:1557–62.
71. Wilhelmsen L, Rosengren A, Eriksson H, et al. Heart failure in the
general population of men—morbidity, risk factors and prognosis.
J Intern Med. 2001;249:253–61.
72. Effects of treatment on morbidity in hypertension. II. Results in
patients with diastolic blood pressure averaging 90 through 114 mm
Hg. JAMA. 1970;213:1143–52.
73. Kostis JB, Davis BR, Cutler J, et al., for the SHEP Cooperative
Research Group. Prevention of heart failure by antihypertensive drug
treatment in older persons with isolated systolic hypertension.
JAMA. 1997;278:212–6.
74. Izzo JL Jr., Gradman AH. Mechanisms and management of hyper-
tensive heart disease: from left ventricular hypertrophy to heart
failure. Med Clin North Am. 2004;88:1257–71.75. Baker DW. Prevention of heart failure. J Card Fail. 2002;8:333–46.
11
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
e65JACC Vol. 53, No. 15, 2009 Hunt et al.
April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure Guidelines76. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for
developing hypertension in middle-aged women and men: The
Framingham Heart Study. JAMA. 2002;287:1003–10.
77. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left
ventricular hypertrophy. Am Heart J. 2001;141:334–41.
78. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the
Joint National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure. Hypertension. 2003;42:1206–52.
79. Hansson L, Zanchetti A, Carruthers SG, et al., for the HOT Study
Group. Effects of intensive blood-pressure lowering and low-dose
aspirin in patients with hypertension: principal results of the Hyper-
tension Optimal Treatment (HOT) randomised trial. Lancet. 1998;
351:1755–62.
80. UK Prospective Diabetes Study Group. Tight blood pressure control
and risk of macrovascular and microvascular complications in type 2
diabetes: UKPDS 38 [published erratum appears in BMJ 1999;318:
29]. BMJ. 1998;317:703–13.
81. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood
pressure reduction: a meta-analysis. Lancet. 2001;358:1305–15.
82. Major outcomes in high-risk hypertensive patients randomized to
angiotensin-converting enzyme inhibitor or calcium channel blocker
vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–97.
83. Yusuf S, Sleight P, Pogue J, et al., for the The Heart Outcomes
Prevention Evaluation Study Investigators. Effects of an angiotensin-
converting-enzyme inhibitor, ramipril, on cardiovascular events in
high-risk patients. N Engl J Med. 2000;342:145–53.
84. Fox KM. Efficacy of perindopril in reduction of cardiovascular events
among patients with stable coronary artery disease: randomised,
double-blind, placebo-controlled, multicentre trial (the EUROPA
study). Lancet. 2003;362:782–8.
85. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on
renal and cardiovascular outcomes in patients with type 2 diabetes
and nephropathy. N Engl J Med. 2001;345:861–9.
86. Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in
the Irbesartan Diabetic Nephropathy Trial of patients with type 2
diabetes and overt nephropathy. Ann Intern Med. 2003;138:542–9.
87. Smith SC Jr., Blair SN, Bonow RO, et al. AHA/ACC Scientific
Statement: AHA/ACC guidelines for preventing heart attack and
death in patients with atherosclerotic cardiovascular disease: 2001
update: a statement for healthcare professionals from the American
Heart Association and the American College of Cardiology. Circu-
lation. 2001;104:1577–9.
88. Taegtmeyer H, McNulty P, Young ME. Adaptation and maladap-
tation of the heart in diabetes: Part I: general concepts. Circulation.
2002;105:1727–33.
89. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart
failure. N Engl J Med. 2002;347:305–13.
90. He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart
failure in US men and women: NHANES I epidemiologic follow-up
study. Arch Intern Med. 2001;161:996–1002.
91. Krumholz HM, Chen YT, Wang Y, et al. Predictors of readmission
among elderly survivors of admission with heart failure. Am Heart J.
2000;139:72–7.
92. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor
of morbidity and mortality in the Studies of Left Ventricular
Dysfunction (SOLVD) Trials and Registry. Am J Cardiol. 1996;77:
1017–20.
93. Vaur L, Gueret P, Lievre M, et al. Development of congestive heart
failure in type 2 diabetic patients with microalbuminuria or protein-
uria: observations from the DIABHYCAR (type 2 DIABetes,
Hypertension, CArdiovascular Events and Ramipril) study. Diabetes
Care. 2003;26:855–60.
94. Heart Outcomes Prevention Evaluation Study Investigators. Effects
of ramipril on cardiovascular and microvascular outcomes in people
with diabetes mellitus: results of the HOPE study and MICRO-
HOPE substudy. Lancet. 2000;355:253–9.
95. Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy
on the kidney in patients with diabetes: a meta-regression analysis.
Ann Intern Med. 1993;118:129–38.
96. Lewis EJ, Hunsicker LG, Bain RP, et al., for the Collaborative Study
Group. The effect of angiotensin-converting-enzyme inhibition on
diabetic nephropathy. N Engl J Med. 1993;329:1456–62.97. Zanella MT, Ribeiro AB. The role of angiotensin II antagonism in
type 2 diabetes mellitus: a review of renoprotection studies. Clin
Ther. 2002;24:1019–34.
98. Kereiakes DJ, Willerson JT. Metabolic syndrome epidemic. Circu-
lation. 2003;108:1552–3.
99. Wilson PW, Grundy SM. The metabolic syndrome: practical guide
to origins and treatment: Part I. Circulation. 2003;108:1422–4.
00. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent
clinical trials for the National Cholesterol Education Program Adult
Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44:
720–32.
01. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-
converting-enzyme inhibition in stable coronary artery disease.
N Engl J Med. 2004;351:2058–68.
02. Kjekshus J, Pedersen TR, Olsson AG, et al. The effects of simvastatin
on the incidence of heart failure in patients with coronary heart
disease [published erratum appears in J Card Fail 1998;4:367]. J Card
Fail. 1997;3:249–54.
03. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on
cardiovascular events in older patients with myocardial infarction and
cholesterol levels in the average range. Results of the Cholesterol and
Recurrent Events (CARE) trial. Ann Intern Med. 1998;129:681–9.
04. The Long-Term Intervention with Pravastatin in Ischaemic Disease
(LIPID) Study Group. Prevention of cardiovascular events and death
with pravastatin in patients with coronary heart disease and a broad
range of initial cholesterol levels. N Engl J Med. 1998;339:1349–57.
05. Walsh CR, Larson MG, Evans JC, et al. Alcohol consumption and
risk for congestive heart failure in the Framingham Heart Study. Ann
Intern Med. 2002;136:181–91.
06. Abramson JL, Williams SA, Krumholz HM, et al. Moderate alcohol
consumption and risk of heart failure among older persons. JAMA.
2001;285:1971–7.
07. Vallebona A. Cardiac damage following therapeutic chest irradiation.
Importance, evaluation and treatment. Minerva Cardioangiol. 2000;
48:79–87.
08. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents:
incidence, treatment and prevention. Drug Saf. 2000;22:263–302.
09. Sparano JA. Cardiac toxicity of trastuzumab (Herceptin): implica-
tions for the design of adjuvant trials. Semin Oncol. 2001;28:20–7.
10. Schimmel KJ, Richel DJ, van den Brink RB, et al. Cardiotoxicity of
cytotoxic drugs. Cancer Treat Rev. 2004;30:181–91.
11. Soni MG, Carabin IG, Griffiths JC, et al. Safety of ephedra: lessons
learned. Toxicol Lett. 2004;150:97–110.
12. Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic
peptides for community screening for left ventricular hypertrophy and
systolic dysfunction: the Framingham heart study. JAMA. 2002;288:
1252–9.
13. Heidenreich PA, Gubens MA, Fonarow GC, et al. Cost-
effectiveness of screening with B-type natriuretic peptide to identify
patients with reduced left ventricular ejection fraction. J Am Coll
Cardiol. 2004;43:1019–26.
14. McMinn TR Jr., Ross J Jr. Hereditary dilated cardiomyopathy. Clin
Cardiol. 1995;18:7–15.
15. Sung RY, Huang GY, Shing MK, et al. Echocardiographic evalua-
tion of cardiac function in paediatric oncology patients treated with or
without anthracycline. Int J Cardiol. 1997;60:239–48.
16. Flather MD, Yusuf S, Kober L, et al., for the ACE-Inhibitor
Myocardial Infarction Collaborative Group. Long-term ACE-
inhibitor therapy in patients with heart failure or left-ventricular
dysfunction: a systematic overview of data from individual patients.
Lancet. 2000;355:1575–81.
17. The SOLVD Investigators. Effect of enalapril on mortality and the
development of heart failure in asymptomatic patients with reduced
left ventricular ejection fractions. [published erratum appears in
N Engl J Med 1992;327:1768]. N Engl J Med. 1992;327:685–91.
18. Pitt B, Williams G, Remme W, et al. The EPHESUS trial:
eplerenone in patients with heart failure due to systolic dysfunction
complicating acute myocardial infarction. Eplerenone Post-AMI
Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther.
2001;15:79–87.
19. McMurray J, Kober L, Robertson M, et al. Antiarrhythmic effect of
carvedilol after acute myocardial infarction: results of the Carvedilol
Post-Infarct Survival Control in Left Ventricular Dysfunction (CAP-
RICORN) trial. J Am Coll Cardiol. 2005;45:525–30.
11
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
e66 Hunt et al. JACC Vol. 53, No. 15, 2009
2009 ACCF/AHA Heart Failure Guidelines April 14, 2009:e1–9020. Leon AS, Franklin BA, Costa F, et al. Cardiac rehabilitation and
secondary prevention of coronary heart disease: an American Heart
Association scientific statement from the Council on Clinical Car-
diology (Subcommittee on Exercise, Cardiac Rehabilitation, and
Prevention) and the Council on Nutrition, Physical Activity, and
Metabolism (Subcommittee on Physical Activity), in collaboration
with the American Association of Cardiovascular and Pulmonary
Rehabilitation. Circulation. 2005;111:369–76.
21. Guerci AD, Gerstenblith G, Brinker JA, et al. A randomized trial of
intravenous tissue plasminogen activator for acute myocardial infarc-
tion with subsequent randomization to elective coronary angioplasty.
N Engl J Med. 1987;317:1613–8.
22. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Mio-
cardico (GISSI). Effectiveness of intravenous thrombolytic treatment
in acute myocardial infarction. Lancet. 1986;1:397–402.
23. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Mio-
cardico. GISSI-3: effects of lisinopril and transdermal glyceryl trini-
trate singly and together on 6-week mortality and ventricular function
after acute myocardial infarction. Lancet. 1994;343:1115–22.
24. Timolol-induced reduction in mortality and reinfarction in patients
surviving acute myocardial infarction. N Engl J Med. 1981;304:
801–7.
25. Beta Blocker Heart Attack Trial Research Group. A randomized trial
of propranolol in patients with acute myocardial infarction. I.
Mortality results. JAMA. 1982;247:1707–14.
26. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.
Effect of ramipril on mortality and morbidity of survivors of acute
myocardial infarction with clinical evidence of heart failure. Lancet.
1993;342:821–8.
27. Chadda K, Goldstein S, Byington R, et al. Effect of propranolol after
acute myocardial infarction in patients with congestive heart failure.
Circulation. 1986;73:503–10.
28. Pfeffer MA, Braunwald E, Moye LA, et al., for the SAVE Investi-
gators. Effect of captopril on mortality and morbidity in patients with
left ventricular dysfunction after myocardial infarction. Results of the
survival and ventricular enlargement trial. N Engl J Med. 1992;327:
669–77.
29. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative
Group. ISIS-4: a randomised factorial trial assessing early oral
captopril, oral mononitrate, and intravenous magnesium sulphate in
58,050 patients with suspected acute myocardial infarction. Lancet.
1995;345:669–85.
30. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril,
or both in myocardial infarction complicated by heart failure, left
ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–906.
31. Vantrimpont P, Rouleau JL, Wun CC, et al., for the SAVE
Investigators. Additive beneficial effects of beta-blockers to
angiotensin-converting enzyme inhibitors in the Survival and Ven-
tricular Enlargement (SAVE) Study. J Am Coll Cardiol. 1997;29:
229–36.
32. Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12–year
survival and life expectancy in patients with left ventricular systolic
dysfunction: a follow-up study. Lancet. 2003;361:1843–8.
33. Desai AS, Fang JC, Maisel WH, et al. Implantable defibrillators for
the prevention of mortality in patients with nonischemic cardiomy-
opathy: a meta-analysis of randomized controlled trials. JAMA.
2004;292:2874–9.
34. The Digitalis Investigation Group. The effect of digoxin on mortality
and morbidity in patients with heart failure. N Engl J Med.
1997;336:525–33.
35. The Multicenter Diltiazem Postinfarction Trial Research Group.
The effect of diltiazem on mortality and reinfarction after myocardial
infarction. N Engl J Med. 1988;319:385–92.
36. Peters KG, Kienzle MG. Severe cardiomyopathy due to chronic
rapidly conducted atrial fibrillation: complete recovery after restora-
tion of sinus rhythm. Am J Med. 1988;85:242–4.
37. Grogan M, Smith HC, Gersh BJ, et al. Left ventricular dysfunction
due to atrial fibrillation in patients initially believed to have idiopathic
dilated cardiomyopathy. Am J Cardiol. 1992;69:1570–3.
38. Bonow RO, Carabello B, de Leon A Jr., et al. Guidelines for the
management of patients with valvular heart disease: executive sum-
mary. A report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines (Committee onManagement of Patients with Valvular Heart Disease). Circulation.
1998;98:1949–84.
39. Bach DS, Bolling SF. Improvement following correction of second-
ary mitral regurgitation in end-stage cardiomyopathy with mitral
annuloplasty. Am J Cardiol. 1996;78:966–9.
40. Connolly HM, Oh JK, Orszulak TA, et al. Aortic valve replacement
for aortic stenosis with severe left ventricular dysfunction. Prognostic
indicators. Circulation. 1997;95:2395–400.
41. Bolling SF, Pagani FD, Deeb GM, et al. Intermediate-term outcome
of mitral reconstruction in cardiomyopathy. J Thorac Cardiovasc
Surg. 1998;115:381–6.
42. Greenberg B, Massie B, Bristow JD, et al. Long-term vasodilator
therapy of chronic aortic insufficiency. A randomized double-blinded,
placebo-controlled clinical trial. Circulation. 1988;78:92–103.
43. Scognamiglio R, Rahimtoola SH, Fasoli G, et al. Nifedipine in
asymptomatic patients with severe aortic regurgitation and normal
left ventricular function. N Engl J Med. 1994;331:689–94.
44. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS
2008 Guidelines for Device-Based Therapy of Cardiac Rhythm
Abnormalities: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines
(Writing Committee to Revise the ACC/AHA/NASPE 2002
Guideline Update for Implantation of Cardiac Pacemakers and
Antiarrhythmia Devices) developed in collaboration with the Amer-
ican Association for Thoracic Surgery and Society of Thoracic
Surgeons. J Am Coll Cardiol. 2008;51:e1–62.
45. Captopril Multicenter Research Group. A placebo-controlled trial of
captopril in refractory chronic congestive heart failure. J Am Coll
Cardiol. 1983;2:755–63.
46. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor
Trials. Overview of randomized trials of angiotensin-converting
enzyme inhibitors on mortality and morbidity in patients with heart
failure. JAMA. 1995;273:1450–6.
47. Sharpe DN, Murphy J, Coxon R, et al. Enalapril in patients with
chronic heart failure: a placebo-controlled, randomized, double-blind
study. Circulation. 1984;70:271–8.
48. Chalmers JP, West MJ, Cyran J, et al. Placebo-controlled study of
lisinopril in congestive heart failure: a multicentre study. J Cardiovasc
Pharmacol. 1987;9 Suppl 3:S89–97.
49. Cleland JG, Dargie HJ, Hodsman GP, et al. Captopril in heart
failure. A double blind controlled trial. Br Heart J. 1984;52:530–5.
50. Cleland JG, Dargie HJ, Ball SG, et al. Effects of enalapril in heart
failure: a double blind study of effects on exercise performance, renal
function, hormones, and metabolic state. Br Heart J. 1985;54:
305–12.
51. Cowley AJ, Rowley JM, Stainer KL, et al. Captopril therapy for heart
failure. A placebo controlled study. Lancet. 1982;2:730–2.
52. Bayliss J, Norell MS, Canepa-Anson R, et al. Clinical importance of
the renin-angiotensin system in chronic heart failure: double blind
comparison of captopril and prazosin. Br Med J (Clin Res Ed).
1985;290:1861–5.
53. Drexler H, Banhardt U, Meinertz T, et al. Contrasting peripheral
short-term and long-term effects of converting enzyme inhibition in
patients with congestive heart failure. A double-blind, placebo-
controlled trial. Circulation. 1989;79:491–502.
54. Erhardt L, MacLean A, Ilgenfritz J, et al., for the Fosinopril
Efficacy/Safety Trial (FEST) Study Group. Fosinopril attenuates
clinical deterioration and improves exercise tolerance in patients with
heart failure. Eur Heart J. 1995;16:1892–9.
55. The CONSENSUS Trial Study Group. Effects of enalapril on
mortality in severe congestive heart failure. Results of the Cooperative
North Scandinavian Enalapril Survival Study (CONSENSUS).
N Engl J Med. 1987;316:1429–35.
56. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril
with hydralazine-isosorbide dinitrate in the treatment of chronic
congestive heart failure. N Engl J Med. 1991;325:303–10.
57. The SOLVD Investigators. Effect of enalapril on survival in patients
with reduced left ventricular ejection fractions and congestive heart
failure. N Engl J Med. 1991;325:293–302.
58. CIBIS-II Investigators and Committee. The Cardiac Insufficiency
Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;
353:9–13.
59. Hjalmarson A, Goldstein S, Fagerberg B, et al., for the MERIT-HF
Study Group. Effects of controlled-release metoprolol on total
11
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
e67JACC Vol. 53, No. 15, 2009 Hunt et al.
April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure Guidelinesmortality, hospitalizations, and well-being in patients with heart
failure: the Metoprolol CR/XL Randomized Intervention Trial in
congestive heart failure (MERIT-HF). JAMA. 2000;283:1295–302.
60. A trial of the beta-blocker bucindolol in patients with advanced
chronic heart failure. N Engl J Med. 2001;344:1659–67.
61. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of
carvedilol and metoprolol on clinical outcomes in patients with
chronic heart failure in the Carvedilol Or Metoprolol European Trial
(COMET): randomised controlled trial. Lancet. 2003;362:7–13.
62. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol
CR/XL Randomised Intervention Trial in Congestive Heart Failure
(MERIT-HF). Lancet. 1999;353:2001–7.
63. Lechat P, Packer M, Chalon S, et al. Clinical effects of beta-
adrenergic blockade in chronic heart failure: a meta-analysis of
double-blind, placebo-controlled, randomized trials. Circulation.
1998;98:1184–91.
64. Packer M, Bristow MR, Cohn JN, et al., for the U.S. Carvedilol
Heart Failure Study Group. The effect of carvedilol on morbidity and
mortality in patients with chronic heart failure. N Engl J Med.
1996;334:1349–55.
65. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival
in severe chronic heart failure. N Engl J Med. 2001;344:1651–8.
66. Dargie HJ. Effect of carvedilol on outcome after myocardial infarc-
tion in patients with left-ventricular dysfunction: the CAPRICORN
randomised trial. Lancet. 2001;357:1385–90.
67. Cleland JG, Pennell DJ, Ray SG, et al. Myocardial viability as a
determinant of the ejection fraction response to carvedilol in patients
with heart failure (CHRISTMAS trial): randomised controlled trial.
Lancet. 2003;362:14–21.
68. Fisher ML, Gottlieb SS, Plotnick GD, et al. Beneficial effects of
metoprolol in heart failure associated with coronary artery disease: a
randomized trial. J Am Coll Cardiol. 1994;23:943–50.
69. Metra M, Nardi M, Giubbini R, et al. Effects of short- and
long-term carvedilol administration on rest and exercise hemody-
namic variables, exercise capacity and clinical conditions in patients
with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994;
24:1678–87.
70. Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left
ventricular function and symptoms in chronic heart failure: a double-
blind randomized study. J Am Coll Cardiol. 1995;25:1225–31.
71. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind,
placebo-controlled study of the long-term efficacy of carvedilol in
patients with severe chronic heart failure. Circulation. 1995;92:1499–
506.
72. Waagstein F, Bristow MR, Swedberg K, et al., for the Metoprolol in
Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial
effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet.
1993;342:1441–6.
73. CIBIS Investigators and Committees. A randomized trial of beta-
blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study
(CIBIS). Circulation. 1994;90:1765–73.
74. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind,
placebo-controlled study of the effects of carvedilol in patients with
moderate to severe heart failure. The PRECISE Trial. Prospective
Randomized Evaluation of Carvedilol on Symptoms and Exercise.
Circulation. 1996;94:2793–9.
75. Colucci WS, Packer M, Bristow MR, et al., for the US Carvedilol
Heart Failure Study Group. Carvedilol inhibits clinical progression in
patients with mild symptoms of heart failure. Circulation. 1996;94:
2800–6.
76. Australia/New Zealand Heart Failure Research Collaborative Group.
Randomised, placebo-controlled trial of carvedilol in patients with
congestive heart failure due to ischaemic heart disease. Lancet.
1997;349:375–80.
77. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in
patients with chronic heart failure and reduced left-ventricular
systolic function intolerant to angiotensin-converting-enzyme inhib-
itors: the CHARM-Alternative trial. Lancet. 2003;362:772–6.
78. Gottlieb SS, Dickstein K, Fleck E, et al. Hemodynamic and
neurohormonal effects of the angiotensin II antagonist losartan in
patients with congestive heart failure. Circulation. 1993;88:1602–9.
79. Crozier I, Ikram H, Awan N, et al., for the Losartan Hemodynamic
Study Group. Losartan in heart failure. Hemodynamic effects and
tolerability. Circulation. 1995;91:691–7.80. Riegger GA, Bouzo H, Petr P, et al., for the Symptom, Tolerability,
Response to Exercise Trial of Candesartan Cilexetil in Heart Failure
(STRETCH) Investigators. Improvement in exercise tolerance and
symptoms of congestive heart failure during treatment with cande-
sartan cilexetil. Circulation. 1999;100:2224–30.
81. Sharma D, Buyse M, Pitt B, et al., for the Losartan Heart Failure
Mortality Meta-analysis Study Group. Meta-analysis of observed
mortality data from all-controlled, double-blind, multiple-dose stud-
ies of losartan in heart failure. Am J Cardiol. 2000;85:187–92.
82. McKelvie RS, Yusuf S, Pericak D, et al., for the RESOLVD Pilot
Study Investigators. Comparison of candesartan, enalapril, and their
combination in congestive heart failure: randomized evaluation of
strategies for left ventricular dysfunction (RESOLVD) pilot study.
Circulation. 1999;100:1056–64.
83. Mazayev VP, Fomina IG, Kazakov EN, et al. Valsartan in heart
failure patients previously untreated with an ACE inhibitor. Int
J Cardiol. 1998;65:239–46.
84. Cohn JN, Tognoni G. A randomized trial of the angiotensin-
receptor blocker valsartan in chronic heart failure. N Engl J Med.
2001;345:1667–75.
85. Wong M, Staszewsky L, Latini R, et al. Valsartan benefits left
ventricular structure and function in heart failure: Val-HeFT echo-
cardiographic study. J Am Coll Cardiol. 2002;40:970–5.
86. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan
in patients with chronic heart failure and reduced left-ventricular
systolic function taking angiotensin-converting-enzyme inhibitors:
the CHARM-Added trial. Lancet. 2003;362:767–71.
87. Heerdink ER, Leufkens HG, Herings RM, et al. NSAIDs associated
with increased risk of congestive heart failure in elderly patients
taking diuretics. Arch Intern Med. 1998;158:1108–12.
88. Herchuelz A, Derenne F, Deger F, et al. Interaction between
nonsteroidal anti-inflammatory drugs and loop diuretics: modulation
by sodium balance. J Pharmacol Exp Ther. 1989;248:1175–81.
89. Gottlieb SS, Robinson S, Krichten CM, et al. Renal response to
indomethacin in congestive heart failure secondary to ischemic or
idiopathic dilated cardiomyopathy. Am J Cardiol. 1992;70:890–3.
90. Bank AJ, Kubo SH, Rector TS, et al. Local forearm vasodilation with
intra-arterial administration of enalaprilat in humans. Clin Pharma-
col Ther. 1991;50:314–21.
91. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators.
Preliminary report: effect of encainide and flecainide on mortality in
a randomized trial of arrhythmia suppression after myocardial infarc-
tion. N Engl J Med. 1989;321:406–12.
92. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of
the antiarrhythmic agent moricizine on survival after myocardial
infarction. N Engl J Med. 1992;327:227–33.
93. Pratt CM, Eaton T, Francis M, et al. The inverse relationship
between baseline left ventricular ejection fraction and outcome of
antiarrhythmic therapy: a dangerous imbalance in the risk-benefit
ratio. Am Heart J. 1989;118:433–40.
93a.Nilsson BB, Westheim A, Risberg MA. Effects of group-based
high-intensity aerobic interval training in patients with chronic heart
failure. Am J Cardiol. 2008;102:1361–5.
93b.Mueller L, Myers J, Kottman W, et al. Exercise capacity, physical
activity patterns and outcomes six years after cardiac rehabilitation in
patients with heart failure. Clin Rehabil. 2007;21:923–31.
93c.Dracup K, Evangelista LS, Hamilton MA, et al. Effects of a
home-based exercise program on clinical outcomes in heart failure.
Am Heart J. 2007;154:877–83.
93d.Jo´nsdo´ttir S, Andersen KK, Sigurosson AF, Sigurosson SB. The
effect of physical training in chronic heart failure. Eur J Heart Fail.
2006;8:97–101.
94. Bokhari F, Newman D, Greene M, et al. Long-term comparison of
the implantable cardioverter defibrillator versus amiodarone: eleven-
year follow-up of a subset of patients in the Canadian Implantable
Defibrillator Study (CIDS). Circulation. 2004;110:112–6.
95. Mark DB, Nelson CL, Anstrom KJ, et al. Cost-effectiveness of
defibrillator therapy or amiodarone in chronic stable heart failure:
results from the Sudden Cardiac Death in Heart Failure Trial
(SCD-HeFT). Circulation. 2006;114:135–42.
96. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable
cardioverter-defibrillator for congestive heart failure. N Engl J Med.
2005;352:225–37.
11
1
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
e68 Hunt et al. JACC Vol. 53, No. 15, 2009
2009 ACCF/AHA Heart Failure Guidelines April 14, 2009:e1–9097. Hebert K, McKinnie J, Horswell R, et al. Expansion of heart failure
device therapy into a rural indigent population in Louisiana: potential
economic and health policy implications. J Card Fail. 2006;12:
689–93.
98. Knight BP, Goyal R, Pelosi F, et al. Outcome of patients with
nonischemic dilated cardiomyopathy and unexplained syncope
treated with an implantable defibrillator. J Am Coll Cardiol. 1999;
33:1964–70.
99. Klein HU, Reek S. The MUSTT study: evaluating testing and
treatment. J Interv Card Electrophysiol. 2000;4 Suppl 1:45–50.
00. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a
defibrillator in patients with myocardial infarction and reduced
ejection fraction. N Engl J Med. 2002;346:877–83.
01. Hohnloser SH, Connolly SJ, Kuck KH, et al. The defibrillator in
acute myocardial infarction trial (DINAMIT): study protocol. Am
Heart J. 2000;140:735–9.
02. Wilkoff BL, Cook JR, Epstein AE, et al. Dual-chamber pacing or
ventricular backup pacing in patients with an implantable defibrilla-
tor: the Dual Chamber and VVI Implantable Defibrillator (DAVID)
Trial. JAMA. 2002;288:3115–23.
03. Beshai JF, Grimm RA, Nagueh SF, et al. Cardiac-resynchronization
therapy in heart failure with narrow QRS complexes. N Engl J Med.
2007;357:2461–71.
04. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac
resynchronization on morbidity and mortality in heart failure. N Engl
J Med. 2005;352:1539–49.
05. Higgins SL, Hummel JD, Niazi IK, et al. Cardiac resynchronization
therapy for the treatment of heart failure in patients with intraven-
tricular conduction delay and malignant ventricular tachyarrhythmias.
J Am Coll Cardiol. 2003;42:1454–9.
06. Xiao HB, Roy C, Fujimoto S, et al. Natural history of abnormal
conduction and its relation to prognosis in patients with dilated
cardiomyopathy. Int J Cardiol. 1996;53:163–70.
07. Shamim W, Francis DP, Yousufuddin M, et al. Intraventricular
conduction delay: a prognostic marker in chronic heart failure. Int
J Cardiol. 1999;70:171–8.
08. Unverferth DV, Magorien RD, Moeschberger ML, et al. Factors
influencing the one-year mortality of dilated cardiomyopathy. Am J
Cardiol. 1984;54:147–52.
09. Blanc JJ, Etienne Y, Gilard M, et al. Evaluation of different
ventricular pacing sites in patients with severe heart failure: results of
an acute hemodynamic study. Circulation. 1997;96:3273–7.
10. Kass DA, Chen CH, Curry C, et al. Improved left ventricular
mechanics from acute VDD pacing in patients with dilated cardio-
myopathy and ventricular conduction delay. Circulation. 1999;99:
1567–73.
11. Toussaint JF, Lavergne T, Ollitraut J, et al. Biventricular pacing in
severe heart failure patients reverses electromechanical dyssynchroni-
zation from apex to base. Pacing Clin Electrophysiol. 2000;23:
1731–4.
12. Nelson GS, Berger RD, Fetics BJ, et al. Left ventricular or biven-
tricular pacing improves cardiac function at diminished energy cost in
patients with dilated cardiomyopathy and left bundle-branch block.
Circulation. 2000;102:3053–9.
13. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchroni-
zation in chronic heart failure. N Engl J Med. 2002;346:1845–53.
14. Young JB, Abraham WT, Smith AL, et al. Combined cardiac
resynchronization and implantable cardioversion defibrillation in
advanced chronic heart failure: the MIRACLE ICD Trial. JAMA.
2003;289:2685–94.
15. McAlister FA, Stewart S, Ferrua S, et al. Multidisciplinary strategies
for the management of heart failure patients at high risk for
admission: a systematic review of randomized trials. J Am Coll
Cardiol. 2004;44:810–9.
16. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization
therapy with or without an implantable defibrillator in advanced
chronic heart failure. N Engl J Med. 2004;350:2140–50.
17. Leclercq C, Walker S, Linde C, et al. Comparative effects of
permanent biventricular and right-univentricular pacing in heart
failure patients with chronic atrial fibrillation. Eur Heart J. 2002;23:
1780–7.
18. Leon AR, Greenberg JM, Kanuru N, et al. Cardiac resynchronization
in patients with congestive heart failure and chronic atrial fibrillation:effect of upgrading to biventricular pacing after chronic right
ventricular pacing. J Am Coll Cardiol. 2002;39:1258–63.
19. Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions
among elderly patients hospitalized for drug toxicity. JAMA. 2003;
289:1652–8.
20. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia
after publication of the Randomized Aldactone Evaluation Study.
N Engl J Med. 2004;351:543–51.
21. Svensson M, Gustafsson F, Galatius S, et al. How prevalent is
hyperkalemia and renal dysfunction during treatment with spirono-
lactone in patients with congestive heart failure? J Card Fail.
2004;10:297–303.
22. Carson P, Ziesche S, Johnson G, et al., for the Vasodilator-Heart
Failure Trial Study Group. Racial differences in response to therapy
for heart failure: analysis of the vasodilator-heart failure trials. J Card
Fail. 1999;5:178–87.
23. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide
dinitrate and hydralazine in blacks with heart failure. N Engl J Med.
2004;351:2049–57.
24. Stevenson WG, Tedrow U. Management of atrial fibrillation in
patients with heart failure. Heart Rhythm. 2007;4:S28–30.
25. Heist EK, Ruskin JN. Atrial fibrillation and congestive heart failure:
risk factors, mechanisms, and treatment. Prog Cardiovasc Dis.
2006;48:256–69.
26. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control
for atrial fibrillation and heart failure. N Engl J Med. 2008;358:
2667–77.
27. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate
control and rhythm control in patients with atrial fibrillation. N Engl
J Med. 2002;347:1825–33.
28. Van Gelder I, Hagens VE, Bosker HA, et al. A comparison of rate
control and rhythm control in patients with recurrent persistent atrial
fibrillation. N Engl J Med. 2002;347:1834–40.
29. The Captopril-Digoxin Multicenter Research Group. Comparative
effects of therapy with captopril and digoxin in patients with mild to
moderate heart failure. JAMA. 1988;259:539–44.
30. Dobbs SM, Kenyon WI, Dobbs RJ. Maintenance digoxin after an
episode of heart failure: placebo-controlled trial in outpatients. Br
Med J. 1977;1:749–52.
31. Lee DC, Johnson RA, Bingham JB, et al. Heart failure in outpa-
tients: a randomized trial of digoxin versus placebo. N Engl J Med.
1982;306:699–705.
32. Guyatt GH, Sullivan MJ, Fallen EL, et al. A controlled trial of
digoxin in congestive heart failure. Am J Cardiol. 1988;61:371–5.
33. DiBianco R, Shabetai R, Kostuk W, et al. A comparison of oral
milrinone, digoxin, and their combination in the treatment of
patients with chronic heart failure. N Engl J Med. 1989;320:677–83.
34. Uretsky BF, Young JB, Shahidi FE, et al., for the PROVED
Investigative Group. Randomized study assessing the effect of
digoxin withdrawal in patients with mild to moderate chronic
congestive heart failure: results of the PROVED trial. J Am Coll
Cardiol. 1993;22:955–62.
35. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin
from patients with chronic heart failure treated with angiotensin-
converting-enzyme inhibitors. RADIANCE Study. N Engl J Med.
1993;329:1–7.
36. Cohn JN. The Vasodilator-Heart Failure Trials (V-HeFT). Mech-
anistic data from the VA Cooperative Studies. Introduction. Circu-
lation. 1993;87:VI1–4.
37. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite
biventricular pacing in patients with heart failure and intraventricular
conduction delay. N Engl J Med. 2001;344:873–80.
38. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator
therapy on mortality in chronic congestive heart failure. Results of a
Veterans Administration Cooperative Study. N Engl J Med. 1986;
314:1547–52.
39. Loeb HS, Johnson G, Henrick A, et al., for the V-HeFT VA
Cooperative Studies Group. Effect of enalapril, hydralazine plus
isosorbide dinitrate, and prazosin on hospitalization in patients with
chronic congestive heart failure. Circulation. 1993;87:VI78–87.
40. Reed SD, Friedman JY, Velazquez EJ, et al. Multinational economic
evaluation of valsartan in patients with chronic heart failure: results
from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J.
2004;148:122–8.
22
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
e69JACC Vol. 53, No. 15, 2009 Hunt et al.
April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure Guidelines41. Setaro JF, Zaret BL, Schulman DS, et al. Usefulness of verapamil for
congestive heart failure associated with abnormal left ventricular
diastolic filling and normal left ventricular systolic performance. Am J
Cardiol. 1990;66:981–6.
42. Packer M, O’Connor CM, Ghali JK, et al., for the Prospective
Randomized Amlodipine Survival Evaluation Study Group. Effect of
amlodipine on morbidity and mortality in severe chronic heart failure.
N Engl J Med. 1996;335:1107–14.
43. McKelvie RS, Teo KK, McCartney N, et al. Effects of exercise
training in patients with congestive heart failure: a critical review.
J Am Coll Cardiol. 1995;25:789–96.
44. Chati Z, Zannad F, Jeandel C, et al. Physical deconditioning may be
a mechanism for the skeletal muscle energy phosphate metabolism
abnormalities in chronic heart failure. Am Heart J. 1996;131:560–6.
45. Sinoway LI. Effect of conditioning and deconditioning stimuli on
metabolically determined blood flow in humans and implications for
congestive heart failure. Am J Cardiol. 1988;62:45E–8E.
46. Mancini DM, Walter G, Reichek N, et al. Contribution of skeletal
muscle atrophy to exercise intolerance and altered muscle metabolism
in heart failure. Circulation. 1992;85:1364–73.
47. Packer M. Hemodynamic consequences of antiarrhythmic drug
therapy in patients with chronic heart failure. J Cardiovasc Electro-
physiol. 1991;2:S240–7.
48. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al., for the
Danish Investigations of Arrhythmia and Mortality on Dofetilide
Study Group. Dofetilide in patients with congestive heart failure and
left ventricular dysfunction. N Engl J Med. 1999;341:857–65.
49. Packer M, Kessler PD, Lee WH. Calcium-channel blockade in the
management of severe chronic congestive heart failure: a bridge too
far. Circulation. 1987;75:V56–64.
50. Elkayam U. Calcium channel blockers in heart failure. Cardiology.
1998;89 Suppl 1:38–46.
51. Packer M, Gottlieb SS, Kessler PD. Hormone-electrolyte interac-
tions in the pathogenesis of lethal cardiac arrhythmias in patients
with congestive heart failure. Basis of a new physiologic approach to
control of arrhythmia. Am J Med. 1986;80:23–9.
52. Packer M. Adaptive and maladaptive actions of angiotensin II in
patients with severe congestive heart failure. Am J Kidney Dis.
1987;10:66–73.
53. Reid JL, Whyte KF, Struthers AD. Epinephrine-induced hypokale-
mia: the role of beta adrenoceptors. Am J Cardiol. 1986;57:23F–7F.
54. Packer M. Potential role of potassium as a determinant of morbidity
and mortality in patients with systemic hypertension and congestive
heart failure. Am J Cardiol. 1990;65:45E–51E.
55. Schwartz AB. Potassium-related cardiac arrhythmias and their treat-
ment. Angiology. 1978;29:194–205.
56. Pitt B, Zannad F, Remme WJ, et al., for the Randomized Aldactone
Evaluation Study Investigators. The effect of spironolactone on
morbidity and mortality in patients with severe heart failure. N Engl
J Med. 1999;341:709–17.
57. Rude RK. Physiology of magnesium metabolism and the important
role of magnesium in potassium deficiency. Am J Cardiol. 1989;63:
31G–4G.
58. Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary
intervention to prevent the readmission of elderly patients with
congestive heart failure. N Engl J Med. 1995;333:1190–5.
59. Shah NB, Der E, Ruggerio C, et al. Prevention of hospitalizations for
heart failure with an interactive home monitoring program. Am
Heart J. 1998;135:373–8.
60. Fonarow GC, Stevenson LW, Walden JA, et al. Impact of a
comprehensive heart failure management program on hospital read-
mission and functional status of patients with advanced heart failure.
J Am Coll Cardiol. 1997;30:725–32.
61. Philbin EF. Comprehensive multidisciplinary programs for the man-
agement of patients with congestive heart failure. J Gen Intern Med.
1999;14:130–5.
62. Packer M, Cohn JN, Abraham WT, et al. Consensus recommenda-
tions for the management of chronic heart failure. Am J Cardiol.
1999;83:1A–38A.
63. Brater DC. Diuretic therapy. N Engl J Med. 1998;339:387–95.
64. Cody RJ, Kubo SH, Pickworth KK. Diuretic treatment for the
sodium retention of congestive heart failure. Arch Intern Med.
1994;154:1905–14.65. Patterson JH, Adams KF Jr., Applefeld MM, et al., for the
Torsemide Investigators Group. Oral torsemide in patients with
chronic congestive heart failure: effects on body weight, edema, and
electrolyte excretion. Pharmacotherapy. 1994;14:514–21.
66. Sherman LG, Liang CS, Baumgardner S, et al. Piretanide, a potent
diuretic with potassium-sparing properties, for the treatment of
congestive heart failure. Clin Pharmacol Ther. 1986;40:587–94.
67. Wilson JR, Reichek N, Dunkman WB, et al. Effect of diuresis on the
performance of the failing left ventricle in man. Am J Med.
1981;70:234–9.
68. Parker JO, for the The Ibopamine Study Group. The effects of oral
ibopamine in patients with mild heart failure—a double blind placebo
controlled comparison to furosemide. Int J Cardiol. 1993;40:221–7.
69. Richardson A, Bayliss J, Scriven AJ, et al. Double-blind comparison
of captopril alone against frusemide plus amiloride in mild heart
failure. Lancet. 1987;2:709–11.
70. Packer M, Medina N, Yushak M, et al. Hemodynamic patterns of
response during long-term captopril therapy for severe chronic heart
failure. Circulation. 1983;68:803–12.
71. Hall SA, Cigarroa CG, Marcoux L, et al. Time course of improve-
ment in left ventricular function, mass and geometry in patients with
congestive heart failure treated with beta-adrenergic blockade. J Am
Coll Cardiol. 1995;25:1154–61.
72. Cody RJ, Franklin KW, Laragh JH. Postural hypotension during tilt
with chronic captopril and diuretic therapy of severe congestive heart
failure. Am Heart J. 1982;103:480–4.
73. Massie B, Kramer B, Haughom F. Postural hypotension and tachy-
cardia during hydralazine–isosorbide dinitrate therapy for chronic
heart failure. Circulation. 1981;63:658–64.
74. Packer M, Lee WH, Medina N, et al. Functional renal insufficiency
during long-term therapy with captopril and enalapril in severe
chronic heart failure. Ann Intern Med. 1987;106:346–54.
75. Risler T, Schwab A, Kramer B, et al. Comparative pharmacokinetics
and pharmacodynamics of loop diuretics in renal failure. Cardiology.
1994;84 Suppl 2:155–61.
76. Murray MD, Forthofer MM, Bennett SK, et al. Effectiveness of
torsemide and furosemide in the treatment of congestive heart failure:
results of a prospective, randomized trial (abstr). Circulation. 1999;
100 Suppl 1:I-300.
77. Cody RJ, Covit AB, Schaer GL, et al. Sodium and water balance in
chronic congestive heart failure. J Clin Invest. 1986;77:1441–52.
78. Vasko MR, Cartwright DB, Knochel JP, et al. Furosemide absorp-
tion altered in decompensated congestive heart failure. Ann Intern
Med. 1985;102:314–8.
79. Brater DC, Chennavasin P, Seiwell R. Furosemide in patients with
heart failure: shift in dose-response curves. Clin Pharmacol Ther.
1980;28:182–6.
80. Vargo DL, Kramer WG, Black PK, et al. Bioavailability, pharmaco-
kinetics, and pharmacodynamics of torsemide and furosemide in
patients with congestive heart failure. Clin Pharmacol Ther. 1995;
57:601–9.
81. Brater DC, Harris C, Redfern JS, et al. Renal effects of cox-2–
selective inhibitors. Am J Nephrol. 2001;21:1–15.
82. Dormans TP, van Meyel JJ, Gerlag PG, et al. Diuretic efficacy of
high dose furosemide in severe heart failure: bolus injection versus
continuous infusion. J Am Coll Cardiol. 1996;28:376–82.
83. Epstein M, Lepp BA, Hoffman DS, et al. Potentiation of furosemide
by metolazone in refractory edema. Curr Ther Res. 1977;21:656–67.
84. Sica DA, Gehr TW. Diuretic combinations in refractory oedema
states: pharmacokinetic-pharmacodynamic relationships. Clin Phar-
macokinet. 1996;30:229–49.
85. Ellison DH. The physiologic basis of diuretic synergism: its role in
treating diuretic resistance. Ann Intern Med. 1991;114:886–94.
86. Oster JR, Epstein M, Smoller S. Combined therapy with thiazide-
type and loop diuretic agents for resistant sodium retention. Ann
Intern Med. 1983;99:405–6.
87. Steiness E, Olesen KH. Cardiac arrhythmias induced by hypokalae-
mia and potassium loss during maintenance digoxin therapy. Br
Heart J. 1976;38:167–72.
88. Solomon R. The relationship between disorders of K and Mg
homeostasis. Semin Nephrol. 1987;7:253–62.
89. Feigenbaum MS, Welsch MA, Mitchell M, et al. Contracted plasma
and blood volume in chronic heart failure. J Am Coll Cardiol.
2000;35:51–5.
22
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
e70 Hunt et al. JACC Vol. 53, No. 15, 2009
2009 ACCF/AHA Heart Failure Guidelines April 14, 2009:e1–9090. Swartz SL, Williams GH, Hollenberg NK, et al. Captopril-induced
changes in prostaglandin production: relationship to vascular re-
sponses in normal man. J Clin Invest. 1980;65:1257–64.
91. Brown NJ, Ryder D, Gainer JV, et al. Differential effects of
angiotensin converting enzyme inhibitors on the vasodepressor and
prostacyclin responses to bradykinin. J Pharmacol Exp Ther. 1996;
279:703–12.
92. Gainer JV, Morrow JD, Loveland A, et al. Effect of bradykinin-
receptor blockade on the response to angiotensin-converting-enzyme
inhibitor in normotensive and hypertensive subjects. N Engl J Med.
1998;339:1285–92.
93. Linz W, Scholkens BA. A specific B2–bradykinin receptor antago-
nist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J
Pharmacol. 1992;105:771–2.
94. McDonald KM, Garr M, Carlyle PF, et al. Relative effects of alpha
1-adrenoceptor blockade, converting enzyme inhibitor therapy, and
angiotensin II subtype 1 receptor blockade on ventricular remodeling
in the dog. Circulation. 1994;90:3034–46.
95. McDonald KM, Mock J, D’Aloia A, et al. Bradykinin antagonism
inhibits the antigrowth effect of converting enzyme inhibition in the
dog myocardium after discrete transmural myocardial necrosis. Cir-
culation. 1995;91:2043–8.
96. Bastien NR, Juneau AV, Ouellette J, et al. Chronic AT1 receptor
blockade and angiotensin-converting enzyme (ACE) inhibition in
(CHF 146) cardiomyopathic hamsters: effects on cardiac hypertrophy
and survival. Cardiovasc Res. 1999;43:77–85.
97. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared
with captopril on mortality in patients with symptomatic heart
failure: randomised trial—the Losartan Heart Failure Survival Study
ELITE II. Lancet. 2000;355:1582–7.
98. The NETWORK Investigators. Clinical outcome with enalapril in
symptomatic chronic heart failure; a dose comparison. Eur Heart J.
1998;19:481–9.
99. Massie BM, Armstrong PW, Cleland JG, et al. Toleration of high
doses of angiotensin-converting enzyme inhibitors in patients with
chronic heart failure: results from the ATLAS trial. The Assessment
of Treatment with Lisinopril and Survival. Arch Intern Med.
2001;161:165–71.
00. Pflugfelder PW, Baird MG, Tonkon MJ, et al., for the Quinapril
Heart Failure Trial Investigators. Clinical consequences of
angiotensin-converting enzyme inhibitor withdrawal in chronic heart
failure: a double-blind, placebo-controlled study of quinapril. J Am
Coll Cardiol. 1993;22:1557–63.
01. Cleland JG, Gillen G, Dargie HJ. The effects of frusemide and
angiotensin-converting enzyme inhibitors and their combination on
cardiac and renal haemodynamics in heart failure. Eur Heart J.
1988;9:132–41.
02. Flapan AD, Davies E, Waugh C, et al. Acute administration of
captopril lowers the natriuretic and diuretic response to a loop
diuretic in patients with chronic cardiac failure. Eur Heart J.
1991;12:924–7.
03. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator
effects of enalapril by aspirin in severe heart failure. J Am Coll
Cardiol. 1992;20:1549–55.
04. Kindsvater S, Leclerc K, Ward J. Effects of coadministration of
aspirin or clopidogrel on exercise testing in patients with heart failure
receiving angiotensin-converting enzyme inhibitors. Am J Cardiol.
2003;91:1350–2.
05. Spaulding C, Charbonnier B, Cohen-Solal A, et al. Acute hemody-
namic interaction of aspirin and ticlopidine with enalapril: results of
a double-blind, randomized comparative trial. Circulation. 1998;98:
757–65.
06. Al Khadra AS, Salem DN, Rand WM, et al. Antiplatelet agents and
survival: a cohort analysis from the Studies of Left Ventricular
Dysfunction (SOLVD) trial. J Am Coll Cardiol. 1998;31:419–25.
07. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and
aspirin on mortality after acute myocardial infarction: subgroup
analysis of the Cooperative New Scandinavian Enalapril Survival
Study II (CONSENSUS II). Am J Cardiol. 1997;79:115–9.
08. Teo KK, Yusuf S, Pfeffer M, et al. Effects of long-term treatment
with angiotensin-converting-enzyme inhibitors in the presence or
absence of aspirin: a systematic review. Lancet. 2002;360:1037–43.09. Harjai KJ, Solis S, Prasad A, et al. Use of aspirin in conjunction with
angiotensin-converting enzyme inhibitors does not worsen long-term
survival in heart failure. Int J Cardiol. 2003;88:207–14.
10. Antiplatelet Trialists’ Collaboration. Collaborative overview of ran-
domised trials of antiplatelet therapy—I: prevention of death, myo-
cardial infarction, and stroke by prolonged antiplatelet therapy in
various categories of patients. [published erratum appears in BMJ
1994;308:1540]. BMJ. 1994;308:81–106.
11. Jones CG, Cleland JG. Meeting report—the LIDO, HOPE, MOX-
CON and WASH studies. Heart Outcomes Prevention Evaluation.
The Warfarin/Aspirin Study of Heart Failure. Eur J Heart Fail.
1999;1:425–31.
12. CAPRIE Steering Committee. A randomised, blinded, trial of
clopidogrel versus aspirin in patients at risk of ischaemic events
(CAPRIE). Lancet. 1996;348:1329–39.
13. Packer M, Medina N, Yushak M. Relation between serum sodium
concentration and the hemodynamic and clinical responses to con-
verting enzyme inhibition with captopril in severe heart failure. J Am
Coll Cardiol. 1984;3:1035–43.
14. Packer M, Lee WH, Kessler PD. Preservation of glomerular filtra-
tion rate in human heart failure by activation of the renin-angiotensin
system. Circulation. 1986;74:766–74.
15. Packer M, Lee WH, Kessler PD, et al. Identification of hyponatre-
mia as a risk factor for the development of functional renal insuffi-
ciency during converting enzyme inhibition in severe chronic heart
failure. J Am Coll Cardiol. 1987;10:837–44.
16. Hasenfuss G, Holubarsch C, Blanchard EM, et al. Influence of
isoproterenol on myocardial energetics. Experimental and clinical
investigations. Basic Res Cardiol. 1989;84 Suppl 1:147–55.
17. Giles TD, Katz R, Sullivan JM, et al., for the Multicenter Lisinopril-
Captopril Congestive Heart Failure Study Group. Short- and long-
acting angiotensin-converting enzyme inhibitors: a randomized trial
of lisinopril versus captopril in the treatment of congestive heart
failure. J Am Coll Cardiol. 1989;13:1240–7.
18. Burnier M, Waeber B, Nussberger J, et al. Effect of angiotensin
converting enzyme inhibition in renovascular hypertension. J Hyper-
tens. 1989;7 Suppl:S27–31.
19. Packer M, Lee WH, Medina N, et al. Influence of diabetes mellitus
on changes in left ventricular performance and renal function pro-
duced by converting enzyme inhibition in patients with severe
chronic heart failure. Am J Med. 1987;82:1119–26.
20. Israili ZH, Hall WD. Cough and angioneurotic edema associated with
angiotensin-converting enzyme inhibitor therapy. A review of the
literature and pathophysiology. Ann Intern Med. 1992;117:234–42.
21. Woo KS, Nicholls MG. High prevalence of persistent cough with
angiotensin converting enzyme inhibitors in Chinese. Br J Clin
Pharmacol. 1995;40:141–4.
22. Cicardi M, Zingale LC, Bergamaschini L, et al. Angioedema
associated with angiotensin-converting enzyme inhibitor use: out-
come after switching to a different treatment. Arch Intern Med.
2004;164:910–3.
23. Warner KK, Visconti JA, Tschampel MM. Angiotensin II receptor
blockers in patients with ACE inhibitor-induced angioedema. Ann
Pharmacother. 2000;34:526–8.
24. Fuchs SA, Meyboom RH, van Puijenbroek EP, et al. Use of
angiotensin receptor antagonists in patients with ACE inhibitor
induced angioedema. Pharm World Sci. 2004;26:191–2.
25. Struthers AD. Angiotensin II receptor antagonists for heart failure
[editorial]. Heart. 1998;80:5–6.
26. Packer M, Kessler PD, Gottlieb SS. Adverse effects of converting-
enzyme inhibition in patients with severe congestive heart failure:
pathophysiology and management. Postgrad Med J. 1986;62 Suppl
1:179–82.
27. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in
patients with chronic heart failure and preserved left-ventricular
ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:
777–81.
28. Struthers AD. Aldosterone escape during angiotensin-converting
enzyme inhibitor therapy in chronic heart failure. J Card Fail.
1996;2:47–54.
29. Hensen J, Abraham WT, Durr JA, et al. Aldosterone in congestive
heart failure: analysis of determinants and role in sodium retention.
Am J Nephrol. 1991;11:441–6.
33
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
e71JACC Vol. 53, No. 15, 2009 Hunt et al.
April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure Guidelines30. Duprez DA, De Buyzere ML, Rietzschel ER, et al. Inverse relation-
ship between aldosterone and large artery compliance in chronically
treated heart failure patients. Eur Heart J. 1998;19:1371–6.
31. Rocha R, Chander PN, Khanna K, et al. Mineralocorticoid blockade
reduces vascular injury in stroke-prone hypertensive rats. Hyperten-
sion. 1998;31:451–8.
32. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade
reduces vascular collagen turnover, improves heart rate variability and
reduces early morning rise in heart rate in heart failure patients.
Cardiovasc Res. 1997;35:30–4.
33. Barr CS, Lang CC, Hanson J, et al. Effects of adding spironolactone
to an angiotensin-converting enzyme inhibitor in chronic congestive
heart failure secondary to coronary artery disease. Am J Cardiol.
1995;76:1259–65.
34. Weber KT, Villarreal D. Aldosterone and antialdosterone therapy in
congestive heart failure. Am J Cardiol. 1993;71:3A–11A.
35. Zannad F. Aldosterone and heart failure. Eur Heart J. 1995;16 Suppl
N:98–102.
35a.Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldoste-
rone blocker, in patients with left ventricular dysfunction after
myocardial infarction. N Engl J Med. 2003;348:1309–21.
36. Smith KM, Macmillan JB, McGrath JC. Investigation of alpha1-
adrenoceptor subtypes mediating vasoconstriction in rabbit cutaneous
resistance arteries. Br J Pharmacol. 1997;122:825–32.
37. Elhawary AM, Pang CC. Alpha 1b-adrenoceptors mediate renal
tubular sodium and water reabsorption in the rat. Br J Pharmacol.
1994;111:819–24.
38. Simons M, Downing SE. Coronary vasoconstriction and catechol-
amine cardiomyopathy. Am Heart J. 1985;109:297–304.
39. Knowlton KU, Michel MC, Itani M, et al. The alpha 1A-adrenergic
receptor subtype mediates biochemical, molecular, and morphologic
features of cultured myocardial cell hypertrophy. J Biol Chem.
1993;268:15374–80.
40. Molina-Viamonte V, Anyukhovsky EP, Rosen MR. An alpha-1-
adrenergic receptor subtype is responsible for delayed afterdepolar-
izations and triggered activity during simulated ischemia and reperfu-
sion of isolated canine Purkinje fibers. Circulation. 1991;84:1732–40.
41. Kaumann AJ, Sanders L. Both beta 1- and beta 2-adrenoceptors
mediate catecholamine-evoked arrhythmias in isolated human right
atrium. Naunyn Schmiedebergs Arch Pharmacol. 1993;348:536–40.
42. Billman GE, Castillo LC, Hensley J, et al. Beta2-adrenergic receptor
antagonists protect against ventricular fibrillation: in vivo and in vitro
evidence for enhanced sensitivity to beta2-adrenergic stimulation in
animals susceptible to sudden death. Circulation. 1997;96:1914–22.
43. Communal C, Singh K, Pimentel DR, et al. Norepinephrine stim-
ulates apoptosis in adult rat ventricular myocytes by activation of the
beta-adrenergic pathway. Circulation. 1998;98:1329–34.
44. Xamoterol in severe heart failure. The Xamoterol in Severe Heart
Failure Study Group. Lancet. 1990;336:1–6.[published erratum ap-
pears in Lancet 1990;336:698]
45. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on the
survival of patients with severe chronic heart failure. N Engl J Med.
2001;344:1651–8.
46. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival
in severe chronic heart failure. N Engl J Med. 2001;344:1651–8.
47. Packer M, Poole-Wilson PA, Armstrong PW, et al., for the ATLAS
Study Group. Comparative effects of low and high doses of the
angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and
mortality in chronic heart failure. Circulation. 1999;100:2312–8.
48. Epstein SE, Braunwald E. The effect of beta adrenergic blockade on
patterns of urinary sodium excretion. Studies in normal subjects and
in patients with heart disease. Ann Intern Med. 1966;65:20–7.
49. Weil JV, Chidsey CA. Plasma volume expansion resulting from
interference with adrenergic function in normal man. Circulation.
1968;37:54–61.
50. Gaffney TE, Braunwald E. Importance of the adrenergic nervous
system in the support of circulatory function in patients with
congestive heart failure. Am J Med. 2000;34:320–4.
51. Gattis WA, O’Connor CM, Gallup DS, et al. Predischarge initiation
of carvedilol in patients hospitalized for decompensated heart failure:
results of the Initiation Management Predischarge: Process for
Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF)
trial. J Am Coll Cardiol. 2004;43:1534–41.52. Waagstein F, Caidahl K, Wallentin I, et al. Long-term beta-blockade
in dilated cardiomyopathy. Effects of short- and long-term metopro-
lol treatment followed by withdrawal and readministration of meto-
prolol. Circulation. 1989;80:551–63.
53. Gattis WA, O’Connor CM, Leimberger JD, et al. Clinical outcomes
in patients on beta-blocker therapy admitted with worsening chronic
heart failure. Am J Cardiol. 2003;91:169–74.
54. MERIT-HF Study Group. Effects of metoprolol CR in patients with
ischemic and dilated cardiomyopathy: the randomized evaluation of
strategies for left ventricular dysfunction pilot study. Circulation.
2000;101:378–84.
55. Akera T, Baskin SI, Tobin T, et al. Ouabain: temporal relationship
between the inotropic effect and the in vitro binding to, and dissocia-
tion from, (NaK)-activated ATPase. Naunyn Schmiedebergs
Arch Pharmacol. 1973;277:151–62.
56. Thames MD. Acetylstrophanthidin-induced reflex inhibition of ca-
nine renal sympathetic nerve activity mediated by cardiac receptors
with vagal afferents. Circ Res. 1979;44:8–15.
57. Ferguson DW, Berg WJ, Sanders JS, et al. Sympathoinhibitory
responses to digitalis glycosides in heart failure patients. Direct
evidence from sympathetic neural recordings. Circulation. 1989;80:
65–77.
58. Torretti J, Hendler E, Weinstein E, et al. Functional significance of
Na-K-ATPase in the kidney: effects of ouabain inhibition. Am J
Physiol. 1972;222:1398–405.
59. Covit AB, Schaer GL, Sealey JE, et al. Suppression of the renin-
angiotensin system by intravenous digoxin in chronic congestive heart
failure. Am J Med. 1983;75:445–7.
60. Gheorghiade M, Ferguson D. Digoxin. A neurohormonal modulator
in heart failure? Circulation. 1991;84:2181–6.
61. Gheorghiade M, Adams KF Jr., Colucci WS. Digoxin in the
management of cardiovascular disorders. Circulation. 2004;109:
2959–64.
62. Rahimtoola SH. Digitalis therapy for patients in clinical heart failure.
Circulation. 2004;109:2942–6.
63. Matsuda M, Matsuda Y, Yamagishi T, et al. Effects of digoxin,
propranolol, and verapamil on exercise in patients with chronic
isolated atrial fibrillation. Cardiovasc Res. 1991;25:453–7.
64. David D, Segni ED, Klein HO, et al. Inefficacy of digitalis in the
control of heart rate in patients with chronic atrial fibrillation:
beneficial effect of an added beta adrenergic blocking agent. Am J
Cardiol. 1979;44:1378–82.
65. Farshi R, Kistner D, Sarma JS, et al. Ventricular rate control in
chronic atrial fibrillation during daily activity and programmed
exercise: a crossover open-label study of five drug regimens. J Am
Coll Cardiol. 1999;33:304–10.
66. Khand AU, Rankin AC, Martin W, et al. Carvedilol alone or in
combination with digoxin for the management of atrial fibrillation in
patients with heart failure? J Am Coll Cardiol. 2003;42:1944–51.
67. Jelliffe RW, Brooker G. A nomogram for digoxin therapy. Am J
Med. 1974;57:63–8.
68. Adams KF Jr., Gheorghiade M, Uretsky BF, et al. Clinical benefits
of low serum digoxin concentrations in heart failure. J Am Coll
Cardiol. 2002;39:946–53.
69. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin
concentration and outcomes in patients with heart failure. JAMA.
2003;289:871–8.
70. Steiner JF, Robbins LJ, Hammermeister KE, et al. Incidence of
digoxin toxicity in outpatients. West J Med. 1994;161:474–8.
71. Arnold SB, Byrd RC, Meister W, et al. Long-term digitalis therapy
improves left ventricular function in heart failure. N Engl J Med.
1980;303:1443–8.
72. Gheorghiade M, Hall VB, Jacobsen G, et al. Effects of increasing
maintenance dose of digoxin on left ventricular function and neuro-
hormones in patients with chronic heart failure treated with diuretics
and angiotensin-converting enzyme inhibitors. Circulation. 1995;92:
1801–7.
73. Slatton ML, Irani WN, Hall SA, et al. Does digoxin provide
additional hemodynamic and autonomic benefit at higher doses in
patients with mild to moderate heart failure and normal sinus
rhythm? J Am Coll Cardiol. 1997;29:1206–13.
74. Fogelman AM, La Mont JT, Finkelstein S, et al. Fallibility of
plasma-digoxin in differentiating toxic from non-toxic patients.
Lancet. 1971;2:727–9.
33
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
e72 Hunt et al. JACC Vol. 53, No. 15, 2009
2009 ACCF/AHA Heart Failure Guidelines April 14, 2009:e1–9075. Ingelfinger JA, Goldman P. The serum digitalis concentration—does
it diagnose digitalis toxicity? N Engl J Med. 1976;294:867–70.
76. Hager WD, Fenster P, Mayersohn M, et al. Digoxin-quinidine
interaction Pharmacokinetic evaluation. N Engl J Med. 1979;300:
1238–41.
77. Bizjak ED, Mauro VF. Digoxin-macrolide drug interaction. Ann
Pharmacother. 1997;31:1077–9.
78. Hedman A. Inhibition by basic drugs of digoxin secretion into
human bile. Eur J Clin Pharmacol. 1992;42:457–9.
79. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the
effect of digoxin for the treatment of heart failure. N Engl J Med.
2002;347:1403–11.
80. Leor J, Goldbourt U, Rabinowitz B, et al., for the SPRINT Study
Group. Digoxin and increased mortality among patients recovering
from acute myocardial infarction: importance of digoxin dose. Car-
diovasc Drugs Ther. 1995;9:723–9.
81. Eichhorn EJ, Gheorghiade M. Digoxin. Prog Cardiovasc Dis.
2002;44:251–66.
82. Uretsky BF, Thygesen K, Armstrong PW, et al. Acute coronary
findings at autopsy in heart failure patients with sudden death: results
from the assessment of treatment with lisinopril and survival (AT-
LAS) trial. Circulation. 2000;102:611–6.
83. Luu M, Stevenson WG, Stevenson LW, et al. Diverse mechanisms
of unexpected cardiac arrest in advanced heart failure. Circulation.
1989;80:1675–80.
84. Packer M. Sudden unexpected death in patients with congestive heart
failure: a second frontier. Circulation. 1985;72:681–5.
85. Kjekshus J. Arrhythmias and mortality in congestive heart failure.
Am J Cardiol. 1990;65:42I–8I.
86. Packer M. Lack of relation between ventricular arrhythmias and
sudden death in patients with chronic heart failure. Circulation.
1992;85:I50–6.
87. Twidale N, McDonald T, Nave K, et al. Comparison of the effects of
AV nodal ablation versus AV nodal modification in patients with
congestive heart failure and uncontrolled atrial fibrillation. Pacing
Clin Electrophysiol. 1998;21:641–51.
88. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of
quinidine therapy for maintenance of sinus rhythm after cardiover-
sion. A meta-analysis of randomized control trials [published erratum
appears in Circulation 1991;83:714]. Circulation. 1990;82:1106–16.
89. Waldo AL, Camm AJ, deRuyter H, et al., for the SWORD
Investigators. Effect of d-sotalol on mortality in patients with left
ventricular dysfunction after recent and remote myocardial infarction.
Survival With Oral d-Sotalol [published erratum appears in Lancet
1996 Aug 10;348(9024):416]. Lancet. 1996;348:7–12.
90. Pratt CM, Camm AJ, Cooper W, et al. Mortality in the Survival
With ORal D-sotalol (SWORD) trial: why did patients die? Am J
Cardiol. 1998;81:869–76.
91. Du XJ, Esler MD, Dart AM. Sympatholytic action of intravenous
amiodarone in the rat heart. Circulation. 1995;91:462–70.
92. Doval HC, Nul DR, Grancelli HO, et al., for the Grupo de Estudio
de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA).
Randomised trial of low-dose amiodarone in severe congestive heart
failure. Lancet. 1994;344:493–8.
93. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients
with congestive heart failure and asymptomatic ventricular arrhyth-
mia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart
Failure. N Engl J Med. 1995;333:77–82.
94. Massie BM, Fisher SG, Radford M, et al., for the CHF-STAT
Investigators. Effect of amiodarone on clinical status and left ventric-
ular function in patients with congestive heart failure. [published
erratum appears in Circulation 1996;94:2668]. Circulation. 1996;93:
2128–34.
95. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator
implantation in patients with nonischemic dilated cardiomyopathy.
N Engl J Med. 2004;350:2151–8.
96. Soejima K, Suzuki M, Maisel WH, et al. Catheter ablation in
patients with multiple and unstable ventricular tachycardias after
myocardial infarction: short ablation lines guided by reentry circuit
isthmuses and sinus rhythm mapping. Circulation. 2001;104:664–9.
97. Elkayam U, Johnson JV, Shotan A, et al. Double-blind, placebo-
controlled study to evaluate the effect of organic nitrates in patients
with chronic heart failure treated with angiotensin-converting en-
zyme inhibition. Circulation. 1999;99:2652–7.98. Garg UC, Hassid A. Nitric oxide-generating vasodilators and
8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and
proliferation of cultured rat vascular smooth muscle cells. J Clin
Invest. 1989;83:1774–7.
99. Calderone A, Thaik CM, Takahashi N, et al. Nitric oxide, atrial
natriuretic peptide, and cyclic GMP inhibit the growth-promoting
effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin
Invest. 1998;101:812–8.
00. Jugdutt BI, Khan MI. Effect of prolonged nitrate therapy on left
ventricular remodeling after canine acute myocardial infarction.
Circulation. 1994;89:2297–307.
01. Massie B, Chatterjee K, Werner J, et al. Hemodynamic advantage of
combined administration of hydralazine orally and nitrates nonpar-
enterally in the vasodilator therapy of chronic heart failure. Am J
Cardiol. 1977;40:794–801.
02. Pierpont GL, Cohn JN, Franciosa JA. Combined oral hydralazine-
nitrate therapy in left ventricular failure. Hemodynamic equivalency
to sodium nitroprusside. Chest. 1978;73:8–13.
03. Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition
of hypertrophy to heart failure. J Am Coll Cardiol. 1996;28:506–14.
04. Keith M, Geranmayegan A, Sole MJ, et al. Increased oxidative stress
in patients with congestive heart failure. J Am Coll Cardiol. 1998;
31:1352–6.
05. Bauer JA, Fung HL. Concurrent hydralazine administration prevents
nitroglycerin-induced hemodynamic tolerance in experimental heart
failure. Circulation. 1991;84:35–9.
06. Gogia H, Mehra A, Parikh S, et al. Prevention of tolerance to
hemodynamic effects of nitrates with concomitant use of hydralazine
in patients with chronic heart failure. J Am Coll Cardiol. 1995;26:
1575–80.
07. Watanabe H, Kakihana M, Ohtsuka S, et al. Preventive effects of
carvedilol on nitrate tolerance—a randomized, double-blind,
placebo-controlled comparative study between carvedilol and aroti-
nolol. J Am Coll Cardiol. 1998;32:1201–6.
08. Watanabe H, Kakihana M, Ohtsuka S, et al. Randomized, double-
blind, placebo-controlled study of carvedilol on the prevention of
nitrate tolerance in patients with chronic heart failure. J Am Coll
Cardiol. 1998;32:1194–200.
09. Silverman ME, Pressel MD, Brackett JC, et al. Prognostic value of
the signal-averaged electrocardiogram and a prolonged QRS in
ischemic and nonischemic cardiomyopathy. Am J Cardiol. 1995;75:
460–4.
10. Fried AG, Parker AB, Newton GE, et al. Electrical and hemody-
namic correlates of the maximal rate of pressure increase in the
human left ventricle. J Card Fail. 1999;5:8–16.
11. Wilensky RL, Yudelman P, Cohen AI, et al. Serial electrocardio-
graphic changes in idiopathic dilated cardiomyopathy confirmed at
necropsy. Am J Cardiol. 1988;62:276–83.
12. Grines CL, Bashore TM, Boudoulas H, et al. Functional abnormal-
ities in isolated left bundle branch block. The effect of interventricular
asynchrony. Circulation. 1989;79:845–53.
13. Xiao HB, Lee CH, Gibson DG. Effect of left bundle branch block on
diastolic function in dilated cardiomyopathy. Br Heart J. 1991;66:
443–7.
14. Takeshita A, Basta LL, Kioschos JM. Effect of intermittent left
bundle branch block on left ventricular performance. Am J Med.
1974;56:251–5.
15. McDonald CD, Burch GE, Walsh JJ. Prolonged bed rest in the
treatment of idiopathic cardiomyopathy. Am J Med. 1972;52:41–50.
16. Hochman JS, Healy B. Effect of exercise on acute myocardial
infarction in rats. J Am Coll Cardiol. 1986;7:126–32.
17. Oh BH, Ono S, Rockman HA, et al. Myocardial hypertrophy in the
ischemic zone induced by exercise in rats after coronary reperfusion.
Circulation. 1993;87:598–607.
18. Jugdutt BI, Michorowski BL, Kappagoda CT. Exercise training after
anterior Q wave myocardial infarction: importance of regional left
ventricular function and topography. J Am Coll Cardiol. 1988;12:
362–72.
19. North TC, McCullagh P, Tran ZV. Effect of exercise on depression.
Exer Sport Sci Rev. 1990;18:379–415.
20. Piepoli MF, Flather M, Coats AJ. Overview of studies of exercise
training in chronic heart failure: the need for a prospective random-
ized multicentre European trial. Eur Heart J. 1998;19:830–41.
44
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
e73JACC Vol. 53, No. 15, 2009 Hunt et al.
April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure Guidelines21. Coats AJ, Adamopoulos S, Meyer TE, et al. Effects of physical
training in chronic heart failure. Lancet. 1990;335:63–6.
22. Hambrecht R, Niebauer J, Fiehn E, et al. Physical training in patients
with stable chronic heart failure: effects on cardiorespiratory fitness
and ultrastructural abnormalities of leg muscles. J Am Coll Cardiol.
1995;25:1239–49.
23. Meyer K, Schwaibold M, Westbrook S, et al. Effects of exercise
training and activity restriction on 6-minute walking test perfor-
mance in patients with chronic heart failure. Am Heart J. 1997;133:
447–53.
24. Kiilavuori K, Toivonen L, Naveri H, et al. Reversal of autonomic
derangements by physical training in chronic heart failure assessed by
heart rate variability. Eur Heart J. 1995;16:490–5.
25. Kostis JB, Rosen RC, Cosgrove NM, et al. Nonpharmacologic
therapy improves functional and emotional status in congestive heart
failure. Chest. 1994;106:996–1001.
26. Keteyian SJ, Levine AB, Brawner CA, et al. Exercise training in
patients with heart failure. A randomized, controlled trial. Ann
Intern Med. 1996;124:1051–7.
27. Meyer TE, Casadei B, Coats AJ, et al. Angiotensin-converting
enzyme inhibition and physical training in heart failure. J Intern
Med. 1991;230:407–13.
28. Demopoulos L, Yeh M, Gentilucci M, et al. Nonselective beta-
adrenergic blockade with carvedilol does not hinder the benefits of
exercise training in patients with congestive heart failure. Circulation.
1997;95:1764–7.
29. European Heart Failure Training Group. Experience from controlled
trials of physical training in chronic heart failure. Protocol and patient
factors in effectiveness in the improvement in exercise tolerance. Eur
Heart J. 1998;19:466–75.
30. Belardinelli R, Georgiou D, Cianci G, et al. Randomized, controlled
trial of long-term moderate exercise training in chronic heart failure:
effects on functional capacity, quality of life, and clinical outcome.
Circulation. 1999;99:1173–82.
31. Hambrecht R, Fiehn E, Weigl C, et al. Regular physical exercise
corrects endothelial dysfunction and improves exercise capacity in
patients with chronic heart failure. Circulation. 1998;98:2709–15.
32. Coats AJ, Adamopoulos S, Radaelli A, et al. Controlled trial of
physical training in chronic heart failure. Exercise performance,
hemodynamics, ventilation, and autonomic function. Circulation.
1992;85:2119–31.
33. Cooksey JD, Reilly P, Brown S, et al. Exercise training and plasma
catecholamines in patients with ischemic heart disease. Am J Cardiol.
1978;42:372–6.
34. Orenstein TL, Parker TG, Butany JW, et al. Favorable left ventric-
ular remodeling following large myocardial infarction by exercise
training. Effect on ventricular morphology and gene expression.
J Clin Invest. 1995;96:858–66.
35. Wang J, Yi GH, Knecht M, et al. Physical training alters the
pathogenesis of pacing-induced heart failure through endothelium-
mediated mechanisms in awake dogs. Circulation. 1997;96:2683–92.
36. Naughton MT, Bradley TD. Sleep apnea in congestive heart failure.
Clin Chest Med. 1998;19:99–113.
37. Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing
and cardiovascular disease: cross-sectional results of the Sleep Heart
Health Study. Am J Respir Crit Care Med. 2001;163:19–25.
38. Tkacova R, Rankin F, Fitzgerald FS, et al. Effects of continuous
positive airway pressure on obstructive sleep apnea and left ventricular
afterload in patients with heart failure. Circulation. 1998;98:
2269–75.
39. Javaheri S. Effects of continuous positive airway pressure on sleep
apnea and ventricular irritability in patients with heart failure.
Circulation. 2000;101:392–7.
40. Malone S, Liu PP, Holloway R, et al. Obstructive sleep apnoea in
patients with dilated cardiomyopathy: effects of continuous positive
airway pressure. Lancet. 1991;338:1480–4.
41. Michaels AD, Accad M, Ports TA, et al. Left ventricular systolic
unloading and augmentation of intracoronary pressure and Doppler
flow during enhanced external counterpulsation. Circulation. 2002;
106:1237–42.
42. Arora RR, Chou TM, Jain D, et al. The multicenter study of
enhanced external counterpulsation (MUST-EECP): effect of EECP
on exercise-induced myocardial ischemia and anginal episodes. J Am
Coll Cardiol. 1999;33:1833–40.43. Bonetti PO, Barsness GW, Keelan PC, et al. Enhanced external
counterpulsation improves endothelial function in patients with
symptomatic coronary artery disease. J Am Coll Cardiol. 2003;41:
1761–8.
44. Linnemeier G, Rutter MK, Barsness G, et al. Enhanced external
counterpulsation for the relief of angina in patients with diabetes:
safety, efficacy and 1-year clinical outcomes. Am Heart J. 2003;146:
453–8.
45. Soran O, Kennard ED, Kelsey SF, et al. Enhanced external coun-
terpulsation as treatment for chronic angina in patients with left
ventricular dysfunction: a report from the International EECP
Patient Registry (IEPR). Congest Heart Fail. 2002;8:297–302.
46. Soran O, Fleishman B, DeMarco T, et al. Enhanced external
counterpulsation in patients with heart failure: a multicenter feasibil-
ity study. Congest Heart Fail. 2002;8:204–8, 227.
47. Goldsmith SR. Congestive heart failure: potential role of arginine
vasopressin antagonists in the therapy of heart failure. Congest Heart
Fail. 2002;8:251–6.
48. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor
blockade with tolvaptan in patients with chronic heart failure: results
from a double-blind, randomized trial. Circulation. 2003;107:
2690–6.
49. Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic
effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor
antagonist, in patients with advanced heart failure. Circulation.
2001;104:2417–23.
50. Gheorghiade M, Gattis WA, O’Connor CM, et al. Effects of
tolvaptan, a vasopressin antagonist, in patients hospitalized with
worsening heart failure: a randomized controlled trial. JAMA. 2004;
291:1963–71.
51. Russell SD, Selaru P, Pyne DA, et al. Rationale for use of an exercise
end point and design for the ADVANCE (A Dose evaluation of a
Vasopressin ANtagonist in CHF patients undergoing Exercise) trial.
Am Heart J. 2003;145:179–86.
52. Magalski A, Adamson P, Gadler F, et al. Continuous ambulatory
right heart pressure measurements with an implantable hemodynamic
monitor: a multicenter, 12-month follow-up study of patients with
chronic heart failure. J Card Fail. 2002;8:63–70.
53. Adamson PB, Magalski A, Braunschweig F, et al. Ongoing right
ventricular hemodynamics in heart failure: clinical value of measure-
ments derived from an implantable monitoring system. J Am Coll
Cardiol. 2003;41:565–71.
54. Chaudhry PA, Mishima T, Sharov VG, et al. Passive epicardial
containment prevents ventricular remodeling in heart failure. Ann
Thorac Surg. 2000;70:1275–80.
55. Raman JS, Hata M, Storer M, et al. The mid-term results of
ventricular containment (ACORN WRAP) for end-stage ischemic
cardiomyopathy. Ann Thorac Cardiovasc Surg. 2001;7:278–81.
56. Di Donato M, Toso A, Maioli M, et al. Intermediate survival and
predictors of death after surgical ventricular restoration. Semin
Thorac Cardiovasc Surg. 2001;13:468–75.
57. Menicanti L, Di Donato M. The Dor procedure: what has changed
after fifteen years of clinical practice? J Thorac Cardiovasc Surg.
2002;124:886–90.
58. Athanasuleas CL, Stanley AW Jr., Buckberg GD, et al., for the
RESTORE Group. Surgical anterior ventricular endocardial resto-
ration (SAVER) in the dilated remodeled ventricle after anterior
myocardial infarction. Reconstructive Endoventricular Surgery, re-
turning Torsion Original Radius Elliptical Shape to the LV. J Am
Coll Cardiol. 2001;37:1199–209.
59. Colucci WS, Elkayam U, Horton DP, et al., for the Nesiritide Study
Group. Intravenous nesiritide, a natriuretic peptide, in the treatment
of decompensated congestive heart failure. N Engl J Med. 2000;343:
246–53.
60. Elkayam U, Akhter MW, Singh H, et al. Comparison of effects on
left ventricular filling pressure of intravenous nesiritide and high-dose
nitroglycerin in patients with decompensated heart failure. Am J
Cardiol. 2004;93:237–40.
61. Intravenous nesiritide vs nitroglycerin for treatment of decompen-
sated congestive heart failure: a randomized controlled trial. JAMA.
2002;287:1531–40.
62. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of wors-
ening renal function with nesiritide in patients with acutely decom-
pensated heart failure. Circulation. 2005;111:1487–91.
44
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
e74 Hunt et al. JACC Vol. 53, No. 15, 2009
2009 ACCF/AHA Heart Failure Guidelines April 14, 2009:e1–9063. Sackner-Bernstein JD, Kowalski M, Fox M, et al. Short-term risk of
death after treatment with nesiritide for decompensated heart failure:
a pooled analysis of randomized controlled trials. JAMA. 2005;293:
1900–5.
64. Azuma J, Sawamura A, Awata N. Usefulness of taurine in chronic
congestive heart failure and its prospective application. Jpn Circ J.
1992;56:95–9.
65. Fazio S, Sabatini D, Capaldo B, et al. A preliminary study of growth
hormone in the treatment of dilated cardiomyopathy. N Engl J Med.
1996;334:809–14.
66. Ferrari R, De Giuli F. The propionyl-L-carnitine hypothesis: an
alternative approach to treating heart failure. J Card Fail. 1997;3:
217–24.
67. Ghatak A, Brar MJ, Agarwal A, et al. Oxy free radical system in heart
failure and therapeutic role of oral vitamin E. Int J Cardiol.
1996;57:119–27.
68. Hamilton MA, Stevenson LW. Thyroid hormone abnormalities in
heart failure: possibilities for therapy. Thyroid. 1996;6:527–9.
69. Soja AM, Mortensen SA. Treatment of congestive heart failure with
coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol
Aspects Med. 1997;18 Suppl:S159–68.
70. Morris CD, Carson S. Routine vitamin supplementation to prevent
cardiovascular disease: a summary of the evidence for the U.S.
Preventive Services Task Force. Ann Intern Med. 2003;139:56–70.
71. Hofman-Bang C, Rehnqvist N, Swedberg K, et al., for the Q10
Study Group. Coenzyme Q10 as an adjunctive in the treatment of
chronic congestive heart failure. J Card Fail. 1995;1:101–7.
72. Watson PS, Scalia GM, Galbraith A, et al. Lack of effect of
coenzyme Q on left ventricular function in patients with congestive
heart failure. J Am Coll Cardiol. 1999;33:1549–52.
73. Baggio E, Gandini R, Plancher AC, et al., for the CoQ10 Drug
Surveillance Investigators. Italian multicenter study on the safety and
efficacy of coenzyme Q10 as adjunctive therapy in heart failure. Mol
Aspects Med. 1994;15 Suppl:s287–94.
74. Miller KL, Liebowitz RS, Newby LK. Complementary and alterna-
tive medicine in cardiovascular disease: a review of biologically based
approaches. Am Heart J. 2004;147:401–11.
75. Vogel JH, Bolling SF, Costello RB, et al. Integrating complementary
medicine into cardiovascular medicine. A report of the American
College of Cardiology Foundation Task Force on Clinical Expert
Consensus Documents (Writing Committee to Develop an Expert
Consensus Document on Complementary and Integrative Medicine).
J Am Coll Cardiol. 2005;46:184–221.
76. Anderson JL. Hemodynamic and clinical benefits with intravenous
milrinone in severe chronic heart failure: results of a multicenter study
in the United States. Am Heart J. 1991;121:1956–64.
77. Hatzizacharias A, Makris T, Krespi P, et al. Intermittent milrinone
effect on long-term hemodynamic profile in patients with severe
congestive heart failure. Am Heart J. 1999;138:241–6.
78. Cadel A, Brusoni B, Pirelli P, et al. Effects of digoxin, placebo and
ibopamine on exercise tolerance and cardiac rhythm of patients with
chronic post-infarct left ventricular failure. Arzneimittelforschung.
1986;36:376–9.
79. Colucci WS, Sonnenblick EH, Adams KF, et al., for the Milrinone
Multicenter Trials Investigators. Efficacy of phosphodiesterase inhi-
bition with milrinone in combination with converting enzyme inhib-
itors in patients with heart failure. J Am Coll Cardiol. 1993;22:
113A–8A.
80. DiBianco R, Shabetai R, Silverman BD, et al. Oral amrinone for the
treatment of chronic congestive heart failure: results of a multicenter
randomized double-blind and placebo-controlled withdrawal study.
J Am Coll Cardiol. 1984;4:855–66.
81. Glover DR, Wathen CG, Murray RG, et al. Are the clinical benefits
of oral prenalterol in ischaemic heart failure due to beta blockade? A
six month randomised double blind comparison with placebo. Br
Heart J. 1985;53:208–15.
82. Goldberg AD, Nicklas J, Goldstein S, for the Imazodan Research
Group. Effectiveness of imazodan for treatment of chronic congestive
heart failure. Am J Cardiol. 1991;68:631–6.
83. Massie B, Bourassa M, DiBianco R, et al. Long-term oral adminis-
tration of amrinone for congestive heart failure: lack of efficacy in a
multicenter controlled trial. Circulation. 1985;71:963–71.84. Narahara KA, for the The Western Enoximone Study Group. Oral
enoximone therapy in chronic heart failure: a placebo-controlled
randomized trial. Am Heart J. 1991;121:1471–9.
85. Roubin GS, Choong CY, Devenish-Meares S, et al. Beta-adrenergic
stimulation of the failing ventricle: a double-blind, randomized trial
of sustained oral therapy with prenalterol. Circulation. 1984;69:
955–62.
86. Uretsky BF, Jessup M, Konstam MA, et al., for the Enoximone
Multicenter Trial Group. Multicenter trial of oral enoximone in
patients with moderate to moderately severe congestive heart failure.
Lack of benefit compared with placebo. Circulation. 1990;82:
774–80.
87. van Veldhuisen DJ, Man in ’t Veld AJ, Dunselman PH, et al.
Double-blind placebo-controlled study of ibopamine and digoxin in
patients with mild to moderate heart failure: results of the Dutch
Ibopamine Multicenter Trial (DIMT). J Am Coll Cardiol. 1993;22:
1564–73.
88. Weber KT, Andrews V, Janicki JS, et al. Pirbuterol, an oral
beta-adrenergic receptor agonist, in the treatment of chronic cardiac
failure. Circulation. 1982;66:1262–7.
89. Cohn JN, Goldstein SO, Greenberg BH, et al., for the Vesnarinone
Trial Investigators. A dose-dependent increase in mortality with
vesnarinone among patients with severe heart failure. N Engl J Med.
1998;339:1810–6.
90. Cowley AJ, Skene AM, for the Enoximone Investigators. Treatment
of severe heart failure: quantity or quality of life? A trial of
enoximone. Br Heart J. 1994;72:226–30.
91. Feldman AM, Bristow MR, Parmley WW, et al., for the Vesnari-
none Study Group. Effects of vesnarinone on morbidity and mortality
in patients with heart failure. N Engl J Med. 1993;329:149–55.
92. Hampton JR, van Veldhuisen DJ, Kleber FX, et al., for the Second
Prospective Randomised Study of Ibopamine on Mortality and
Efficacy (PRIME II) Investigators. Randomised study of effect of
ibopamine on survival in patients with advanced severe heart failure.
Lancet. 1997;349:971–7.
93. Lubsen J, Just H, Hjalmarsson AC, et al. Effect of pimobendan on
exercise capacity in patients with heart failure: main results from the
Pimobendan in Congestive Heart Failure (PICO) trial. Heart.
1996;76:223–31.
94. Packer M, Carver JR, Rodeheffer RJ, et al., for the PROMISE Study
Research Group. Effect of oral milrinone on mortality in severe
chronic heart failure. N Engl J Med. 1991;325:1468–75.
95. Applefeld MM, Newman KA, Sutton FJ, et al. Outpatient dobut-
amine and dopamine infusions in the management of chronic heart
failure: clinical experience in 21 patients. Am Heart J. 1987;114:
589–95.
96. Elis A, Bental T, Kimchi O, et al. Intermittent dobutamine treat-
ment in patients with chronic refractory congestive heart failure: a
randomized, double-blind, placebo-controlled study. Clin Pharmacol
Ther. 1998;63:682–5.
97. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and
diastolic heart failure: Part I: diagnosis, prognosis, and measurements
of diastolic function. Circulation. 2002;105:1387–93.
98. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left
ventricular systolic function; epidemiology, clinical characteristics,
and prognosis. J Am Coll Cardiol. 2004;43:317–27.
99. Aronow WS, Ahn C, Kronzon I. Prognosis of congestive heart
failure in elderly patients with normal versus abnormal left ventricular
systolic function associated with coronary artery disease. Am J
Cardiol. 1990;66:1257–9.
00. Davie AP, Francis CM, Caruana L, et al. The prevalence of left
ventricular diastolic filling abnormalities in patients with suspected
heart failure. Eur Heart J. 1997;18:981–4.
01. Dougherty AH, Naccarelli GV, Gray EL, et al. Congestive heart
failure with normal systolic function. Am J Cardiol. 1984;54:778–82.
02. Iriarte M, Murga N, Sagastagoitia D, et al. Congestive heart failure
from left ventricular diastolic dysfunction in systemic hypertension.
Am J Cardiol. 1993;71:308–12.
03. Litwin SE, Grossman W. Diastolic dysfunction as a cause of heart
failure. J Am Coll Cardiol. 1993;22:49A–55A.
04. Burkhoff D, Maurer MS, Packer M. Heart failure with a normal
ejection fraction: is it really a disorder of diastolic function? Circu-
lation. 2003;107:656–8.
55
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
e75JACC Vol. 53, No. 15, 2009 Hunt et al.
April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure Guidelines05. Brutsaert DL, Sys SU, Gillebert TC. Diastolic failure: pathophysiology
and therapeutic implications [published erratum appears in J Am Coll
Cardiol. 1993;22:1272]. J Am Coll Cardiol. 1993;22:318–25.
06. Mendes LA, Davidoff R, Cupples LA, et al. Congestive heart failure
in patients with coronary artery disease: the gender paradox. Am
Heart J. 1997;134:207–12.
07. Senni M, Redfield MM. Heart failure with preserved systolic
function. A different natural history? J Am Coll Cardiol. 2001;38:
1277–82.
08. Redfield MM. Heart failure—an epidemic of uncertain proportions.
N Engl J Med. 2002;347:1442–4.
09. Banerjee P, Banerjee T, Khand A, et al. Diastolic heart failure:
neglected or misdiagnosed? J Am Coll Cardiol. 2002;39:138–41.
10. Konstam MA. Systolic and diastolic dysfunction in heart failure?
Time for a new paradigm. J Card Fail. 2003;9:1–3.
11. van Kraaij DJ, van Pol PE, Ruiters AW, et al. Diagnosing diastolic
heart failure. Eur J Heart Fail. 2002;4:419–30.
12. Vasan RS, Levy D. Defining diastolic heart failure: a call for
standardized diagnostic criteria. Circulation. 2000;101:2118–21.
13. Vasan RS, Benjamin EJ, Levy D. Congestive heart failure with
normal left ventricular systolic function. Clinical approaches to the
diagnosis and treatment of diastolic heart failure. Arch Intern Med.
1996;156:146–57.
14. Kessler KM. Heart failure with normal systolic function. Update of
prevalence, differential diagnosis, prognosis, and therapy. Arch Intern
Med. 1988;148:2109–11.
15. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and
prognosis of diastolic heart failure: an epidemiologic perspective.
J Am Coll Cardiol. 1995;26:1565–74.
16. Nishimura RA, Tajik AJ. Evaluation of diastolic filling of left
ventricle in health and disease: doppler echocardiography is the
clinician’s Rosetta Stone. J Am Coll Cardiol. 1997;30:8–18.
17. Tresch DD. The clinical diagnosis of heart failure in older patients.
J Am Geriatr Soc. 1997;45:1128–33.
18. Lenihan DJ, Gerson MC, Hoit BD, et al. Mechanisms, diagnosis, and
treatment of diastolic heart failure. Am Heart J. 1995;130:153–66.
19. Ghali JK, Kadakia S, Cooper RS, et al. Bedside diagnosis of
preserved versus impaired left ventricular systolic function in heart
failure. Am J Cardiol. 1991;67:1002–6.
20. Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic
applications for the study of diastolic function. J Am Coll Cardiol.
1998;32:865–75.
21. Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of
B-natriuretic peptide in detecting diastolic dysfunction: comparison
with Doppler velocity recordings. Circulation. 2002;105:595–601.
22. Aronow WS, Kronzon I. Effect of enalapril on congestive heart
failure treated with diuretics in elderly patients with prior myocardial
infarction and normal left ventricular ejection fraction. Am J Cardiol.
1993;71:602–4.
23. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no
propranolol on total mortality plus nonfatal myocardial infarction in
older patients with prior myocardial infarction, congestive heart
failure, and left ventricular ejection fraction  or  40% treated with
diuretics plus angiotensin-converting enzyme inhibitors. Am J Car-
diol. 1997;80:207–9.
24. Warner JG Jr., Metzger DC, Kitzman DW, et al. Losartan improves
exercise tolerance in patients with diastolic dysfunction and a hyper-
tensive response to exercise. J Am Coll Cardiol. 1999;33:1567–72.
25. Brutsaert DL, Rademakers FE, Sys SU. Triple control of relaxation:
implications in cardiac disease. Circulation. 1984;69:190–6.
26. Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on
cardiovascular morbidity and mortality in patients with isolated
systolic hypertension and left ventricular hypertrophy: a Losartan
Intervention for Endpoint Reduction (LIFE) substudy. JAMA.
2002;288:1491–8.
27. Cotter G, Weissgarten J, Metzkor E, et al. Increased toxicity of high-dose
furosemide versus low-dose dopamine in the treatment of refractory con-
gestive heart failure. Clin Pharmacol Ther. 1997;62:187–93.
28. Faris R, Flather MD, Purcell H, et al. Diuretics for heart failure.
Cochrane Database Syst Rev. 2006;CD003838.
29. Costanzo MR, Saltzberg M, O’Sullivan J, et al. Early ultrafiltration in
patients with decompensated heart failure and diuretic resistance.
J Am Coll Cardiol. 2005;46:2047–51.30. Domanski M, Norman J, Pitt B, et al. Diuretic use, progressive heart
failure, and death in patients in the Studies Of Left Ventricular
Dysfunction (SOLVD). J Am Coll Cardiol. 2003;42:705–8.
31. Cicoira M, Zanolla L, Rossi A, et al. Long-term, dose-dependent
effects of spironolactone on left ventricular function and exercise
tolerance in patients with chronic heart failure. J Am Coll Cardiol.
2002;40:304–10.
32. Faris R, Flather M, Purcell H, et al. Current evidence supporting the
role of diuretics in heart failure: a meta analysis of randomised
controlled trials. Int J Cardiol. 2002;82:149–58.
33. Jessup M, Banner N, Brozena S, et al. Optimal pharmacologic and
non-pharmacologic management of cardiac transplant candidates:
approaches to be considered prior to transplant evaluation: Interna-
tional Society for Heart and Lung Transplantation guidelines for the
care of cardiac transplant candidates—2006. J Heart Lung Trans-
plant. 2006;25:1003–23.
34. McAlister FA, Lawson FM, Teo KK, et al. A systematic review of
randomized trials of disease management programs in heart failure.
Am J Med. 2001;110:378–84.
35. Whellan DJ, Hasselblad V, Peterson E, et al. Metaanalysis and
review of heart failure disease management randomized controlled
clinical trials. Am Heart J. 2005;149:722–9.
36. Yancy CW, Krum H, Massie BM, et al. The Second Follow-up
Serial Infusions of Nesiritide (FUSION II) trial for advanced heart
failure: study rationale and design. Am Heart J. 2007;153:478–84.
37. Clark RA, Inglis SC, McAlister FA, et al. Telemonitoring or structured
telephone support programmes for patients with chronic heart failure:
systematic review and meta-analysis. BMJ. 2007;334:942.
38. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical
left ventricular assistance for end-stage heart failure. N Engl J Med.
2001;345:1435–43.
39. Lietz K, Long JW, Kfoury AG, et al. Outcomes of left ventricular
assist device implantation as destination therapy in the post-
REMATCH era: implications for patient selection. Circulation.
2007;116:497–505.
40. Connors AF Jr., Speroff T, Dawson NV, et al., for the SUPPORT
Investigators. The effectiveness of right heart catheterization in the
initial care of critically ill patients. JAMA. 1996;276:889–97.
41. Wu AH, Aaronson KD, Bolling SF, et al. Impact of mitral valve
annuloplasty on mortality risk in patients with mitral regurgitation and
left ventricular systolic dysfunction. J Am Coll Cardiol. 2005;45:381–7.
42. Mann DL, Acker MA, Jessup M, et al. Clinical evaluation of the
CorCap Cardiac Support Device in patients with dilated cardiomy-
opathy. Ann Thorac Surg. 2007;84:1226–35.
43. Sindone AP, Keogh AM, Macdonald PS, et al. Continuous home
ambulatory intravenous inotropic drug therapy in severe heart failure:
safety and cost efficacy. Am Heart J. 1997;134:889–900.
44. Miller LW, Merkle EJ, Herrmann V. Outpatient dobutamine for
end-stage congestive heart failure. Crit Care Med. 1990;18:S30–S33.
45. Krell MJ, Kline EM, Bates ER, et al. Intermittent, ambulatory
dobutamine infusions in patients with severe congestive heart failure.
Am Heart J. 1986;112:787–91.
46. Oliva F, Latini R, Politi A, et al. Intermittent 6-month low-dose
dobutamine infusion in severe heart failure: DICE multicenter trial.
Am Heart J. 1999;138:247–53.
47. Pepi M, Marenzi GC, Agostoni PG, et al. Sustained cardiac diastolic
changes elicited by ultrafiltration in patients with moderate conges-
tive heart failure: pathophysiological correlates. Br Heart J. 1993;70:
135–40.
48. Iorio L, Simonelli R, Nacca RG, et al. Daily hemofiltration in severe
heart failure. Kidney Int Suppl. 1997;59:S62–5.
49. Ashton CM, Kuykendall DH, Johnson ML, et al. The association
between the quality of inpatient care and early readmission. Ann
Intern Med. 1995;122:415–21.
50. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe
congestive heart failure during treatment with enalapril (the Coop-
erative North Scandinavian Enalapril Survival Study [CONSEN-
SUS] Trial). Am J Cardiol. 1992;70:479–87.
51. Bristow MR, Gilbert EM, Abraham WT, et al., for the MOCHA
Investigators. Carvedilol produces dose-related improvements in left
ventricular function and survival in subjects with chronic heart failure.
Circulation. 1996;94:2807–16.
55
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
e76 Hunt et al. JACC Vol. 53, No. 15, 2009
2009 ACCF/AHA Heart Failure Guidelines April 14, 2009:e1–9052. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan
versus captopril in patients over 65 with heart failure (Evaluation of
Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747–52.
53. Massie BM, Kramer BL, Topic N. Lack of relationship between the
short-term hemodynamic effects of captopril and subsequent clinical
responses. Circulation. 1984;69:1135–41.
54. Stevenson LW, Massie BM, Francis GS. Optimizing therapy for
complex or refractory heart failure: a management algorithm. Am
Heart J. 1998;135:S293–S309.
55. Mudge GH, Goldstein S, Addonizio LJ, et al. 24th Bethesda
conference: cardiac transplantation. Task Force 3: recipient guide-
lines/prioritization. J Am Coll Cardiol. 1993;22:21–31.
56. Miller LW. Listing criteria for cardiac transplantation: results of an
American Society of Transplant Physicians-National Institutes of
Health conference. Transplantation. 1998;66:947–51.
57. Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise
oxygen consumption for optimal timing of cardiac transplantation in
ambulatory patients with heart failure. Circulation. 1991;83:778–86.
58. Magovern GJ. Introduction to the history and development of
skeletal muscle plasticity and its clinical application to cardiomyo-
plasty and skeletal muscle ventricle. Semin Thorac Cardiovasc Surg.
1991;3:95–7.
59. Batista RJ, Verde J, Nery P, et al. Partial left ventriculectomy to treat
end-stage heart disease. Ann Thorac Surg. 1997;64:634–8.
60. McCarthy JF, McCarthy PM, Starling RC, et al. Partial left
ventriculectomy and mitral valve repair for end-stage congestive heart
failure. Eur J Cardiothorac Surg. 1998;13:337–43.
61. Goldstein DJ, Oz MC, Rose EA. Implantable left ventricular assist
devices. N Engl J Med. 1998;339:1522–33.
62. Rose EA, Moskowitz AJ, Packer M, et al. The REMATCH trial:
rationale, design, and end points. Randomized Evaluation of Me-
chanical Assistance for the Treatment of Congestive Heart Failure.
Ann Thorac Surg. 1999;67:723–30.
63. Helman DN, Maybaum SW, Morales DL, et al. Recurrent remod-
eling after ventricular assistance: is long-term myocardial recovery
attainable? Ann Thorac Surg. 2000;70:1255–8.
64. Chin MH, Goldman L. Gender differences in 1-year survival and
quality of life among patients admitted with congestive heart failure.
Med Care. 1998;36:1033–46.
65. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement
of B-type natriuretic peptide in the emergency diagnosis of heart
failure. N Engl J Med. 2002;347:161–7.
66. Moe GW, Howlett J, Januzzi JL, et al. N-terminal pro-B-type
natriuretic peptide testing improves the management of patients with
suspected acute heart failure: primary results of the Canadian pro-
spective randomized multicenter IMPROVE-CHF study. Circula-
tion. 2007;115:3103–10.
67. Mebazaa A, Gheorghiade M, Pina IL, et al. Practical recommenda-
tions for prehospital and early in-hospital management of patients
presenting with acute heart failure syndromes. Crit Care Med.
2008;36:S129–S139.
68. Costanzo MR, Johannes RS, Pine M, et al. The safety of intravenous
diuretics alone versus diuretics plus parenteral vasoactive therapies in
hospitalized patients with acutely decompensated heart failure: a
propensity score and instrumental variable analysis using the Acutely
Decompensated Heart Failure National Registry (ADHERE) data-
base. Am Heart J. 2007;154:267–77.
69. Metra M, Torp-Pedersen C, Cleland JG, et al. Should beta-blocker
therapy be reduced or withdrawn after an episode of decompensated
heart failure? Results from COMET. Eur J Heart Fail. 2007;9:901–9.
70. Fonarow GC, Abraham WT, Albert NM, et al. Influence of
beta-blocker continuation or withdrawal on outcomes in patients
hospitalized with heart failure: findings from the OPTIMIZE-HF
program. J Am Coll Cardiol. 2008;52:190–9.
71. Lappe JM, Muhlestein JB, Lappe DL, et al. Improvements in 1-year
cardiovascular clinical outcomes associated with a hospital-based
discharge medication program. Ann Intern Med. 2004;141:446–53.
72. Naylor M, Brooten D, Jones R, et al. Comprehensive discharge
planning for the hospitalized elderly. A randomized clinical trial. Ann
Intern Med. 1994;120:999–1006.
73. Naylor MD, Brooten DA, Campbell RL, et al. Transitional care of
older adults hospitalized with heart failure: a randomized, controlled
trial. J Am Geriatr Soc. 2004;52:675–84.74. Casey DE Jr., Abraham WT, Guo L, et al. Reducing heart failure
hospitalizations and readmissions with Heart Failure Advocates: a
call to action for nursing. Circulation. 2007;115:e559–60.
75. Windham BG, Bennett RG, Gottlieb S. Care management inter-
ventions for older patients with congestive heart failure. Am J Manag
Care. 2003;9:447–59.
76. Phillips CO, Wright SM, Kern DE, et al. Comprehensive discharge
planning with postdischarge support for older patients with conges-
tive heart failure: a meta-analysis. JAMA. 2004;291:1358–67.
77. Koelling TM, Johnson ML, Cody RJ, et al. Discharge education
improves clinical outcomes in patients with chronic heart failure.
Circulation. 2005;111:179–85.
78. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration
versus intravenous diuretics for patients hospitalized for acute decom-
pensated heart failure. J Am Coll Cardiol. 2007;49:675–83.
79. Cuffe MS, Califf RM, Adams KF Jr., et al. Short-term intravenous
milrinone for acute exacerbation of chronic heart failure: a random-
ized controlled trial. JAMA. 2002;287:1541–7.
80. Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of
congestive heart failure and pulmonary artery catheterization effec-
tiveness: the ESCAPE trial. JAMA. 2005;294:1625–33.
81. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with
preserved ejection fraction in a population-based study. N Engl
J Med. 2006;355:260–9.
82. Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal
hospitalization for heart failure on subsequent mortality in patients
with chronic heart failure. Circulation. 2007;116:1482–7.
83. Fonarow GC, Heywood JT, Heidenreich PA, et al. Temporal trends
in clinical characteristics, treatments, and outcomes for heart failure
hospitalizations, 2002 to 2004: findings from Acute Decompensated
Heart Failure National Registry (ADHERE). Am Heart J. 2007;153:
1021–8.
84. Brown DW, Haldeman GA, Croft JB, et al. Racial or ethnic
differences in hospitalization for heart failure among elderly adults:
Medicare, 1990 to 2000. Am Heart J. 2005;150:448–54.
85. Klapholz M, Maurer M, Lowe AM, et al. Hospitalization for heart
failure in the presence of a normal left ventricular ejection fraction:
results of the New York Heart Failure Registry. J Am Coll Cardiol.
2004;43:1432–8.
86. Haldeman GA, Croft JB, Giles WH, et al. Hospitalization of
patients with heart failure: National Hospital Discharge Survey, 1985
to 1995. Am Heart J. 1999;137:352–60.
87. Konstam MA, Gheorghiade M, Burnett JC Jr., et al. Effects of oral
tolvaptan in patients hospitalized for worsening heart failure: the
EVEREST Outcome Trial. JAMA. 2007;297:1319–31.
88. Young JB, Abraham WT, Bourge RC, et al. Task force 8: training in
heart failure endorsed by the Heart Failure Society of America. J Am
Coll Cardiol. 2008;51:383–9.
89. Adams J, Lindenfeld J, Arnold J, et al. HFSA 2006 Comprehensive
Heart Failure Practice Guideline. J Card Fail. 2006;12:e1–119.
89a.Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for
the diagnosis and treatment of acute and chronic heart failure 2008.
Eur Heart J. 2008;29:2388–442.
90. Cotter G, Felker GM, Adams KF, et al. The pathophysiology of
acute heart failure—is it all about fluid accumulation? Am Heart J.
2008;155:9–18.
91. Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure
survey programme—a survey on the quality of care among patients
with heart failure in Europe. Part 1: patient characteristics and
diagnosis. Eur Heart J. 2003;24:442–63.
92. Latini R, Masson S, Anand IS, et al. Prognostic value of very low
plasma concentrations of troponin T in patients with stable chronic
heart failure. Circulation. 2007;116:1242–9.
93. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007
guidelines for the management of patients with unstable angina/non–
ST-elevation myocardial infarction: a report of the American College
of Cardiology/American Heart Association Task Force on Practice
Guidelines (Writing Committee to Revise the 2002 Guidelines for
the Management of Patients With Unstable Angina/Non-ST-
Elevation Myocardial Infarction) developed in collaboration with the
American College of Emergency Physicians, the Society for Cardio-
vascular Angiography and Interventions, and the Society of Thoracic
Surgeons endorsed by the American Association of Cardiovascular
55
5
5
5
5
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
e77JACC Vol. 53, No. 15, 2009 Hunt et al.
April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure Guidelinesand Pulmonary Rehabilitation and the Society for Academic
Emergency Medicine. J Am Coll Cardiol. 2007;50:e1–157.
94. Peacock WF, Fonarow GC, Emerman CL, et al. Impact of early
initiation of intravenous therapy for acute decompensated heart
failure on outcomes in ADHERE. Cardiology. 2007;107:44–51.
95. Maisel AS, Peacock WF, McMullin N, et al. Timing of immuno-
reactive B-type natriuretic peptide levels and treatment delay in acute
decompensated heart failure: an ADHERE (Acute Decompensated
Heart Failure National Registry) analysis. J Am Coll Cardiol.
2008;52:534–40.
96. Shankar SS, Brater DC. Loop diuretics: from the Na-K-2Cl trans-
porter to clinical use. Am J Physiol Renal Physiol. 2003;284:F11–21.
97. Wilcox CS, Mitch WE, Kelly RA, et al. Response of the kidney to
furosemide. I. Effects of salt intake and renal compensation. J Lab
Clin Med. 1983;102:450–8.
98. Cleland JG, Coletta A, Witte K. Practical applications of intravenous
diuretic therapy in decompensated heart failure. Am J Med. 2006;
119:S26–S36.
99. Firth JD, Raine AE, Ledingham JG. Raised venous pressure: a direct
cause of renal sodium retention in oedema? Lancet. 1988;1:1033–5.
00. Pivac N, Rumboldt Z, Sardelic S, et al. Diuretic effects of furosemide
infusion versus bolus injection in congestive heart failure. Int J Clin
Pharmacol Res. 1998;18:121–8.
01. Salvador DR, Rey NR, Ramos GC, et al. Continuous infusion versus
bolus injection of loop diuretics in congestive heart failure. Cochrane
Database Syst Rev. 2005;CD003178.
02. Bourge RC, Tallaj JA. Ultrafiltration: a new approach toward
mechanical diuresis in heart failure. J Am Coll Cardiol. 2005;46:
2052–3.
03. Bart BA, Boyle A, Bank AJ, et al. Ultrafiltration versus usual care for
hospitalized patients with heart failure: the Relief for Acutely
Fluid-Overloaded Patients With Decompensated Congestive Heart
Failure (RAPID-CHF) trial. J Am Coll Cardiol. 2005;46:2043–6.
04. Jaski BE, Ha J, Denys BG, et al. Peripherally inserted veno-venous
ultrafiltration for rapid treatment of volume overloaded patients.
J Card Fail. 2003;9:227–31.
05. Dupuis J, Lalonde G, Lemieux R, et al. Tolerance to intravenous
nitroglycerin in patients with congestive heart failure: role of increased
intravascular volume, neurohumoral activation and lack of prevention
with N-acetylcysteine. J Am Coll Cardiol. 1990;16:923–31.
06. Fung HL, Bauer JA. Mechanisms of nitrate tolerance. Cardiovasc
Drugs Ther. 1994;8:489–99.
07. Elkayam U, Kulick D, McIntosh N, et al. Incidence of early tolerance
to hemodynamic effects of continuous infusion of nitroglycerin in
patients with coronary artery disease and heart failure. Circulation.
1987;76:577–84.
08. Wang DJ, Dowling TC, Meadows D, et al. Nesiritide does not
improve renal function in patients with chronic heart failure and
worsening serum creatinine. Circulation. 2004;110:1620–5.
09. Witteles RM, Kao D, Christopherson D, et al. Impact of nesiritide on
renal function in patients with acute decompensated heart failure and
pre-existing renal dysfunction a randomized, double-blind, placebo-
controlled clinical trial. J Am Coll Cardiol. 2007;50:1835–40.
10. Silver MA, Yancy CW. Using homeostatic peptides in decompen-
sated heart failure a reasonable paradigm but a flawed practice? J Am
Coll Cardiol. 2007;50:1841–3.
11. O’Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous
dobutamine is associated with an increased risk of death in patients with
advanced heart failure: insights from the Flolan International Random-
ized Survival Trial (FIRST). Am Heart J. 1999;138:78–86.
12. Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes
and vasodilator therapy in hospitalized patients with severe heart
failure. Am Heart J. 2007;153:98–104.
13. Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality
in patients with acute decompensated heart failure requiring intrave-
nous vasoactive medications: an analysis from the Acute Decompen-
sated Heart Failure National Registry (ADHERE). J Am Coll
Cardiol. 2005;46:57–64.
14. Shah MR, Hasselblad V, Stevenson LW, et al. Impact of the
pulmonary artery catheter in critically ill patients: meta-analysis of
randomized clinical trials. JAMA. 2005;294:1664–70.
15. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous
thromboembolism: the Seventh ACCP Conference on Antithrom-
botic and Thrombolytic Therapy. Chest. 2004;126:338S–400S.16. Bonow RO, Bennett S, Casey DE Jr., et al. ACC/AHA clinical
performance measures for adults with chronic heart failure: a report of
the American College of Cardiology/American Heart Association Task
Force on Performance Measures (Writing Committee to Develop Heart
Failure Clinical Performance Measures) endorsed by the Heart Failure
Society of America. J Am Coll Cardiol. 2005;46:1144–78.
17. Fonarow GC, Yancy CW, Heywood JT. Adherence to heart failure
quality-of-care indicators in US hospitals: analysis of the ADHERE
Registry. Arch Intern Med. 2005;165:1469–77.
18. Krumholz HM, Baker DW, Ashton CM, et al. Evaluating quality of
care for patients with heart failure. Circulation. 2000;101:e122–40.
19. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Persistent use of
evidence-based pharmacotherapy in heart failure is associated with
improved outcomes. Circulation. 2007;116:737–44.
20. The Agency for Healthcare Quality and Research 30 Safe Practices
for Better Health Care. Available at: http://www.ahrq.gov/qual/
30safe.htm. Accessed March 1, 2008.
21. The Joint Commission2008 National Patient Saftey Goals. Available
at: http://www.jointcommission.org/PatientSafety/NationalPatient
SafetyGoals/08_hap_npsgs.htm. Accessed March 1, 2008.
22. Levenson JW, McCarthy EP, Lynn J, et al. The last six months of life
for patients with congestive heart failure. J Am Geriatr Soc. 2000;
48:S101–9.
23. Morrison RS, Maroney-Galin C, Kralovec PD, et al. The growth of
palliative care programs in United States hospitals. J Palliat Med.
2005;8:1127–34.
24. Qaseem A, Snow V, Shekelle P, et al. Evidence-based interventions
to improve the palliative care of pain, dyspnea, and depression at the
end of life: a clinical practice guideline from the American College of
Physicians. Ann Intern Med. 2008;148:141–6.
25. Lorenz KA, Lynn J, Dy SM, et al. Evidence for improving palliative
care at the end of life: a systematic review. Ann Intern Med.
2008;148:147–59.
25a.Lorenz K, Lynn J, Dy S, et al. Evidence for improving palliative care at
the end of life: a systematic review. Ann Intern Med. 2008;148:147–59.
25b.Qaseem A, Snow V, Shekelle P, et al. Evidence-based interventions
to improve the palliative care of pain, dyspnea, and depression at the
end of life: a clinical practice guideline from the American College of
Physicians. Ann Intern Med. 2008;148:141–6.
26. Trivedi AN, Zaslavsky AM, Schneider EC, et al. Relationship
between quality of care and racial disparities in Medicare health
plans. JAMA. 2006;296:1998–2004.
27. Yancy CW. The prevention of heart failure in minority communities
and discrepancies in health care delivery systems. Med Clin North
Am. 2004;88:1347–68.
28. Clinical Quality Improvement Network Investigators. Mortality risk
and patterns of practice in 4606 acute care patients with congestive
heart failure. The relative importance of age, sex, and medical
therapy. Arch Intern Med. 1996;156:1669–73.
29. Herholz H, Goff DC, Ramsey DJ, et al. Women and Mexican
Americans receive fewer cardiovascular drugs following myocardial
infarction than men and non-Hispanic whites: the Corpus Christi
Heart Project, 1988–1990. J Clin Epidemiol. 1996;49:279–87.
30. Stafford RS, Saglam D, Blumenthal D. National patterns of
angiotensin-converting enzyme inhibitor use in congestive heart
failure. Arch Intern Med. 1997;157:2460–4.
31. Kimmelstiel C, Goldberg RJ. Congestive heart failure in women:
focus on heart failure due to coronary artery disease and diabetes.
Cardiology. 1990;77 Suppl 2:71–9:71–9.
32. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-
converting enzyme inhibitors and beta-blockers in the management
of left ventricular systolic dysfunction according to race, gender, and
diabetic status: a meta-analysis of major clinical trials. J Am Coll
Cardiol. 2003;41:1529–38.
33. Kostis JB, Shelton B, Gosselin G, et al., for the SOLVD Investiga-
tors. Adverse effects of enalapril in the Studies of Left Ventricular
Dysfunction (SOLVD). Am Heart J. 1996;131:350–5.
34. Cheitlin MD, Hutter AM Jr., Brindis RG, et al. ACC/AHA expert
consensus document. Use of sildenafil (Viagra) in patients with
cardiovascular disease. American College of Cardiology/American
Heart Association. J Am Coll Cardiol. 1999;33:273–82.
35. Webb DJ, Muirhead GJ, Wulff M, et al. Sildenafil citrate potentiates
the hypotensive effects of nitric oxide donor drugs in male patients
with stable angina. J Am Coll Cardiol. 2000;36:25–31.
66
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
e78 Hunt et al. JACC Vol. 53, No. 15, 2009
2009 ACCF/AHA Heart Failure Guidelines April 14, 2009:e1–9036. Witzig R. The medicalization of race: scientific legitimization of a
flawed social construct. Ann Intern Med. 1996;125:675–9.
37. Dries DL, Exner DV, Gersh BJ, et al. Racial differences in the
outcome of left ventricular dysfunction [published erratum appears in
N Engl J Med 1999;341:298]. N Engl J Med. 1999;340:609–16.
38. Alexander M, Grumbach K, Remy L, et al. Congestive heart failure
hospitalizations and survival in California: patterns according to
race/ethnicity. Am Heart J. 1999;137:919–27.
39. Philbin EF, DiSalvo TG. Influence of race and gender on care
process, resource use, and hospital-based outcomes in congestive
heart failure. Am J Cardiol. 1998;82:76–81.
40. Rathore SS, Foody JM, Wang Y, et al. Race, quality of care, and
outcomes of elderly patients hospitalized with heart failure. JAMA.
2003;289:2517–24.
41. Ayanian JZ, Weissman JS, Chasan-Taber S, et al. Quality of care by
race and gender for congestive heart failure and pneumonia. Med
Care. 1999;37:1260–9.
42. Committee on Understanding and Eliminating Racial and Ethnic
Disparities in Health Care. Smedley BD, Stith AY, Nelson AR, editors.
Unequal Treatment: Confronting Racial and Ethnic Disparities in
Health Care. Washington, DC: National Academy Press, 2003.
43. Oster A, Bindman AB. Emergency department visits for ambulatory
care sensitive conditions: insights into preventable hospitalizations.
Med Care. 2003;41:198–207.
44. Davis SK, Liu Y, Gibbons GH. Disparities in trends of hospitaliza-
tion for potentially preventable chronic conditions among African
Americans during the 1990s: implications and benchmarks. Am J
Public Health. 2003;93:447–55.
45. Exner DV, Dries DL, Domanski MJ, et al. Lesser response to
angiotensin-converting-enzyme inhibitor therapy in black as com-
pared with white patients with left ventricular dysfunction. N Engl
J Med. 2001;344:1351–7.
46. Domanski MJ, Borkowf CB, Campeau L, et al., for the Post-CABG
Trial Investigators. Prognostic factors for atherosclerosis progression
in saphenous vein grafts: the postcoronary artery bypass graft (Post-
CABG) trial. J Am Coll Cardiol. 2000;36:1877–83.
47. Yancy CW, Fowler MB, Colucci WS, et al. Race and the response to
adrenergic blockade with carvedilol in patients with chronic heart
failure. N Engl J Med. 2001;344:1358–65.
48. Jarcho J, Naftel DC, Shroyer TW, et al., for the Cardiac Transplant
Research Database Group. Influence of HLA mismatch on rejection
after heart transplantation: a multiinstitutional study. J Heart Lung
Transplant. 1994;13:583–95.
49. Suthanthiran M, Li B, Song JO, et al. Transforming growth
factor-beta 1 hyperexpression in African-American hypertensives: A
novel mediator of hypertension and/or target organ damage. Proc
Natl Acad Sci U S A. 2000;97:3479–84.
50. McNamara DM, Holubkov R, Janosko K, et al. Pharmacogenetic
interactions between beta-blocker therapy and the angiotensin-
converting enzyme deletion polymorphism in patients with conges-
tive heart failure. Circulation. 2001;103:1644–8.
51. Mason DA, Moore JD, Green SA, et al. A gain-of-function
polymorphism in a G-protein coupling domain of the human
beta1-adrenergic receptor. J Biol Chem. 1999;274:12670–4.
52. Small KM, Wagoner LE, Levin AM, et al. Synergistic polymor-
phisms of beta1- and alpha2C-adrenergic receptors and the risk of
congestive heart failure. N Engl J Med. 2002;347:1135–42.
53. Kupari M, Lindroos M, Iivanainen AM, et al. Congestive heart
failure in old age: prevalence, mechanisms and 4–year prognosis in
the Helsinki Ageing Study. J Intern Med. 1997;241:387–94.
54. Wolinsky FD, Overhage JM, Stump TE, et al. The risk of hospital-
ization for congestive heart failure among older adults. Med Care.
1997;35:1031–43.
55. Philbin EF, Rocco TA Jr., Lynch LJ, et al. Predictors and determi-
nants of hospital length of stay in congestive heart failure in ten
community hospitals. J Heart Lung Transplant. 1997;16:548–55.
56. Candlish P, Watts P, Redman S, et al. Elderly patients with heart
failure: a study of satisfaction with care and quality of life. Int J Qual
Health Care. 1998;10:141–6.
57. Krumholz HM, Parent EM, Tu N, et al. Readmission after hospi-
talization for congestive heart failure among Medicare beneficiaries.
Arch Intern Med. 1997;157:99–104.
58. Zieman SJ, Fortuin NJ. Hypertrophic and restrictive cardiomyopa-
thies in the elderly. Cardiol Clin. 1999;17:159–72.59. Hughes CV, Wong M, Johnson G, et al., for the V-HeFT VA
Cooperative Studies Group. Influence of age on mechanisms and
prognosis of heart failure. Circulation. 1993;87:VI111–7.
60. Kober L, Torp-Pedersen C, Ottesen M, et al., for the TRACE Study
Group. Influence of gender on short- and long-term mortality after
acute myocardial infarction. Am J Cardiol. 1996;77:1052–6.
61. Cody RJ, Torre S, Clark M, et al. Age-related hemodynamic, renal,
and hormonal differences among patients with congestive heart
failure. Arch Intern Med. 1989;149:1023–8.
62. Doba N, Tomiyama H, Nakayama T. Drugs, heart failure and quality
of life: what are we achieving? What should we be trying to achieve?
Drugs Aging. 1999;14:153–63.
63. ACE Inhibitor Myocardial Infarction Collaborative Group. Indica-
tions for ACE inhibitors in the early treatment of acute myocardial
infarction: systematic overview of individual data from 100,000
patients in randomized trials. Circulation. 1998;97:2202–12.
64. Murray MD, Haag KM, Black PK, et al. Variable furosemide
absorption and poor predictability of response in elderly patients.
Pharmacotherapy. 1997;17:98–106.
65. Robinson T, Gariballa S, Fancourt G, et al. The acute effects of a
single dopamine infusion in elderly patients with congestive cardiac
failure. Br J Clin Pharmacol. 1994;37:261–3.
66. Aronow WS. Postinfarction use of beta-blockers in elderly patients.
Drugs Aging. 1997;11:424–32.
67. Schwartz JB. Calcium antagonists in the elderly. A risk-benefit
analysis. Drugs Aging. 1996;9:24–36.
68. Wenger AL. Oral anticoagulant therapy at elderly age: heart failure
and nonvalvular atrial fibrillation. Am J Ger Card. 1996;5:78–83.
69. Rich MW, Woods WL, Davila-Roman VG, et al. A randomized
comparison of intravenous amrinone versus dobutamine in older
patients with decompensated congestive heart failure. J Am Geriatr
Soc. 1995;43:271–4.
70. Morisco C, Condorelli M, Crepaldi G, et al. Lisinopril in the
treatment of congestive heart failure in elderly patients: comparison
versus captopril. Cardiovasc Drugs Ther. 1997;11:63–9.
71. Rich MW, Gray DB, Beckham V, et al. Effect of a multidisciplinary
intervention on medication compliance in elderly patients with
congestive heart failure. Am J Med. 1996;101:270–6.
72. Ni H, Nauman DJ, Hershberger RE. Managed care and outcomes of
hospitalization among elderly patients with congestive heart failure.
Arch Intern Med. 1998;158:1231–6.
73. Ware JE Jr., Bayliss MS, Rogers WH, et al. Differences in 4-year
health outcomes for elderly and poor, chronically ill patients treated
in HMO and fee-for-service systems. Results from the Medical
Outcomes Study. JAMA. 1996;276:1039–47.
74. Solang L, Malmberg K, Ryden L. Diabetes mellitus and congestive
heart failure. Further knowledge needed. Eur Heart J. 1999;20:
789–95.
75. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure
in subjects with normal versus reduced left ventricular ejection
fraction: prevalence and mortality in a population-based cohort. J Am
Coll Cardiol. 1999;33:1948–55.
76. Sahai A, Ganguly PK. Congestive heart failure in diabetes with
hypertension may be due to uncoupling of the atrial natriuretic
peptide receptor-effector system in the kidney basolateral membrane.
Am Heart J. 1991;122:164–70.
77. Galderisi M, Anderson KM, Wilson PW, et al. Echocardiographic
evidence for the existence of a distinct diabetic cardiomyopathy (the
Framingham Heart Study). Am J Cardiol. 1991;68:85–9.
78. Zarich SW, Nesto RW. Diabetic cardiomyopathy. Am Heart J.
1989;118:1000–12.
79. Randomised trial of cholesterol lowering in 4444 patients with
coronary heart disease: the Scandinavian Simvastatin Survival Study
(4S). Lancet. 1994;344:1383–9.
80. SHEP Cooperative Research Group. Prevention of stroke by anti-
hypertensive drug treatment in older persons with isolated systolic
hypertension. Final results of the Systolic Hypertension in the Elderly
Program (SHEP). JAMA. 1991;265:3255–64.
81. Curb JD, Pressel SL, Cutler JA, et al., for the Systolic Hypertension
in the Elderly Program Cooperative Research Group. Effect of
diuretic-based antihypertensive treatment on cardiovascular disease
risk in older diabetic patients with isolated systolic hypertension.
[published erratum appears in JAMA 1997;277:1356]. JAMA. 1996;
276:1886–92.
66
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
e79JACC Vol. 53, No. 15, 2009 Hunt et al.
April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure Guidelines82. Swan JW, Anker SD, Walton C, et al. Insulin resistance in chronic
heart failure: relation to severity and etiology of heart failure. J Am
Coll Cardiol. 1997;30:527–32.
83. Watanabe K, Sekiya M, Tsuruoka T, et al. Relationship between
insulin resistance and cardiac sympathetic nervous function in essen-
tial hypertension. J Hypertens. 1999;17:1161–8.
84. Zimlichman R, Zaidel L, Nofech-Mozes S, et al. Hyperinsulinemia
induces myocardial infarctions and arteriolar medial hypertrophy in
spontaneously hypertensive rats. Am J Hypertens. 1997;10:646–53.
85. Holmang A, Yoshida N, Jennische E, et al. The effects of hyperin-
sulinaemia on myocardial mass, blood pressure regulation and central
haemodynamics in rats. Eur J Clin Invest. 1996;26:973–8.
86. Zimlichman R, Zeidel L, Gefel D, et al. Insulin induces medial
hypertrophy of myocardial arterioles in rats. Am J Hypertens.
1995;8:915–20.
87. Krentz AJ, Bailey CJ, Melander A. Thiazolidinediones for type 2
diabetes. New agents reduce insulin resistance but need long term
clinical trials. BMJ. 2000;321:252–3.
88. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid
retention, and congestive heart failure: a consensus statement from
the American Heart Association and American Diabetes Association.
October 7, 2003. Circulation. 2003;108:2941–8.
89. Schulman DS, Flores AR, Tugoen J, et al. Antihypertensive treat-
ment in hypertensive patients with normal left ventricular mass is
associated with left ventricular remodeling and improved diastolic
function. Am J Cardiol. 1996;78:56–60.
90. Habib GB, Mann DL, Zoghbi WA. Normalization of cardiac
structure and function after regression of cardiac hypertrophy. Am
Heart J. 1994;128:333–43.
91. Ryden L, Armstrong P, Cleland JG, for the ATLAS Investigators.
High dose ACE-inhibitor strategy is more effectice than low-dose in
diabetic patients with congestive heart failure (abstr). J Am Coll
Cardiol. 1999;33 Suppl A:188.
92. Packer M, Kukin ML. Management of patients with heart failure
and angina: do coexistent diseases alter the response to cardiovascular
drugs? [editorial comment]. J Am Coll Cardiol. 1991;17:740–2.
93. Elkayam U, Johnson JV, Shotan A, et al. Intermittent large dose
nitrates added to standard therapy, improves left ventricular function
and exercise capacity in patients with chronic heart failure (abstr).
J Am Coll Cardiol. 1999;33 Suppl A:188.
94. Sussex BA, Campbell NR, Raju MK, et al. The antianginal efficacy
of isosorbide dinitrate therapy is maintained during diuretic treat-
ment. Clin Pharmacol Ther. 1994;56:229–34.
95. Parker JD, Parker AB, Farrell B, et al. Effects of diuretic therapy on
the development of tolerance to nitroglycerin and exercise capacity in
patients with chronic stable angina. Circulation. 1996;93:691–6.
96. Agostoni PG, De Cesare N, Doria E, et al. Afterload reduction: a
comparison of captopril and nifedipine in dilated cardiomyopathy. Br
Heart J. 1986;55:391–9.
97. Tan LB, Murray RG, Littler WA. Felodipine in patients with
chronic heart failure: discrepant haemodynamic and clinical effects.
Br Heart J. 1987;58:122–8.
98. Elkayam U, Amin J, Mehra A, et al. A prospective, randomized,
double-blind, crossover study to compare the efficacy and safety of
chronic nifedipine therapy with that of isosorbide dinitrate and their
combination in the treatment of chronic congestive heart failure.
Circulation. 1990;82:1954–61.
99. Cohn JN, Ziesche S, Smith R, et al., for the Vasodilator-Heart
Failure Trial (V-HeFT) Study Group. Effect of the calcium antag-
onist felodipine as supplementary vasodilator therapy in patients with
chronic heart failure treated with enalapril: V-HeFT III. Circulation.
1997;96:856–63.
00. Packer M. Calcium channel blockers in chronic heart failure. The
risks of “physiologically rational” therapy [editorial; comment]. Cir-
culation. 1990;82:2254–7.
01. Elkayam U, Weber L, McKay C, et al. Spectrum of acute hemody-
namic effects of nifedipine in severe congestive heart failure. Am J
Cardiol. 1985;56:560–6.
02. Barjon JN, Rouleau JL, Bichet D, et al. Chronic renal and neurohu-
moral effects of the calcium entry blocker nisoldipine in patients with
congestive heart failure. J Am Coll Cardiol. 1987;9:622–30.
03. Goldstein RE, Boccuzzi SJ, Cruess D, et al., for the Adverse
Experience Committee and the Multicenter Diltiazem Postinfarction
Research Group. Diltiazem increases late-onset congestive heartfailure in postinfarction patients with early reduction in ejection
fraction. Circulation. 1991;83:52–60.
04. Littler WA, Sheridan DJ., for the UK Study Group. Placebo
controlled trial of felodipine in patients with mild to moderate heart
failure. Br Heart J. 1995;73:428–33.
05. Mohindra SK, Udeani GO. Long-acting verapamil and heart failure
[letter]. JAMA. 1989;261:994.
06. Mullins ME, Horowitz BZ, Linden DH, et al. Life-threatening
interaction of mibefradil and beta-blockers with dihydropyridine
calcium channel blockers. JAMA. 1998;280:157–8.
07. Benatar D, Hall V, Reddy S, et al. Clinical and neurohormonal
effects of nicardipine hydrochloride in patients with severe chronic
heart failure receiving angiotensin-converting enzyme inhibitor ther-
apy. Am J Ther. 1998;5:25–32.
08. Levine TB, Bernink PJ, Caspi A, et al. Effect of mibefradil, a T-type
calcium channel blocker, on morbidity and mortality in moderate to
severe congestive heart failure: the MACH-1 study. Mortality
Assessment in Congestive Heart Failure Trial. Circulation. 2000;
101:758–64.
09. Quality of life in patients randomly assigned to treatment groups.
Coronary artery surgery study (CASS): a randomized trial of coronary
artery bypass surgery. Circulation. 1983;68:951–60.
10. Parisi AF, Folland ED, Hartigan P, for the Veterans Affairs ACME
Investigators. A comparison of angioplasty with medical therapy in
the treatment of single-vessel coronary artery disease. N Engl J Med.
1992;326:10–6.
11. Passamani E, Davis KB, Gillespie MJ, et al. A randomized trial of
coronary artery bypass surgery. Survival of patients with a low ejection
fraction. N Engl J Med. 1985;312:1665–71.
12. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM
guidelines for the management of patients with chronic stable angina:
a report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Committee on
Management of Patients With Chronic Stable Angina). J Am Coll
Cardiol. 1999;33:2092–197.
13. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial
infarction and unstable angina in patients with low ejection fractions.
Lancet. 1992;340:1173–8.
14. Rutherford JD, Pfeffer MA, Moye LA, et al., for the SAVE
Investigators. Effects of captopril on ischemic events after myocardial
infarction. Results of the Survival and Ventricular Enlargement trial.
Circulation. 1994;90:1731–8.
15. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline
update for coronary artery bypass graft surgery: a report of the
American College of Cardiology/American Heart Association Task
Force on Practice Guidelines (Committee to Update the 1999
Guidelines for Coronary Artery Bypass Graft Surgery). Available at:
http://www.acc.org/clinical/guidelines/cabg/cabg.pdf. Accessed June
30, 2005.
16. Di Carli MF, Asgarzadie F, Schelbert HR, et al. Quantitative
relation between myocardial viability and improvement in heart
failure symptoms after revascularization in patients with ischemic
cardiomyopathy. Circulation. 1995;92:3436–44.
17. Elefteriades JA, Tolis G Jr., Levi E, et al. Coronary artery bypass
grafting in severe left ventricular dysfunction: excellent survival with
improved ejection fraction and functional state. J Am Coll Cardiol.
1993;22:1411–7.
18. Pagano D, Bonser RS, Townend JN, et al. Predictive value of
dobutamine echocardiography and positron emission tomography in
identifying hibernating myocardium in patients with postischaemic
heart failure. Heart. 1998;79:281–8.
19. Baker DW, Jones R, Hodges J, et al. Management of heart failure.
III. The role of revascularization in the treatment of patients with
moderate or severe left ventricular systolic dysfunction. JAMA.
1994;272:1528–34.
20. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006
Guidelines for the Management of Patients with Atrial Fibrillation:
a report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines and the European
Society of Cardiology Committee for Practice Guidelines (Writing
Committee to Revise the 2001 Guidelines for the Management of
Patients With Atrial Fibrillation): developed in collaboration with
the European Heart Rhythm Association and the Heart Rhythm
Society. Circulation. 2006;114:e257–354.
77
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
e80 Hunt et al. JACC Vol. 53, No. 15, 2009
2009 ACCF/AHA Heart Failure Guidelines April 14, 2009:e1–9021. Stevenson WG, Stevenson LW. Atrial fibrillation in heart failure
[editorial; comment]. N Engl J Med. 1999;341:910–1.
22. Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated
with an increased risk for mortality and heart failure progression in
patients with asymptomatic and symptomatic left ventricular systolic
dysfunction: a retrospective analysis of the SOLVD trials. Studies of
Left Ventricular Dysfunction. J Am Coll Cardiol. 1998;32:695–703.
23. Pardaens K, Van Cleemput J, Vanhaecke J, et al. Atrial fibrillation is
associated with a lower exercise capacity in male chronic heart failure
patients. Heart. 1997;78:564–8.
24. Hasenfuss G, Holubarsch C, Hermann HP, et al. Influence of the
force-frequency relationship on haemodynamics and left ventricular
function in patients with non-failing hearts and in patients with
dilated cardiomyopathy. Eur Heart J. 1994;15:164–70.
25. Kass DA. Force-frequency relation in patients with left ventricular
hypertrophy and failure. Basic Res Cardiol. 1998;93 Suppl 1:108–16.
26. Yu CM, Sanderson JE. Right and left ventricular diastolic function in
patients with and without heart failure: effect of age, sex, heart rate,
and respiration on Doppler-derived measurements. Am Heart J.
1997;134:426–34.
27. Komamura K, Shannon RP, Pasipoularides A, et al. Alterations in
left ventricular diastolic function in conscious dogs with pacing-
induced heart failure. J Clin Invest. 1992;89:1825–38.
28. Van den Berg MP, Tuinenburg AE, van Veldhuisen DJ, et al.
Cardioversion of atrial fibrillation in the setting of mild to moderate
heart failure. Int J Cardiol. 1998;63:63–70.
29. Crijns HJ, Van den Berg MP, Van Gelder IC, et al. Management of
atrial fibrillation in the setting of heart failure. Eur Heart J. 1997;18
Suppl C:C45–9.
30. Shivkumar K, Jafri SM, Gheorghiade M. Antithrombotic therapy in
atrial fibrillation: a review of randomized trials with special reference
to the Stroke Prevention in Atrial Fibrillation II (SPAF II) Trial.
Prog Cardiovasc Dis. 1996;38:337–42.
31. Botker HE, Toft P, Klitgaard NA, et al. Influence of physical exercise
on serum digoxin concentration and heart rate in patients with atrial
fibrillation. Br Heart J. 1991;65:337–41.
32. Deedwania PC, Singh BN, Ellenbogen K, et al., for the Department
of Veterans Affairs CHF-STAT Investigators. Spontaneous conver-
sion and maintenance of sinus rhythm by amiodarone in patients with
heart failure and atrial fibrillation: observations from the veterans
affairs congestive heart failure survival trial of antiarrhythmic therapy
(CHF-STAT). Circulation. 1998;98:2574–9.
33. Wood MA, Brown-Mahoney C, Kay GN, et al. Clinical outcomes
after ablation and pacing therapy for atrial fibrillation: a meta-
analysis. Circulation. 2000;101:1138–44.
34. Ozcan C, Jahangir A, Friedman PA, et al. Long-term survival after
ablation of the atrioventricular node and implantation of a permanent
pacemaker in patients with atrial fibrillation. N Engl J Med. 2001;
344:1043–51.
35. Ozcan C, Jahangir A, Friedman PA, et al. Significant effects of
atrioventricular node ablation and pacemaker implantation on left
ventricular function and long-term survival in patients with atrial
fibrillation and left ventricular dysfunction. Am J Cardiol. 2003;92:
33–7.
36. Boos CJ, Carlsson J, More RS. Rate or rhythm control in persistent
atrial fibrillation? QJM. 2003;96:881–92.
37. Naccarelli GV, Rinkenberger RL, Dougherty AH, et al. Adverse
effects of amiodarone. Pathogenesis, incidence and management.
Med Toxicol Adverse Drug Exp. 1989;4:246–53.
38. Greene HL, Graham EL, Werner JA, et al. Toxic and therapeutic
effects of amiodarone in the treatment of cardiac arrhythmias. J Am
Coll Cardiol. 1983;2:1114–28.
39. Fuster V, Gersh BJ, Giuliani ER, et al. The natural history of
idiopathic dilated cardiomyopathy. Am J Cardiol. 1981;47:525–31.
40. Stratton JR, Nemanich JW, Johannessen KA, et al. Fate of left
ventricular thrombi in patients with remote myocardial infarction or
idiopathic cardiomyopathy. Circulation. 1988;78:1388–93.
41. Jafri SM. Hypercoagulability in heart failure. Semin Thromb He-
most. 1997;23:543–5.
42. Dunkman WB, Johnson GR, Carson PE, et al., for the V-HeFT VA
Cooperative Studies Group. Incidence of thromboembolic events in
congestive heart failure. Circulation. 1993;87:VI94–101.
43. Dunkman WB. Thromboembolism and antithrombotic therapy in
congestive heart failure. J Cardiovasc Risk. 1995;2:107–17.44. Cioffi G, Pozzoli M, Forni G, et al. Systemic thromboembolism in
chronic heart failure. A prospective study in 406 patients. Eur
Heart J. 1996;17:1381–9.
45. Baker DW, Wright RF. Management of heart failure. IV. Antico-
agulation for patients with heart failure due to left ventricular systolic
dysfunction. JAMA. 1994;272:1614–8.
46. Katz SD. Left ventricular thrombus and the incidence of thrombo-
embolism in patients with congestive heart failure: can clinical factors
identify patients at increased risk? J Cardiovasc Risk. 1995;2:97–102.
47. Al Khadra AS, Salem DN, Rand WM, et al. Warfarin anticoagula-
tion and survival: a cohort analysis from the Studies of Left
Ventricular Dysfunction. J Am Coll Cardiol. 1998;31:749–53.
48. Kilborn MJ, Karasik PE, Fisher SG, Domanski MJ, Singh SN,
Fletcher RD. Anticoagulation in patients with congestive heart
failure: evidence for lack of mortality benefit (abstr). Circulation
1999;100 Suppl 1:I-537.
49. Dries DL, Domanski MJ, Waclawiw MA, et al. Effect of antithrom-
botic therapy on risk of sudden coronary death in patients with
congestive heart failure. Am J Cardiol. 1997;79:909–13.
50. Stratton JR, Resnick AD. Increased embolic risk in patients with left
ventricular thrombi. Circulation. 1987;75:1004–11.
51. Philbin EF, Santella RN, Rocco TA Jr. Angiotensin-converting
enzyme inhibitor use in older patients with heart failure and renal
dysfunction. J Am Geriatr Soc. 1999;47:302–8.
52. Alpert MA. Cardiovascular factors influencing survival in dialysis
patients. Adv Perit Dial. 1996;12:110–9:110–9.
53. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as
compared with low hematocrit values in patients with cardiac disease
who are receiving hemodialysis and epoetin. N Engl J Med. 1998;
339:584–90.
54. Biasioli S, Barbaresi F, Barbiero M, et al. Intermittent venovenous
hemofiltration as a chronic treatment for refractory and intractable
heart failure. ASAIO J. 1992;38:M658–63.
55. Weber KT, Wilson JR, Janicki JS, et al. Exercise testing in the
evaluation of the patient with chronic cardiac failure. Am Rev Respir
Dis. 1984;129:S60–S62.
56. Singh SN, Fisher SG, Deedwania PC, et al., for the Congestive
Heart Failure-Survival Trial of Antiarrhythmic Therapy (CHF-
STAT) Investigators. Pulmonary effect of amiodarone in patients
with heart failure (Veterans Affairs Cooperative Study No. 320).
J Am Coll Cardiol. 1997;30:514–7.
57. Sparano JA. Doxorubicin/taxane combinations: cardiac toxicity and
pharmacokinetics. Semin Oncol. 1999;26:14–9.
58. Ibrahim NK, Hortobagyi GN, Ewer M, et al. Doxorubicin-induced
congestive heart failure in elderly patients with metastatic breast
cancer, with long-term follow-up: the M.D. Anderson experience.
Cancer Chemother Pharmacol. 1999;43:471–8.
59. Dieras V. Taxanes in combination with doxorubicin in the treatment
of metastatic breast cancer. Semin Oncol. 1998;25:18–22.
60. Shapiro CL, Hardenbergh PH, Gelman R, et al. Cardiac effects of
adjuvant doxorubicin and radiation therapy in breast cancer patients.
J Clin Oncol. 1998;16:3493–501.
61. Hortobagyi GN. Anthracyclines in the treatment of cancer. An
overview. Drugs. 1997;54 Suppl 4:1–7.
62. Schaadt B, Kelbaek H. Age and left ventricular ejection fraction
identify patients with advanced breast cancer at high risk for
development of epirubicin-induced heart failure. J Nucl Cardiol.
1997;4:494–501.
63. McNeil C. Herceptin raises its sights beyond advanced breast cancer
[news]. J Natl Cancer Inst. 1998;90:882–3.
64. Feldman AM, Lorell BH, Reis SE. Trastuzumab in the treatment of
metastatic breast cancer: anticancer therapy versus cardiotoxicity.
Circulation. 2000;102:272–4.
65. Arsenian MA. Cardiovascular sequelae of therapeutic thoracic radi-
ation. Prog Cardiovasc Dis. 1991;33:299–311.
66. Meinardi MT, van der Graaf WT, van Veldhuisen DJ, et al.
Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev.
1999;25:237–47.
67. Swain SM, Whaley FS, Gerber MC, et al. Delayed administration of
dexrazoxane provides cardioprotection for patients with advanced
breast cancer treated with doxorubicin-containing therapy. J Clin
Oncol. 1997;15:1333–40.
77
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
8
8
8
8
8
8
8
8
8
8
8
e81JACC Vol. 53, No. 15, 2009 Hunt et al.
April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure Guidelines68. Wiseman LR, Spencer CM. Dexrazoxane. A review of its use as a
cardioprotective agent in patients receiving anthracycline-based che-
motherapy. Drugs. 1998;56:385–403.
69. Grumbach IM, Heermann K, Figulla HR. Low prevalence of
hepatitis C virus antibodies and RNA in patients with myocarditis
and dilated cardiomyopathy. Cardiology. 1998;90:75–8.
70. Frustaci A, Calabrese F, Chimenti C, et al. Lone hepatitis C virus
myocarditis responsive to immunosuppressive therapy. Chest. 2002;
122:1348–56.
71. Frustaci A, Chimenti C, Calabrese F, et al. Immunosuppressive
therapy for active lymphocytic myocarditis: virological and immuno-
logic profile of responders versus nonresponders. Circulation. 2003;
107:857–63.
72. Lipshultz SE. Dilated cardiomyopathy in HIV-infected patients.
N Engl J Med. 1998;339:1153–5.
73. Lipshultz SE, Easley KA, Orav EJ, et al., for the Pediatric Pulmonary
and Cardiac Complications of Vertically Transmitted HIV Infection
(P2C2 HIV) Study Group. Left ventricular structure and function in
children infected with human immunodeficiency virus: the prospec-
tive P2C2 HIV Multicenter Study. Circulation. 1998;97:1246–56.
74. Lewis W, Grupp IL, Grupp G, et al. Cardiac dysfunction occurs in
the HIV-1 transgenic mouse treated with zidovudine. Lab Invest.
2000;80:187–97.
75. Barbaro G, Fisher SD, Lipshultz SE. Pathogenesis of HIV-associated
cardiovascular complications. Lancet Infect Dis. 2001;1:115–24.
76. Horwich TB, Fonarow GC, Hamilton MA, et al. Anemia is
associated with worse symptoms, greater impairment in functional
capacity and a significant increase in mortality in patients with
advanced heart failure. J Am Coll Cardiol. 2002;39:1780–6.
77. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney
function and anemia as risk factors for mortality in patients with left
ventricular dysfunction. J Am Coll Cardiol. 2001;38:955–62.
78. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous
erythropoietin and intravenous iron for the treatment of the anemia
of severe, resistant congestive heart failure improves cardiac and renal
function and functional cardiac class, and markedly reduces hospital-
izations. J Am Coll Cardiol. 2000;35:1737–44.
79. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of
mild anemia in severe, resistant congestive heart failure using subcu-
taneous erythropoietin and intravenous iron: a randomized controlled
study. J Am Coll Cardiol. 2001;37:1775–80.
80. Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on
exercise capacity in patients with moderate to severe chronic heart
failure. Circulation. 2003;107:294–9.
81. Krumholz HM, Phillips RS, Hamel MB, et al. Resuscitation pref-
erences among patients with severe congestive heart failure: results
from the SUPPORT project. Study to Understand Prognoses and
Preferences for Outcomes and Risks of Treatments. Circulation.
1998;98:648–55.
82. Wachter RM, Luce JM, Hearst N, et al. Decisions about resuscita-
tion: inequities among patients with different diseases but similar
prognoses. Ann Intern Med. 1989;111:525–32.
83. Greco PJ, Schulman KA, Lavizzo-Mourey R, et al. The Patient
Self-Determination Act and the future of advance directives. Ann
Intern Med. 1991;115:639–43.
84. Stevenson LW. Rites and responsibility for resuscitation in heart
failure: tread gently on the thin places [editorial; comment]. Circu-
lation. 1998;98:619–22.
85. The SUPPORT Principal Investigators. A controlled trial to improve
care for seriously ill hospitalized patients. The study to understand
prognoses and preferences for outcomes and risks of treatments
(SUPPORT) [published erratum appears in JAMA 1996;275:1232].
JAMA. 1995;274:1591–8.
86. Borggrefe M, Chen X, Martinez-Rubio A, et al. The role of
implantable cardioverter defibrillators in dilated cardiomyopathy. Am
Heart J. 1994;127:1145–50.
87. AGS Ethics Committee. The care of dying patients: a position
statement from the American Geriatrics Society. J Am Geriatr Soc.
1995;43:577–8.
88. Gibbs JS, McCoy AS, Gibbs LM, et al. Living with and dying from
heart failure: the role of palliative care. Heart. 2002;88 Suppl 2:ii36–9.
89. Fox E, Landrum-McNiff K, Zhong Z, et al., for the SUPPORT
Investigators. Evaluation of prognostic criteria for determining hos-
pice eligibility in patients with advanced lung, heart, or liver disease.Study to Understand Prognoses and Preferences for Outcomes and
Risks of Treatments. JAMA. 1999;282:1638–45.
90. Standards and Accreditation Committee, Medical Guidelines Task
Force, Stuart B, Alexander C, Arenella C, et al. Medical guidelines
for determining prognosis in selected noncancer diseases. Alexandria,
VA: National Hospice Organization. 1996;1–28.
91. Konstam M, Dracup K, Baker D, et al. Heart failure: evaluation and care
of patients with left-ventricular systolic dysfunction. 1994; Clinical
Practice Guideline No. 11, AHCPR publication No. 94–1612.
92. Philbin EF, Rocco TA Jr., Lindenmuth NW, et al. Clinical outcomes
in heart failure: report from a community hospital-based registry.
Am J Med. 1999;107:549–55.
93. Krumholz HM, Wang Y, Parent EM, et al. Quality of care for elderly
patients hospitalized with heart failure. Arch Intern Med. 1997;157:
2242–7.
94. Kahn KL, Rogers WH, Rubenstein LV, et al. Measuring quality of
care with explicit process criteria before and after implementation of
the DRG-based prospective payment system. JAMA. 1990;264:
1969–73.
95. Rubenstein LV, Kahn KL, Reinisch EJ, et al. Changes in quality of
care for five diseases measured by implicit review, 1981 to 1986.
JAMA. 1990;264:1974–9.
96. Oddone EZ, Weinberger M, Horner M, et al., for the Veterans
Affairs Cooperative Studies in Health Services Group on Primary Care
and Hospital Readmissions. Classifying general medicine readmissions.
Are they preventable? J Gen Intern Med. 1996;11:597–607.
97. Weingarten S, Riedinger M, Conner L, et al. Reducing lengths of
stay in the coronary care unit with a practice guideline for patients
with congestive heart failure. Insights from a controlled clinical trial.
Med Care. 1994;32:1232–43.
98. National Health Service Centre for Reviews and Dissemination.
Getting evidence into practice. Effective Health Care. 1999;5:1–16.
99. Oxman AD, Thomson MA, Davis DA, et al. No magic bullets: a
systematic review of 102 trials of interventions to improve profes-
sional practice. CMAJ. 1995;153:1423–31.
00. Bero LA, Grilli R, Grimshaw JM, et al., for the Cochrane Effective
Practice and Organization of Care Review Group. Closing the gap
between research and practice: an overview of systematic reviews of
interventions to promote the implementation of research findings.
BMJ. 1998;317:465–8.
01. Soumerai SB, Avorn J. Principles of educational outreach (‘academic
detailing’) to improve clinical decision making. JAMA. 1990;263:549–56.
02. Rich MW. Heart failure disease management: a critical review.
J Card Fail. 1999;5:64–75.
03. Rich MW, Nease RF. Cost-effectiveness analysis in clinical practice:
the case of heart failure. Arch Intern Med. 1999;159:1690–700.
04. Marshall MN, Shekelle PG, Leatherman S, et al. The public release
of performance data: what do we expect to gain? A review of the
evidence. JAMA. 2000;283:1866–74.
05. Chin MH, Friedmann PD, Cassel CK, et al. Differences in generalist
and specialist physicians’ knowledge and use of angiotensin-
converting enzyme inhibitors for congestive heart failure. J Gen
Intern Med. 1997;12:523–30.
06. Edep ME, Shah NB, Tateo IM, et al. Differences between primary care
physicians and cardiologists in management of congestive heart failure:
relation to practice guidelines. J Am Coll Cardiol. 1997;30:518–26.
07. Baker DW, Hayes RP, Massie BM, et al. Variations in family
physicians’ and cardiologists’ care for patients with heart failure. Am
Heart J. 1999;138:826–34.
08. Reis SE, Holubkov R, Edmundowicz D, et al. Treatment of patients
admitted to the hospital with congestive heart failure: specialty-
related disparities in practice patterns and outcomes. J Am Coll
Cardiol. 1997;30:733–8.
09. Philbin EF, Weil HF, Erb TA, et al. Cardiology or primary care for
heart failure in the community setting: process of care and clinical
outcomes. Chest. 1999;116:346–54.
10. Auerbach AD, Hamel MB, Davis RB, et al., for the SUPPORT
Investigators. Resource use and survival of patients hospitalized with
congestive heart failure: differences in care by specialty of the
attending physician. Study to Understand Prognoses and Preferences
for Outcomes and Risks of Treatments. Ann Intern Med. 2000;132:
191–200.
A
A
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
e82 Hunt et al. JACC Vol. 53, No. 15, 2009
2009 ACCF/AHA Heart Failure Guidelines April 14, 2009:e1–90PPENDIX 1. AUTHOR RELATIONSHIPS WITH INDUSTRY—ACC/AHA 2005 GUIDELINES FOR THE DIAGNOSIS
ND MANAGEMENT OF CHRONIC HEART FAILURE IN THE ADULT
Committee Member Research Grant Speakers’ Bureau Stock Ownership
Board of
Directors
Consultant/
Advisory Member
r. William T. Abraham ● Amgen
● Biosite
● Biotronik
● Cardio Dynamics International
● Guidant
● Medtronic
● Myogen
● Orqis Medical
● Otsuka Maryland Research
Institute
● Scios
● Vasogen
● Yamanouchi
● GlaxoSmithKline
● Guidant
● Medtronic
● Merck
● Pfizer
● Scios
● St. Jude Medical
None None None
r. Marshall H. Chin None None None None None
r. Arthur M. Feldman ● Amgen
● AstraZeneca
● GlaxoSmithKline
● Guidant
● Medtronic
● Pfizer
● Scios
● Vasomedical
● AstraZeneca
● GlaxoSmithKline
● Guidant
● Johnson & Johnson
● Medtronic
● Vasomedical
None None None
r. Gary S. Francis None None None None None
r. Theodore G. Ganiats None None None None None
r. Sharon Ann Hunt None None None None None
r. Mariell Jessup None None None None ● ACORN
● Medtronic
● GlaxoSmithKline
r. Marvin A. Konstam ● GlaxoSmithKline ● AstraZeneca
● GlaxoSmithKline
● Merck
● Novartis
None None ● AstraZeneca
● GlaxoSmithKline
● Merck
● Novartis
r. Donna M. Mancini None None None None None
r. Keith A. Michl None None None None None
r. John A. Oates ● McNeil
● Merck
None None None ● McNeil
● Merck
r. Peter S. Rahko ● Bristol-Myers Squibb
● Myogen
● Novartis
● Boehringer-Ingelheim
● Novartis
● Pfizer
None None ● GlaxoSmithKline
r. Marc A. Silver ● Pfizer ● GlaxoSmithKline ● Cardiodynamics None None
r. Lynne Warner
Stevenson
● Medtronic None None None ● Medtronic
● Scios
r. Clyde W. Yancy ● NitroMed
● Scios
● GlaxoSmithKline
● Medtronic
● Novartis
● Pfizer
● Scios
None None ● GlaxoSmithKline
● Medtronic
● Scios
A
D
D
D
D
D
D
D
D
N
D
D
D
e83JACC Vol. 53, No. 15, 2009 Hunt et al.
April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure GuidelinesPPENDIX 2. PEER REVIEWER RELATIONSHIPS WITH INDUSTRY—ACC/AHA 2005 GUIDELINES FOR THE
IAGNOSIS AND MANAGEMENT OF CHRONIC HEART FAILURE IN THE ADULT
Peer Reviewer
Name* Representation Research Grant
Speakers’ Bureau/
Honoraria Stock Ownership
Consultant/
Advisory Board
r. Mihai Gheorghiade Official Reviewer—AHA ● GlaxoSmithKline
● Otzuka
● Sigma Tau
● Pfizer None ● GlaxoSmithKline
● Medtronic
● Otzuka
● Sigma Tau
r. Jonathan L.
Halperin
Official Reviewer—ACCF/AHA
Task Force Lead Review
None ● AstraZeneca
● Bristol-Myers Squibb/
Sanofi Partnership
None ● AstraZeneca
● Bayer AG
● Boehringer Ingelheim
● Bristol-Myers Squibb/
Sanofi Partnership
r. Jagat Narula Official Reviewer—AHA None None None None
r. Milton Packer Official Reviewer—ACCF/AHA None None ● Discovery
Laboratories
● Titan
Pharmaceuticals
● Abbott
● Actelion
● AstraZeneca
● Cardiodynamics
● Discovery Laboratories
● GlaxoSmithKline
● Orion Pharmaceuticals
● Titan Pharmaceuticals
● Yamanouchi
r. Ileana L. Pina Official Reviewer—AHA ● Biosite
● Centers for Medicare
and Medicaid
Services
● National Institutes of
Health
● AstraZeneca
● GlaxoSmithKline
● Novartis
● Pfizer
None ● AstraZeneca
● Food and Drug
Administration–Center
for Devices and
Radiological Health
r. Miguel A.
Quinones
Official Reviewer—ACCF
Board of Trustees
None None None ● Proctor & Gamble
r. Richard F. Wright Official Reviewer—ACCF
Board of Governors
None ● AstraZeneca
● Bristol-Myers Squibb
● Novartis
● Cardiodynamics ● Bristol-Myers Squibb
● Cardiodynamics
● Novartis
ancy M. Albert, CNS Content Reviewer—AHA HF
and Transplantation
Committee
None ● GlaxoSmithKline
● Medtronic
● Scios
Pharmaceuticals
None ● GlaxoSmithKline
r. Jeffrey L. Anderson Content Reviewer—Individual
Review
None ● Johnson & Johnson
Merck
● Merck
● Merck-Schering-
Plough
None ● Johnson & Johnson
Merck
● Merck
● Merck-Schering-Plough
r. Elliott M. Antman Content Reviewer—Individual
Review
● AstraZeneca
● Biosite
● Boehringer
Mannheim
● Bristol-Myers Squibb
● Centocor
● CV Therapeutics
● Dade
● Dendrion
● Eli Lilly
● Genentech
● Merck
● Millennium
● Sanofi-Aventis
● Sunol Molecular
None None None
r. Malcolm O. Arnold Content Reviewer—ACCF HF
Data Standards Committee
None ● Aventis
● Merck-Frosst
● Novartis
● Pfizer
None ● Aventis
● Merck-Frosst
● Novartis
● Pfizer
DD
D
D
D
D
D
D
D
D
e84 Hunt et al. JACC Vol. 53, No. 15, 2009
2009 ACCF/AHA Heart Failure Guidelines April 14, 2009:e1–90Peer Reviewer
Name* Representation Research Grant
Speakers’ Bureau/
Honoraria Stock Ownership
Consultant/
Advisory Board
r. John P. Boehmer Content Reviewer—Individual
Review
● Acorn Cardiovascular
● Amgen
● Cardiovascular Bio
Therapeutics
● Guidant
● Medtronic
● Myogen
● Orion
Pharmaceuticals
None None None
r. Michael R. Bristow Content Reviewer—Individual
Review
None None None ● AstraZeneca
● Cardiac Dimensions
● Covalent
● C2R
● CVRx
● Genzyme
● GlaxoSmithKline
● Guidant
● Merck
● Mitsubishi
● Mylan
● Myogen
● Novartis
● Scios Pharmaceuticals
r. Alfred E. Buxton Content Reviewer—ACCF/AHA
Ventricular Arrhythmias and
Sudden Cardiac Death
Guideline Committee
● Guidant
● Medtronic
● St. Jude
None None ● Medtronic
r. Charles E. Canter Content Reviewer—AHA
Committee on HF and
Transplantation
● Novartis None None None
r. Donald E. Casey Content Reviewer—ACCF HF
Performance Measures
Committee
None None None None
r. Michael P.
Cinquegrani
Content Reviewer—ACCF HF
Data Standards Committee
None None ● Medtronic
● Pfizer
None
r. Teresa De Marco Content Reviewer—Individual
Review
● Scios
Pharmaceuticals
● Guidant
● Medtronic
● Scios
Pharmaceuticals
None ● Guidant
● Medtronic
● Scios Pharmaceuticals
r. Gordon A. Ewy Content Reviewer—ACCF/AHA
Coronary Artery Bypass
Graft Surgery Guideline
Writing Committee
None ● AstraZeneca
● GlaxoSmithKline
● Kos
● Merck
● Pfizer
● Schering-Plough
● Wyeth-Ayerst
None None
r. Gregg C. Fonarow Content Reviewer—AHA
Quality of Care and
Outcomes Committee
● Amgen
● Biosite
● Bristol-Myers Squibb
● GlaxoSmithKline
● Guidant
● Medtronic
● Merck
● Pfizer
● Scios
Pharmaceuticals
● Amgen
● Biosite
● Bristol-Myers Squibb
● GlaxoSmithKline
● Guidant
● Medtronic
● Merck
● Pfizer
● Scios
Pharmaceuticals
None ● Amgen
● Biosite
● Bristol-Myers Squibb
● GlaxoSmithKline
● Guidant
● Medtronic
● Merck
● Pfizer
● Scios Pharmaceuticals
r. Michael M. Givertz Content Reviewer—AHA
Committee on HF and
Transplantation
None None None None
DD
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
e85JACC Vol. 53, No. 15, 2009 Hunt et al.
April 14, 2009:e1–90 2009 ACCF/AHA Heart Failure GuidelinesPeer Reviewer
Name* Representation Research Grant
Speakers’ Bureau/
Honoraria Stock Ownership
Consultant/
Advisory Board
r. David C. Goff Content Reviewer—AHA
Quality of Care and
Outcomes Committee
None ● Pfizer None ● Johnson & Johnson
● Pfizer
r. Edward P.
Havranek
Content Reviewer—ACCF HF
Data Standards Committee
None None None None
r. Paul A.
Heidenreich
Content Reviewer—ACCF HF
Data Standards Committee
None None None None
r. Mark A. Hlatky Content Reviewer—ACCF HF
Performance Measures
Committee
None None None None
r. Judith S. Hochman Content Reviewer—ACCF/AHA
ST-Elevation Myocardial
Infarction Guideline Writing
Committee
● Arginox
● Eli Lilly
None None ● Datascope
● Diachii
● Millenium
● Sanofi-Aventis
● Proctor & Gamble
r. Marrick L. Kuckin Content Reviewer—Individual
Review
● AstraZeneca
● Myogen
● Vasogen
● AstraZeneca
● Myogen
None ● AstraZeneca
r. Barry M. Massie Content Reviewer—Individual
Review
None None None None
ebra Moser, MN, RN Content Reviewer—AHA
Quality of Care and
Outcomes Committee
None None None None
r. Erik Magnus
Ohman
Content Reviewer—Individual
Review
● Berlex
● Bristol-Myers
Squibb/Sanofi
● Millenium
● Schering-Plough
None ● Medtronic None
r. Eric N. Prystowsky Content
Reviewer—ACCF/AHA/ESC
Atrial Fibrillation
None None None ● Guidant
r. Andrew L. Smith Content Reviewer—ACCF HF
Performance Measures
Committee
● Guidant
● Medtronic
● Nitromed
● Guidant
● Medtronic
None None
r. George Sopko Content Reviewer—AHA
Committee on HF and
Transplantation
None None None None
r. Karl T. Weber Content Reviewer—Individual
Review
None None None None
r. William S.
Weintraub
Content Reviewer—AHA
Quality of Care and
Outcomes Committee
● Pfizer ● Pfizer None ● Pfizer
r. Deborah Allen Organizational—American
Academy of Family
Physicians
None None None None
r. Denise Barnard Organizational Reviewer—
Heart Failure Society of
America
None None None None
r. Jonathan Howlett Organizational Reviewer—
Heart Failure Society of
America
● AstraZeneca None None ● AstraZeneca
● Bristol-Myers Squibb/
Sanofi
● Merck
● Novartis
● Servier
DD
D
D
D
T
t
A
A
A
A
A
A
A
B
C
C
D
D
E
E
F
H
H
e86 Hunt et al. JACC Vol. 53, No. 15, 2009
2009 ACCF/AHA Heart Failure Guidelines April 14, 2009:e1–90Peer Reviewer
Name* Representation Research Grant
Speakers’ Bureau/
Honoraria Stock Ownership
Consultant/
Advisory Board
r. Ijaz A. Kahn Organizational Reviewer—
American College of Chest
Physicians
None None None None
r. JoAnn Lindenfeld Organizational Reviewer—
Heart Failure Society of
America
● Bristol-Myers
Squibb/Sanofi
● Medtronic
● Myogen
● Novocardia
● Pfizer
● Scios
Pharmaceuticals
None None None
r. Mandeep R. Mehra Organizational Reviewer—
International Society for
Heart and Lung
Transplantation
● AstraZeneca
● Biosite Diagnostics
● Guidant
● Medtronic
● Merck
● Scios
● AstraZeneca
● Biosite Diagnostics
● Guidant
● Medtronic
● Merck
● Novartis
● Scios
● Hommed ● AstraZeneca
● Biosite Diagnostics
● Guidant
● Medtronic
● Merck
● Novartis
● Scios
r. Alan Miller Organizational Reviewer—
Heart Failure Society of
America
● Amgen
● AstraZeneca
● GlaxoSmithKline
● Myogen
● NitroMed
● Novartis
● Pfizer
● AstraZeneca
● Bristol-Myers Squibb/
Sanofi
● GlaxoSmithKline
● Novartis
● Pfizer
● Wyeth
None ● GlaxoSmithKline
● Pfizer
r. K. Vijayaraghavan Organizational Reviewer—
American College of Chest
Physicians
● Amgen
● AstraZeneca
● Cardiodynamics
● Kos
● Merck-Schering-
Plough
● Myogen
● Pfizer
● GlaxoSmithKline
● Guidant
● Merck
● Medtronic
● Novartis
● Pfizer
● Scios
Pharmaceuticals
None None
his table represents the relationships of peer reviewers with industry that were disclosed at the time of peer review of this guideline. It does not necessarily reflect relationships with industry at the
ime of publication.
*Names are listed in alphabetical order within each category of review.
PPENDIX 3. REMATCH TRIAL ABBREVIATIONS
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RB angiotensin II receptor blocker LBBB left bundle-branch block
TPase adenosine triphosphatase LV left ventricular
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PO erythropoietin REMATCH Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure
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